FALLER ANDREW (GB)
MACPHERSON DAVID TIMOTHY (GB)
MILNER PETER HENRY (GB)
NAYLOR ALAN (GB)
REDSHAW SALLY (GB)
STANWAY STEVEN JAMES (GB)
VESEY DAVID R (GB)
WALTER DARYL S (GB)
DEMONT EMMANUEL H (GB)
FALLER ANDREW (GB)
MACPHERSON DAVID TIMOTHY (GB)
MILNER PETER HENRY (GB)
NAYLOR ALAN (GB)
REDSHAW SALLY (GB)
STANWAY STEVEN JAMES (GB)
VESEY DAVID R (GB)
WALTER DARYL S (GB)
| WO2002002512A2 | 2002-01-10 | |||
| WO2002002505A2 | 2002-01-10 | |||
| WO1998033795A1 | 1998-08-06 |
Thompson, Clive Beresford (Corporate Intellectual Property 980 Great West Roa, Brentford Middlesex TW8 9GS, GB)
| 1. | A compound of formula (I) : wherein R1 represents C16 alkyl, C26 alkenyl, halogen, C16 alkoxy, amino, cyano, hydroxy, aryl, heteroaryl or heterocyclyl ; R2a represents hydrogen, C13 alkyl, C13 alkoxy or halogen ; m and n independently represent 0,1 or 2; X represents CO, SO or SO2 ; p represents an integer from 1 to 3; R2b represents hydrogen, Cul6 alkyl, C26 alkenyl, halogen, C16 alkoxy, amino, cyano, hydroxy, aryl, heteroaryl or heterocyclyl ; R3 represents halogen, C16 alkyl, C26 alkenyl, aryl, heteroaryl, heterocyclyl, C16 alkylaryl, C16 alkylheteroaryl, C16 alkylheterocyclyl, C26 alkenylaryl, C26 alkenylheteroaryl, C26 alkenylheterocyclyl, C38 cycloalkyl, C16 alkylC38 cycloalkyl, cyano, azido, nitro,NR7R8, <BR> <BR> NR9COR10, NR11SO2R12, OR13, SO2R14, SR15, C#CR16, C16 alkyl(CF2)qCF3, CONR17R18, COOR'9,CI6 alkylNR20R21 orC16 alkylN3, or R3 and R2b together with the phenyl group to which they are attached form a naphthyl or benzofused heterocyclic or heteroaryl ring optionally substituted by one or two C16 alkyl groups; R4 represents C26 alkynyl, C16 alkylaryl, C16 alkylheteroaryl or C16 alkylheterocyclyl ; R5 represents hydrogen, C110 alkyl, C310 cycloalkyl, C310 cycloalkenyl, aryl, heteroaryl, heterocyclyl, C16 alkylC310 cycloalkyl, C310 cycloalkylC110 alkyl, C310 cycloalkylC16 alkyl aryl, C310 cycloalkylaryl, C16 alkylarylheteroaryl, C(RaRb)CONHC16 alkyl, C(RcRd) CONHC310 cycloalkyl, C16 alkylSC16 alkyl, C16 alkylNReRf, C16 alkylaryl, C16 alkyl heteroaryl, C16 alkylheterocyclyl C16 alkylC16 alkoxyaryl, C16 alkoxyheteroaryl orC16 alkylC16 alkoxyheterocyclyl ; R', RB, R9, Rlo, R13, R14, R15, R16, 17, R18, R19, R20 and R21 independently represent hydrogen, C16 alkyl, C26 alkenyl, C38 cycloalkyl, aryl, heteroaryl, heterocyclyl, C16 alkylC38 cycloalkyl, Ci. alkylaryl, C16 alkylheteroaryl, C16 alkylheterocyclyl or COC16 alkyl ; R", R12, Ra, RC, Re and Rf independently represent hydrogen, Ci. alkyl or C38 cycloalkyl ; Rb and Rd independently represent hydrogen, C16 alkyl, C38 cycloalkyl or C16 alkylSO2C16 alkyl ; q represents 1 to 3; wherein said alkyl groups may be optionally substituted by one or more (eg. 1,2 or 3) halogen, C16 alkyl, C16 alkoxy, C26 alkenoxy, C38 cycloalkyl, amino, cyano or hydroxy groups; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more (eg. 1,2 or 3) Ci. alkyl, C26 alkenyl, C26 alkynyl, halogen, haloC16 alkyl,OCF3, oxo, C16 alkoxy,C16 alkoxyCN, amino, cyano, nitro, NR22COR23, CONR22R23, COOR22, SO2R22, C16 alkylNR22 R23 (wherein R22 and R23 independently represent hydrogen or Ci. alkyl), C16 alkylC16 alkoxy, C16 alkanol or hydroxy groups; or a pharmaceutical acceptable salt or solvate thereof. |
| 2. | A compound according to claim 1 which is a compound of formula E1E744 or a pharmaceutical acceptable salt thereof. |
| 3. | A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutical acceptable salt or solvate thereof in admixture with one or more pharmaceutical acceptable diluents or carriers. |
| 4. | A compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof for use as a pharmaceutical. |
| 5. | Use of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof in the treatment of diseases characterised by elevated amyloid levels or ßamyloid deposits. |
| 6. | Use of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of diseases characterised by elevated ßamyloid levels or ßamyloid deposits. |
| 7. | A method of treatment or prophylaxis of diseases characterised by elevated ßamyloid levels or ßamyloid deposits which comprises administering to a patient an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof. |
| 8. | A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of diseases characterised by elevated ßamyloid levels or ßamyloid deposits. |
Alzheimer's disease is a degenerative brain disorder in which extracellular deposition of Ap in the form of senile plaques represents a key pathological hallmark of the disease (Selkoe, D. J.
(2001) Physiological Reviews 81: 741-766). The presence of senile plaques is accompanied by a prominent inflammatory response and neuronal loss. ß-amyloid (AP) exists in soluble and insoluble, fibrilla forms and a specific fibrilla form has been identified as the predominant neurotoxic species (Vassar, R. and Citron, M. (2000) Neuron 27: 419-422). In addition it has been reported that dementia correlates more closely with the levels of soluble amyloid rather than plaque burden (Naslund, J. et al. (2000) J. Am. Med. Assoc. 12: 1571-1577; Younkin, S.
(2001) Nat. Med. 1: 8-19). Ap is known to be produced through the cleavage of the beta amyloid precursor protein (also known as APP) by an aspartyl protease enzyme known as Asp2 (also known as P-secretase, BACE1 or Memapsin) (De Strooper, B. and Konig, G.
(1999) Nature 402: 471-472).
Therefore, it has been proposed that inhibition of the Asp2 enzyme would reduce the level of APP processing and consequently reduce the levels of Ap peptides found within the brain.
Therefore, it is also thought that inhibition of the Asp2 enzyme would be an effective therapeutic target in the treatment of Alzheimer's disease.
APP is cleaved by a variety of proteolytic enzymes (De Strooper, B. and Konig, G. (1999) Nature 402: 471-472). The key enzymes in the amyloidogenic pathway are Asp2 (ß- secretase) and y-secretase both of which are aspartic proteinases and cleavage of APP by these enzymes generates Ap. The non-amyloidogenic, a-secretase pathway, which precludes Ap formation, has been shown to be catalysed by a number of proteinases, the best candidate being ADAM10, a disintegrin and metalloproteinase. Asp1 has been claimed to show both a-and P-secretase activity in vitro. The pattern of expression of Asp1 and Asp2 are quite different, Asp2 is most highly expressed in the pancreas and brain while Asp1 expression occurs in many other peripheral tissues. The Asp2 knockout mouse indicates that lack of Asp2 abolished A (3 production and also shows that in this animal model endogenous Asp1 cannot substitute for the Asp2 deficiency (Luo, Y. et al. (2001) Nat Neurosci. 4: 231-232; Cai, H. et. al. (2001) Nat Neurosci. 4: 233-234; Roberds, S. L. et al. (2001) Hum. Mol. Genet.
10: 1317-1324).
For an agent to be therapeutically useful in the treatment of Alzheimer's disease it is preferable that said agent is a potent inhibitor of the Asp2 enzyme, but should ideally also be selective for Asp2 over other enzymes of the aspartyl proteinase family, e. g Cathepsin D
(Connor, G. E. (1998) Cathepsin D in Handbook of Proteolytic Enzymes, Barrett, A. J., Rawlings, N. D. , & Woesner, J. F. (Eds) Academic Press London. pp828-836).
WO 01/70672, WO 02/02512, WO 02/02505, WO 02/02506 and WO 03/040096 (Elan Pharmaceuticals Inc.) describe a series of hydroxyethylamine compounds having p-secretase activity which are implicated to be useful in the treatment of Alzheimer's disease.
We have found a novel series of compounds which are potent inhibitors of the Asp2 enzyme, thereby indicating the potential for these compounds to be effective in the treatment of Alzheimer's disease.
Thus, according to a first aspect of the present invention we provide a compound of formula (1) : (I) wherein R1 represents C16 alkyl, C26 alkenyl, halogen, C16 alkoxy, amino, cyano, hydroxy, aryl, heteroaryl or heterocyclyl ; R2a represents hydrogen, C1-3 alkyl, C13 alkoxy or halogen ; m and n independently represent 0,1 or 2; X represents CO, SO or SO2 ; p represents an integer from 1 to 3; R2b represents hydrogen, Cul-6 alkyl, C26 alkenyl, halogen, C16 alkoxy, amino, cyano, hydroxy, aryl, heteroaryl or heterocyclyl ; R3 represents halogen, Cul-6 alkyl, C2-6 alkenyl, aryl, heteroaryl, heterocyclyl, -C1-6 alkyl-aryl, - C1-6 alkyl-heteroaryl, -C1-6 alkyl-heterocyclyl, -C2-6 alkenyl-aryl, -C2-6 alkenyl-heteroaryl, -C2-6 alkenyl-heterocyclyl, C38 cycloalkyl,-C16 alkyl-C38 cycloalkyl, cyano, azido, nitro,-NR7R3,- <BR> <BR> NR9COR10, -NR11SO2R12, -OR13, -SO2R14, -SR15, -C#CR16, -C1-6 alkyl-(CF2)qCF3, -CONR17R18, COOR19, -C1-6 alkyl-NR20R21 or -C1-6 alkyl-N3 or R3 and R2b together with the phenyl group to which they are attached form a naphthyl or benzofused heterocyclic or heteroaryl ring optionally substituted by one or two C1-6 alkyl groups; R4 represents-C2-6 alkynyl, -C1-6 alkyl-aryl, -C1-6 alkyl-heteroaryl or -C1-6 alkyl-heterocyclyl ; R5 represents hydrogen, -C1-10 alkyl, -C3-10 cycloalkyl, -C3-10 cycloalkenyl, aryl, heteroaryl, heterocyclyl,-C16 alkyl-C3-10 cycloalkyl, -C3-10 cycloalkyl-C1-10 alkyl, -C3-10 cycloalkyl-C1-6 alkyl- ary cycloalkyl-aryl, -C1-6 alkyl-aryl-heteroaryl, -C(RaRb)-CONH-C1-6 alkyl, -C(RcRd)- CONH-C310 cycloalkyl, -C1-6 alkyl-S-C1-6 alkyl, -C1-6 alkyl-NReRf, -C1-6 alkyl-aryl, C1-6 alkyl- heteroaryl,-C16 alkyl-heterocyclyl-C1-6 alkyl-C1-6 alkoxy-aryl, -C1-6 alkyl-C1-6 alkoxy-heteroaryl or-Ci. alkyl-C_6 alkoxy-heterocyclyl ;
R7, R8, R9 Rlo, R13, R14, R15, R16, R17, R18, R19, R20 and R21 independently represent hydrogen, Ci. alkyl, C26 alkenyl, C3-8 cycloalkyl, aryl, heteroaryl, heterocyclyl,-C16 alkyl-C38 cycloalkyl,- C1-6 alkyl-aryl, -C1-6 alkyl-heteroaryl, -C1-6 alkyl-heterocyclyl or -CO-C1-6 alkyl ; R", R12, Ra, RC, Re and Rf independently represent hydrogen, Ci. alkyl or C38 cycloalkyl ; Rb and Rd independently represent hydrogen, Ci-6 alkyl, C3-8 cycloalkyl or -C1-6 alkyl-SO2-C1-6 alkyl ; q represents 1 to 3; wherein said alkyl groups may be optionally substituted by one or more (eg. 1,2 or 3) halogen, Ci. alkyl, C1-6 alkoxy, C2-6 alkenoxy, C3-8 cycloalkyl, amino, cyano or hydroxy groups; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more (eg. 1,2 or 3) Ci. alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, halo16 alkyl,-OCF3, oxo, Ci. alkoxy,-C16 alkoxy-CN, amino, cyano, nitro, -NR22COR23, -CONR22R23, -COOR22,-SO2R22,-C16 alkyl-NR22 R23 (wherein R22 and R23 independently represent hydrogen or Ci. alkyl), -C1-6 alkyl-C1-6 alkoxy, -C1-6 alkanol or hydroxy groups; or a pharmaceutical acceptable salt or solvate thereof.
In one particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein: X represents CO or SO2 ; and R2a represents hydrogen, C1-3 alkyl or halogen ; and R3 and R2b together with the phenyl group which they are attached form an unsubstituted benzofused heterocyclic or heteroaryl ring; and R4 represents -C1-6 alkyl-aryl,-C16 alkyl-heteroaryl or-C16 alkyl-heterocyclyl ; and R5 represents hydrogen, -C1-10 alkyl, -C3-8 cycloalkyl, -C3-8 cycloalkenyl, aryl, heteroaryl, heterocyclyl,-C16 alkyl-C3-8 cycloalkyl, -C1-6 alkyl-aryl-heteroaryl, -C(RaRb)-CONH-C1-6 alkyl, - C (RcRd)-CONH-C3-8 cycloalkyl, -C1-6 alkyl-S-C1-6 alkyl, -C1-6 alkyl-NReRf, -C1-6 alkyl-aryl, -C1-6 alkyl-heteroaryl, -C1-6 alkyl-heterocyclyl -C1-6 alkyl-C1-6 alkoxy-aryl, -C1-6 alkyl-C1-6 alkoxy- heteroaryl or-C16 alkyl-C16 alkoxy-heterocyclyl ; and said alkyl groups may be optionally substituted by one or more (eg. 1,2 or 3) halogen, C16 alkoxy, amino, cyano or hydroxy groups; and wherein said aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more (eg. 1,2 or 3) C1-6 alkyl, halogen,-OCF3, oxo, C16 alkoxy, amino, cyano, nitro,- NR22COR23, -C1-6 alkyl-NR22R23 (wherein R22 and R23 independently represent hydrogen or Ci. alkyl), -C1-6 alkyl-C1-6 alkoxy, -C1-6 alkanol or hydroxy groups.
References to alkyl include references to both straight chain and branched chain aliphatic isomers of the corresponding alkyl. It will be appreciated that references to alkenyl and alkenoxy shall be interpreted similarly. It will also be appreciated that when an alkenyl or alkenoxy group is attached to an O, N or S atom the double bond is not at the alpha position relative to said O, N or S atom.
References to cycloalkyl include references to all alicyclic (including branched) isomers of the corresponding alkyl. When a cycloalkyl group is substituted by two or more Ci. alkyl groups,
said cycloalkyl groups together with any two alkyl groups may form a bridged cycloalkyl group which includes bicycloheptyl, adamantyl, bicyclo-octyl and the like.
References to'aryl'include references to monocyclic carbocyclic aromatic rings (eg. phenyl) and bicyclic carbocyclic aromatic rings (e. g. naphthyl) or carbocyclic benzofused rings (eg. Cs- 8 cycloalkyl fused to a phenyl ring, such as dihydroindenyl or tetrahydronaphthalenyl).
References to'heteroaryl'include references to mono-and bicyclic heterocyclic aromatic rings containing 1-4 hetero atoms selected from nitrogen, oxygen and sulphur. Examples of monocyclic heterocyclic aromatic rings include e. g. thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, pyridyl, tetrazolyl and the like. Examples of bicyclic heterocyclic aromatic rings include eg. quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.
References to'heterocyclyl'include references to a 5-7 membered non-aromatic monocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, sulphur or oxygen. Examples of heterocyclic non-aromatic rings include e. g. morpholinyl, piperidinyl, piperazinyl, thiomorpholinyl, oxathianyl, dithianyl, dioxan, pyrrolidinyl, dioxolanyl, oxathiolanyl, imidazolidinyl, pyrazolidinyl and the like.
References to'benzofused heterocyclyl or heteroaryl ring'include quinolinyl, isoquinolinyl, indolyl, indazolyl, dihydroindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, dihydrochromene, benzotriazolyl, tetrahydroquinoxalinyl and the like.
Preferably, m is 0 or 1, preferably 0. When m represents 1, R'is preferably aryl (eg. phenyl).
Preferably, n is 0 or 1, more preferably 1.
When n represents 1, R2a is preferably C13 alkoxy (eg. methoxy) or halogen (eg. fluorine), more preferably halogen (eg. fluorine).
When n represents 1, R2a is preferably in the ortho position of the phenyl ring.
When X represents SO2, p is preferably 2 or 3, more preferably 2 and when X represents CO, p is preferably 1 or 2, more preferably 1.
Preferably, R2b is : hydrogen; halogen (eg. chlorine or fluorine) ;
Chalky) (eg. methyl) ; C1-6 alkoxy (eg. methoxy); or heterocyclyl (eg. pyrrolidinyl) optionally substituted by an oxo group (eg. 2- oxopyrrolidin-1-yl).
More preferably, R2b is hydrogen or halogen (eg. fluorine), most preferably hydrogen.
Preferably, R3 represents : Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl or t-butyl) optionally substituted by one or more (eg. 1,2 or 3) hydroxy, halogen (eg. fluorine) or CI-6 alkoxy groups (eg. methoxy or ethoxy); 2-6 alkenyl (eg. propenyl) ; C3-8 cycloalkyl (eg. cyclopentyl or cyclohexyl) ; cyano; heterocyclyl (eg. piperidinyl, pyrrolidinyl or isothiazolidinyl) optionally substituted by one or two oxo groups; - NR'Rs ; -OR13; -SR15 ; or -CONR17R18.
Also preferably, R3 and R2b together with the phenyl group which they are attached represent indolyl, indazolyl, dihydroindolyl, benzofuranyl, dihydrochromenyl, benzotriazolyl, benzimidazolyl or tetrahydroquinoxalinyl, optionally substituted by one or two Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl or pentyl) groups. More preferably R3 and R2b together with the phenyl group which they are attached represent benzimidazolyl or indolyl substituted by a Ci. alkyl group (eg. ethyl).
More preferably, R3 represents: Ci. alkyl (eg. n-propyl) ; -NR7R8 ; C3-8 cycloalkyl (eg. cyclopentyl or cyclohexyl) ; -OR13 ; or CoNR17R18 Preferably, R7 and R8 independently represent: hydrogen; Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, i-propyl, i-butyl,-CH2C (CH3) 3, -CH (CH2CH3) CH2CH3 or- (CH2) 2CH (CH3) 2); C3-8 cycloalkyl (eg. cyclopentyl or cyclohexyl) ; aryl (eg. phenyl) ; -C16 alkyl-C38 cycloalkyl (eg.-CH2-cyclopropyl) ; -C16 alkyl-aryl (eg.-CH2-phenyl or-(CH2) 2-phenyl) ; or
-CO-C1-6 alkyl (eg. -COCH3).
More preferably, R7 represents hydrogen and R8 represents C16 alkyl (particularly ethyl or isopropyl, especially ethyl).
Preferably, R13 represents Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec- butyl or t-butyl or pentyl) optionally substituted by a hydroxy or Ci. alkoxy (eg. methoxy) group, more preferably R13 represents ethyl or i-propyl.
Preferably, R15 represents Ci. alkyl (eg. methyl or ethyl).
Preferably, R 17 and R'8 both represent Ci. alkyl (eg. both represent propyl or one represents propyl and the other represents methyl).
Preferably, R4 represents-C16 alkyl-aryl (eg. benzyl) or -C1-6 alkyl-heteroaryl (eg.-CH2- pyridinyl,-CH2-thiazolyl,-CH2-furanyl,-CH2-thienyl or-CH2-pyrazolyl) optionally substituted by one or two halogen atoms (eg. chlorine or fluorine). More preferably, R4 represents-C16 alkyl-aryl (eg. benzyl) optionally substituted by one or two halogen atoms (eg. chlorine or fluorine), most preferably R4 represents unsubstituted benzyl.
Preferably, R5 represents -C110 alkyl (eg. methyl, ethyl, n-propyl, n-butyl, n-pentyl or n-hexyl) optionally substituted by one or more C1-6 alkyl (eg. methyl), Ci. alkoxy (eg. methoxy or- OCH2CH (CH3) 2) or 62-6 alkenoxy (eg. -OCH2C (CH3) =CH2) groups; -C3-10 cycloalkyl (eg. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicycloheptyl, adamantyl or bicyclo-octyl) optionally substituted by one or more Ci. alkyl (eg. methyl, ethyl or propyl) or halogen (eg. fluorine) groups; -C16 alkyl-C310 cycloalkyl (eg.-CH2-cyclohexyl or-CH2-cyclopropyl) ; -aryl (eg. phenyl, dihydroindenyl or tetrahydronaphthalenyl) optionally substituted by one or more hydroxy or Ci. alkoxy (eg. methoxy) groups; -C1-6 alkyl-aryl (eg. benzyl, -ethyl-phenyl, -ethyl-naphthyl, -propyl-phenyl, -C (H) (Me)- phenyl,-C (H) (Et)-phenyl-C (Me) (Me)-benzyl or-C (Me) (Me)-phenyl) optionally substituted by one or more halogen (eg. chlorine, bromine or fluorine), hydroxy,-OCF3, haloC16 alkyl (eg. - CH2CF3 or-CF3), Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl or t- butyl), C2-6 alkenyl (eg. ethenyl), C2-6 alkynyl, C16 alkoxy (eg. methoxy, ethoxy, propoxy, isopropoxy or methylethoxy), cyano, nitro,-COOR22 (eg. COOH or COOMe),-S02R22 (eg. - SO2Me),-NR22CoR23 (eg. NHCOCH3),-C16 alkyl-NR22R23 (eg. -CH2N(CH3)2), -C1-6 alkyl-C1-6 alkoxy (eg.-CH20C (CH3) 3),-C16 alkanol (eg. -CH2OH) or -C1-6 alkoxy-CN (eg. OCH2CN) groups; -C1-6 alkyl-heteroaryl (eg. -CH2-furanyl, -CH2-quinolinyl, -CH2-thiophenyl, -CH2- <BR> <BR> <BR> indolyl,-CH2-benzoimidazolyl,-CH2-imidazolyl,-CH2-benzofuran yl,-CH2-thiazolyl,-CH2- pyridinyl, -CH2-benzothiazolyl, -CH2-pyrazolyl, -CH2-isoxazolyl, -CH2-oxazolyl, -CH2-pyrrolyl, -CH2-dihydrobenzofuranyl, -CH2-dihydrobenzodioxinyl or -CH2-dihydrochromenyl) optionally
substituted by one or more Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec- butyl or t-butyl), C26 alkenyl (eg. ethenyl or propenyl), C2-6 alkynyl, halogen (eg. bromine or chlorine), haloC16 alkyl (eg. fluoroethyl or trifluoroethyl), cyano, C1-6 alkoxy (eg. methoxy),- CONR22R23 (eg. -CONHMe) or -COOR22 (eg. -COOMe) groups; -heterocyclyl (eg. tetrahydropyranyl or tetrahydrothiopyranyl) ; -C16 alkyl-heterocyclyl (eg.-CH2-tetrahydropyranyl) ; -C3-10 cycloalkyl-C1-10 alkyl (eg. -cyclobutyl-isopropyl, -cyclobutyl-ethyl, -cyclobutyl- propyl,-cyclopropyl-ethyl,-cyclopropyl-propyl,-cyclopropyl-i sopropyl,-cyclopropyl-t-butyl,- cyclopropyl-CH2CH (CH3) 2,-cyclopropyl- (CH2) 2CH (CH3) 2,-cyclopropyl- (CH2) 2CH (CH3) 2 or- cyclopropyl- (CH2) 3CH (CH3) 2); -C310 cycloalkyl-C16 alkyl-aryl (eg.-cyclopropyl-CH2-phenyl) optionally substituted by one or more halogen (eg. chlorine) atoms; -C3-10 cycloalkyl-aryl (eg. -cyclopropyl-phenyl) optionally substituted by one or more halogen (eg. chlorine, bromine or fluorine), hydroxy,-OCF3, halo16 alkyl (eg.-CH2CF3 or- CF3), Ci. alkyl (eg. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl or t-butyl), C26 alkenyl (eg. ethenyl), C2-6 alkynyl, C1-6 alkoxy (eg. methoxy, ethoxy, propoxy, isopropoxy or methylethoxy), cyano, nitro,-COOR22 (eg. COOH or COOMe),-SO2R22 (eg.-S02Me),- NR22CoR23 (eg. NHCOCH3),-C16 alkyl-NR22R23 (eg. -CH2N (CH3) 2), -C1-6 alkyl-C16 alkoxy (eg.
-CH2OC (CH3) 3),-C16 alkanol (eg. -CH2OH) or -C1-6 alkoxy-CN (eg. OCH2CN) groups; -C(RaRb)-CONH-C1-6 alkyl (eg. -C (RaRb)-CONH-i-butyl) ; -C(RcRd)-CONH-C3-10 cycloalkyl (eg. C (RcRd)-CONH-cyclohexyl) ; -C1-6 alkyl-S-C1-6 alkyl (eg. -propyl-S-methyl or -dimethylethyl-S-isobutyl) ; or -C16 alkyl-NReRf (eg.-dimethylpropyl-NReRf) More preferably R5 represents: -C3-10 cycloalkyl (eg. cyclohexyl) ; -C16 alkyl-aryl (eg. benzyl) optionally substituted by one or more halogen (eg. chlorine, bromine or fluorine),-OCF3 or haloC16 alkyl (eg. -CF3) groups; -C1-6 alkyl-heteroaryl (eg. -CH2-thienyl, -CH2-pyrazolyl or -CH2-isoxazolyl) optionally substituted by one or more Ci. alkyl (eg. methyl, ethyl, isopropyl, propyl or butyl) or halo16 alkyl (eg. CH2CF3) groups; or -heterocyclyl (eg. tetrahydropyranyl).
Preferably, q represents 1 or 2.
Preferably, Ra represents hydrogen or Ci. alkyl (methyl).
Preferably, Rb and Rd independently represent C16 alkyl (eg. methyl, ethyl, propyl or butyl) or- Ci. alkyl-SO2-C1-6 alkyl (eg. -CH2CH2SO2CH3) optionally substituted by one or more hydroxy groups.
Preferably, R'represents hydrogen or Ci. alkyl (methyl).
Preferably, Re and Rf both represent C16 alkyl (eg. methyl).
Preferred compounds according to the invention includes examples E1-E744 as shown below, or a pharmaceutical acceptable salt thereof.
More preferred compounds according to the invention include : formic acid-5-cyclopentyl-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yi)-N- [ (1S, 2R)-3-{[(1- ethyl-1 H-pyrazol-4-yl) methyl] amino}-2-hydroxy-1-(phenylmethyl) propyl]-2-fluorobenzamide (1 : 1) ; formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-N- [ (1S, 2R) -2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-5- [ (1- methylethyl) amino] benzamide (1: 1); formic acid - 3-(1,1-dioxidotetrahydro-2H-1,2-thiazin-2-yl)-N-[(1S,2R)-3-{ [(1-ethyl-1H-pyrazol- 4-yl) methyl] amino}-2-hydroxy-1- (phenylmethyl) propyl]-2-fluoro-5- [ (1- methylethyl) amino] benzamide (1: 1); formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-N- { (1S, 2R) -2-hydroxy-1- (phenylmethyl)-3- [ ( {3- [ (trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-5- [ (1- methylethyl) amino] benzamide (1: 1); formic acid-N- ( (1 S, 2R)-1-benzyl-3- { [4-fluoro-3- (trifluoromethyl) benzyl] amino}-2- hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino)-2-fluorobenzamide (1: 1) ; <BR> <BR> <BR> 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-2-fluoro-N- [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3-({[3-(trifluoromethyl) phenyl] methyl} amino) propyl] benzamide; formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-N-[(1S,2R)-3-{[(5- ethyl-3-thienyl) methyl] amino}-2-hydroxy-1-(phenylmethyl) propyl] benzamide (1: 1); and formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-2-fluoro-N-{(1S, 2R) - 2-hydroxy-1-(phenylmethyl)-3-[({3-[(trifluoromethyl) oxy] phenyl} methyl) amino] propyl} benzamide (1: 1) or a pharmaceutically acceptable salt thereof.
The compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutical acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci. , 1977,66, 1-19, such as acid addition salts formed with inorganic or organic acids e. g. hydrochlorides, hydrobromides, sulphates, phosphates, acetates, benzoates, citrates, nitrates, succinates, lactates, tartrates, fumarates, maleates, 1-hydroxy-2-naphthoates, palmoates, methanesulphonates, p-toluenesulphonates, naphthalenesulphonates, formates or trifluoroacetates. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.
The present invention also includes within its scope prodrugs of compounds of formula (I). As used herein, the term"prodrug"means a compound which is converted within the body, e. g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutical acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery
Systems, Vol. 14 of the A. C. S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and in D. Fleisher, S. Ramon and H. Barbra"Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which are incorporated herein by reference. Esters may be active in their own right and/or be hydrolysable under in vivo conditions in the human body. Suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.
The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be solvate, eg. as the hydrate. This invention includes within its scope stoichiometric solvates (eg. hydrates) as well as compounds containing variable amounts of solvent (eg. water).
Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e. g. diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof. Preferably, compounds of formula (I) are in the form of a single enantiomer of formula (la) : (la) The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention.
A process according to the invention for preparing a compound of formula (I) which comprises: (a) reacting a compound of formula (II)
(II) or an activated and optionally protected derivative thereof wherein R', m, X, p, R2a, n, R2b and R3 are as defined above, with a compound of formula (III) (111) wherein R4 and R5 are as defined above; or (b) preparing a compound of formula (I) which comprises reductive amination of a compound of formula (IV) (IV) wherein R', m, X, p, R2a, n, R2b, R3 and R4 are as defined above, with an appropriate aldehyde or ketone; or (c) deprotecting a compound of formula (I) which is protected; and optionally thereafter (d) interconversion of compounds of formula (I) to other compounds of formula (I).
Process (a) typically comprises the use of water soluble carbodiimide, HOBT and a suitable base such as tertiary alkylamine or pyridine in a suitable solvent such as DMF and at a suitable temperature, eg. between 0°C and room temperature.
Process (b) typically comprises the use of sodium borohydride triacetate in the presence of a suitable solvent, such as ethanol and dichloromethane and at a suitable temperature, e. g. between 0°C and room temperature.
In process (c), examples of protecting groups and the means for their removal can be found in T. W. Greene and P. G. M. Wuts'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 3rd Ed. 1999). Suitable amine protecting groups include aryl sulphonyl (e. g. tosyl), acyl (e. g. acetyl), carbamoyl (e. g. benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e. g. benzyl), which may be removed by hydrolysis or hydrogenolysis as appropriate. Other suitable amine protecting groups include trifluoroacetyl (-COCF3) which may be removed by base catalysed hydrolysis. Suitable hydroxy protecting groups would be silyl based groups such as t- butyldimethylsilyl, which may be removed using standard methods, for example use of an acid
such as trifluoroacetic or hydrochloric acid or a fluoride source such as tetra n- butylammonium fluoride.
Process (d) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, aromatic substitution, ester hydrolysis, amide bond formation or removal and sulphonylation. An example of such an interconversion reaction may include interconversion of a compound of formula (I) wherein R3 represents a C2 6 alkenyl containing group to a corresponding compound of formula (I) wherein R3 represents a Ci. alkyl containing group, using standard hydrogenation or reductive conditions. A further example of such an interconversion reaction may include interconversion of a compound of formula (I) wherein R3 represents-C16 alkyl-N3 to a corresponding compound of formula (I) wherein R3 represents-C16 alkyl-NH2, using standard hydrogenation or reductive conditions.
A yet further example of such an interconversion reaction may include interconversion of a compound of formula (I) wherein R3 represents a nitro group to a corresponding compound of formula (I) wherein R3 represents NH2, using standard hydrogenation or reductive conditions.
Compounds of formula (II) or activated and optionally protected derivatives thereof may be prepared in accordance with the following process: wherein R2a, n, R2b, R3, p, X, R'and m are as defined above and L1 and 2 independently represent a suitable leaving group such as a halogen atom (eg. iodine, chlorine or bromine).
Step (i) typically comprises the use of a suitable solvent such as dichloromethane and a suitable base such as triethylamine.
Step (ii) typically comprises the use of sodium hydride in the presence of a suitable solvent such as tetrahydrofuran under nitrogen.
Compounds of formula (II) or activated and optionally protected derivatives thereof may also be prepared in accordance with the following process:
2a 0 1--X 2. 0 (R) m Step (i) N R2bt P I OH ' \ MLJ (V) (R1) m (I ) 3 nu 3 R p (Vill) R wherein R", n, R, R, p, X, R'and m are as defined above and L'represents a suitable leaving group such as a halogen atom (eg. iodine, chlorine or bromine).
Step (i) typically comprises the use of caesium carbonate, 4,5-bis (diphenylphosphino)-9, 9- dimethylxanthene and a suitable catalyst such as tris (dibenzylideneacetone) dipalladium (0) under suitable conditions such as reflux under argon in the presence of a suitable solvent such as dioxan.
Compounds of formula (III) may be prepared in accordance with the following process: R4 FR7 St P/Rs St H\/Rs H 0 H OH H H OH H (IX) (X) (111) wherein R4 and R5 are as defined above and P'represents a suitable amine protecting group, such as t-butoxycarbonyl.
Step (i) typically comprises the reaction of a compound of formula (IX) with a compound of formula NH2R5 in the presence of a suitable solvent, e. g. ethanol at a suitable temperature, e. g. reflux.
Step (ii) typically comprises the use of suitable deprotection reactions as described above for process (c), eg. when P'represents t-butoxycarbonyl, deprotection typically comprises the use of trifluoroacetic acid in the presence of a suitable solvent, such as dichloromethane at a suitable temperature, e. g. between 0°C and room temperature.
Compounds of formula (IV) may be prepared in accordance with the following process: Ra Ra Ra Step (i) Step (ii) 2 H 0 H OH H H OH H (IX) (X) a (Xl) Step (iii) i (R1) m N (R) Pz Step (iV) H Pz -ici' 2b H OH H IN OH H R3 (Xlil) (ill) Ru Step (v) O ra (R) (R 2a)"0 R \I \I/ Rzb/H OH H R (IV)
wherein R', m, X, p, R2a, n, R2b, R3, R4 and P'are as defined above and p2 represents a suitable amine protecting group different to P1, such as-COOCH2-phenyl.
Step (i) typically comprises the reaction of a compound of formula (IX) in aqueous ammonia in the presence of a suitable solvent, e. g. ethanol at a suitable temperature, e. g. reflux.
When p2 represents-COOCH2-phenyl, step (ii) typically comprises the use of CICOOCH2- phenyl in the presence of a suitable base, e. g. triethylamine, a suitable solvent, e. g. dimethylformamide at a suitable temperature, e. g. between 0°C and room temperature.
Step (iii) typically comprises the use of suitable deprotection reactions as described above for process (c), eg. when p1 represents t-butoxycarbonyl, deprotection typically comprises the use of trifluoroacetic acid in the presence of a suitable solvent, such as dichloromethane at a suitable temperature, e. g. between 0°C and room temperature.
Step (iv) typically comprises reacting a compound of formula (XII) with a compound of formula (II) in the presence of water soluble carbodiimide and HOBT.
Step (iv) typically comprises the use of suitable deprotection reactions as described above for process (c), eg. when p2 represents-COOCH2-phenyl, deprotection typically comprises the use of a suitable catalyst, eg. palladium in the presence of a suitable solvent, e. g. water and
ethanol and in the presence of a suitable hydrogen source, e. g. ammonium formate at a suitable temperature, eg. 60°C.
Compounds of formula (V) are either commercially available or may be prepared by interconversion of commercially available compounds of formula (V).
Compounds of formula (VI), (VIII) and (IX) are either known or may be prepared in accordance with known procedures.
As a further aspect of the invention there is thus provided a compound of formula (I) or a pharmaceutical acceptable salt or solvate thereof for use as a pharmaceutical, particularly in the treatment of patients with diseases characterised by elevated ß-amyloid levels or i- amyloid deposits.
According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of patients with diseases characterised by elevated ß-amyloid levels or ß-amyloid deposits.
In a further or alternative aspect there is provided a method for the treatment of a human or animal subject with diseases characterised by elevated ß-amyloid levels or ß-amyloid deposits, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.
As a further aspect of the invention there is thus provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of diseases characterised by elevated ß-amyloid levels or ß-amyloid deposits.
It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of diseases characterised by elevated ß-amyloid levels or P-amyloid deposits.
The compounds according to the invention may be formulated for administration in any convenient way, and the invention therefore also includes within its scope pharmaceutical compositions for use in the therapy of diseases characterised by elevated ß-amyloid levels or p-amyloid deposits, comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together, if desirable, with one or more physiologically acceptable diluents or carriers.
It will be appreciated that diseases characterised by elevated ß-amyloid levels or ß-amyloid deposits include Alzheimer's disease, mild cognitive impairment, Down's syndrome, hereditary cerebral haemorrhage with ß-amyloidosis of the Dutch type, cerebral ß-amyloid angiopathy
and various types of degenerative dementias, such as those associated with Parkinson's disease, progressive supranuclear palsy, cortical basal degeneration and diffuse Lewis body type of Alzheimer's disease.
Most preferably, the disease characterised by elevated ß-amyloid levels or ß-amyloid deposits is Alzheimer's disease.
There is also provided a process for preparing such a pharmaceutical formulation which comprises mixing the ingredients.
Compounds of formula (I) may be used in combination with other therapeutic agents. Suitable examples of such other therapeutic agents may be acetylcholine esterase inhibitors (such as tetrahydroaminoacridine, donepezil hydrochloride and rivastigmine), gamma secretase inhibitors, anti-inflammatory agents (such as cyclooxygenase 11 inhibitors), antioxidants (such as Vitamin E and ginkolidesor), statins or p-glycoprotein (P-gp) inhibitors (such as cyclosporin A, verapamil, tamoxifen, quinidine, Vitamin E-TGPS, ritonavir, megestrol acetate, progesterone, rapamycin, 10,11-methanodibenzosuberane, phenothiazines, acridine derivatives such as GF120918, FK506, VX-710, LY335979, PSC-833, GF-102 and 918).
When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.
The compounds according to the invention may, for example, be formulated for oral, inhaled, intranasal, buccal, enteral, parenteral, topical, sublingual, intrathecal or rectal administration, preferably for oral administration.
Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, cellulose or polyvinyl pyrrolidone ; fillers, for example, lactose, microcrystalline cellulose, sugar, maize-starch, calcium phosphate or sorbitol ; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica ; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate ; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol ; or preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The
preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e. g. mannitol) as appropriate.
For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.
The compounds may also be formulated as suppositories, e. g. containing conventional suppository bases such as cocoa butter or other glycerides.
The compounds according to the invention may also be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi- dose containers with an added preservative. The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or tonicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e. g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.
When the compounds of the invention are administered topically they may be presented as a cream, ointment or patch.
The composition may contain from 0. 1 % to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 3000 mg; and such unit doses may be administered more than once a day, for example one, two, three or four times per day (preferably once or twice); and such therapy may extend for a number of weeks, months or years.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
Examples Preparation of Intermediates Description 1 3-Amino-5-nitro-benzoic acid methyl ester (D1) To a solution of 3-amino-5-nitro-benzoic acid (65 g, 357 mmol, 1 equiv) in MeOH (650 ml) at 0 C was added SOCI2 dropwise (39 ml, 536 mmol, 1.5 equiv). The resulting solution was
allowed to warm to room temperature and stirred for 16 h. A further portion of SOCI2 (10 ml, 137 mmol, 0.4 equiv) was added dropwise and the solution was stirred at room temperature for 5 h, at 50 C for 2 h and then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. The solid residue was triturated with AcOEt/iso-hexane to give 3-amino-5-nitro-benzoic acid methyl ester (D1) (55 g, 78%) as a pale yellow solid.
Description 2 3- (4-Chloro-butanoylamino)-5-nitro-benzoic acid methyl ester (D2) To a solution of 3-amino-5-nitro-benzoic acid methyl ester (D1) (38 g, 194 mmol, 1 equiv) in CH2CI2 (350 ml) was added NEt3 (32 ml, 230 mmol, 1.2 equiv) followed by 4-chlorobutyryl chloride (24.7 mi, 220 mmol, 1.13 equiv) dropwise over 20 mn. The resulting mixture was allowed to warm to room temperature and stirred for 30 min. The organic phase was then washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with iso-hexane and Et20 to give 3- (4-chloro-butanoylamino)-5-nitro- benzoic acid methyl ester D2 (56 g, 96%) as a brown solid.
Description 3 3- (5-Chloro-pentanoylamino)-5-nitro-benzoic acid methyl ester (D3) 5-Chlorovaleryl chloride (2.64 g, 17 mmol, 1.1 equiv) in CH2CI2 (5 ml) was added over 2 min to a stirred solution of 3-amino-5-nitro-benzoic acid methyl ester (D1) (3 g, 15.3 mmol, 1 equiv) and NEt3 (2.6 ml, 18 mmol, 1.2 equiv) in CH2CI2 (30 ml). The resulting mixture was stirred for 1 h at room temperature then washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with CH2CI2 to give 3- (5-Chloro- pentanoylamino)-5-nitro-benzoic acid methyl ester D3 (6g, 112%) as a brown oil.
Description 4a 3-Amino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) A flask was charged with 3-nitro-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B27) (5 g, 19 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 750 mg, 7.5% w/w), NH4COOH (11.9 g, 190 mmol, 10 equiv) H20 (30 ml) and MeOH (60 ml). The resulting mixture was stirred at 50°C for 1.5 h, cooled to room temperature and the catalyst was filtered off through a pad of celite. Most of the MeOH was removed in vacuo and the residue diluted with saturated aqueous NaHC03 solution. The aqueous phase was extracted twice with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give an off white solid. The catalyst was then washed three times with DMF and the combined organic phases concentrated in vacuo. The residue was combined with the material obtained previously and was triturated with Et20 to give amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (3.9 g, 88%) as a white solid which was used in the next step without further purification.
Description 4a (Alternative Procedure)
3-Amino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) To a solution of 3-amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (D6) (2.2 g, 10 mmol, 1 equiv) in MeOH/Et2O (1: 1,20 ml) was added 1- (3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (2.3 g, 12 mmol, 1.2 equiv), DMAP (112 mg, 1 mmol, 0.1 equiv) and the resulting mixture was stirred at room temperature for 16 h then diluted with AcOEt. The organic phase was washed with saturated aqueous NaHCO3 solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3-amino-5- (2-oxo- pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (1.6 g, 68%) as a white solid.
Description 4b 3-Amino-5- (2-oxo-piperidin-1-yi)-benzoic acid methyl ester (D4b) Description 4b was prepared in an analogous manner to Description 4a from 3-nitro-5- (2-oxo- piperidin-1-yl)-benzoic acid methyl ester (B82).
Description 5 3-Bromo-5-nitro-benzoic acid (D5) To a solution of 3-amino-5-nitro-benzoic acid (17.6 g, 96.6 mmol, 1 equiv) in 48% aqueous HBr solution (180 ml) at 0°C was added portionwise NaNO2 (8.67 g, 126 mmol, 1.3 equiv) over 20 min. The temperature was kept below 8 C during this addition. The resulting mixture was then added to a suspension of CuBr (9.7 g, 67.6 mmol, 0.7 equiv) in 48% aqueous HBr solution (50 ml) at 65 C over 40 min. The temperature was kept above 60C during the addition. The resulting mixture was stirred at 70 C for 45 min, cooled to room temperature and diluted with 1L of water. The aqueous phase was extracted three times with Et20. The combined organic layers were washed twice with H2O, dried over MgS04 and concentrated in vacuo to give 3-bromo-5-nitro-benzoic acid (D5) (21 g, 88%) as a brown solid. [M-H]-= 245.7, RT = 2.82 min Description 6 3-Amino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (D6) To a solution of 3-nitro-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A27) (4 g, 16 mmol, 1 equiv) in MeOH/H20 (9: 1,40 ml) was added 10% palladium on charcoal (50% wet, 800 mg, 0.1 equiv w/w). The resulting mixture was stirred for 6 h at atmospheric pressure under an atmosphere of hydrogen. The catalyst was removed by filtration through a pad of celite and the solvent was removed in vacuo. The residue was dried at 60°C under vacuum for 16 h to give 3-amino- 5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (D6) (3.34 g, 15.2 mmol, 95%) as a pale brown solid.
[M-H]-= 218.8, RT = 1.86 min Description 7 3-Bromo-5-iodo-benzoic acid (D7) Description 7 is commercially available from Avocado Research Chemicals Ltd.
Description 8a 3-Bromo-5-iodo-benzoic acid methyl ester (D8a)
To a solution of 3-bromo-5-iodo-benzoic acid (D7) (14.6 g, 44.7 mmol, 1 equiv) in MeOH (150 ml) at 0 C was added SOCS (3.9 ml, 53.6 mmol, 1.2 equiv). The resulting solution was refluxed for 2 h, cooled to room temperature and concentrated in vacuo. The residue was diluted with AcOEt and washed twice with 2N aqueous NaOH solution then brine, dried over MgS04 and concentrated in vacuo to give 3-bromo-5-iodo-benzoic acid methyl ester (D8a) (14.8 g, 97%) as a pale brown solid.
Description 8b 3-Bromo-5-iodo-benzoic acid tert-butyl ester (D8b) To a solution of 3-bromo-5-iodo-benzoic acid (D7) (50 g, 153 mmol, 1 equiv) in CH2CI2 (500 ml) was added 1- (3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (30.8 g, 160 mmol, 1.05 equiv), DMAP (14 g, 114 mmol, 0.75 equiv) and tert butanol (90 ml, 917 mmol, 6 equiv). The resulting mixture was stirred at room temperature for 48 h. DMAP (4.67 g, 38 mmol, 0.25 equiv) was then added and the solution was stirred for another 24 h then concentrated in vacuo. The residue was dissolved in AcOEt and washed sequentially with 2N aqueous HCI solution, 1 N aqueous NaOH solution and brine, dried over MgS04 and concentrated in vacuo to give 3-bromo-5-iodo-benzoic acid tert-butyl ester (D8b) (50.6 g, 86%) as a brown solid.
Description 8b (Alternative Procedure) 3-Bromo-5-iodo-benzoic acid tert-butyl ester (D8b) To a solution of 3-bromo-5-iodo-benzoic acid (D7) (50 g, 153 mmol, 1 equiv) in CH2CI2 (500 mi) was added 1- (3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (30.8 g, 160 mmol, 1.05 equiv), DMAP (14 g, 114 mmol, 0.75 equiv) and tert-butanol (90 ml, 917 mmol, 6 equiv). The resulting mixture was stirred at room temperature for 48 h then DMAP (4.67 g, 38 mmol, 0.25 equiv) was added, and the solution was stirred for another 24 h then concentrated in vacuo. The residue was diluted with AcOEt and washed sequentially with 2N aqueous HCI solution, 1 N aqueous NaOH solution and brine, dried over MgS04 and concentrated in vacuo to give 3-bromo-5-iodo-benzoic acid tert-butyl ester (D8b) (50.6 g, 86%) as a brown solid.
Description 9a 3-Bromo-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester D9a A flask was charged under nitrogen with 3-bromo-5-iodo-benzoic acid methyl ester (D8a) (14.8 g, 43.4 mmol, 1 equiv), Cs2CO3 (21 g, 65 mmol, 1.5 equiv), tris (dibenzylideneacetone) dipalladium (0) (794 mg, 0.87 mmol, 0.02 equiv), Xantphos (1.5 g, 2.6 mmol, 0.06 equiv) and dioxan (150 ml). Pyrrolidin-2-one (5 ml, 5.54 mmol, 1.5 equiv) was then added via syringe and the resulting mixture was stirred at 55 C for 5 days then cooled to room temperature and concentrated in vacuo. The residue was partitioned between H2O and AcOEt and the aqueous phase was re-extracted with AcOEt. The combined organic solutions were dried over MgS04 and concentrated in vacuo to give a solid residue. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 4/1 to 1/1) gave 3-bromo- 5- (2-oxo-pyrrolidin-1-yi)-benzoic acid methyl ester (D9a) (6.4 g, 50%) as a white solid. [M+H] + = 299.9, RT = 2.95 min
Description 9a (Alternative Procedure) 3-Bromo-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D9a) To a solution of 3-bromo-5- (4-chloro-butanoylamino)-benzoic acid methyl ester (D13) (530 mg, 1.6 mmol, 1 equiv) in THF (5 ml) at room temperature was added NaH (60% in mineral oil, 64 mg, 1.7 mmol, 1.1 equiv) and the resulting mixture was stirred at room temperature for 2 h. H20 was then added and the resulting mixture was diluted with AcOEt. The two layers were separated and the organic phase dried over MgS04 and concentrated in vacuo to give 3- bromo-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid methyl ester (D9a) (361 mg, 76%) as a yellow solid. [M-H]-= 296.3, RT = 2.49.
Description 9b 3-Bromo-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D9b) A flask was charged under nitrogen with bromo-5-iodo-benzoic acid terf-butyl ester (D8b) (11.5 g, 30 mmol, 1 equiv), Cs2CO3 (13.7 g, 42 mmol, 1.5 equiv), tris (dibenzylideneacetone) dipalladium (0) (549 mg, 0.6 mmol, 0.02 equiv), Xantphos (1.04 g, 1.8 mmol, 0.06 equiv) and dioxan (100 ml). Pyrrolidin-2-one (2.5 ml, 33 mmol, 1.1 equiv) was then added via syringe and the resulting mixture was stirred at 60 C for 60 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between H2O and AcOEt and the aqueous phase re-extracted with AcOEt. The combined organic solutions were dried over MgS04 and concentrated in vacuo to give a solid residue which was triturated with Et20 to give 3-bromo-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D9b) (6.63 g, 65%) as an off white solid. The filtrate was concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 4/1 to 1/1) gave a further 1.46g (14%) of 3-bromo-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid tert-butyl ester (D9b) as a white solid.
[M+H-tBu)] + = 285.9, RT = 3.46 min Description 10 3-Bromo-5-(2-oxo-piperidin-1-yl)-benzoic acid tert-butyl ester (D10) A flask was charged under nitrogen with 3-bromo-5-iodo-benzoic acid tert-butyl ester (D8b) (6.42 g, 16.7 mmol, 1 equiv), Cs2C03 (7.6 g, 23.4 mmol, 1.4 equiv), tris (dibenzylideneacetone) dipalladium (0) (307 mg, 0.33 mmol, 0.02 equiv), Xantphos (578 mg, 1 mmol, 0.06 equiv) and dioxan (120 ml). 8-Valerolactam (1.9 ml, 20 mmol, 1.2 equiv) was then added via syringe and the resulting mixture was stirred at 60°C for 40 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between H20 and AcOEt and the aqueous phase was re-extracted with AcOEt. The combined organic solutions were dried over MgS04 and concentrated in vacuo Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 3/1 to 1/1) gave 3-bromo-5- (2-oxo-piperidin-1-yl)-benzoic acid tert-butyl ester (D10) (4 g, 68%) as a white solid. RT = 2.88 min Description 11 3-Bromo-5-nitro-benzoic acid methyl ester (D11)
To a solution of 3-bromo-5-nitro-benzoic acid (D5) (22.3 g, 90.6 mmol, 1 equiv) in MeOH (300 ml) at 0°C was added SOCI2 (7.9 ml, 108 mmol, 1.2 equiv) dropwise. The resulting solution was stirred at reflux for 4 hours then cooled to room temperature and concentrated in vacuo.
The residue was diluted with AcOEt, washed twice with 2N aqueous NaOH solution and once with brine, dried over MgS04 and concentrated in vacuo to give 3-bromo-5-nitro-benzoic acid methyl ester (D11) (22.1 g, 94%) as a pale brown solid. RT = 3.18 min Description 11 (Alternative Procedure) 3-Bromo-5-nitro-benzoic acid methyl ester (D11) To an ice cold solution of 3-bromo-5-nitro-benzoic acid (D5) (2.5 g, 10 mmol, 1 equiv) in MeOH (25 mi) was added SOCS (1 ml, 15 mmol, 1.5 equiv) dropwise. The resulting solution was allowed to warm to room temperature and was then stirred at 60°C for 3 h, cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic layer was washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give 3-bromo-5-nitro-benzoic acid methyl ester (D11) (2.6 g, 100%) as a yellow solid. RT = 3.22 min Description 12 3-Amino-5-bromo-benzoic acid methyl ester (D12) To a solution of 3-bromo-5-nitro-benzoic acid methyl ester (D11) (12.1 g, 46.5 mmol, 1 equiv) in MeOH (200 ml) was added SnCI2 (44 g, 233 mmol, 5 equiv). The resulting mixture was stirred at reflux for 4 h, cooled to room temperature and concentrated in vacuo. The residue was partitioned between ice-cold AcOEt and H2O. The aqueous phase was basified with 2N aqueous NaOH solution until a white precipitate appeared, then slowly with 12.5N aqueous NaOH solution until this precipitate disappeared. The temperature was kept below 10 C during this addition. The two layers were separated and the aqueous phase extracted with AcOEt.
The combined organic layers were washed with brine, dried over MgS04 and concentrated in vacuo to give 3-amino-5-bromo-benzoic acid methyl ester (D12) (9.9 g, 93%) as a brown solid.
Description 13 3-bromo-5- (4-chloro-butanoylamino)-benzoic acid methyl ester (D13) To a solution of 3-amino-5-bromo-benzoic acid methyl ester (D12) (460 mg, 2.0 mmol, 1 equiv) in CH2CI2 (10 mi) at room temperature was added NEt3 (306 gui, 2.2 mmol, 1.1 equiv) then 4-chlorobutyrylchloride (247, ul, 2.2 mmol, 1.1 equiv). The resulting mixture was stirred at room temperature for 16 h and then diluted with AcOEt. The organic phase was washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo to give 3-bromo-5- (4- chloro-butanoylamino)-benzoic acid methyl ester (D13) (530 mg, 79 %) as a pale yellow oil.
RT = 2.88 s Description 14 3- (3-Chloro-propane-1-sulfonylamino)-5-nitro-benzoic acid methyl ester (D14)
To a solution of 3-amino-5-nitro-benzoic acid methyl ester (D1) (45 g, 229 mmol, 1 equiv) in CH2CI2 (450 mi) was added pyridine (18.5 ml, 229 mmol, 1 equiv), DMAP (100 mg, 0.8 mmol, catalytic) and 3-chloropropanesulfonyl chloride (28 ml, 230 mmol, 1 equiv). The resulting mixture was stirred for 40 h then diluted with AcOEt. The organic phase was diluted with 2N aqueous HCI solution. The resulting solid was filtered to give 3- (3-chloro-propane-1- sulfonylamino)-5-nitro-benzoic acid methyl ester (23 g, 32%). The filtrate was separated and the organic phase was washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with AcOEt and iso-hexane to give a further 50 g (65%) of 3- (3-chloro-propane-l-sulfonylamino)-5-nitro-benzoic acid methyl ester (D14) as a pale brown solid. [M-H]-= 334.9, RT = 3.11 min Description 15 3-(1, 1-Dioxo-1t-isothiazolidin-2-yl)-5-nitro-benzoic acid methyl ester (D15) To a solution of 3- (3-chloro-propane-1-sulfonylamino)-5-nitro-benzoic acid methyl ester (D14) (73g, 217 mmol, 1 equiv) in EtOH (600 mi) was added Et3N (60 ml, 430 mmol, 2 equiv) and the resulting mixture was refluxed for 3 h, cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt, washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with iso-hexane and AcOEt to give 3-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-5-nitro-benzOic acid methyl ester (D15) (58 g, 88%) as a pale brown solid. [M+H+NH3] + = 318.0, RT = 2.78 min Description 15 (Alternative Procedure) 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-nitro-benzoic acid methyl ester (D15) A 50 ml flask was charged under nitrogen with 3-bromo-5-nitro-benzoic acid methyl ester (D11) (1 g, 3.8 mmol, 1 equiv), Cs2CO3 (536 mg, 4.4 mmol, 1.2 equiv) tris (dibenzylideneacetone) dipalladium (0) (5 mg, 0.0055 mmol, 0.0154 equiv), Xantphos (10 mg, 0.014 mmol, 0.04 equiv) and toluene (15 ml). Isothiazolidine 1,1-dioxide (D22a) (536 mg, 4.4 mmol, 1.1 equiv) was then added and the resulting mixture was stirred at 90°C for 16 hours then cooled to room temperature and diluted with H20 and AcOEt. The layers were separated, the aqueous phase diluted with a saturated aqueous NaHC03 solution and extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give 3- (1, 1-dioxo-116-isothiazolidin-2-yl)-5-nitro-benzoic acid methyl ester (D15) (187 mg, 16%) as a yellow solid. [M+H+NH3] + = 318.0, RT = 2. 81 min Description 16 3-Amino-5-(1, 1-dioxo-1t-isothiazolidin-2-yl)-benzoic acid methyl ester (D16) A flask was charged with 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-nitro-benzoic acid methyl ester (D15) (25 g, 83 mmol, 1 equiv) and 10% palladium (0) on charcoal (50% wet, 5 g, 10% w/w) and EtOH (500 ml). The resulting suspension was stirred under an atmosphere of hydrogen (atmospheric pressure) for 4 h and the catalyst was filtered off through a pad of celite. The catalyst was washed three times with DMF and the combined organic layers were concentrated in vacuo. The residue was dissolved in AcOEt and filtered again through celite
in order to remove residual catalyst. The organic phase was concentrated in vacuo. The residue was triturated with Et20 to give 3-amino-5-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-benzoic acid methyl ester (D16) (18 g, 80%) as a pale brown solid. [M+H] + = 271.0, RT = 2.16 min Description 17 3-Bromo-5-(1, 1-dioxo-1 t-isothiazolidin-2-yl)-benzoic acid ter-butyl ester (D17) A flask was charged under nitrogen with 3-bromo-5-iodo-benzoic acid tert-butyl ester D8b (1 g, 2.6 mmol, 1 equiv), Cs2CO3 (1.26 g, 3.9 mmol, 1.5 equiv), tris (dibenzylideneacetone) dipalladium (0) (12 mg, 0.013 mmol, 0.005 equiv), Xantphos (22 mg, 0.038 mmol, 0.015 equiv) and toluene (20 ml). Isothiazolidine 1,1-dioxide (D22a) (350 mg, 2.9 mmol, 1.1 equiv) was then added and the resulting mixture was stirred at 100°C for 16 h then cooled to room temperature and diluted with AcOEt. The organic phase was washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3-bromo-5-(1, 1-dioxo-116-isothiazolidin-2-yl)-benzOic acid tert-butyl ester (D17) (350 mg 38%) as a white solid.
Description 18 3-bromo-5-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-benzoic acid ter-butyl ester (D18) Description 18 was prepared in an analogous manner to Description 17b from 3-bromo-5- iodo-benzoic acid tert-butyl ester (D8b) (5.2 g, 13.6 mmol) and [1,2] thiazinane 1,1-dioxide (D22b) which gave the title compound (D18) (1.8 g, 34%) as a pale yellow solid.
[M+H-tert-Bu]+ = 335.9, RT = 3.26 min Description 19 3-Bromo-5- (3-chloro-propane-1-sulfonylamino)-benzoic acid methyl ester (D19) To a solution of 3-amino-5-bromo-benzoic acid methyl ester (D12) (2.3 g, 10 mmol, 1 equiv) in CH2CI2 (30 ml) was added pyridine (1.6 ml, 20 mmol, 2 equiv), DMAP (320 mg, 2.5 mmol, 2.5 equiv) and 3-chlorosulphonyl chloride (1.46 ml, 12 mmol, 1.2 equiv) dropwise. The resulting mixture was stirred at room temperature for 16 h then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase washed sequentially with 2N aqueous HCI solution, saturated aqueous NaHC03 solution and brine, dried over MgS04 and concentrated in vacuo to give 3-bromo-5- (3-chloro-propane-1-sulfonylamino)-benzoic acid methyl ester (D19) (3.36 g, 91%) as a red solid.
[M-H]-= 369.9, RT = 3.25 min Description 20 4-Chloro-1-butanesulfonyl chloride (D20) To a mixture of [1,2] oxathiane 2,2-dioxide (D23) (50 g, 367 mmol, 1 equiv) and SOCS (29 ml, 401 mmol, 1.1 equiv) was added DMF (4 mi, 51.6 mmol, 0.14 equiv). The resulting mixture was stirred under nitrogen at 70 C for 3 days. A second portion of SOC12 (10 ml, 137 mmol, 0. 37 equiv) was added. The mixture was stirred at 70 C for another 3 days and then cooled to room temperature and concentrated in vacuo. The residue was diluted with toluene then
concentrated in vacuo. This procedure was repeated and the residue was dried under vacuum for 16 h to give crude 4-chloro-1-butanesulfonyl chloride (D20) (63 g, 90%).
Description 21 a 3-Chloro-1-propanesulfonamide (D21a) To an ice-cooled solution of 3-chloro-1-propanesulfonyl chloride (Chem. Pharm. Bull, 40 (1), 75-84,1999) (30 ml, 250 mmol, 1 equiv) in CH2CI2 (150 ml) was slowly added aqueous ammonia solution (32%, 30 ml). The resulting mixture was stirred at room temperature for 16 h and H20 (20 mi) was added. The layers were separated and the organic layer was dried over MgS04 and concentrated in vacuo to give crude 3-chloro-1-propanesulfonamide (D21a) (27 g, 69%) as a white solid Chem. Pharm. Bull, 40 (1), 75-84,1999].
Description 21 b 3-Chloro-1-butanesulfonamide (D21 b) To an ice-cooled solution of 4-chloro-1-butanesulfonyl chloride (D20) (43 g, 225 mmol, 1 equiv) in CH2CI2 (350 ml) was slowly added aqueous ammonia solution (25%, 140 ml). The resulting mixture was stirred at room temperature for 16 h then concentrated in vacuo. The residue was diluted with AcOEt and washed with brine. The organic phase was dried over MgS04 and concentrated in vacuo to give crude 3-chloro-1-butanesulfonamide (D21b) (31g, 88%).
Description 22a Isothiazolidine 1,1-dioxide (D22a) To a solution of 3-chloro-1-propanesulfonamide (D21a) (27 g, 170 mmol, 1 equiv) in EtOH (250 mi) at room temperature was added NaOEt (11.7 g, 170 mmol, 1 equiv). The resulting mixture was refluxed for 5 h then cooled to room temperature and concentrated in vacuo. The residual solid was extracted thoroughly with CH2CI2 and the extracts were concentrated in vacuo to give isothiazolidine 1,1-dioxide (D22a) (20 g, 100%).
Description 22b [1,2] Thiazinane 1,1-dioxide (D22b) To a solution of 3-chloro-1-butanesulfonamide (D21b) (31 g, 200 mmol, 1 equiv) in EtOH (500 ml) at room temperature was added NaOEt (14.9 g, 220 mmol, 1.1 equiv). The resulting mixture was refluxed for 5 h then cooled to room temperature and concentrated in vacuo. The residual solid was extracted thoroughly with CH2CI2 and the extracts were concentrated in vacuo. The residual solid was triturated with Et20 to give [1,2] thiazinane 1,1-dioxide (D22b) (18.7 g, 69%) as a pale brown solid.
Description 23 4-chloro-3, 5-dinitrobenzoic acid (D23) Description 23 is commercially available from Sigma-Aldrich Company.
Description 24
4-Methoxy-3,5-dinitro-benzoic acid (D24) To a solution of KOH (1.12 g, 20 mmol, 1 equiv) in MeOH (20 ml) at 0C was added portionwise 4-chloro-3, 5-dinitrobenzoic acid (D23) (4.93 g, 20 mmol, 1 equiv). The resulting mixture was refluxed for 1 h then cooled to room temperature. A second portion of KOH (1.12 g, 20 mmol, 1 equiv) was added and the mixture refluxed for 90 min, cooled to room temperature and diluted with H2O. The aqueous phase was acidified to pH 1 and extracted with AcOEt. The organic phase was dried over MgS04 and concentrated in vacuo to give crude 4-methoxy-3,5-dinitro-benzoic acid (D24) (4.49 g, 93%) as a light brown solid.
Description 25 4-Methoxy-3,5-dinitro-benzoic acid methyl ester (D25) To a solution of crude 4-methoxy-3,5-dinitro-benzoic acid (D24) (4.43 g, 17.3 mmol, 1 equiv) in MeOH (60 ml) was added concentrated H2SO4 (4 ml). The resulting mixture was refluxed for 3 h, cooled to room temperature and concentrated in vacuo. The residue was partitioned between H20 and AcOEt. The two layers were separated and the organic phase was washed with saturated aqueous NaHCO3 solution, dried over MgS04 and concentrated in vacuo.
Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 85/15) gave 4- methoxy-3,5-dinitro-benzoic acid methyl ester (D25) (2.84 g, 65%) as an off white solid.
The following descriptions were prepared in an analogous manner to Description 25 from commercially available starting materials: Description Starting material 4-Chloro-3, 5-dinitro-benzoic acid methyl ester (D25a) D24a 3-Amino-4-chloro-benzoic acid methyl ester (D27c) D26 Description 27a 3, 5-Diamino-4-chloro-benzoic acid methyl ester (D27a) A mixture of 4-chloro-3, 5-dinitro-benzoic acid methyl ester (D25a) (2.6 g, 10 mmol, 1 equiv) and SnCI2 (18.95 g, 100 mmol, 10 equiv) in MeOH (80 ml) was refluxed for 1 h, cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and 2N aqueous NaOH solution. The organic phase was dried over MgS04 and concentrated in vacuo. The residue was triturated with 1: 1 Et2O/iso-hexane to give 3, 5-diamino-4-chloro- benzoic acid methyl ester (D27a) (1.56 g, 78%) as a light orange solid.
The following Description was prepared in an analogous manner to Description 27a (using 5 equivalents of SnCI2 for nitroaryls and 10 equivalents for bis nitroaryls) from the starting material indicated in the hPlnw tahlP | Description | Starting material 3, 5-Diamino-4-methox-benzoic acid methyl ester (D27b) D25b Description 28c 4-Chloro-3- (4-chloro-butanoylamino)-benzoic acid methyl ester (D28c)
4-Chlorobutyryl chloride (2.82 g, 20 mmol, 2.0 equiv) in CH2CI2 (5 ml) was added over 2 min to a stirred solution of 3-amino-4-chloro-benzoic acid methyl ester (D27c) (1.66 g, 10 mmol, 1 equiv) and NEt3 (2.22 g, 22 mmol, 2.2 equiv) in CH2CI2 (40 ml). The resulting mixture was stirred for 1 h at room temperature then washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with CH2CI2to give 4-chloro-3- (4-chloro-butanoylamino)-benzoic acid methyl ester (D28c) (1.81 g, 48%) as a pale pink solid.
The following Descriptions were prepared in an analogous manner to the process described in D28c from the starting material indicated in the below table : Description Precursor 4-Chloro-3, 5-bis- 4-chloro-butanoylamino)-benzoic acid methyl ester (D28a) D27a 3, 5-Bis- (4-chloro-butanoylamino)-4-methoxy-benzoic acid methyl ester (D28b) D27b Description 30 (Benzyl-ethyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D30) A flask was charged under nitrogen with 3-bromo-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid test- butyl ester (D9b) (4.6 g, 13 mmol, 1 equiv), sodium tert-butoxide (1.9 g, 19.5 mmol, 1.5 equiv), tris (dibenzylideneacetone) dipalladium (0) (395 mg, 0.65 mmol, 0.05 equiv), 2- (dicyclohexylphosphino) biphenyl (341 mg, 0.97 mmol, 0.075 equiv) and toluene (100 ml). N- Ethylbenzylamine (2.9 mi, 19.5 mmol, 1.5 equiv) was then added via syringe and the resulting mixture was stirred at 90 C for 2 h then cooled to room temperature, diluted with H20 and AcOEt. The layers were separated, the aqueous phase diluted with saturated aqueous NaHC03 solution and extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 1/2) gave (benzyl-ethyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D30) (3 g, 60%) as a white solid.
[M+H] + = 395.0, RT = 3.70 min.
Descriptions 31-35 (D31-D35) Descriptions 31-35 were prepared in an analogous manner to D30 from the appropriate aryl bromide and amine starting materials listed in the below table : Description Aryl bromide Amine [M+H] + RT (min) (Benzyl-methyl-amino)-(2-oxo-pyrrolidin-1-D9b H 381. 1 3. 59 yl)-benzoic acid tert-butyl ester (D31) (Benzyl-methyl-amino)- (2-oxo-piperidin-1- D10 H 395. 2 3. 51 yl)-benzoic acid tert-butyl ester (D32) H (Benzyl-ethyl-amino)- (2-oxo-piperidin-1-yl)- D10 benzoic acid test-butyl ester (D33) v (Benzyl-methyl-amino)-(1, 1-dioxo-1/6-D17, N 417. 1 3. 51 isothiazolidin-2-yl)-benzoic acid tert-butyl ester D34 (Benzyl-ethyl-amino)- (1, 1-dioxo-If- D18 r 445. 2 3. 82 [1, 2] thiazinan-2-yl)-benzoic acid teint-butyl ester (D35)
Description 36 3-Hydroxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (D36) To a solution of 3-amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (D6) (280 mg, 1.25 mmol, 1 equiv) in a mixture of 2N aqueous HCI solution (2. 5ml) and MeOH (5ml) at 0 °C was added NaN3 (190 mg, 2.75 mmol, 2.2 equiv) portionwise over 20 min. H20 (5ml) was added and the resulting mixture was heated at 90°C for 1 h then cooled to room temperature and diluted with AcOEt. The two layers were separated and the aqueous phase was extracted twice with AcOEt (20 ml). The combined organic layers were washed with brine (20 ml), dried over MgS04 and concentrated in vacuo to give a crude product which was triturated with Et2O/MeOH to give 3-hydroxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (D36) (110 mg, 40%) as a light tan solid.
Description 37 3-Hydroxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D37) 3-Hydroxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (D36) (400 mg, 1.72 mmol, 1 equiv) was heated at reflux in a mixture of MeOH (20 ml) and concentrated H2SO4 (4 drops) for 7 h. The solution was then cooled to room temperature and concentrated in vacuo to give of 3- hydroxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D37) (300 mg, 74%) as a light brown solid.
Description 37 (Alternative Procedure) 3-Hydroxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D37) 3-Amino-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid methyl ester (D4a) (1.50 g, 6.4 mmol, 1 equiv) was dissolved in a mixture of 2N aqueous HCI solution (25 ml) and MeOH (50 ml) at 0 °C and treated portionwise with NaN3 (950 mg, 13.8 mmol, 2.2 equiv) over 20 min. H20 (50mi) was added and the resulting mixture was heated at 90 °C for 45 min then cooled to room temperature and diluted with Et2O (300 ml). The two layers were separated and the organic phase was dried over MgS04 and concentrated in vacuo to give 3-hydroxy-5- (2-oxo-pyrrolidin- 1-yl)-benzoic acid methyl ester (D37) (1.0 g, 67%) as a tan solid.
Description 38 3- (3-Benzyloxy-propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D38) A solution of 3-hydroxy-5- (2-oxopyrrolidin-1-yl)-benzoic acid methyl ester (D37) (300 mg, 1.28 mmol, 1 equiv), 3-benzyloxypropan-1-ol (0.28 ml, 1.79 mmol, 1.4 equiv) and triphenyl phosphine (470 mg, 1.79 mmol, 1.4 equiv) in THF (10 ml) at room temperature was treated dropwise with DEAD (0.282 ml, 1.79 mmol, 1.4 equiv). The mixture was stirred for 16 h at room temperature then concentrated in vacuo. Purification by flash chromatography on silica gel (ethyl acetate/iso-hexane: 1/4 to 1/1) gave 3- (3-benzyloxy-propoxy)-5- (2-oxo-pyrrolidin-1- yl)-benzoic acid methyl ester (D38).
Description 39 Description 39 was prepared in an analogous manner to Description 38 from Description 37 using the appropriate alcohol indicated in the table below :
.. Alcohol Description Alcohol 3- (2-Benzyloxy-ethoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid HO~osn methyl ester (D39) Description 40 3-(2-benzyloxy-ethoxy)-5-(2-oxo-pyrrolndin-1-yl)-benzoic acid (D40) Description 40 was prepared by saponification of Description 39 in accordance with known procedures.
Description 41 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-hydroxy-benzoic acid methyl ester (D41) 1-[3-Amino-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)-phenyl]-pro pan-1-one (D16) (1.0 g, 3.7 mmol, 1 equiv) dissolved in a mixture of 2N aqueous HCI solution (15 ml) and MeOH (30 ml) was stirred at 0 °C and treated portionwise with sodium nitrite (550 mg, 8.0 mmol, 2.2 equiv) over 20 min. H2O (50 mi) was added and the resulting mixture was heated at 90 °C for 45 min, cooled, and diluted with Et2O (300 ml) The two layers were separated and the organic phase dried over MgS04 and concentrated in vacuo to give crude 3-(1,1-dioxo-1/6-isothiazolindin-2-yl)- 5-hydroxy-benzoic acid methyl ester (D41) (800 mg, 80%) as a brown oil.
Description 41 (Alternative Procedure) 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-hydroxy-benzoic acid methyl ester (D41) A mixture of 3-benzyloxy-5-(1, 1-dioxo-116-isothiazolidin-2-yl)-benzOic acid methyl ester (D54) (4.5 g, 12.5 mmol, 1 equiv), NH4COOH (7.7 g, 125 mmol, 10 equiv) and 10% Pd on charcoal (50% wet, 1. 0g, 11 % w/w) in MeOH (150mol) and H20 (10 ml) was heated at 50 °C for 2 h. The cooled reaction mixture was filtered through a pad of celite and concentrated in vacuo. H20 (100 ml) was added to the filtrate which was then extracted with AcOEt (150 ml). The organic solution was dried over MgS04 and concentrated in vacuo. The residue was crystallised from Et20 to yield of 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-hydroxy-benzoic acid methyl ester (D41) (2.6 g, 77%) as a white solid.
Description 42 5-hydroxy-isophthalic acid dimethyl ester (D42) Description 42 is commercially available from Sigma-Aldrich Company.
Description 43 5-Ethoxy-isophthalic acid dimethyl ester (D43)
K2CO3 (31.6 g, 223 mmol, 2.23 equiv) and iodoethane (17.8 ml, 230 mmol, 2.3 equiv) were added to a solution of 5-hydroxy-isophthalic acid dimethyl ester (D42) (21 g, 100 mmol, 1 equiv) in acetone (500 ml) at room temperature. The resulting solution was refluxed for 16 h, then cooled to room temperature and concentrated in vacuo. The residue was partitioned between H20 and AcOEt. The aqueous phase was extracted with AcOEt and the combined organic layers were washed with 2N aqueous NaOH solution and brine, dried over MgS04 and concentrated in vacuo to give 5-ethoxy-isophthalic acid dimethyl ester (D43) (23 g, 96%) as a white solid. RT = 3.13 min Description 44 5-Benzyloxy-isophthalic acid dimethyl ester (D44) K2CO3 (21 g, 153 mmol, 2 equiv) and benzyl bromide (11 ml, 92 mmol, 1.2 equiv) were added to a solution of 5-hydroxy-isophthalic acid dimethyl ester (D42) (16. 1g, 76.7 mmol, 1 equiv) in acetone (400 ml) at room temperature. The resulting solution was refluxed for 18 h, cooled to room temperature and concentrated in vacuo. The residue was partitioned between H20 and AcOEt. The aqueous phase was extracted with AcOEt and the combined organic layers were washed with 2N aqueous NaOH solution and brine, dried over MgS04 and concentrated in vacuo to give 5-benzyloxy-isophthalic acid dimethyl ester (D44) (24.2 g, 105%) as a white solid. [M+H] + = 301.0, RT = 3.50 min Description 45 5-Ethoxy-isophthalic acid monomethyl ester (D45) To a solution of 5-ethoxy-isophthalic acid dimethyl ester (D43) (22 g, 92.4 mmol, 1 equiv) in MeOH (440 ml) was added 1 N aqueous NaOH solution (87.8 ml, 87.8 mmol, 0.95 equiv) and the resulting solution was stirred at room temperature for 17 h. Most of the MeOH was removed in vacuo and the residue was partitioned between AcOEt and 1 N aqueous NaOH solution. The aqueous layer was extracted with AcOEt, acidified to pH 1 and re-extracted with AcOEt. The second organic extract was dried over MgS04 and concentrated in vacuo to give 5-ethoxy-isophthalic acid monomethyl ester (D45) (17 g, 82%) as a white solid. [M+H+NH3] + 242.0, RT = 2.79 min Description 46 5-Benzyloxy-isophthalic acid monomethyl ester (D46) To a solution of 5-benzyloxy-isophthalic acid dimethyl ester (D44) (24 g, 80 mmol, 1 equiv) in MeOH (300 ml) was added 1 N aqueous NaOH solution (76 ml, 76 mmol, 0.95 equiv) and the resulting solution was stirred at room temperature for 17 h. A second portion of 1 N aqueous NaOH solution (15 ml, 15 mmol, 0.2 equiv) was added and the solution stirred for another 6 h.
Most of the MeOH was removed in vacuo and the residue was partitioned between AcOEt and 1 N aqueous NaOH solution. The aqueous layer was extracted with AcOEt, acidified to pH 1 and re-extracted with AcOEt. The second organic extract was dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 5-benzyloxy-isophthalic acid monomethyl ester (D46) (15.5 g, 68%) as a white solid. [M+H] + = 2.86. 0, RT = 3.32 min
Description 47 3-Benzyloxycarbonylamino-5-ethoxy-benzoic acid methyl ester (D47) NEt3 (14.2 ml, 102 mmol, 1.3 equiv) and diphenylphosphoryl azide (22 ml, 102 mmol, 1.3 equiv) were added to a suspension of 5-ethoxy-isophthalic acid monomethyl ester (D45) (17.6 g, 78.6 mmol, 1 equiv) in toluene (250 ml) and the mixture heated at 80 C for 3 h. Benzyl alcohol (12 ml, 118 mmol, 1.5 equiv) was added and the resulting mixture was refluxed for 4 h, cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt (300 ml) and the resulting solution was washed with 2N aqueous HCI solution (100 ml) followed by saturated aqueous NaHC03 solution (100 ml), dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3- benzyloxycarbonylamino-5-ethoxy-benzoic acid methyl ester (D47) (15 g, 62%) as a white solid. [M-H]-= 328.1, RT = 3.46 min Description 48 3-Benzyloxy-5- (2-trimethylsilanyl-ethoxycarbonylamino)-benzoic acid methyl ester (D48) NEt3 (8.2 g, 81 mmol, 1.5 equiv) and diphenylphosphoryl azide (22.3 g, 81 mmol, 1.5 equiv) were added to a suspension of 5-benzyloxy-isophthalic acid monomethyl ester (D46) (15.5 g, 54.2 mmol, 1 equiv) in toluene (120 ml) and the resulting mixture heated at 80 C for 3 h. 2- Trimethylsilylethanol (12.7 g, 108 mmol, 2 equiv) was added and the resulting mixture was refluxed for 4 h, cooled to room temperature and concentrated in vacuo. The residue was dissolved in EtOAc (300 ml) and the resulting solution was washed with 2N aqueous HCI solution (100 mi) followed by saturated aqueous NaHC03 solution (100 ml), dried over MgS04 and concentrated in vacuo. The residue was triturated with Et2O and iso-hexane to give 3- benzyloxy-5- (2-trimethylsilanyl-ethoxycarbonylamino)-benzoic acid methyl ester (D48) (8.5 g, 40%) as a white solid.
Description 49 3-Amino-5-ethoxy-benzoic acid methyl ester (D49) A mixture of 3-benzyloxycarbonylamino-5-ethoxy-benzoic acid methyl ester (D47) (15 g, 45.5 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 1.5 g, 5% w/w) and NH4COOH (15 g, 455 mmol, 10 equiv) H20 (50 ml) and MeOH (200 ml) was stirred at 50 C for 2h. The mixture was cooled to room temperature and the catalyst was filtered off through a pad of celite. Most of the MeOH was removed in vacuo and the residue was partitioned between saturated aqueous NaHC03 solution and AcOEt. The aqueous phase was re-extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give 3-amino- 5-ethoxy-benzoic acid methyl ester (D49) (8.8 g, 99%) as a pale green solid which was used in the next step without further purification. [M+H] + = 196.1, RT = 2.49 min Description 50 3-Amino-5-benzyloxy-benzoic acid methyl ester hydrochloride (D50) 3-Benzyloxy-5- (2-trimethylsilanyl-ethoxycarbonylamino)-benzoic acid methyl ester (D48) (8.5 g, 21.2 mmol, 1 equiv) in THF (40 ml) was treated with 1 M tetrabutyl ammonium fluoride in
THF (40 ml, 40 mmol, 1.9 equiv) and the resulting solution stirred at room temperature for 16 h then concentrated in vacuo. The residue was dissolved in AcOEt (200 ml) and washed with H20 (200 ml) then dried over MgS04 and concentrated in vacuo. The residue was redissolved in Et2O/EtOAc and treated with 2N HCI in Et20 to give, after filtration, 3-amino-5-benzyloxy- benzoic acid methyl ester hydrochloride (D50) (5.0 g, 80%) as a white solid.
Description 51 3- (4-Chloro-butanoylamino)-5-ethoxy-benzoic acid methyl ester (D51) 3-Amino-5-ethoxy-benzoic acid methyl ester (D49) (4.0 g, 20.5 mmol, 1 equiv) was suspended in CH2CI2 (40 ml) and treated at room temperature with NEt3 (2.32 g, 23mmol, 1.1 equiv). The resulting solution was cooled to 0 C and 4-chlorobutyryl chloride (3.1 g, 22 mmol, 1.1 equiv) was added dropwise. The resulting mixture was stirred at 0 C for 3 h then allowed to warm to room temperature. The solution was washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo to give of 3- (4-chloro-butanoylamino)-5-ethoxy- benzoic acid methyl ester (D51) (7.0 g, 115%) as a brown oil.
Description 52 3-Benzyloxy-5- (3-chloro-propane-l-sulfonylamino)-benzoic acid methyl ester (D52) A suspension of 3-amino-5-benzyloxy-benzoic acid methyl ester hydrochloride (D50) (5.0 g, 17 mmol, 1 equiv) in CH2Ci2 (100 mi) was treated with DMAP (400 mg, 3.2 mmol) and pyridine (3.5 g, 44 mmol, 2.6 equiv) followed by 3-chloropropanesulfonyl chloride (3.54 g, 20 mmol, 1.2 equiv) dropwise at room temperature. The resulting mixture was stirred for 16 h then concentrated in vacuo. The residue was dissolved in AcOEt (200 ml) and the resulting solution was washed with 2N aqueous HCI solution (100 ml) followed by saturated aqueous NaHC03 solution (100 ml), dried over MgS04 and concentrated in vacuo to give 3-benzyloxy- 5- (3-chloro-propane-1-sulfonylamino)-benzoic acid methyl ester (D52) (6.0 g, 97%) as a pale pink solid. [M+H] + = 366.1, RT = 2.34 min Description 53 3- (3-Chloro-propane-1-sulfonylamino)-5-ethoxy-benzoic acid methyl ester (D53) A suspension of 3-amino-5-ethoxy-benzoic acid methyl ester (D49) (4.0 g, 20.5 mmol, 1 equiv) in CH2CI2 (100 ml) was treated with DMAP (400 mg, 3.2 mmol,) and pyridine (1.74 g, 22 mmol, 1.1 equiv) followed by 3-chloropropanesulfonyl chloride (3.89 g, 22 mmol, 1.1 equiv) dropwise. The resulting mixture was stirred for 16 h then concentrated in vacuo. The residue was dissolved in AcOEt (200 mi) and the resulting solution was washed with 2N aqueous HCI solution (100 ml) followed by saturated aqueous NaHC03 solution (100 ml), then dried over MgS04 and concentrated in vacuo to give 3- (3-chloro-propane-1-sulfonylamino)-5-ethoxy- benzoic acid methyl ester (D53) (6.7 g, 98%) as a pale orange solid.
Description 54 3-Benzyloxy-5-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-benzoic acid methyl ester (D54) A solution of 3-benzyloxy-5- (3-chloro-propane-1-sulfonylamino)-benzoic acid methyl ester (D52) (6.0 g, 17 mmol, 1 equiv) in EtOH (80 ml) was treated with NEt3 (3.4 g, 34 mmol, 2
equiv). The resulting mixture was refluxed for 6 h, cooled to room temperature and concentrated in vacuo to give 3-benzylOxy-5-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-benzOic acid methyl ester (D54) (4.5 g, 74%) as a pale pink solid.
Description 55 5-Dimethylthiocarbamoyloxy-isophthalic acid dimethyl ester (D55) o a solution of 5-hydroxy-isophthalic acid dimethyl ester (D42) (21 g, 100 mmol, 1 equiv) in DMF (300 ml) at room temperature was added DABCO (14.6 g, 130 mmol, 1.3 equiv) followed by dimethylthiocarbamoyl chloride (14.8 g, 120 mmol, 1.2 equiv). The resulting mixture was stirred at room temperature for 16 h and at 60°C for 2 h, then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H20 and the aqueous phase re-extracted with AcOEt. The combined organic solution was washed sequentially with 5% aqueous citric acid solution, 2N aqueous NaOH solution and brine, then dried over MgS04 and concentrated in vacuo to give 5-dimethylthiocarbamoyloxy-isophthalic acid dimethyl ester (D55) (23.5 g, 79%) as a pale yellow oil. [M+H] + = 298.0, RT = 3.06 min Description 56 5-Dimethylcarbamoylsulfanyl-isophthalic acid dimethyl ester (D56) 5-Dimethylthiocarbamoyloxy-isophthalic acid dimethyl ester (D55) (15.5 g, 52.2 mmol, 1 equiv) was stirred at 200 C for 24 h under nitrogen then cooled to room temperature.
Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 4/1 then 3/1) gave 5- dimethylcarbamoylsulfanyl-isophthalic acid dimethyl ester (D56) (7.0 g, 45%) and recovered 5-dimethylthiocarbamoyloxy-isophthalic acid dimethyl ester (D55) (2.77 g, 18%), both as white solids. [M+H] + = 298.0, RT = 2.92 min Description 57 5-Dimethylcarbamoylsulfanyl-isophthalic acid monomethyl ester (D57) To a solution of 5-dimethylcarbamoylsulfanyl-isophthalic acid dimethyl ester (D56) (6 g, 20.2 mmol, 1 equiv) in THF (100 ml) at room temperature was added 2N aqueous NaOH solution (9.6 mi, 19.2 mmol, 0.95 equiv). The resulting mixture was stirred for 11 h and then partitioned between AcOEt and H2O. The two layers were separated and the aqueous phase extracted with AcOEt. After acidification to pH 1, the aqueous phase was extracted twice with AcOEt.
The organic solution was dried over MgS04 then concentrated in vacuo to give 5- dimethylcarbamoylsulfanyl-isophthalic acid monomethyl ester (D57) (4.54 g, 79%) as a white solid.
Description 58 tert-Butoxycarbonylamino-dimethylcarbamoylsulfanyl-benzoic acid methyl ester (D58) To a solution of crude 5-dimethylcarbamoylsulfanyl-isophthalic acid monomethyl ester (D57) (4.56 g, 16.1 mmol, 1 equiv) in toluene (100 ml) was added triethylamine (6.7 ml, 48 mmol, 3 equiv) and diphenylphosphoryl azide (5.2 ml, 24 mmol, 1.5 equiv). The resulting mixture was stirred under nitrogen at 80 C for 3 h and then tert-butanol (4.6 ml, 48 mmol, 3 equiv) was added. The solution was stirred at 80 C for another 16 h then cooled to room temperature and
concentrated in vacuo. The crude product was dissolved in AcOEt and the resulting solution washed sequentially with 2N aqueous NaOH solution, 2N aqueous HCI solution and brine, dried over MgSO4 and concentrated in vacuo. Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 3/1 to 6/4) gave tert-butoxycarbonylamino- dimethylcarbamoylsulfanyl-benzoic acid methyl ester (D58) (2.24 g, 40%) as a white solid.
Description 59 3-tert-Butoxycarbonylamino-5-mercapto-benzoic acid (D59) To a solution of tert-butoxycarbonylamino-dimethylcarbamoylsulfanyl-benzoic acid methyl ester (D58) (2.24 g, 6.3 mmol, 1 equiv) in MeOH (30 ml) and H20 (23 mi) was added 2N aqueous NaOH solution (7 ml, 14mmol, 2.2 equiv). The resulting mixture was refluxed for 3 h and then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and 1 N aqueous NaOH solution. The aqueous phase was acidified to pH 1 and extracted twice with AcOEt. The combined organic solutions were dried over MgS04 then concentrated in vacuo to give 3-tert-butoxycarbonylamino-5-mercapto-benzoic acid (D59) (1.54 g, 90%) as a white solid.
Description 60 3-tert-Butoxycarbonylamino-5-methylsulfanyl-benzoic acid methyl ester (D60) To a solution of 3-tert-butoxycarbonylamino-5-mercapto-benzoic acid (D59) (0.68 g, 2.52 mmol, 1 equiv) in acetone (15 mi) was added K2CO3 (3.5 g, 25.3 mmol, 10 equiv) and iodomethane (473 Ri, 7.59 mmol, 3 equiv). The resulting mixture was stirred at 50 C for 2 h, cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H2O. The organic layer was washed with H20 and brine, dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 85/15) gave 3-tert-butoxycarbonylamino-5-methylsulfanyl-benzoic acid methyl ester (D60) (0.47 g, 63%) as a white solid. [M-H]'= 296. 1, RT = 3.51 min Description 61 3-tert-Butoxycarbonylamino-5-ethylsulfanyl-benzoic acid ethyl ester (D61) Description 61 was obtained from 0.68 g (2.53 mmol) of 3-teff-butoxycarbonylamino-5- methylsulfanyl-benzoic acid methyl ester (D59) and iodoethane using the procedure described in Description 60, which yielded the title compound (D61) (0.58 g, 71%) as a white solid. [M- H]-= 324.2, RT = 3.79 min Description 62 3-Amino-5-methylsulfanyl-benzoic acid methyl ester hydrochloride (D62) 3-tert-Butoxycarbonylamino-5-methylsulfanyl-benzoic acid methyl ester (D60) (0.54 g, 1.82 mmol, 1 equiv) was dissolved in dioxan (2 ml) and 4M HCI in dioxan (16 mmol, 4 ml, 8.8 equiv) was added. The solution was stirred at room temperature for 2 h allowing the hydrochloride salt of the amine to precipitate. This precipitate was filtered off, washed with Et20 and dried giving 3-amino-5-methylsulfanyl-benzoic acid methyl ester hydrochloride (D62) (0.224 g, 52%). [M+H] + = 198.1, RT = 2.68 min
Description 63 3-Amino-5-ethylsulfanyl-benzoic acid ethyl ester hydrochloride (D63) Description 63 was prepared from 0.57 g (1.75 mmol) of 3-tert-butoxycarbonylamino-5- ethylsulfanyl-benzoic acid ethyl (D61) in an analogous manner to that described in Description 62 which yielded 0.335 g (73%) of 3-amino-5-ethylsulfanyl-benzoic acid ethyl ester hydrochloride (D63) as a white solid. [M+H] + = 226.1, RT = 3. 13 min Description 64 3- (4-Chloro-butanoylamino)-5-methylsulfanyl-benzoic acid methyl ester (D64) To a solution of 3-amino-5-methylsulfanyl-benzoic acid methyl ester hydrochloride (D62) (0.13 g, 0.556 mmol, 1 equiv) in dry CH2CI2 (2 ml) at 0 C was added NEt3 (193 ml, 1.39 mmol, 2.5 equiv) then 4-chlorobutyryl chloride (69 ml, 0.612 mmol, 1.1 equiv), dropwise, over 2 min. The resulting solution was stirred at OC for 15 min then at room temperature for 30 min. The solution was then diluted with AcOEt, washed sequentially with 2N aqueous HCI solution, saturated aqueous NaHC03 solution and brine, dried over Na2SO4 and concentrated in vacuo to give 3- (4-chloro-butanoylamino)-5-methylsulfanyl-benzoic acid methyl ester (D64) (173 mg , 103%) as pale yellow crystals. [M+H] + = 302.0, RT = 3.20 min Description 65 3- (4-Chloro-butanoylamino)-5-ethylsulfanyl-benzoic acid ethyl ester (D65) Description 65 was prepared from 140 mg (0.535 mmol) of 3-amino-5-ethylsulfanyl-benzoic acid ethyl ester hydrochloride (D63) in an analogous manner to that described in Description 64 which yielded 182 mg (103%) of 3- (4-chloro-butanoylamino)-5-ethylsulfanyl-benzoic acid ethyl ester (D65) as pale yellow crystals. [M+H] + = 330.0, RT = 3.51 min Description 66 3- (3-Chloro-propane-l-sulfonylamino)-5-methylsulfanyl-benzoic acid methyl ester (D66) To a solution of 3-amino-5-methylsulfanyl-benzoic acid methyl ester hydrochloride (D62) (130 mg, 0.556 mmol, 1 equiv) in CH2CI2 (2 ml) was added pyridine (142 ml, 1.75 mmol, 3 equiv), DMAP (6.8 mg, 0.056 mmol, 0.1 equiv) and then 3-chloropropane sulfonyl chloride (71 l, 0.584 mmol, 1.05 equiv) dropwise over 2 min. The resulting mixture was stirred at room temperature for 2 h, diluted with AcOEt, washed sequentially with 2N aqueous HCI solution, saturated aqueous NaHCO3 solution and brine, dried over Na2SO4 and concentrated in vacuo to give 3- (3-chloro-propane-1-sulfonylamino)-5-methylsulfanyl-benzoic acid methyl ester (D66) (196 mg, 104%) as light brown crystals.
[M-H]-= 336.0 RT = 3.20 min Description 67 3- (3-Chloro-propane-1-sulfonylamino)-5-ethylsulfanyl-benzoic acid ethyl ester (D67) Description 67 was prepared from 140 mg (0.6 mmol) of 3-amino-5-ethylsulfanyl-benzoic acid ethyl ester hydrochloride (D63) in an analogous manner to that described in Description 66
which yielded 200 mg (102%) of crude 3- (3-chloro-propane-1-sulfonylamino)-5-ethylsulfanyl- benzoic acid ethyl ester (D67) as light brown crystals.
[M-H] -= 364.0, RT = 3.49 min Description 68 3-(2-Oxo-piperidin-1-yl)-5-(E/Z)-propenyl-benzoic acid ter-butyl ester (D68) To a solution of 3-bromo-5-(2-oxo-piperidin-1-yl)-benzoic acid tert-butyl ester (D10) (500 mg, 1.4 mmol, 1 equiv) in DME (14 ml) and H2O (4 ml) was added tetrakis (triphenylphosphine)- palladium (0) (81 mg, 0.07 mmol, 0.05 equiv), and the suspension was stirred for 10 min. 2,4, 6 Tripropenylcyclotriboroxane-pyridine complex (394 mg, 1.4 mmol, 1 equiv) and K2CO3 (193 mg, 1.4 mmol, 1 equiv) were added and the resulting mixture was stirred at 90 C for 1 h, cooled to room temperature and diluted with AcOEt. The organic phase was washed with H2O, dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (iso-hexane/AcOEt: 4/1) gave 3-(2-oxo-piperidin-1-yl)-5-(E/Z)-propenyl-benzoic acid tert-butyl ester (D68) (480 mg, 100%) of adduct as a pale yellow oil. [M+H] + = 316.2, RT = 3.41 min Descriptions 69-72 Descriptions 69-72 were prepared in an analogous manner to that described for Description 68 from the appropriate aryl bromide starting material indicated in the below table using the appropriate 2,4, 6 trialkenylcyclotriboroxane-pyridine complex as described by F. Kerins and D. F. O'Shea in J. Orq. Chem, 2002, 67, 4968-4971: Description Aryl bromide [M+H] + RT (min) 3- (1, 1-Dioxo-11- [1, 2] thiazinan-2-yl)-5- (E/Z)- D18 (-tBu) 3.61 propenyl-benzoic acid tert-butyl ester (D69) 296.1 3- (2-Oxo-pyrrolidin-1-yl)-5-vinyl-benzoic acid D9a methyl ester (D70) 3-Isopropenyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic D9a 260.0 2.96 acid methyl ester (D71) 3- (2-Oxo-pyrrolidin-1-yl)-5- (E/Z)-propenyl- D9a 260.0 2.97 benzoic acid methyl ester (D72) Description 73 3-Cyclopent-2-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester; 3-Cyclopent-3-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester; and 3-Cyclopent-1-enyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D73) To a solution of 3-bromo-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D9a) (686 mg, 2.3 mmol, 1 equiv) in DMF (3 ml) was added cyclopentene (409 gl, 4.6 mmol, 2 equiv), palladium (II) acetate (26 mg, 0.12 mmol, 0.05 equiv), tri (o-tolyl) phosphine (71 mg, 0.23 mmol, 0.1 equiv) and triethylamine (969 µl, 7 mmol, 3 equiv). The resulting mixture was stirred at 125°C for 16 h then cooled to room temperature and partitioned between H2O and Et20. The two layers were separated and the organic phase was dried over Na2SO4 and concentrated in vacuo to give a mixture of 3-cyclopent-2-enyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl
ester, 3-cyclopent-3-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester and 3-cyclopent- 1-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D73) (562 mg, 85%) as a brown oil.
Description 74 3-Cyclohex-2-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester; 3-Cyclohex-3-enyl-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid methyl ester; and 3-Cyclohex-1-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D74) Description 74 was prepared in an analogous manner to that described for Description 73 from 686 mg (mmol) of 3-bromo-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D9a) and cyclohexene which yielded 207 mg (30%) of 3-cyclohex-2-enyl-5-(2-oxo-pyrrolidin-1-yl)- benzoic acid methyl ester, 3-cyclohex-3-enyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester and 3-cyclohex-1-enyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D74) after purification by flash chromatography on silica gel (iso-hexane/EtOAc: 5/1) Description 75 3-(1, 1-DioXo-116-isothiazolidin-2-yl)-5-(3-hydroxy-3-methyl-but-1 -ynyl)-benzoic acid tert- butyl ester (D75) To a solution of 3-bromo-5-(1, 1-dioxo-116-isothiazolidin-2-yl)-benzOic acid test-butyl ester (D17) (376 mg, 1 mmol, 1 equiv) in DME (5 ml) and H20 (5 ml) were added K2CO3 (345 mg, 2.5 mmol, 2.5 equiv), Cul (8 mg, 0.04 mmol, 0.04 equiv), triphenyl phosphine (21 mg, 0.08 mmol, 0.08 equiv), 10% palladium on charcoal (21 mg, 0.02 mmol, 0.02 equiv) and the solution was stirred at room temperature for 15 min. 2-Methyl-3-butyne-2-ol (254 pI, 2.5 mmol, 2.5 equiv) was added and the resulting mixture was stirred at 80C for 16 h then cooled to room temperature. The catalyst was removed by filtration through a pad of celite and the filtrate was diluted with AcOEt. The organic phase was washed with 2N aqueous HCI solution, saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (iso-hexane/AcOEt: 4/1 to 2/1) gave 3- (1, 1-dioxo-lf- isothiazolidin-2-yl)-5- (3-hydroxy-3-methyl-but-1-ynyl)-benzoic acid tert-butyl ester (D75) (142 mg, 37%) as a colorless oil which solidified on standing.
Description 76 3- (3-Hydroxy-3-methyl-but-1-ynyl)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D76) Description 76 was prepared using an analogous process to that described for Description 75 from 390 mg of 3-bromo-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid test-butyl ester (D9b) which yielded 300 mg (76%) of 3- (3-hydroxy-3-methyl-but-1-ynyl)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D76) as a white foam.
Description 77 5-nitro-isophthalic acid monomethyl ester (D77) Description 77 is commercially available from Sigma-Aldrich Company.
Description 78
5-Nitro-isophthalic acid 1-tert-butyl ester 3-methyl ester (D78) A mixture of 5-nitro-isophthalic acid monomethyl ester (D77) (5.0 g, 22.2 mmol, 1 equiv), tert- BuOH (8.2 g, 111 mmol, 5 equiv), EDAC. HCI (4.8 g, 25 mmol, 1.1 equiv) and DMAP (205 mg, 1.68 mmol, 0.07 equiv) dissolved in CH2CI2 (50 mi) was stirred for 1 h at room temperature The mixture was then diluted with CH2CI2 (50 ml), washed with 2N aqueous HCI solution (50 mi) and saturated aqueous NaHC03 solution (50 ml), dried over MgS04 and concentrated in vacuo to give of 5-nitro-isophthalic acid 1-fert-butyl ester 3-methyl ester (D78) (5.3 g, 85%) as a pale yellow oil.
Description 79 5-Amino-isophthalic acid 1-tert-butyl ester 3-methyl ester (D79) A mixture of 5-nitro-isophthalic acid 1-tert-butyl ester 3-methyl ester (D78) (5.3 g, 19 mmol, 1 equiv), NH4COOH (11.9 g, 190 mmol, 10 equiv) and 10% Palladium on charcoal (50% wet, 0.75g, 7% w/w) in EtOH (50 ml) and H2O (25 ml) was heated at 50 °C for 30 min. MeOH (20 ml) was added and the resulting solution was heated at 50 °C for another hour then cooled to room temperature, filtered through a pad of celite and concentrated in vacuo. The residue was diluted with saturated aqueous NaHC03 solution (100 ml) and the aqueous phase was extracted with AcOEt (150 ml). The organic phase was dried over MgS04 and concentrated in vacuo. The residue was triturated with iso-hexane to give of 5-amino-isophthalic acid 1-test- butyl ester 3-methyl ester (D79) (3.4 g, 71%) as a white solid.
Description 80 5- (4-Chloro-butanoylamino)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D80) A suspension of 5-amino-isophthalic acid 1-tert-butyl ester 3-methyl ester (D79) (3.4 g, 13.5 mmol, 1 equiv) in CH2CI2 (25 ml) was treated with NEt3 (2.32 g, 23 mmol, 1.1 equiv) and cooled to 0°C. 4-chlorobutyryl chloride (1.6 g, 15.7 mmol, 1.1 equiv) was added dropwise and the resulting solution was stirred at 0 °C for 3 h then allowed to warm to room temperature and washed with 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with iso-hexane and Et2O to give 5- (4-chloro-butanoylamino)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D80) (4.5 g, 94%) as a white solid.
Description 81 5- (3-Chloro-propane-1-sulfonylamino)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D81) To a solution of 5-amino-isophthalic acid 1-tert-butyl ester 3-methyl ester (D79) (5.0 g, 20 mmol, 1 equiv), DMAP (0.3 g, 2.46 mmol, 0.12 equiv) and pyridine (1.64 g, 20 mmol, 1 equiv) in CH2CI2 (80 mi) was added 3-chloropropanesulfonyl chloride (2.4 ml, 20 mmol, 1 equiv) dropwise. The resulting mixture was stirred for 16 h then diluted with AcOEt (150 ml). The organic phase was washed with 2N aqueous HCI solution and saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give 5-(3-chloro-propane-1- sulfonylamino)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D81) (7. 8 g, 99%) as a pale orange solid.
Description 82 5-(1, 1-Dioxo-1 t-isothiazolidin-2-yl)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D82) A mixture of 5- (3-chloro-propane-l-sulfonylamino)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D81) (7.8 g, 20 mmol, 1 equiv) and NEt3 (4.0 g, 40 mmol, 2 equiv) in EtOH (100 ml) was refluxed for 3 h, cooled to room temperature and concentrated in vacuo. The residue was diluted with AcOEt and the organic phase was washed with 2N aqueous HCI solution and saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give 5- (1, 1-dioxo-1/6-isothiazolidin-2-yl)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D82) (4.4 g, 62%) as a white solid.
Description 83 5-(1, 1-Dioxo-1t-isothiazolidin-2-yl)-isophthalic acid monomethyl ester (D83) A suspension of 5-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-isophthalic acid 1-tert-butyl ester 3-methyl ester (D82) (4.4 g, 12.4 mmol, 1 equiv) in CH2CI2 (10 ml) was treated with TFA (10ml) and the resulting mixture was stirred for 2 h at room temperature. Toluene (10 ml) was added and the resulting mixture was concentrated in vacuo. The residue was triturated with Et20 to give 5- (1, 1-dioxo-1/6-isothiazolidin-2-yl)-isophthalic acid monomethyl ester (D83) (3.6 g, 97%) as a white solid.
Description 84 3-(1, 1-DioXo-1F-isothiazolidin-2-yl)-5-hydroxymethyl-benzoic acid methyl ester (D84) A solution of 5-(1, 1-dioxo-116-isothiazolidin-2-yl)-isophthalic acid monomethyl ester (D83) (500 mg, 1.67 mmol, 1 equiv) in THF (30 ml) was treated with BH3-Me2S (2M solution in THF, 1.0 ml, 2 mmol, 1.2 equiv) and the mixture was refluxed for 30 min and then cooled to room temperature. MeOH (5 ml) was added dropwise and the resulting mixture was concentrated in vacuo. The residue was diluted with AcOEt (100 ml), and the resulting solution was washed with 2N aqueous HCI solution (100 ml) and saturated aqueous NaHC03 solution, dried over MgSO4. and concentrated in vacuo to give 3-(1, 1-dioxo-1/8-isothiazolidin-2-yl)-5- hydroxymethyl-benzoic acid methyl ester (D84) (450 mg, 95%) as a clear, colourless oil.
Description 85 3-(1, 1-Dioxo-1 F-isothiazolidin-2-yl)-5-methanesulfonyloxymethyl-benzoic acid methyl ester (D85) A solution of 3-(1,1-dioxo-1/6isothiazolindin-2-yl)-5-ethoxymethyl-benzoic acid (D84) (400 mg, 1.4 mmol, 1 equiv) in CH2CI2 (20 ml) was treated with NEt3 (303 mg, 3.0 mmol, 2.1 equiv) and methanesulfonic anhydride (261 mg, 1.5 mmol, 1.1 equiv) and stirred for 30 min at room temperature. The solution was then washed with 2N aqueous HCI solution (30 ml) and saturated aqueous NaHCO3 solution (30 ml), dried over MgS04 and concentrated in vacuo.
The residue was triturated in Et20 to give 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- methanesulfonyloxymethyl-benzoic acid methyl ester (D85) (390 mg, 77%) as a white solid.
Description 86
3-(1, 1-Dioxo-1t-isothiazolidin-2-yl)-5-formyl-benzoic acid methyl ester (D86) A solution of 3- (I, I-dioxo-lf-isothiazolidin-2-yl)-5-hydroxymethyl-benzoic acid methyl ester (D84) (500 mg, 1.8 mmol, 1 equiv) in CH2CI2 (20 ml) was treated with Mon02 (763 mg, 8.8 mmol, 4.9 equiv) and the resulting mixture was stirred for 3 h at room temperature. A second portion of Mn02 (500 mg, 5.8 mmol, 3.2 equiv) was added and the mixture stirred for 3 h when a third portion of Mn02 (300mg, 3.5 mmol, 1.9 equiv) was added. The mixture was stirred for 2 h and then filtered through a pad of celite. The filtrate was concentrated in vacuo to give 3- (1, 1-dioxo-1/6-isothiazolidin-2-yl)-5-formyl-benzOic acid methyl ester (D86) (450 mg, 88%) as a yellow waxy solid.
Description 87 5-Nitro-N, N-dipropyl-isophthalamic acid methyl ester (D87) A suspension of 5-nitro-isophthalic acid monomethyl ester (D77) (1.0 g, 4.44 mmol, 1 equiv) in CH2CI2 (40 ml) was treated with (COCI) 2 (655 mg, 5.2 mmol, 1.2 equiv) followed by a few drops of DMF. The resulting mixture was stirred for 1 h at room temperature and then dipropylamine (1.65 g, 15 mmol, 3.4 equiv) was added and the resulting solution stirred for a further 30 min. The solution was then washed with 2N aqueous HCI solution (50 ml), saturated aqueous NaHCO3 solution (50 ml), dried over MgS04 and concentrated in vacuo to give 5-nitro-N, N-dipropyl-isophthalamic acid methyl ester (D87) (1.5 g, 110%) as a pale yellow oil.
Description 88 5-Amino-N, N-dipropyl-isophthalamic acid methyl ester (D88) A mixture of 5-nitro-N, N-dipropyl-isophthalamic acid methyl ester (D87) (1.5 g, 4.9 mmol, 1 equiv), NH4COOH (3.0 g, 49 mmol, 10 equiv), 10% Pd on charcoal (50% wet, 250 mg, 0.082 equiv w/w), EtOH (20 ml) and H20 (10 ml) was heated at 50°C for 90 min. The mixture was cooled to room temperature, filtered through a pad of celite and concentrated in vacuo. The residue was dissolved in AcOEt (200 ml) and the resulting solution was washed with saturated NaHC03 solution (100ml), dried over MgS04 and concentrated in vacuo to give 5-amino-N, N- dipropyl-isophthalamic acid methyl ester (D88) (1.2 g, 88%) as a white waxy solid.
Description 89 5- (4-Chloro-butanoylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D89) A solution of 5-amino-N, N-dipropyl-isophthalamic acid methyl ester (D88) (1.2 g, 4.3 mmol, 1 equiv) in CH2CI2 (10 ml) was treated with NEt3 (525 mg, 5.2 mmol, 1.2 equiv). The solution was cooled to 0 °C and 4-chlorobutyryl chloride (733 mg, 5.0 mmol, 1.2 equiv) was added dropwise. The reaction mixture was then allowed to warm to room temperature and stirred for 1 h. The solution was washed with 2N aqueous HCI solution (20 ml), dried over MgS04 and concentrated in vacuo to give 5- (4-chloro-butanoylamino)-NN-dipropyl-isophthalamic acid methyl ester (D89) (1.7 g, 104%) as a colourless oil.
Description 90
5- (5-Chloro-pentanoylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D90) Description 90 was prepared in an analogous manner to Description 89 from 5-amino-N, N- dipropyl-isophthalamic acid methyl ester (D88) and 5-chlorovaleryl chloride.
Description 91 5- (3-Chloro-propane-1-sulfonylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D91) A solution of 5-amino-N, N-dipropyl-isophthalamic acid methyl ester (D88) (1.4 g, 5.0 mmol, 1 equiv), DMAP (100 mg) and pyridine (392 mg, 5.0 mmol, 1.1 equiv) in CH2CI2 (20 ml) was treated dropwise with 3-chloropropane-1-sulfonyl chloride (946 mg, 5.3 mmol, 1.1 equiv). The resulting mixture was stirred for 16 h at room temperature and then diluted with AcOEt (100 ml). The resulting solution was washed with 2N aqueous HCI solution (50 ml) followed by saturated aqueous NaHC03 solution (50 ml), dried over MgS04 and concentrated in vacuo.
The residue was triturated with Et20 to give 5- (3-chloro-propane-1-sulfonylamino)-N, N- dipropyl-isophthalamic acid methyl ester (D91) (1.8 g, 86%) as a pink solid.
Description 92 5- (4-Chloro-butane-l-sulfonylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D92) Description 92 was prepared in an analogous manner to Description 91 from 5-amino-N, N- dipropyl-isophthalamic acid methyl ester (D88) and 4-chloro-butane-l-sulfonyl chloride.
Description 93 (2S, 3R)-3-Hydroxy-2-((S)-2-hydroxy-1-phenyl-ethylamino)-hexanoic acid methyl ester (D93) Description 93 was obtained according to Alker, D.; Hamblett, G.; Harwood, L. M.; Robertson, S. M.; David, J.; Williams, C. E. Tetrahedron, 54 (22), 1998,6089-6098.
Description 94 (2S, 3R)-2-tert-Butoxycarbonylamino-3-hydroxy-hexanoic acid methyl ester (D94) (2S, 3R)-3-Hydroxy-2-((S)-2-hydroxy-1-phenyl-ethylamino)-hexanoic acid methyl ester (D93) (2.88 g, 10.25 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 2 g, 35% w/w), HCOOH (5 ml, excess) in MeOH (50 ml) were stirred at 60°C for 1 h. The mixture was then cooled to room temperature, filtered through a pad of celite then concentrated in vacuo. The residue was dissolved in dioxan/water (1/1, 50 ml) and NaHC03 (10g, excess) then di-tert-butyl dicarbonate (3.37 g, 15 mmol, 1.5 equiv) were added. The resulting mixture was stirred at room temperature for 2 h then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed successively with 2N aqueous HCI solution and saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (CH2CI2/MeOH : 99/1) gave (2S, 3R)-2-teff- Butoxycarbonylamino-3-hydroxy-hexanoic acid methyl ester (D94) (1.88 g, 70%) as a colourless gum.
Description 95 (S)-2-tert-butoxycarbonylamino-4-methylsulfanyl-butyric acid (D95) Description 95 is commercially available from Sigma-Aldrich Company.
Description 96 ((S)-1-lsobutylcarbamoyl-3-methylsulfanyl-propyl)-carbamic acid ter-butyl ester (D96) (S)-2-tert-butoxycarbonylamino-4-methylsulfanyl-butyric acid (D95) (2.0 g, 8.0 mmol, 1 equiv), EDAC. HCI (1.84 g, 9.6 mmol, 1.2 equiv), HOBT (1.47 g, 9.6 mmol, 1.2 equiv), 4- ethylmorpholine (1.76 g, 16 mmol, 2 equiv) and iso-butylamine (952 ml, 9.6 mmol, 1.2 equiv) in CH2CI2 (10 ml) were stirred at room temperature for 16 h. The solution was concentrated in vacuo and the residue dissolved in AcOEt. The organic phase was washed with 2N aqueous HCI solution, saturated aqueous NaHC03 solution and brine, dried over MgS04 and concentrated in vacuo to give ((S)-1-isobutylcarbamoyl-3-methylsulfanyl-propyl)-carbamic acid test-butyl ester (D96) (2.38 g, 98%) as a colourless oil.
Description 97 (3-methoxy-phenyl)-acetic acid ethyl ester (D97) Description 97 is commercially available from Sigma-Aldrich Company.
Description 98 2- (3-Methoxy-phenyl)-2-methyl-propionic acid ethyl ester (D98) To a solution of (3-methoxy-phenyl)-acetic acid ethyl ester (D97) (19.72 g, 0,101 m, 1 equiv) in THF (200 ml) was added NaH (8.8g, 0.222 mol, 2.2 equiv) then iodomethane (26 ml, 0.4 mol, 4 equiv). The resulting mixture was stirred at room temperature for 16 h then partitioned between AcOEt and a saturated NaHC03 aqueous solution. The two layers were separated and the organic phase washed with brine, dried over MgS04 and concentrated in vacuo to give 2- (3-methoxy-phenyl)-2-methyl-propionic acid ethyl ester (D98) (20.85 g, 98%) as an orange oil.
Description 99 2- (3-Methoxy-phenyl)-2-methyl-propionic acid (D99) To a solution of 2- (3-methoxy-phenyl)-2-methyl-propionic acid ethyl ester (D98) (20.95g, 94 mmol, 1 equiv) in EtOH (200 ml) was added 2N NaOH aqueous solution (90 ml, 180 mmol, 1.9 equiv) and the resulting mixture was stirred at 70°C for 16 h then cooled to room temperature. Most of EtOH was removed in vacuo and the residue extracted with AcOEt then acidified to pH 1. The aqueous phase was then extracted with AcOEt and the organic phase dried over MgS04 and concentrated in vacuo to give 2- (3-methoxy-phenyl)-2-methyl-propionic acid (D99) (15g, 82%) as a yellow oil.
Description 100 [1- (3-Methoxy-phenyl)-l-methyl-ethyl]-carbamic acid benzyl ester (D100) To a solution of 2- (3-methoxy-phenyl)-2-methyl-propionic acid (D99) (1g, 5.15 mmol, 1 equiv) in toluene (20 ml) at room temperature was added NEt3 (1.07 ml, 7.72 mmol, 1.5 equiv) and
then diphenylphosphoryl azide (2.2 ml, 10.3 mmol, 2 equiv). The resulting mixture was then heated at 80°C for 2 h then benzyl alcohol (1.61 ml, 15.45 mmol, 3 equiv) was added and the solution heated for a further 2 h, cooled to room temperature and partitioned between EtOAc and a saturated NaHC03 aqueous solution. The two layers were separated and the aqueous phase dried over MgSO4 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9/1) gave [1- (3-methoxy-phenyl)-1-methyl- ethyl]-carbamic acid benzyl ester (D100) (1g, 65%) a yellow gum.
Description 101 ((S)-(S)-1-oxiranyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester (D101) Description 101 is commercially available from Chirex (ref 1819W94, lot#9924382).
Description 102 ( (1S, 2R)-3-Amino-1-benzyl-2-hydroxy-propyl)-carbamic acid tert-butyl ester (D102) To a solution of ((S)-(S)-1-oxiranyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester (D101) (25 g, 95.1 mmol, 1 equiv)) in MeOH (350 ml) was added aqueous ammonia (32% w/w, 180 ml, 3.2 mol, 3.3 equiv). The resulting mixture was stirred at room temperature for 16 h then concentrated in vacuo to give ( (1S, 2R)-3-amino-1-benzyl-2-hydroxy-propyl)-carbamic acid tert-butyl ester (D102) (25.2 g, 95%) as a white solid.
Description 103 ((2R, 3S)-3-teff-Butoxycarbonylamino-2-hydroxy-4-phenyl-butyl)-car bamic acid benzyl ester (D103) A solution of ((1 S, 2R)-3-amino-1-benzyl-2-hydroxy-propyl)-carbamic acid teint-butyl ester (D102) (25.6 g, 91.4 mmol, 1 equiv) in DMF (250 ml) at 0°C was treated with NEt3 (15 ml, 108 mmol, 1.2 equiv) and then with benzyl chloroformate (14 ml, 98 mmol, 1.1 equiv) in DMF (50 ml) dropwise. The resulting solution was stirred at 0°C for 1 h and at room temperature for 16 h and then concentrated in vacuo. The residue was partitioned between AcOEt and saturated aqueous NaHC03 solution. The resulting precipitate was diluted with H20 and filtered to give ( (2R, 3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenyl-butyl)-car bamic acid benzyl ester (D103) (31.5 g, 83%) as a white solid.
Description 104 ((2R, 3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-carbamic acid benzyl ester (D104) A solution of ((2R, 3S)-3-teff-butoxyCarbonylamino-2-hydroxy-4-phenyl-butyl)-car bamic acid benzyl ester (D103) (31.5 g, 76.1 mmol, 1 equiv) in THF (300 ml) was treated with 4N HCI solution in dioxan (40 mi, 160 mmol, 2.1 equiv). The resulting solution was stirred at room temperature for 2 h then concentrated in vacuo. The residue was triturated with Et20/iso- hexane to give ((2R, 3S)-3-amino-2-hydroxy-4-phenyl-butyl)-carbamic acid benzyl ester hydrochloride (D104) (22.1 g, 83%) as a white solid.
Description 105
[ (2R, 3S)-2-Hydroxy-3- (1- [3- (2-oxo-pyrrolidin-1-yl)-5-pentyloxy-phenyl]-methanoyl}- amino)-4-phenyl-butyl]-carbamic acid benzyl ester (D105) To a suspension of 3- (2-oxo-pyrrolidin-1-yl)-5-pentyloxy-benzoic acid (A13) (530 mg, 1.82 mmol, 1 equiv) in CH2CI2 (20 ml) were added HOBT (300 mg, 2.2 mmol, 1.2 equiv) and EDAC. HCI (420 mg, 2.2 mmol, 1.2 equiv). After stirring for 5 min, 3- (2-oxo-pyrrolidin-1-yl)-5- pentyloxy-benzoic acid hydrochloride (D104) (570 mg, 1.82 mmol, 1 equiv) was added and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was then diluted with CH2CI2 (20 ml) washed with saturated aqueous NaHCO3 solution, dried over MgS04 and concentrated in vacuo to give [ (2R, 3S)-2-hydroxy-3- ( {1- [3- (2-oxo-pyrrolidin-1-yl)- 5-pentyloxy-phenyl]-methanoyl}-amino)-4-phenyl-butyl]-carbam ic acid benzyl ester (D105) (510 mg, 48 %) as a white solid.
Description 106 [ 3S)-3-({1-13-Ethylamino-5-(2-oxo-pyrrolidin-1-yl)-phenyl]-me thanoyl}-amino)-2- hydroxy-4-phenyl-butyl]-carbamic acid benzyl ester (D106) Description 106 was prepared in an analogous manner to Description 105 from 3- (2-oxo- pyrrolidin-1-yl)-5-pentyloxy-benzoic acid hydrochloride (D104) and 3-ethylamino-5- (2-oxo- pyrrolidin-1-yl)-benzoic acid (A31).
Description 107 [ (2R, 3S)-3-({1-l3-lsopropylamino-5-(2-oxo-pyrrolidin-1-yl)-phenyl ]-methanoyl}-amino)-2- hydroxy-4-phenyl-butyl]-carbamic acid benzyl ester (D107) Description 107 was prepared in an analogous manner to Description 105 from 3- (2-oxo- pyrrolidin-1-yl)-5-isopropylamino-benzoic acid hydrochloride (A44) and ( (2R, 3S) -3-amino-2- hydroxy-4-phenyl-butyl)-carbamic acid benzyl ester (D104).
Description 108-119 The following compounds (D108-D119) were prepared from Description 104 in an analogous manner to the process described for Description 105 using the appropriate acid. Description Acid Phenylmethyl [(2R,3S)-3-({[3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A73 ethylamino)phenyl]carbonyl}amino)-2-hydroxy-4-phenylbutyl carbamate (D108) Phenylmethyl [(2R,3S)-3-({[3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A119 (ethylamino)-2-fluorophenyl] carbonyl} amino)-2-hydroxy-4-phenylbutyl] carbamate (D109) Phenylmethyl [(2R,3S)-3-({[3-cyclopentyl-5-(2-oxo-1- A107 pyrrolidinyl)penyl]carbonyl}amino)-2-hydroxy-4-phenylbutyl]c arbamate (D110) Phenylmethyl [(2R,3S)-2-hydroxy-3-({[3-[(1-methylethyl)oxy]-5-(2-oxo-1- A12 pyrrolidinyl) phenyl] carbonyl} amino)-4-phenylbutyl] carbamate (D111) Phenylmethyl { (2R, 3S)-3- [ ( {3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- [ (1- A168 methylethyl) oxy] phenyl} carbonyl) amino]-2-hydroxy-4-phenylbutyl} carbamate (D112) Phenylmethyl [ (2R, 3S)-3- ( { [3-cyclopentyl-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin- A126 2-yl) henyl]carbonyl}amino)-2-hydroxy-4-phenylbutyl carbamate (D113) Phenylmethyl [ (2R, 3S)-3- ( { [3- (ethyloxy)-5- (2-oxo-1- A11 rrolidinyl)phenyl]carbonyl}amino)-2-hydroxy-4-phenylbutyl carbamate (D114) Phenylmethyl [(2R,3S)-3-({[3-(1,1-dioxido-2-isothiazolindinyl)-5- A18 (ethyloxy) phenyl] carbonyl} amino)-2-hydroxy-4-phenylbutyl] carbamate (dol 15) Phenylmethyl {(2R,3S)-3-[({3-(1,1-dioxido-2-isothiazolidinyl)-5-[(1-methy lethyl) A19 oxy] henyl}carbonyl)amino]-2-hydroxy-4-phenylbutyl carbamate D116 Phenylmethyl [(2R,3S)-3-({[3-cyclopentyl-5-(1,1-dioxido-2-isothiazolidiny l) A169 phenyl] carbonyl} amino)-2-hydroxy-4-phenylbutyl] carbamate (D117) Phenylmethyl [(2R,3S)-3-({[3-(1,1-dioxido-2-isothiazolidinyl)-5- A70 ethylamino)phenyl]carbonyl}amino)-2-hydroxy-4-phenylbutyl] carbamate D118) Phenylmethyl [(2R,3S)-3-({[3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-A170 ethyloxy)phenyl]carbonyl}amono)-2-hydroxy-4-phenylbutyl] carbamate D119) Description 120-131 The following compounds (D120-D131) were prepared in an analogous manner to the process described for Example 182 using the appropriate precursor: Description Precursor N-[(1S,2R)-3-Amino-2-hydroxy-1-(phenylmethyl)propyl]-3-(1,1- D108 dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino) benzamide (D120) N- [ (1 S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido D109 tetrahydro-2H-1,2-thiazin-2-yl)-5-(ethylamino)-2-fluorobenza mide (D121 N- [ (1 S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (2-oxo- D110 1-pyrrolidinyl) benzamide D122 N- [ (1 S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3- [ (1-methylethyl) oxy]- D111 5-(2-oxo-1-pyrrolidinyl benzamide D123 N- [ (1 S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3- (1, 1- D112 dioxidotetrahydro-2H-1,2-thiazin-2-yl)-5-[(1-methylethyl)oxy ] benzamide (D124) N- [ (1S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (1, 1- D113 dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzamide D125 N- [ (1S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3- (ethyloxy)-5- (2-oxo- D114 1-pyrrolidinyl) benzamide D126 N-[(1S,2R)-3-Amino-2-hydroxy-1-(phenylmethyl)propyl]-3-(1,1- dioxido-2- D115 isothiazolidinyl)-5-(ethyloxy)benzamide (D127) N-[(1S,2R)-3-Amino-2-hydroxy-1-(phenylmethyl)propyl]-3-(1,1- dioxido-2- D116 isothiazolidinyl)-5-[(1-methylethyl)oxy]benzamide (D128) N- [ (1S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (1, 1- D117 dioxido-2-isothiazolidinyl) benzamide (D 129) N- [ (1 S, 2R)-3-Amino-2-hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido-2- D118 isothiazolidinyl)-5-(ethylamino) benzamide (D130) N- [ (1 S, 2R)-3-Amino-2-hydroxy-1-(phenylmethyl)propyl]-3-(1,1- D119 dioxidotetrahydro-2H-1,2-thiazin-2-yl)-5-(ethyloxy) benzamide (D131)
Description 132 Methyl 3-nitro-5- [ (1E/-1-propen-1-yl] benzoate (D132) Methyl 3-nitro-5- [ Z)-1-propen-1-yl] benzoate (D132) was prepared from methyl 3-bromo-5- nitrobenzoate (D11) in an analogous manner to that described for Description 68 (D68). No molecular ion. RT = 3.42 min.
Description 133 Methyl 3-amino-5-propylbenzoate (D133) Methyl 3-amino-5-propylbenzoate (D133) was prepared from methyl 3-nitro-5- [ (1E/Z)-1- propen-1-yl] benzoate (D132) in an analogous manner to that described for Ester 116 (B116).
Description 134 Methyl 3- [ (3-buten-1-ylsulfonyl) amino]-5-propylbenzoate (D134) To a solution of methyl 3-amino-5-propylbenzoate (D133) (2.49 g, 12.9 mmol, 1 equiv) in CH2CI2 (25 ml) were added pyridine (1. 13 ml, 14 mmol, 1.1 equiv), 2-propene-1-sulfonyl chloride (2 g, 12.9 mmol, 1 equiv) and DMAP (350 mg, 2.9 mmol, 0.2 equiv) and the resulting mixture was stirred at room temperature for 4 days. The solution was diluted with AcOEt and the organic phase was washed with H20, dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 4: 1) gave methyl 3- [ (3-buten-1-ylsulfonyl) amino]-5-propylbenzoate (D134) (1.3 g, 32%) as a colourless oil. [M-H]-= 310.0, RT = 3.39 min.
Description 135 Methyl 3- [ (3-buten-1-ylsulfonyl) (2-propen-1-yl) amino]-5-propylbenzoate (D135) To a solution of methyl 3- [ (3-buten-1-ylsulfonyl) amino]-5-propylbenzoate (D134) (1.3 g, 4.2 mmol, 1 equiv), 2-propen-1-ol (280111, 4.2 mmol, 1 equiv) and triphenylphosphine (1.28 g, 4.9 mmol, 1.15 equiv) in toluene (20 ml) at room temperature was slowly added diisopropyl azodicarboxylate (964 ml, 4.9 mmol, 1.15 equiv). The resulting solution was stirred at this temperature for 30 min then concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 4: 1) gave methyl 3- [ (3-buten-1-yisulfonyl) (2- propen-1-yl) amino]-5-propylbenzoate (D135) (1.1 g, 75%) as a yellow oil.
[M+H] + = 352.1, RT = 3.63 min.
Description 136 2-Fluoro-3, 5-dinitrobenzoic acid (D136) A 70% aqueous HN03 solution (80 ml) was added dropwise to H2SO4 (160 ml). The temperature was kept below 10°C using an ice-bath. 2-Fluoro benzoic acid (14 g, 0.1 mol, 1 equiv) was added portionwise over 5 min then the colorless suspension was slowly warmed to 90°C and stirred at this temperature for 1 h then at 100°C for 3 h. The solution was then cooled to room temperature and carefully poured into ice (1 I) diluted with H2O (1. 5 1). The aqueous phase was extracted 3 times with AcOEt and the combined organic layers dried over MgS04 and concentrated in vacuo. The residue was triturated with EtaO to give 2-fluoro-3, 5-
dinitrobenzoic acid (D136) (13.6 g, 59%) as a pale yellow solid which was used in the next step without further purification. No molecular ion, RT = 2.06 min.
Description 137 Methyl 2-fluoro-3, 5-dinitrobenzoate (D137) Methyl 2-fluoro-3, 5-dinitrobenzoate (D137) was prepared in an analogous manner to Description 25 (D25) from 2-fluoro-3, 5-dinitrobenzoic acid (D136).
Description 138 Methyl 3-amino-2-fluoro-5-nitrobenzoate (D138) To a solution of methyl 2-fluoro-3, 5-dinitrobenzoate (D137) (24.4 g, 0.1 mol, 1 equiv) in AcOH (1 I) was added iron (27.5 g, 0.5 mol, 5 equiv) and the resulting suspension was vigorously stirred for 1 h. The temperature was kept below 35°C by small amount of cooling using an ice bath during that period. Toluene (200 ml) was added and the suspension filtered through a pad of celite. The remaining solution was concentrated in vacuo and the residue partitioned between AcOEt and a saturated aqueous NaHC03 solution. The two layers were separated and the aqueous phase was extracted twice with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give methyl 3-amino-2-fluoro-5-nitrobenzoate (D138) (17 g, 79%) as a yellow solid which was used in the next step without further purification. [M-H]-= 212.9, RT = 2.68 min.
Description 139 Methyl 3- [ (4-chlorobutanoyl) amino]-2-fluoro-5-nitrobenzoate (D139) To a solution of methyl 3-amino-2-fluoro-5-nitrobenzoate (D138) (12 g, 56 mmol, 1 equiv) in CH2CI2 (150 ml) at room temperature were added NEt3 (11.7 ml, 84 mmol, 1.5 equiv) and 4- chlorobutanoyl chloride (6.9 ml, 61.6 mmol, 1.1 equiv) and the resulting mixture was stirred for 2 h then washed with a 2N aqueous HCI solution and a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 4/1) gave methyl 3- [ (4- chlorobutanoyl) amino]-2-fluoro-5-nitrobenzoate (D139) (16.2 g, 91 %) as a yellow solid. [M+H] + = 319.1, RT = 3.12 min.
Description 140 Methyl 2-fluoro-5-nitro-3-(2-oxo-1-pyrrolidinyl) benzoate (D140) To a solution of methyl 3- [ (4-chlorobutanoyl) amino]-2-fluoro-5-nitrobenzoate (D139) (8.5 g, 26.7 mmol, 1 equiv) in THF (100 ml) was added NaH (60% dispersion in mineral oil, 1.17 g, 29.4 mmol, 1.1 equiv) and the resulting mixture was stirred at room temperature for 1.5 h then diluted with AcOEt. The organic phase was washed with H2O, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso- hexane/AcOEt: 2/1) gave methyl 2-fluoro-5-nitro-3-(2-oxo-1-pyrrolidinyl) benzoate (D140) (3.3 g, 43%) as a yellow solid. [M+H] + = 283.1, RT = 2.53 min.
Description 141
Methyl 3-{bis [(3-chloropropyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D141) To a solution of methyl 3-amino-2-fluoro-5-nitrobenzoate (D138) (500 mg, 2.34 mmol, 1 equiv) in CH2CI2 (50 mi) was added NEt3 (840 p1, 6.0 mmol, 2.6 equiv) then 3-chloro-1- propanesulfonyl chloride (624 µl, 5.0 mmol, 2.1 equiv) and the resulting mixture was stirred for 1 h. The organic phase was then washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo to give methyl 3- {bis [ (3-chloropropyl) sulfonyl] amino}-2-fluoro-5- nitrobenzoate (D141) (900 mg, 78%) as a brown foam which was used in the next step without further purification. No molecular ion, RT = 3.51 min.
Description 142 Methyl 3-{bisl (4-chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D142) Methyl 3- {bis [ (4-chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D142) was obtained from methyl 3-amino-2-fluoro-5-nitrobenzoate (D138) in an analogous manner to that described for methyl 3-{bis[(3-chloropropyl)sulfonyl]amino}-2-fluoro-5-nitrobenzo ate (D141) using 4-chloro-1-butanesulfonyl chloride (D20) instead of 3-chloro-1-propanesulfonyl chloride.
[M+H+NH3] + = 540.1, RT = 3.62 min.
Description 143 3- ( [ (3-Chloropropyl) sulfonyl] amino)-2-fluoro-5-nitrobenzoic acid (D143) To a solution of crude methyl 3- {bis [ (3-chloropropyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D141) (900 mg, 1.81 mmol, 1 equiv) in MeOH (25 ml) was added a 2N aqueous NaOH solution (15 mi, 30 mmol, excess) and the resulting mixture was stirred for 1 h. Most of MeOH was removed in vacuo and the residue partitioned between AcOEt and a 2N aqueous HCI solution. The two layers were separated and the aqueous phase was dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20/iso-hexane to give 3- { [ (3- chloropropyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoic acid (D143) (600 mg, 97%) as a light tan solid which was used in the next step without further purification. No molecular ion, RT = 3.05 min.
Description 144 3-{1 (4-Chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoic acid (D144) 3-{[(4-Chlorobutyl)sulfonyl]amino}-2-fluoro-5-nitrobenzoic acid (D144) was obtained from methyl 3- {bis [ (4-chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D142) in an analogous manner to the process described for 3- { [ (3- chloropropyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoic acid (D143).
Description 145 Methyl 3-{1 (3-chloropropyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D145) Methyl 3-{[(3-chloropropyl)sulfonyl]amino}-2-fluoro-5-nitrobenzoate (D145) was prepared in an analogous manner to Description 25 from 3- { [ (3- chloropropyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoic acid (D143). [M-H]-= 353.0, RT = 3.05 min.
Description 146 Methyl 3-{1 (4-chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D146) Methyl 3-{[(4-chlorobutyl)sulfonyl]amino}-2-fluoro-5-nitrobenzoate (D146) was prepared in an analogous manner to Description 25 from 3- { [ (4- chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzOic acid (D144). [M+H+NH3] + = 386.1, RT = 3. 13 min.
Description 147 Methyl 3- (1, 1-dioxido-2-isothiazolidinyl)-2-fluoro-5-nitrobenzoate (D147) To a solution of methy 3-{[(3-chloropropyl)sulfonyl]amino}-2-fluoro-5-nitrobenzoate (D145) (300 mg, 0.85 mmol, 1 equiv). in EtOH (30 ml) was added NEt3 (280 ul, 2 mmol, 2.3 equiv) and the resulting solution was refluxed for 1.5 h then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with AcOEt/Et2O to give methyl 3- (1, 1-dioxido-2-isothiazolidinyl)-2- fluoro-5-nitrobenzoate (D147) (150 mg, 55%) as a light tan solid which was used in the next step without further purification. [M+H+ NH3] + = 336.3, RT = 2.50 min.
Description 148 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-5-nitrobenzoate (D148) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-5-nitrobenzoate (D148) was prepared in an analogous manner to the process for methyl 3- (1, 1-dioxido-2-isothiazolidinyl)- 2-fluoro-5-nitrobenzoate (D147) from methyl 3-{[(4-chlorobutyl)sulfonyl]amino}-2-fluoro-5- nitrobenzoate (D146). [M+H+ NH3] + = 350.1, RT = 2.79 min.
Description 149 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2- (methyloxy)-5-nitrobenzoate (D149) To a solution of methyl 3-{[(4-chlorobutyl) sulfonyl] amino}-2-fluoro-5-nitrobenzoate (D146) (1.5 g, 4.1 mmol, 1 equiv) in MeOH (30 ml) was added NEt3 (1.2 ml 8.6 mmol, 2.1 equiv) and the resulting solution was refluxed for 15 h then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with AcOEt/Et2O to give methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2- (methyloxy)-5-nitrobenzoate (D149) (1.2 g, 55%) as a light brown solid which was used in the next step without further purification. [M+H] + = 345.1, RT = 2. 80 min.
Description 150 Methyl 5-amino-2-fluoro-3- (2-oxo-1-pyrrolidinyl) benzoate (D150) To a solution of methyl 2-fluoro-5-nitro-3-(2-oxo-1-pyrrolidinyl) benzoate (D140) (3.3 g, 11.7 mmol, 1 equiv) in EtOH (100 ml) and H20 (10 ml) were added NH4COOH (7.4 g, 117 mmol, 10 equiv) and 10% palladium on charcoal (50% wet, 660 mg, 10% w/w) and the resulting mixture was refluxed for 2 h then cooled to room temperature. The catalyst was removed by
filtration through a pad of celite and most of the solvent removed in vacuo. The residue was partitioned between AcOEt and H20 and the two layers were separated. The organic phase was dried over MgS04 and concentrated in vacuo to give methyl 5-amino-2-fluoro-3-(2-oxo-1- pyrrolidinyl) benzoate (D150) (1.85 g, 63%) as a pale yellow solid which was used in the next step without further purification. [M+H]'= 253.0, RT = 2. 12 min.
Descriptions 151-153 (D151-153) The following compounds have been made from the appropriate precursor in an analogous manner to the process described for methyl 5-amino-2-fluoro-3- (2-oxo-1-pyrrolidinyl) benzoate (D150). Description Precursor [M+H] + RT (min) Methyl 5-amino-3- (1, 1-dioxido-2-isothiazolidinyl)-2- D147 289.1 2.12 fluorobenzoate (D151) Methyl 5-amino-3- (1, 1-dioxidotetrahydro-2H-1, 2- D148 303.1 2.33 thiazin-2-yl)-2-fluorobenzoate (D152) Methyl 5-amino-3- (1, 1-dioxidotetrahydro-2H-1, 2- D149 315.1 2.18 thiazin-2-yl)-2-(methylox benzoate D153 Description 154 Methyl 2-fluoro-5-({14-(methyloxy) phenyl] methyl} amino)-3-(2-oXo-1- pyrrolidinyl) benzoate (D154) Methyl 2-fluoro-5- ( { [4- (methyloxy) phenyl] methyl} amino)-3- (2-oxo-1-pyrrolidinyl) benzoate (D154) was prepared from methyl 5-amino-2-fluoro-3-(2-oxo-1-pyrrolidinyl) benzoate (D150) in an analogous manner to the process described for Ester 35 (B35) using 4- (methyloxy) benzaldehyde instead of propionaldehydr. [M+H] + = 373.4, RT = 2.85 min.
Description 155 Methyl 5-(ethyl {[4-(methyloxy) phenylimethyl} amino)-2-fluoro-3-(2-oXo-1- pyrrolidinyl) benzoate (D155) Methyl 5-(ethyl {[4-(methyloxy) phenyl] methyl} amino)-2-fluoro-3-(2-oXo-1-pyrrolidinyl) benzoate (D155) was prepared from methyl 2-fluoro-5-({[4-(methyloxy)phenyl]methyl}amino)-3-(2-oxo-1- pyrrolidinyl) benzoate (D154) in an analogous manner to the process described for Ester 35 (B35) using acetaldehyde instead of propionaldehydr. [M+H] + = 401.4, RT = 3.11 min.
Description 156 Methyl 5-bromo-2-fluoro-3-(2-oxo-1-pyrrolidinyl) benzoate (D156) To a solution of methyl 5-amino-2-fluoro-3-(2-oxo-1-pyrrolidinyl) benzoate (D150) (650 mg, 2.6 mmol, 1 equiv) in a 48% aqueous HBr solution at 0°C was added NaNO2 portionwise and the resulting mixture was stirred at 0°C for 30 min. CuBr (260 mg, 1.82 mmol, 0.7 equiv) in a 48% aqueous HBr solution (1 mi) was added and the resulting mixture stirred at 90°C for 1 h then cooled to room temperature and partitioned between H20 and AcOEt. The two layers were separated and the organic phase was dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 2/1)
gave methyl 5-bromo-2-fluoro-3- (2-oxo-1-pyrrolidinyl) benzoate (D156) (145 mg, 18%) as a white solid. [M+H]+ = 318.1, RT = 2.51 min.
Descriptions 157-158 (D157-158) The following compounds were prepared in an analogous manner to the process described for Description 156 (D156) from the appropriate aniline : Description Precursor RT (min) Methyl 5-bromo-3- (1, 1-dioxido-2-isothiazolidinyl)-2- D151 2.55 fluorobenzoate D157 Methyl 5-bromo-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin- D152 2-yl)-2-fluorobenzoate (D158) Descriptions 159-161 (D159-161) The following compounds were prepared in an analogous manner to the process described for Description 68 (D68) from the appropriate aryl bromide indicated in the below table : Description Precursor [M+H] + RT (min) Methyl 2-fluoro-3- (2-oxo-1-pyrrolidinyl)-5- [ (1E/Z)-1- D156 278.4 2.60 propen-1-yl] benzoate D159 Methyl3- (1, 1-dioxido-2-isothiazolidinyl)-2-fluoro-5- D157 314.2 2.67 [(1 E/Z)-1-propen-1-yl] benzoate (D160) Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- D158 2-fluoro-5- [ (1E/Z)-1-propen-1-yl] benzoate (D161) Description 162 Methyl 4-methyl-3,5-dinitrobenzoate (D162) Methyl 4-methyl-3, 5-dinitrobenzoate (D162) was prepared in an analogous manner to Description 25 from commercially available 4-methyl-3, 5-dinitrobenzoic acid. [M+H] + = 240.2, RT = 3.07 min.
Description 163 Methyl 3-amino-4- (methyloxy)-5-nitrobenzoate (D163) To a solution of methyl 4- (methyloxy)-3, 5-dinitrobenzoate (D25) (5.0 g, 19.5 mmol, 1 equiv) in AcOH (150 ml) at room temperature was added iron powder (9.0 g, 161 mmol, 8.2 equiv) portionwise and the resulting mixture was stirred for 3 h. Toluene (500 ml) was added and the organic phase was filtered through a pad of celite then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Trituration of the residue with Et20/iso-hexane gave methyl 3-amino-4-(methyloxy)-5-nitrobenzoate (D163) (3.65 g, 83%) as a yellow solid which was used in the next step without further purification. [M+H] + = 226.9, RT = 2. 76 min.
Description 164 Methyl 3-amino-4-methyl-5-nitrobenzoate (D164)
Methyl 3-amino-4-methyl-5-nitrobenzoate (D164) was obtained from methyl 4-methyl-3, 5- dinitrobenzoate (D162) in an analogous manner to the process described for methyl 3-amino- 4-(methyloxy)-5-nitrobenzoate (D163). [M+H] + = 211.0, RT = 2.81 min.
Description 165 Methyl 3-iodo-4-(methyloxy)-5-nitrobenzoate (D165) To a solution of methyl 3-amino-4-(methyloxy)-5-nitrobenzoate (D163) (370 mg, 1.64 mmol, 1 equiv) in toluene (20 ml) at 0°C was added iodine (218 mg, 0.86 mmol, 0.5 equiv) then 1,1- dimethylethyl nitrite (200 mg, 1.75 mmol, 1.1 equiv) and the resulting mixture was stirred at room temperature for 15 h then partitioned between AcOEt and brine. The two layers were separated and the organic phase was dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel gave methyl 3-iodo-4- (methyloxy)-5-nitrobenzoate (D165) (280 mg, 51%) as a light brown solid. No molecular ion.
RT = 3.33 min.
Description 166 Methyl 4-(methyloxy)-3-nitro-5-[(1E/Z)-1-propen-1-yl] benzoate (D166) Methyl 4- (methyloxy)-3-nitro-5- [ (1E/Z)-1-propen-1-yl] benzoate (D166) was prepared from methyl 3-iodo-4-(methyloxy)-5-nitrobenzoate (D165) in an analogous manner to the process described for Description 68 (D68). No molecular ion. RT = 3.46 min.
Description 167 Methy ! 3-amino-4- (methyioxy)-5- [ (1E/Z)-1-propen-1-yijbenzoate (D167) To a solution of methyl 4- (methyloxy)-3-nitro-5- [ (1E/Z)-1-propen-1-yl] benzoate (D166) (1.0 g, 4.0 mmol, 1 equiv) in AcOH (150 ml) at room temperature was added iron powder (1.4 g, 25 mmol, 6.25 equiv) portionwise and the resulting mixture was stirred for 3 h at room temperature. Iron powder (1 g, 17.9 mmol, 4.2 equiv) was added and the mixture stirred for another hour. Iron powder (1 g, 17.9 mmol, 4.2 equiv) was then added again and the mixture stirred at 45°C for 3 h then cooled to room temperature and stirred at this temperature for 14 h. Toluene (200 ml) was added and the organic phase was filtered through a pad of celite then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give methyl 3-amino-4- (methyloxy)-5- [ (1E/Z)-1-propen-1-yl] benzoate (D167) (800 mg, 90%) as a brown oil which was used in the next step without further purification. [M+H] + = 222.1, RT = 2.99 min.
Description 168 Methyl 3-{bis [(4-chlorobutyl) sulfonyl] amino}-4-(methyloxy)-5-[(1E/Z)-1-propen-1- yl] benzoate (D168) To a solution of 3-amino-4- (methyloxy)-5- [ (1E/Z)-1-propen-1-yl] benzoate (D167) (800 mg, 3.6 mmol, 1 equiv) in CH2CI2 (50 ml) was added NEt3 (1.5 ml, 10.8 mmol, 3.0 equiv) then 4- chloro-1-butanesulfonyl chloride (D20) (2 g, 10.8 mmol, 3.0 equiv) and the resulting mixture was stirred for 1 h. The organic phase was then washed with a 2N aqueous HCI solution and
a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9/1 to 3/1) gave methyl 3-{bis[(4-chlorobutyl)sulfonyl]amino}-4-(methyloxy)-5-[(1E/Z )-1-propen-1- yl] benzoate (D168) (1.0 g, 52%) as a pale yellow oil.
Description 169 3-{[(4-Chlorobutyl)sulfonyl]amino}-4-(methyloxy)-5-[(1E/Z)-1 -propen-1-yl] benzoic acid (D169) To a solution of methyl 3- {bis [ (4-chlorobutyl) sulfonyl] amino}-4- (methyloxy)-5- [ (1E/Z)-1-propen- 1-yl] benzoate (D168) (1.0 g, 1.88 mmol, 1 equiv) in MeOH (20 ml) was added a 2N aqueous NaOH solution (10 ml, 20 mmol, excess) and the resulting mixture was stirred for 1 h. Most of MeOH was removed in vacuo and the residue partitioned between AcOEt and a 2N aqueous HCI solution. The two layers were separated and the aqueous phase was dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20/iso-hexane to give 3-{[(4- chlorobutyl) sulfonyl] amino}-4- (methyloxy)-5- [ (1E/Z)-1-propen-1-yl] benzoic acid (D169) (470 mg, 69%) as a light cream solid which was used in the next step without further purification.
[M-H]-= 360. 0, RT = 3. 19 min.
Description 170 Methyl 3-{[(4-chlorobutyl) sulfonyl] amino}-4-(methyloxy)-5-[(1E)-1-propen-1-yl] benzoate (D170) Methyl 3-{[(4-chlorobutyl)sulfonyl]amino}-4-(methyloxy)-5-[(1E/Z)-1 -propen-1-yl] benzoate (D170) was prepared from 3-{[(4-chlorobutyl)sulfonyl]amino}-4-(methyloxy)-5-[(1E/Z)-1 - propen-1-yl] benzoic acid (D169) in an analogous manner to Description 25 (D25).
Descriptions 171-172 (D171-172) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Description 2 (D2): Description Precursor [M+H] + RT (min) Methyl 3- [ (4-chlorobutanoyl) amino]-4- (methyloxy)-5- D163 331.0 3.13 nitrobenzoate (D171) Methyl3- [ (4-chlorobutanoyl) amino]-4-methyl-5- D164 315.1 3.02 nitrobenzoate (D172) Descriptions 173-174 (D173-174) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Description 14 (D14) : Description Precursor [M-H]-RT (min) Methyl 3- { [ (3-chloropropyl) sulfonyl] amino}-4- D163 364.9 3.10 methyloxy)-5-nitrobenzoate (D173 Methyl 3- { [ (3-chloropropyl) sulfonyl] amino}-4-methyl- D164 349.0 3.12 5-nitrobenzoate (D174)
Descriptions 175-176 (D175-176) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Description 14 (D14) using 4-chloro-1- butanesulfonyl chloride (D20) instead of 3-chloro-1-propanesulfonyl chloride : Description Precursor [M-H]- RT (min Methyl 3-{[(4-chlorobutyl)sulfonyl]amino}-4- D163 (methyloxy)-5-nitrobenzoate (D175) Methyl3- { [ (4-chlorobutyl) sulfonyl] amino}-4-methyl- D164 362.8 3.21 5-nitrobenzoate (D176) Descriptions 177-178 (D177-178) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Ester 27 (B27): Description Precursor [M+H] + RT (min) Methyl 4- (methyloxy)-3-nitro-5- (2-oxo-1-pyrrolidinyl) D171 295.1 2.61 benzoate (D177) Methyl 4-methyl-3-nitro-5-(2-oxo-1-pyrrolidinyl) D172 279.0 2.60 benzoate D178 Descriptions 179-182 (D179-182) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Description 15 (D15) : Description Precursor [M+H] + RT (min) Methyl3- (1, 1-dioxido-2-isothiazolidinyl)-4- D173 331.0 2.78 (methyloxy)-5-nitrobenzoate (D179) Methyl 3-(1,1-dioxido-2-isothiazolidinyl)-4-methyl-5- D174 nitrobenzoate D180 Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- D175 345.0 2.90 4-(methyloxy)-5-nitrobenzoate (D181 Methyl 3-(1,1-dioxidotetrahydro-2H-1,2-thiazin-2-yl)- D176 329.0 2.93 4-methyl-5-nitrobenzoate (D182) Descriptions 183-188 (D183-188) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for the synthesis of Description 16 (D16) using the appropriate precursor indicated in the below table : Description Precursor [M+H] + RT (min) methyl 3-amino-4-(methyloxy)-5-(2-oxo-1-D177 265.1 2.18 pyrrolidinyl) benzoate (D183) methyl 3-amino-4-methyl-5-(2-oxo-1-pyrrolidinyl) D178 249.1 2.16 benzoate (D184) methyl 3-amino-5-(1,1-dioxido-2-isothiazolidinyl)-4- D179 301.0 2.25 (methyloxy) benzoate D185 methyl 3-amino-5- (1, 1-dioxido-2-isothiazolidinyl)-4- D180 285.0 2.22 methylbenzoate (D186) methyl3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2- D181 315.1 2.40 thiazin-2-yl)-4-(methyloxy) benzoate (D187) methyl3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2- D182 299.0 2.42 thiazin-2-yl)-4-methylbenzoate (D188)
Description 189 4- ( (Z/E)-But-2-enylamino)-3, 5-diiodo-benzoic acid ethyl ester (D189) To a solution of 4-amino-3, 5-diiodo-benzoic acid ethyl ester (commercially available from Maybridge) (72.6 g, 0.17 mmol, 1 equiv) in DMF (450 ml) at 0°C under nitrogen was added NaH (60% in mineral oil, 7.3 g, 0.18 mmol, 1.05 equiv) portionwise over 2 min. After 10 min crotyl bromide (21.5 ml, 0.21 mmol, 1.2 equiv) in DMF (50 ml) was added via cannula over 5 min and the resulting mixture was allowed to warm to room temperature over 30 min. 5 MI of EtOH were added and the mixture was concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with H20. The aqueous phase was extracted with AcOEt and the combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo to give 4- ( (Z/E)-but-2-enylamino)-3, 5-diiodo-benzoic acid ethyl ester (D189) (82 g, 100%) as a pink solid which was used in the next step without further purification. [M+H] + = 472.0, RT = 4.93 min.
Description 190 3-Ethyl-7-iodo-1 H-indole-5-carboxylic acid ethyl ester (D190) To a solution of 4- ( (Z/E)-but-2-enylamino)-3, 5-diiodo-benzoic acid ethyl ester (D189) (15 g, 31.8 mmol, 1 equiv) in DMF (150 ml) at room temperature under nitrogen were added Pd (OAc) 2 (357 mg, 1.6 mmol, 0.05 equiv), NaCOOH (6.5 g, 95.6 mmol, 3 equiv), Na2CO3 (8.4 g, 79.6 mmol, 2.5 equiv) and NBu4CI (8.0 g, 35.0 mmol, 1.1 equiv). The resulting suspension was stirred under nitrogen at 80°C for 30 min then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H20 and the two phases were separated. The organic phase was dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9/1) gave 3-ethyl-7-iodo-1 H-indole-5-carboxylic acid ethyl ester (D190) (6.3 g, 58%) as a white solid. [M+H] + = 344.0, RT = 3.86 min.
Description 191 1, 1-Dimethylethyl 3-bromo-5-(2-oxo-5-phenyl-1-piperidinyl) benzoate (D191) A flask was charged under nitrogen with 3-bromo-5-iodo-benzoic acid methyl ester (D8b) (840 mg, 2.2 mmol, 1.1 equiv), Cs2CO3 (900 mg, 2.8 mmol, 1.4 equiv), tris (dibenzylideneacetone) dipalladium (0) (92 mg, 0.1 mmol, 0.05 equiv), Xantphos (120 mg, 0.2 mmol, 0.1 equiv) and toluene (40 ml). 5-Phenyl-2-piperidinone (Koelsch, J. Am. Chem.
Soc. 1943, (65), 2093,350 mg, 2 mmol, 1equiv) was then added and the resulting mixture was stirred at 100 C for 2.5 h then cooled to room temperature and concentrated in vacuo.
The residue was partitioned between AcOEt and a saturated aqueous NaHCO3 solution. The
layers were separated and the organic phase was dried over MgS04 and concentrated in vacuo to give a solid residue. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 4/1 to 1/1) gave 1, 1-dimethylethyl 3-bromo-5-(2-oxo-5-phenyl-1- piperidinyl) benzoate (D191) (480 mg, 51%) as a white solid. [M+H] + = 432.2, RT = 3.82 min.
Description 192 1, 1-Dimethylethyl 3- (2-oxo-5-phenyl-1-piperidi nyl)-5- [ (1 E/-1-propen-1-yl] benzoate (D192) 1, 1-Dimethylethyl 3- (2-oxo-5-phenyl-1-piperidinyl)-5- [ (1E/Z)-1-propen-1-yl] benzoate (D192) was prepared in an analogous manner to the process described for Description 68 (D68) from 1, 1-dimethylethyl 3-bromo-5-(2-oxo-5-phenyl-1-piperidinyl) benzoate (D191). [M+H] + = 392.3, RT = 3.83 min.
Description 193 Methyl 3- (I, I-dioxidotetrahydro-2H-1, 2-thiazin-2-yi)-5-nitrobenzoate (Dl93) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (D193) was obtained from methyl 3-bromo-5-nitrobenzoate (D11) in an analogous manner to the process described for Description 15 (D15) (alternative procedure) using tetrahydro-2H-1,2-thiazine 1,1-dioxide (D22b) instead of isothiazolidine 1,1-dioxide (D22a). [M+H+NH3] + = 332.2, RT = 2.75 min.
Description 194 Methyl 3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D194) Methyl 3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D194) was obtained from methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (D193) in an analogous manner to the process described for Description 2 (D2).
[M+H] + = 285. 1, RT = 2. 12 min.
Description 195 Methyl 3- [ (4-chlorobutanoyl) amino]-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D195) Methyl 3- [ (4-chlorobutanoyl) amino]-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D195) was obtained from methyl 3-amino-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D16) in an analogous manner to the process described for Description 13 (D13).
Description 196 Methyl 3-amino-4-methyl-5-nitrobenzoate (D196) To a solution of methyl 4-methyl-3, 5-dinitrobenzoate (D162) (30 g, 0.125 mmol, 1 equiv) in MeOH (150 ml) and cyclohexene (300 ml) was added 10% palladium on charcoal (50% wet, 3 g, 5% w/w) and the resulting suspension was refluxed for 7 h then cooled to room temperature. The catalyst was filtered off through a pad of celite and most of the solvent was removed in vacuo. The precipitate formed was filtered off to give methyl 3-amino-4-methyl-5- nitrobenzoate (D196) (22 g, 84%) as a yellow solid which was used in the next step without further purification. [M+H] + = 211.0, RT = 2.81 min.
Description 197 Methyl 4-nitro-1H-indazole-6-carboxylate (D197) To a suspension of 3-amino-4-methyl-5-nitrobenzoate (D196) (3.5 g, 16.7 mmol, 1 equiv) in H20 (100 ml) at 0°C was added 36% aqueous HCI solution (15 mi) and the resulting suspension was treated with NaN02 (1.35 g, 19.6 mmol, 1.2 equiv) then warmed to room temperature and stirred for 1.5 h. The insoluble material was removed by filtration and small amounts of urea were added to the mother liquors. The resulting solution was diluted with H20 (500 ml) and treated with H2SO4 (17.5 ml) then heated at 50°C for 15 min, cooled to room temperature and extracted with AcOEt. The organic phase was dried over MgS04 then concentrated in vacuo. The residue was triturated with MeOH to give methyl 4-nitro-1 H- indazole-6-carboxylate (D197) (0.8 g, 22%) as a cream solid which was used in the next step without further purification. [M+H] + = 222.1, RT = 2.84 min.
Description 198 Methyl 1-ethyl-4-nitro-1 H-indazole-6-carboxylate (D198) To a solution of methyl 4-nitro-1H-indazole-6-carboxylate (D197) (500 mg, 2.3 mmol, 1 equiv) in DMF (10 ml) at room temperature was added K2CO3 (346 mg, 2.5 mmol, 1.1 equiv) then ethyl iodide (200 gl, 2.5 mmol, 1.1 equiv). The resulting suspension was stirred at room temperature for 15 min then at 40°C for 30 min, cooled to room temperature and partitioned between AcOEt and a 2N aqueous HCI solution. The two layers were separated and the organic phase dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 2/1) gave methyl 1-ethyl-4-nitro-1 H- indazole-6-carboxylate (D198) (200 mg, 35%) as a pale yellow solid. [M+H]+ = 250.1, RT = 3.11 min.
Description 199 Methyl 4-amino-1-ethyl-1H-indazole-6-carboxylate (D199) To a solution of methyl 1-ethyl-4-nitro-1H-indazole-6-carboxylate (D198) (2.2 g, 8.8 mmol, 1 equiv) in MeOH (100 mi) and H2O (10 mi) was added 10% palladium on charcoal (50% wet, 700 mg, 16% w/w) and the resulting mixture was stirred at 60°C for 30 min then cooled to room temperature. The catalyst was removed by filtration through a pad of celite and most of the solvent removed in vacuo. The residue was partitioned between AcOEt and a saturated aqueous NaHC03 solution and the two layers were separated. The organic phase was dried over MgS04 and concentrated in vacuo. The residue was triturated with iso-hexane to give methyl 4-amino-1-ethyl-1H-indazole-6-carboxylate (D199) (1.55 g, 80%) which was used in the next step without further purification. [M+H] + = 220.1, RT = 3.31 min.
Description 200 Methyl 4- [ (E)-2- (dimethylamino) ethenyl]-3, 5-dinitrobenzoate (D200) To a solution of methyl 4-methyl-3, 5-dinitrobenzoate (D162) (20 g, 83.3 mmol, 1 equiv) in DMF (30 ml) was added N, N-dimethylformamide dimethylacetal (35 ml, excess) and the resulting solution was stirred at 45°C for 30 min then cooled to room temperature and concentrated in vacuo. Trituration of the residue with Et20/iso-hexane gave methyl 4-[(E)-2-
(dimethylamino) ethenyl]-3, 5-dinitrobenzoate (D200) (20 g, 81 %) as a dark red solid which was used in the next step without further purification.
Description 201 Methyl 4-amino-1H-indole-6-carboxylate (D201) To a solution of methyl 4- [ (E)-2- (dimethylamino) ethenyl]-3, 5-dinitrobenzoate (D200) (10 g, 34 mmol, 1 equiv) in MeOH (250 ml) was added 10% palladium on charcoal (50% wet, 1.0 g, 5% w/w) and the resulting mixture was stirred under an atmosphere of hydrogen for 7 h. The catalyst was removed by filtration through a pad of celite and the solution concentrated in vacuo. The residue was triturated with AcOEt/iso-hexane to give methyl 4-amino-1 H-indole-6- carboxylate (D201) (5 g, 77%) as a dark pink solid. [M+H] + = 191.0, RT = 1.20 min.
Description 202 Methyl 4-amino-1-ethyl-1H-indole-6-carboxylate (D202) To a solution of methyl 4-amino-1 H-indole-6-carboxylate (D201) (900 mg, 4,74 mmol, 1 equiv) in DMF (25 mi) at room temperature was added NaH (60% dispersion in mineral oil, 200 mg, 5 mmol, 1.05 equiv) and after 15 min ethyl iodide (400 pI, 5 mmol, 1.05 equiv). The resulting mixture was stirred for 30 min then most of the solvent was removed in vacuo. The residue was diluted with AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 1/1) gave an oil which was diluted with Et20 and treated with a 4N HCI solution in Et20. The precipitate obtained was filtrated off to give methyl 4-amino-1-ethyl-1H-indole-6-carboxylate hydrochloride salt (D202) (800 mg, 66%) as a white solid. [M+H] + = 219.0, RT = 2.50 min.
Description 203 Methyl 4-amino-3,5-dinitrobenzoate (D203) Methyl 4-amino-3,5-dinitrobenzoate (D203) was prepared in an analogous manner to Description 25 from commercially available 4-amino-3,5-dinitrobenzoic acid.
[M-H]-= 240.1, RT = 2.42 min.
Description 204 Methyl 3, 4-diamino-5-nitrobenzoate (D204) To a solution of methyl 4-amino-3,5-dinitrobenzoate (D203) (3.0 g, 12.4 mmol, 1 equiv) in MeOH (40 mi) and cyclohexane (80 mi) was added 10% palladium on charcoal (50% wet, 2.0 g, 33% w/w) and the resulting mixture was refluxed for 30 min then cooled to room temperature. The catalyst was filtered off through a pad of celite and washed with DMF. The combined organic phases were concentrated in vacuo and the residue triturated with Et20/iso- hexane to give methyl 3,4-diamino-5-nitrobenzoate (D204) (2.1 g, 80%) as a red solid which was used in the next step without further purification.
[M+H] + = 212.2, RT = 2.46 min.
Description 205 Methyl 4-amino-3- (ethylamino)-5-nitrobenzoate (D205) To a solution of methyl 3,4-diamino-5-nitrobenzoate (D204) (1.5 g, 7.1 mmol, 1 equiv) in DMF (30 ml) at room temperature was added K2CO3 (2.2 g, 16.0 mmol, 2.25 equiv) then ethyl iodide (1.28 ml, 16.0 mmol, 2.25 equiv). The resulting suspension was stirred at 60°C for 2 h then ethyl iodide (1 ml, 12.5 mmol, 1.8 equiv) was added and the resulting mixture stirred for another 6 h then cooled to room temperature and partitioned between AcOEt and a saturated aqueous NaHC03 solution. The two layers were separated and the organic phase washed with H2O, dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give methyl 4-amino-3- (ethylamino)-5-nitrobenzoate (D205) (0.85 g, 50%) as a red solid which was used in the next step without further purification. [M+H] + = 240.2, RT = 2.95 min.
Description 206 Methyl 1-ethyl-4-nitro-1H-benzimidazole-6-carboxylate (D206) Methyl 4-amino-3- (ethylamino)-5-nitrobenzoate (D205) (850 mg, 3.55 mmol, 1 equiv) was dissolved in formic acid (20 ml) and the resulting solution was stirred at 100°C for 45 min then cooled to room temperature and diluted with AcOEt (200 ml). The organic phase was washed with a 2N aqueous NaOH solution, dried over MgS04 and concentrated in vacuo to give methyl 1-ethyl-4-nitro-1 H-benzimidazole-6-carboxylate (D206) (700 mg, 79%) as a tan solid which was used in the next step without further purification. [M+H] + = 250.1, RT = 2.41 min.
Description 207 Methyl 4-amino-1-ethyl-1H-benzimidazole-6-carboxylate (D207) To a solution of methyl 1-ethyl-4-nitro-1H-benzimidazole-6-carboxylate (D206) (700 mg, 2.81 mmol, 1 equiv) in MeOH (50 ml) and H20 (5 ml) was added 10% palladium on charcoal (50% wet, 400 mg, 28% w/w) and NH4COOH (1.77 g, 28.1 mmol, 10 equiv) and the resulting mixture was stirred at 70°C for 30 min then cooled to room temperature. The catalyst was filtered off through a pad of celite and most of the MeOH was removed in vacuo. The residue was diluted with AcOEt and the organic layer was washed with a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give methyl 4-amino-1-ethyl-1H- benzimidazole-6-carboxylate (D207) (500 mg, 81 %) as a white solid which was used in the next step without further purification. [M+H] + = 220.2, RT = 2.17 min.
Description 208 Methyl 4- [ (2-chloroethyl) amino] -3,5-dinitrobenzoate (D208) To a solution of methyl 4-chloro-3, 5-dinitrobenzoate (D25a) (5.0 g, 19.2 mmol, 1 equiv) in MeOH (300 ml) was added 2-chloroethylamine hydrochloride (4.64 mg, 40 mmol, 2.1 equiv) and NEt3 (5.5 ml, 40 mmol, 2.1 equiv) and the resulting mixture was refluxed for 5 min then cooled to room temperature. Most of the solvent was evaporated in vacuo and the residue filtered off to give methyl 4-[(2-chloroethyl) amino] -3,5-dinitrobenzoate (D208) (9 g, 156%) as a yellow solid which was used in the next step without further purification.
[M+H] + = 304.1, RT = 3.06 min.
Description 209 Methyl 8-nitro-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (D209) To a solution of crude methyl 4-[(2-chloroethyl) amino] -3,5-dinitrobenzoate (D208) (9 g, 19.2 mmol, 1 equiv) in MeOH (75 ml) and cyclohexene (150 ml) was added 10% palladium on charcoal (50% wet, 4.5 g, 25% w/w) and the resulting mixture was refluxed for 3 h then cooled to room temperature. The catalyst was filtered off through a pad of celite and most of the solvent was removed in vacuo. The residue was partitioned between AcOEt and a 2N aqueous HCI solution and the two layers were separated. The aqueous phase was extracted twice with AcOEt and the combined organic layers were washed with a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 1/1) gave methyl 8-nitro-1,2, 3,4- tetrahydro-6-quinoxalinecarboxylate (D209) (1.5 g, 34%) as a red solid. [M-H]-= 236. 2, RT = 2.65 min.
Description 210 Methyl 4-ethyl-8-nitro-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (D210) Methyl 4-ethyl-8-nitro-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (D210) was prepared from methyl 8-nitro-1,2, 3, 4-tetrahydro-6-quinoxalinecarboxylate (D209) in an analogous manner to the process described for Ester 35 (B35) using acetaldehyde instead of propionaldehyde.
[M+H] + = 266.3, RT = 3.07 min.
Description 211 Methyl 8-amino-4-ethyl-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (D211) Methyl 8-amino-4-ethyl-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (D211) was prepared from methyl 4-ethyl-8-nitro-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (D210) in an analogous manner to the process described for Description 207 (D207). [M+H] + = 236.2, RT = 2.23 min.
Description 212 Ethyl 4-amino-3-nitrobenzoate (D212) Ethyl 4-amino-3-nitrobenzoate (D212) was prepared in an analogous manner to Description 25 from commercially available 4-amino-3-nitrobenzoic acid using EtOH as solvent instead of MeOH.
Description 213 Ethyl 4-amino-3-bromo-5-nitrobenzoate (D213) To a solution of ethyl 4-amino-3-nitrobenzoate (D212) (21.0 g, 100 mmol, 1 equiv) in CH2CI2 (500 ml) at room temperature was added bromine (6.7 mi, 130 mmol, 1.3 equiv) and the resulting mixture was refluxed for 4 h then bromine (2 ml, 40 mmol, 0.4 equiv) was added and the resulting mixture refluxed for another 3 h then cooled to room temperature. The organic phase was washed twice with a 10% aqueous Na2S203 solution and twice with H20, dried over MgS04 and concentrated in vacuo to give ethyl 4-amino-3-bromo-5-nitrobenzoate (D213) (27.1 g, 94%) as a yellow solid which was used in the next step without further purification.
Description 214 Ethyl 3-bromo-5-nitro-4-[(trifluoroacetyl) amino] benzoate (D214) To a solution of ethyl 4-amino-3-bromo-5-nitrobenzoate (D213) (27.1 g, 93.1 mmol, 1 equiv) in CH2CI2 (500 ml) at room temperature was added N, N-diisopropylethylamine (22 ml, 130 mmol, 1.4 equiv) and trifluoroacetic acid anhydride (15.8 ml, 111.7 mmol, 1.2 equiv) and the resulting mixture was stirred for 2 h. N, N-diisopropylethylamine (22 ml, 130 mmol, 1.4 equiv) and trifluoroacetic acid anhydride (15.8 ml, 111.7 mmol, 1.2 equiv) were added and the resulting mixture was stirred for another 2 h. H2O was added and the two layers were separated. The organic phase was washed twice with a 2N aqueous HCI solution, H2O, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9/1 to 3/1) gave ethyl 3-bromo-5-nitro-4- [(trifluoroacetyl) amino] benzoate (D214) (29.4 g, 82%) as a yellow solid.
Description 215 Ethyl 3-bromo-4- [ (3-methyl-2-buten-1-yi) (trifluoroacetyl) amino] -5-nitrobenzoate (D215) To a solution of ethyl 3-bromo-5-nitro-4- [ (trifluoroacetyl) amino] benzoate (D214) (12.0 g, 31.3 mmol, 1 equiv) in CH3CN (100 mi) was added K2CO3 (5.6 g, 40 mmol, 1.3 equiv) and 1- bromo-3-methyl-2-butene (5.1 mi, 43.8 mmol, 1.4 equiv) and the resulting mixture was refluxed for 1 h then cooled to room temperature. The precipitate formed was filtered off through a pad of celite and washed with CH3CN. The combined organic layers were concentrated in vacuo and the residue diluted with AcOEt. The organic layer was washed with brine, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9/1 to 4/1) gave ethyl 3-bromo-4- [ (3-methyl- 2-buten-1-yl) (trifluoroacetyl) amino] -5-nitrobenzoate (D215) (12.9 g, 91%) as an orange oil.
Descriptions 216-217 (D216-217) The following compounds were obtained from ethyl 3-bromo-5-nitro-4- [ (trifluoroacetyl) amino] benzoate (D214) in an analogous manner using the appropriate allyl bromide: Description Allyl bromide Ethyl 3-bromo-4- [ (2E/Z)-2-buten-1-yl (trifluoroacetyl) amino]-5-/Br nitrobenzoate (D216) Ethyl 3-bromo-5-nitro-4-[2-propen-1-XzBr yl (trifluoroacetyl) amino] benzoate (D217) Description 218 Ethyl 3- (1-methylethyl)-7-nitro-1H-indole-5-carboxylate (D218) To a solution of ethyl 3-bromo-4- [ (3-methyl-2-buten-1-yl) (trifluoroacetyl) amino] -5- nitrobenzoate (D215) (12.9 g, 28.5 mmol, 1 equiv) in DMF (130 ml) were added HCOONa (1.94 g, 28.5 mmol, 1 equiv), Na2CO3 (7.54 g, 71.2 mmol, 2.5 equiv), Bu4NCI (8.7 g, 31.3 mmol, 1.1 equiv) and palladium (II) acetate (320 mg, 1.42 mmol, 0.05 equiv) and the resulting mixture was stirred under nitrogen for 1 h then cooled to room temperature and concentrated
in vacuo. The residue was partitioned between AcOEt and H20 and the two layers were separated. The insoluble material in the aqueous phase was filtered off through a pad of celite and the aqueous layer extracted twice with AcOEt. The combined organic layers were washed with brine, dried over MgS04 and concentrated in vacuo to give methyl 3- (1-methylethyl)-7- nitro-1 H-indole-5-carboxylate (D218) (10.1 g, 128%) as a black solid which was used in the next step without further purification.
Descriptions 219-220 (D219-220) The following compounds were obtained in an analogous manner using the appropriate precursor: Description Precursor Ethyl 3-ethyl-7-nitro-1 H-indole-5-carboxylate (D219) D216 Ethyl 3-methyl-7-nitro-1H-indole-5-carboxylate (D220) D217 Description 221 Ethyl 7-amino-3- (1-methylethyl)-1H-indole-5-carboxylate (D221) To a solution of crude ethyl 3- (1-methylethyl)-7-nitro-1H-indole-5-carboxylate (D218) (10.1 g, 28.5 mmol, 1 equiv) in MeOH (250 mi) and H20 (25 mi) was added 10% palladium on charcoal (50% wet, 1.5 g, 8% w/w) and NH4COOH (17 g, 280 mmol, 10 equiv) and the resulting mixture was stirred at 70°C for 3 h then cooled to room temperature. The catalyst was filtered off through a pad of celite and most of the MeOH was removed in vacuo. The residue was diluted with AcOEt and the organic layer was washed with a saturated NaHC03 aqueous solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 3/1 to 1/1) gave methyl 7-amino-3- (1- methylethyl)-1 H-indole-5-carboxylate (D221) (1.47 g, 21 %) as a white solid.
Descriptions 222-223 (D222-223) The following compounds were obtained in an analogous manner to the process described for Description 221 using the appropriate precursor: Description Precursor Ethyl 7-amino-3-ethyl-1H-indole-5-carboxylate (D222) D219 Ethyl 7-amino-3-methyl-1H-indole-5-carboxylate (D223) D220 Descriptions 224-230 (D224-230) The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Description 2 (D2): DescriDtion Precursor [M+H1+ RT (min) Ethyl 7- [ (4-chlorobutanoyl) amino]-3-methyl-I H-D223 indole-5-carboxylate (D224) Ethyl 7-[(4-chlorobutanoyl) amino]-3-ethyl-1H-D222 indole-5-carboxylate (D225) Ethyl 7-[(4-chlorobutanoyl) amino]-3-(1-D221 methylethyl)-1H-indole-5-carboxylate (D226) Methyl 4- [ (4-chlorobutanoyl) amino]-1-ethyl-1H- D207 benzimidazole-6-carboxylate (D227) Methyl 4- [ (4-chlorobutanoyl) amino]-lH-indole-6- D201 295. 0 2.63 carboxylate (D228) Methyl 4- [ (4-chlorobutanoyl) amino]-1-ethyl-1H D199 324.3 2.70 indazole-6-carboxylate (D229) Methyl 8- [ (4-chlorobutanoyl) amino]-4-ethyl- D211 340.2 2.73 1,2, 3, 4-tetrahydro-6-quinoxalinecarboxylate (D230)
Description 231 Methyl 4-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-6-carboxylate (D231) Methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-6-carboxylate (D231) was obtained from 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-6-carboxylic acid (A155) in an analogous manner to Description 25 (D25).
Description 232 1- (1, 1-Dimethylethyl) 6-methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole- 1, 6-dicarboxylate (D232) To a solution of methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-6-carboxylate (D231) (308 mg, 1.0 mmol, 1 equiv) in CH2CI2 (10 ml) were added NEt3 (166 RI, 1.2 mmol, 1.2 equiv), bis (1, 1-dimethylethyl) dicarbonate (251 mg, 1.15 mmol, 1.15 equiv) and DMAP (12 mg, 0.1 mmol, 0.1 equiv) and the resulting mixture was stirred at room temperature for 30 min. The organic phase was washed with a 2N aqueous HCI solution and a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Trituration in Et20/iso-hexane gave 1- (1, 1-dimethylethyl) 6-methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin- 2-yl)-1 H-indole-1, 6-dicarboxylate (D232) (150 mg, 37%) as a white solid which was used in the next step without further purification. [M+H+NH3] + = 426.2, RT = 3.38 min.
Description 233 1- (1, 1-Dimethylethyl) 6-methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro- 1H-indole-1, 6-dicarboxylate (D233) 1- (1, 1-Dimethylethyl) 6-methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1H- indole-1, 6-dicarboxylate (D233) was obtained from 1-(1,1-dimethylethyl) 6-methyl 4-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-1, 6-dicarboxylate (D232) in an analogous manner to the process described for Ester 116 (B116). No molecular ion, RT = 3.23 min.
Description 234 Methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1 H-indole-6-carboxylate hydrochloride salt (D234) 1- (1, 1-Dimethylethyl) 6-methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1H- indole-1, 6-dicarboxylate (D233) (500 mg, 1.2 mmol, 1 equiv) was dissolved in a 4N HCI
solution in Et2O (10 mi, 40 mmol, excess) and the resulting solution was stirred at room temperature for 1 h then concentrated in vacuo. Trituration of the residue with Et2O gave methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1 H-indole-6-carboxylate hydrochloride salt (D234) (430 mg, 100%) as a white solid which was used in the next step without further purification. [M+H] + = 311. 0, RT = 2. 16 min.
Description 235 <BR> <BR> <BR> Methyl 1-acetyl-4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1 H-indole-6- carboxylate (D235) To a solution of methyl 4-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1H-indole-6- carboxylate hydrochloride salt (D234) (350 mg, 1.0 mmol, 1 equiv) in AcOEt (5 ml) were added NEt3 (140 ml, 1.0 mmol, 1 equiv) and acetic anhydride (0.5 ml, 5.6 mmol, 5.6 equiv) and the resulting mixture was stirred at 50°C for 30 min then cooled to room temperature and washed with a 2N aqueous HCI solution followed by a saturated aqueous NaHC03 solution, then dried over MgS04 and concentrated in vacuo to give methyl 1-acetyl-4- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1H-indole-6-carboxylate (D235) as a white solid which was used in the next step without further purification. [M+H]+ = 353.2, RT = 2.24 min.
Description 236 Methyl 4-{bisl (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-indole-6-carboxylate (D236) To a solution of methyl 4-amino-1-ethyl-1 H-indole-6-carboxylate hydrochloride salt (D202) (1.7 g, 6.68 mmol, 1 equiv) in CH2CI2 (50 ml) was added NEt3 (4.2 ml, 30 mmol, 4.5 equiv) then 3-chloro-1-propanesulfonyl chloride (1.8 ml, 15.0 mmol, 2.2 equiv) and the resulting mixture was stirred for 2 h. The organic phase was washed with a 2N aqueous HCI solution and a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 1/1) gave methyl 4- {bis [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-indole-6-carboxylate (D236) (1.85 g, 55%) as a light tan solid. [M-H]-= 498.1, RT = 3.51 min.
Description 237 Methyl 4- {bis [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-indazole-6-carboxylate (D237) Methyl 4- {bis [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1 H-indazole-6-carboxylate (D237) was obtained from methyl 4-amino-1-ethyl-1H-indazole-6-carboxylate in an analogous manner to the process described for methyl 4-{bis[(3-chloropropyl)sulfonyl]amino}-1-ethyl-1H-indole-6- carboxylate (D236). [M+H] + = 500.1, RT = 3.50 min.
Description 238 Methyl 8-{bisl (3-chloropropyl) sulfonyl] amino}-4-ethyl-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxylate (D238) Methyl 8-{bis[(3-chloropropyl)sulfonyl]amino}-4-ethyl-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxylate (D238) was obtained from methyl 8-amino-4-ethyl-1, 2,3, 4-tetrahydro- 6-quinoxalinecarboxylate (D211) in an analogous manner to the process described for methyl
4- {bis [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1 H-indole-6-carboxylate (D236). [M+H] + = 517.2, RT = 3. 32 min.
Description 239 Methyl 4-{bisl (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-benzimidazole-6-carboxylate (D239) Methyl 4-{bis[(3-chloropropyl)sulfonyl]amino}-1-ethyl-1H-benzimidaz ole-6-carboxylate (D239) was obtained from methyl 4-amino-1-ethyl-1 H-benzimidazole-6-carboxylate (D207) in an analogous manner to the process described for methyl 4- {bis [ (3-chloropropyl) sulfonyl] amino)- 1-ethyl-1 H-indole-6-carboxylate (D236). [M+H] + = 500.3, RT = 3.20 min.
Description 240 4-{1 (3-Chloropropyl) sulfonyl] amino}-1-ethyl-1H-indole-6-carboxylic acid (D240) To a solution of methyl 4- {bis [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-indole-6-carboxylate (D236) (1.8 g, 3.6 mmol, 1 equiv) in MeOH (100 ml) was added a 2N aqueous NaOH solution (20 ml, 40 mmol, excess) and the resulting mixture was stirred for 1 h. Most of MeOH was removed in vacuo and the residue partitioned between AcOEt and a 2N aqueous HCI solution.
The two layers were separated and the aqueous phase was dried over MgS04 and concentrated in vacuo to give 4-{[(3-chloropropyl)sulfonyl]amino}-1-ethyl-1H-indole-6- carboxylic acid (D240) (930 mg, 75%) as a brown oil which was used in the next step without further purification.
Description 241 Methyl 4- { [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-indole-6-carboxylate (D241) Methyl 4-{[(3-chloropropyl)sulfonyl]amino}-1-ethyl-1H-indole-6-carb oxylate (D241) was obtained from 4-{[(3-chloropropyl)sulfonyl]amino}-1-ethyl-1H-indole-6-carb oxylic acid (D240) in an analogous manner to Description 25 (D25). [M+H] + = 359.2, RT = 3.12 min.
Description 242 Ethyl 7-{1 (4-chlorobutyl) sulfonyl] amino}-3-ethyl-1H-indole-5-carboxylate (D242) To a solution of ethyl 7-amino-3-ethyl-1H-indole-5-carboxylate (D222) (150 mg, 0.65 mmol, 1 equiv) in CH2CI2 (10 ml) at room temperature were added pyridine (115 pI, 1.42 mmol, 2.2 equiv), 4-chloro-1-butanesulfonyl chloride (D20) (259 mg, 1.36 mmol, 2.1 equiv) and DMAP (8 mg, 0.065 mmol, 0.1 equiv) and the resulting mixture was stirred for 1 h then diluted with AcOEt and washed with a 2N aqueous HCI solution and brine, then dried over MgSO4 and concentrated in vacuo to give ethyl 7-{[(4-chlorobutyl)sulfonyl]amino}-3-ethyl-1H-indole-5- carboxylate (D242) (230 mg, 92%) as a purple oil which was used in the next step without further purification. [M+H] + = 387.3, RT = 3.35 min.
Description 243 Ethyl 7-{1 (3-chloropropyl) sulfonyl] amino}-3-ethyl-1H-indole-5-carboxylate (D243) Ethyl 7-{[(3-chloropropyl)sulfonyl]amino}-3-ethyl-1H-indole-5-carb oxylate (D243) was obtained from ethyl 7-amino-3-ethyl-1H-indole-5-carboxylate (D222) in an analogous manner to the
process described for Description 242 (D242) using 3-chloro-1-propanesulfonyl chloride instead of 4-chloro-1-butanesulfonyl chloride (D20). [M+H] + = 373.0, RT = 3.49 min.
Description 244 3,4-Diamino-5-nitrobenzoic acid (D244) To a solution of 4-amino-3, 5-dinitrobenzoic acid (10 g, 44 mmol, 1 equiv) in DME (100 mi) and CHCI3 (10 ml) under nitrogen was added 10% palladium on charcoal (50% wet, 1 g, 5% w/w) and the resulting suspension was stirred under an atmosphere of nitrogen (35 psi) for 15 h.
10% Palladium on charcoal (50% wet, 1 g, 5% w/w) was added and the resulting suspension was stirred under an atmosphere of hydrogen (35 psi) for another 15 h. The catalyst was filtered off through a pad of celite and the solution was concentrated in vacuo to give 3,4- diamino-5-nitrobenzoic acid (D244) (9.85 g, 113%) as a red solid which was used in the next step without further purification. [M-H]-= 196.1, RT = 2.15 min Description 245 Methyl 3,4-diamino-5-nitrobenzoate (D245) Methyl 3,4-diamino-5-nitrobenzoate (D245) was prepared in an analogous manner to Description 25 from 3,4-diamino-5-nitrobenzoic acid (D244). [M+H] + = 212.2, RT = 2.40 min.
Description 246 Methyl 4-nitro-1H-1, 2, 3-benzotriazole-6-carboxylate (D246) To a solution of methyl 3,4-diamino-5-nitrobenzoate (D245) (2.5 g, 12 mmol, 1 equiv) in AcOH (10 ml) at room temperature was added NaNO2 (900 mg, 13 mmol, 1.1 equiv) and the resulting mixture was stirred at 60°C for 1 h, cooled to room temperature and concentrated in vacuo. the residue was partitioned between AcOEt and a 5% aqueous citric acid solution and the layers were separated. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. Trituration of the residue in Et2O/iso-hexane gave methyl 4-nitro-1 H- 1,2, 3-benzotriazole-6-carboxylate (D246) (2.08 g, 78%) as an orange solid which was used in the next step without further purification.
[M+H] + = 223.3, RT = 2.31 min.
Description 247 Methyl 4-amino-1H-1, 2, 3-benzotriazole-6-carboxylate (D247) Methyl 4-amino-1H-1, 2, 3-benzotriazole-6-carboxylate (D247) was obtained from methyl 4- nitro-1 H-1, 2, 3-benzotriazole-6-carboxylate (D246) in an analogous manner to the process described for methyl 5-amino-2-fluoro-3-(2-oxo-1-pyrrolidinyl) benzoate (D150).
[M+H] + = 193.3, RT = 2.01 min.
Description 248 Methyl 4- [ (4-chlorobutanoyl) amino]-1H-1, 2, 3-benzotriazole-6-carboxylate (D248) Methyl 4- [ (4-chlorobutanoyl) amino]-1H-1, 2, 3-benzotriazole-6-carboxylate (D248) was obtained from methyl 4-amino-1H-1, 2, 3-benzotriazole-6-carboxylate (D247) in an analogous manner to the process described for Description 2 (D2). No molecular ion, RT = 3.19 min.
Description 249 Methyl 4- (2-oxo-1-pyrrolidinyl)-1H-1, 2, 3-benzotriazole-6-carboxylate (D249) Methyl 4- (2-oxo-1-pyrrolidinyl)-1H-1, 2, 3-benzotriazole-6-carboxylate (D249) was obtained from methyl 4-[(4-chlorobutanoyl)amino]-1H-1, 2, 3-benzotriazole-6-carboxylate (D248) in an analogous manner to the process described for Ester 27 (B27).
[M+H] + = 261.2, RT = 2.25 min.
Description 250 Methyl 4-nitro-1H-benzimidazole-6-carboxylate (D250) A solution of methyl 3,4-diamino-5-nitrobenzoate (D245) (1.3 g, 6.16 mmol, 1 equiv) in HCOOH (20 ml) was stirred at 100°C for 1 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and a 2N aqueous NaOH solution and the layers were separated. The organic phase was dried over MgSO4 and concentrated in vacuo to give methyl 4-nitro-1H-benzimidazole-6-carboxylate (D250) (1.5 g, 110%) as a light brown solid which was used in the next step without further purification.
[M+H] + = 222.3, RT = 2.29 min.
Description 251 Methyl 4-amino-1H-benzimidazole-6-carboxylate (D251) Methyl 4-amino-1 H-benzimidazole-6-carboxylate (D251) was obtained from methyl 4-nitro-1H- benzimidazole-6-carboxylate (D250) in an analogous manner to the process described for methyl 5-amino-2-fluoro-3-(2-oxo-1-pyrrolidinyl) benzoate (D150). [M+H] + = 192.3, RT = 1.55 min.
Description 252 Methyl 4- { [ (4-chlorobutyl) sulfonyl] amino}-1H-benzimidazole-6-carboxylate (D252) To a solution of methyl 4-amino-1H-benzimidazole-6-carboxylate (D251) (1.1 g, 5.76 mmol, 1 equiv) in CH2CI2 (80 ml) at room temperature were added pyridine (1.02 ml, 12.67 mmol, 2.2 equiv), 4-chloro-1-butanesulfonyl chloride (D20) (2.31 g, 12.1 mmol, 2.1 equiv) and DMAP (704 mg, 5.76 mmol, 1 equiv) and the resulting mixture was stirred for 1 h then concentrated in vacuo. The residue was diluted with AcOEt and the organic phase was washed with a 2N aqueous HCI solution and brine, then dried over MgS04 and concentrated in vacuo.
Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 2/3) gave methyl 4-{[(4-chlorobutyl)sulfonyl]amino}-1H-benzimidazole-6-carbox ylate (D252) (1 g, 50%) as a colorless oil. [M+H] + = 346.1, RT = 2.97 min.
Description 253 Methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazi n-2-yl)-1 H-benzimidazole-6-carboxylate (D253) To a solution of methyl 4- { [ (4-chlorobutyl) sulfonyl] amino}-1H-benzimidazole-6-carboxylate (D252) (1 g, 3.23 mmol, 1 equiv) in EtOH (50 ml) was added NEt3 (2 ml, excess) and the resulting solution was stirred at 70°C for 2 days. then cooled to room temperature and
concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 5% aqueous citric acid solution. The aqueous phase was saturated with NaCI and extracted twice with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (CH2CI2/MeOH : 96/4 to 90/10) gave methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H- benzimidazole-6-carboxylate (D253) (250 mg, 25%) as a pale yellow solid. [M+H] + = 310.3, RT=2. 11 min.
Description 254 Methyl 4-hydroxy-3,5-diiodobenzoate (D254) Methyl 4-hydroxy-3,5-diiodobenzoate (D254) was prepared in an analogous manner to Description 25 (D25) from commercially available 4-hydroxy-3,5-diiodobenzoic acid.
Description 255 Methyl 4-[(2E/Z)-2-buten-1-yloxy]-3, 5-diiodobenzoate (D255) To a solution of methyl 4-hydroxy-3,5-diiodobenzoate (D254) (26.9 g, 66.7 mmol, 1 equiv) in acetone (250 mi) at room temperature were added K2CO3 (13.8 g, 100 mmol, 1.5 equiv) and 1-bromo-2-butene (8.25 ml, 80 mmol, 1.2 equiv) and the resulting suspension was stirred at 55°C for 15 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H20 and the two layers were separated. The organic phase was washed with a 2N aqueous NaOH solution and brine, dried over MgS04 and concentrated in vacuo to give methyl 4-[(2E/Z)-2-buten-1-yloxy]-3, 5-diiodobenzoate (D255) (28.6 g, 94%) as a white solid which was used in the next step without further purification.
Description 256 Methyl 3, 5-diiodo-4- (2-propen-1-yloxy) benzoate (D256) Methyl 3, 5-diiodo-4- (2-propen-1-yloxy) benzoate (D256) was obtained from methyl 4-hydroxy- 3,5-diiodobenzoate (D254) in an analogous manner to the process described for Description 255 (D255) using 3-bromo-1-propene instead of 1-bromo-2-butene.
Description 257 Methyl 4- (3-buten-1-yloXy)-3, 5-diiodobenzoate (D257) Methyl 4- (3-buten-1-yloxy)-3, 5-diiodobenzoate (D257) was obtained from methyl 4-hydroxy- 3,5-diiodobenzoate (D254) in an analogous manner to the process described for Description 255 (D255) using 4-bromo-1-butene instead of 1-bromo-2-butene. [M+H] += 458.8, RT = 4.05 min.
Description 258 Methyl 4-[(2E/Z)-2-buten-1-yloxy]-3-iodo-5-(2-oxo-1-pyrrolidinyl) benzoate (D258) To a solution of methyl 4-[(2E/Z)-2-buten-1-yloxy]-3, 5-diiodobenzoate (D255) (5 g, 11 mmol, 1 equiv) in toluene (50 ml) were added 2-pyrrolidinone (1.08 g, 13 mmol, 1.2 equiv), K3PO4 (4.46 g, 21 mmol, 2 equiv), Cul (105 mg, 0.55 mmol, 0.05 equiv) and dimethyl ethylene diamine (117 pI, 1.1 mmol, 0.1 equiv) and the resulting mixture was stirred at 100°C for 15 h
then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H2O and the layers were separated. The organic phase was dried under MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 1/1) gave methyl 4-[(2E/Z)-2-buten-1-yloxy]-3-iodo-5-(2-oxo-1- pyrrolidinyl) benzoate (D258) (1.4 g, 31 %) as a colorless oil. [M+H] + = 415. 9, RT = 3.27 min.
Description 259 Methyl 3-iodo-5- (2-oxo-1-pyrrolidinyl)-4- (2-propen-1-yloxy) benzoate (D259) Methyl 3-iodo-5- (2-oxo-1-pyrrolidinyl)-4- (2-propen-1-yloxy) benzoate (D259) was obtained from methyl 3, 5-diiodo-4- (2-propen-1-yloxy) benzoate (D256) in an analogous manner to the process described for Description 258 (D258).
Description 260 Methyl 4- (3-buten-1-yloxy)-3-iodo-5- (2-oxo-1-pyrrolidinyl) benzoate (D260) Methyl 4- (3-buten-1-yloxy)-3-iodo-5- (2-oxo-1-pyrrolidinyl) benzoate (D260) was obtained from methyl 4- (3-buten-1-yloxy)-3, 5-diiodobenzoate (D257) in an analogous manner to the process described for Description 258 (D258). [M+H] + = 416.0, RT = 3.02 min.
Description 261 Methyl 4-methyl-8-(2-oxo-1-pyrrolidinyl)-2H-chromene-6-carboxylate and methyl 4- (ethyloxy)-3- [ethyl (propanoyl) amino]-5- (1-methylethenyl) benzoate (D261) Methyl 4-methyl-8-(2-oxo-1-pyrrolidinyl)-2H-chromene-6-carboxylate and methyl 4- (ethyloxy)- 3- [ethyl (propanoyl) amino]-5- (1-methylethenyl) benzoate (D261) were obtained from methyl 4- (3-buten-1-yloxy)-3-iodo-5- (2-oxo-1-pyrrolidinyl) benzoate (D260) in an analogous manner to the process described for methyl 3-ethyl-7- (2-oxo-1-pyrrolidinyl)-1-benzofuran-5-carboxylate (B163). [M+H] + = 288.1, RT = min.
Description 262 Methyl 3-bromo-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D262) Methyl 3-bromo-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D262) was obtained from methyl 3-bromo-5-iodobenzoate (D8a) in an analogous manner to the process described for Description 17 (D17) using D8a instead of D8b as starting material.
Description 263 Methyl 3-bromo-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D263) Methyl 3-bromo-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D263) was obtained from methyl 3-bromo-5-iodobenzoate (D8a) in an analogous manner to the process described for Description 18 (D18) using D8a instead of D8b as starting material.
Description 264 Methyl 3- (3-cyclopenten-1-yi)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate; Methyl 3- (2-cyclopenten-1-yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate; Methyl 3- (1-cyclopenten-1-yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D264)
Methyl 3- (3-cyclopenten-1-yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate, methyl 3- (2-cyclopenten-1-yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate and methyl 3- (1-cyclopenten-1-yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D264) have been obtained from methyl 3-bromo-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D262) in an analogous manner to the process described for Description 73 (D73) Description 265 Methyl 3- (1-cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate; Methyl 3- (2-cyclopenten-1-yi)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yI) benzoate; Methyl 3- (3-cyclopenten-1-yi)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D265) Methyl 3- (l-cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate, methyl 3- (2-cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate and methyl 3- (3- cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D265) have been obtained from methyl 3-bromo-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D263) in an analogous manner to the process described for Description 73 (D73).
Description 266 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (D266) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (D266) was obtained from methyl 3-bromo-5-nitrobenzoate (D11) in an analogous manner to the process described for Description 15 (D15) using Description 22b (D22b) instead of Description D22a (D22a).
Description 267 Methyl 3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D267) Methyl 3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D267) was obtained from methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (D266) in an analogous manner to the process described for Description 16 (D16).
Description 268 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-hydroxybenzoate (D268) To a solution of methyl 3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D267) (7.5 g, 26.4 mol, 1 equiv) in a 2N aqueous HCI solution (75 mi) and MeOH (75 ml) at 0°C was added NaNO2 (4.0 g, 58.1 mmol, 2.2 equiv) portionwise over 20 min. MeOH (50 mi) and H20 (200 mi) were added and the resulting mixture was stirred at 95°C for 1 h then cooled to room temperature. Most of the MeOH was removed in vacuo and the resulting aqueous phase was extracted with AcOEt. The insoluble material was filtered off to give methyl 3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-hydroxybenzoate (D) (0.63 g, 8%). The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo to give a brown residue which was redissolved in AcOEt. The organic phase was extracted with a saturated aqueous Na2CO3 solution and the aqueous phase was extracted three times with Et20 then acidified to pH 1 and re-extracted three times with AcOEt. The combined organic phases were washed
with brine, dried over MgS04 and concentrated in vacuo to give methyl 3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-hydroxybenzoate (D268) (2.2 g, 30%).
Description 269 Methyl 5-(1-cyclopenten-1-yl)-3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2- fluorobenzoate ; methyl 5- (2-cyclopenten-1-yl)-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- yl)-2-fluorobenzoate ; methyl 5-(3-cyclopenten-1-yl)-3-(1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-yl)-2-fluorobenzoate (D269) Methyl 5-(1-cyclopenten-1-yl)-3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluorobenzoate ; methyl 5- (2-cyclopenten-1-yl)-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluorobenzoate ; methyl 5- (3-cyclopenten-1-yl)-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluorobenzoate (D269) were obtained from Description 158 (D158) in an analogous manner to the process described for Description 73 (D73) Description 270 Ethyl 2-methyl-2- [3- (trifluoromethyl) phenyl] propanoate (D270) Ethyl 2-methyl-2- [3- (trifluoromethyl) phenyl] propanoate (D270) was obtained from ethyl [3- (trifluoromethyl) phenyl] acetate in an analogous manner to the process described for Description 98 (D98).
Description 271 2-Methyl-2- [3- (trifluoromethyl) phenyl] propanoic acid (D271) 2-Methyl-2- [3- (trifluoromethyl) phenyl] propanoic acid (D271) was obtained from ethyl 2-methyl- 2- [3- (trifluoromethyl) phenyl] propanoate (D270) in an analogous manner to the process described for Description 99 (D99).
Description 272 Phenylmethyl {1-methyl-1- [3- (trifluoromethyl) phenyl] ethyl} carbamate (D272) Phenylmethyl {1-methyl-1-[3-(trifluoromethyl)phenyl]ethyl} carbamate (D272) was obtained from 2-methyl-2- [3- (trifluoromethyl) phenyl] propanoic acid (D271) in an analogous manner to the process described for Description 100 (D100).
Description 273 2-({[(1, 1-Dimethylethyl) oxylcarbonyl} amino)-2-methylpropyl methanesulfonate (D273) To a solution of 1, 1-dimethylethyl (2-hydroxy-1, 1-dimethylethyl) carbamate (5.1 g, 27 mmol, 1 equiv) in CH2CI2 (100 ml) at room temperature were added NEt3 (11.3 ml, 81 mmol, 3 equiv) and methanesulfonyl chloride (28.3 mmol, 2.2 ml, 1.05 equiv) and the resulting solution was stirred for 2 h then partitioned between AcOEt and a saturated aqueous NaHC03 solution.
The two layers were separated and the organic phase dried over MgS04 and concentrated in vacuo to give 2-({[(1,1-dimethylethyl) oxy] carbonyl} amino)-2-methylpropyl methanesulfonate (D273) (7.8 g, 108%) as a yellow oil which was used in the next step without further purification.
Description 274 1, 1-Dimethylethyl [1, 1-dimethyl-2- (phenyloxy) ethyl] carbamate (D274) To a solution of phenol (2.1 g, 22.4 mmol, 3 equiv) in DMF (10 ml) at room temperature were added NaH (60% dispersion in mineral oil, 360 mg, 9.0 mmol, 1.2 equiv) and after 10 min 2- ({[(1,1-dimethylethyl) oxy] carbonyl} amino)-2-methylpropyl methanesulfonate (D273) (2 g, 7.5 mmol, 1 equiv) and the resulting solution was stirred at 50°C for 2 h then cooled to room temperature and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9/1 to 6/1) gave 1, 1-dimethylethyl [1, 1-dimethyl-2- (phenyloxy) ethyl] carbamate (D274) (180 mg, 9%) as a yellow oil.
Description 275 1, 1-Dimethylethyl {1, 1-dimethyl-2-l (phenylmethyl) oxylethyl} carbamate (D275) 1, 1-Dimethylethyl {1, 1-dimethyl-2-[(phenylmethyl) oxy] ethyl} carbamate (D275) was prepared from 2-({[(1,1-dimethylethyl) oxy] carbonyl} amino)-2-methylpropyl methanesulfonate (D273) in an analogous manner to 1, 1-dimethylethyl [1, 1-dimethyl-2- (phenyloxy) ethyl] carbamate (D274) using phenylmethanol instead of phenol.
Description 276 1, 1-Dimethylethyl {1, 1-dimethyl-2-1 (2-methylpropyl) thiolethyl} carbamate (D276) 1, 1-Dimethylethyl {1, 1-dimethyl-2-[(2-methylpropyl) thio] ethyl} carbamate (D276) was prepared from 2-({[(1,1-dimethylethyl) oxy] carbonyl} amino)-2-methylpropyl methanesulfonate (D273) in an analogous manner to 1, 1-dimethylethyl [1, 1-dimethyl-2-(phenyloxy) ethyl] carbamate (D274) using 2-methyl-1-propanethiol instead of phenol.
Description 277 1, 1-Dimethylethyl (4, 4-difluorocyclohexyl) carbamate (D277) To a solution of 1, 1-dimethylethyl (4-oxocyclohexyl) carbamate (1 g, 4.69 mmol, 1 equiv) in CH2CI2 (15 ml) was added DAST (1.05 mi, 7.98 mmol, 1.7 equiv) and the resulting mixture was stirred for 15 h. A saturated aqueous NaHC03 solution was added and the resulting biphasic mixture was stirred vigorously for 1 h. The two layers were separated and the aqueous phase extracted with CH2CI2. The combined organic phase were dried over MgS04 and concentrated in vacuo to give 1, 1-dimethylethyl (4, 4-difluorocyclohexyl) carbamate (D277) (1.03 g, 93%) as a beige solid which was used in the next step without further purification.
Descriptions 278-281 (D278-281) The following acids have been obtained by alkylation of cyclobutanecarboxylic acid as described in: K. Tani, A. Naganawa, A. Ishida, K. Sagawa, H. Harada, M. Ogawa, T.
Maruyama, S. Ohuchida, H. Nakai, K. Kondo, M. Toda Bio. Med. Chem. 2002,10, 1093-1106: Description 1-Ethylcyclobutanecarboxylic acid (D278) 1-Propylcyclobutanecarboxylic acid (D279) 1-(1-Methylethyl) cyclobutanecarboxylic acid (D280)
1- [ (3-Chlorophenyl) methyl] cyclobutanecarboxylic acid (D281) Descriptions 282-285 (D282-285) The following compounds have been obtained from their precursors in an analogous manner to the process described for Description 100 (D100) : Description Precursor Phenylmethyl (1-ethylcyclobutyl) carbamate (D282) D278 Phenylmethyl (1-propylcyclobutyl) carbamate (D283) D279 Phenylmethyl [1-(1-methylethyl)cyclobutyl carbamate (D284) D280 Phenylmethyl {1- [ (3-chlorophenyl) methyl] cyclobutyI} carbamate (D285) D281 Descriptions 286-293 (D286-293) The following amides were obtained via a Ritter reaction as described in: M. Mousseron Bull.
Soc. Chim. Fr. 1957,596. : Description Precursor N- (1-Methylcyclohexyl) acetamide (D286) Ho N- (l-Ethylcyclohexyl) acetamide (D287) < Ho N- (1-Methylcyclopentyl) acetamide (D288) HO N- (1-Propylcyclopentyl) acetamide (D289) \ HOLZ N- (l-Propylcyclohexyl) acetamide (D290) HOt N- (1, 1-Dimethylhexyl) acetamide (D291) 0 N- [2- (3-Chlorophenyl)-1, 1-dimethylethyl] acetamide (D292) o ce N- {1, 1-Dimethyl-2- [3- (methyloxy) phenyl] ethyl} acetamide (D293) oo Description 294 4, 4-Dimethylcyclohexanone (D294)
4, 4-Dimethylcyclohexanone (D294) was obtained from 4, 4-dimethyl-2-cyclohexen-1-one in an analogous manner to the process described for ester 116 (B116).
Description 295 3, 3-Dimethylcyclopentanone (D295) 3, 3-Dimethylcyclopentanone (D295) was obtained from 4, 4-dimethyl-2-cyclopenten-1-one in an analogous manner to the process described for 4, 4-dimethylcyclohexanone (D294).
Description 296 4, 4-Dimethylcyclohexanone oxime (D296) To a solution of 4, 4-dimethylcyclohexanone (D294) (9.2 g, 73 mmol, 1 equiv) in EtOH (50 ml) and H20 (50 mi) were added NH2OH. HCI (6.6 g, 94.5 mmol, 1.3 equiv) and Na2CO3 (10.06 g, 94.5 mmol, 1.3 equiv) and the resulting cloudy solution was refluxed for 2 h then cooled to room temperature. Most of EtOH was removed in vacuo and the aqueous phase was extracted twice with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give 4, 4-dimethylcyclohexanone oxime (D296) (10 g, 97%) as a colourless solid which was used in the next step without purification.
Descriptions 297-298 (D297-298) The following oxime were obtained for their precursor in an analogous manner to the process described for Description (D296). Description Precursor 1E/Z)-2,2-Dimethylcyclohexanone oxime (D297) D294 (1E/Z)-3, 3-Dimethylcyclopentanone oxime (D298) D295 Descriptions 299-311 (D299-311) The following compounds have been obtained from (2S)-2- (1-methylethyl)-3, 6-bis (methyloxy)- 2,5-dihydropyrazine according to the general procedure described in: P. dalla Croce, C. la Rosa, E. Pizzatti Tetrahedron : Asymmetry 2000, 11, 2635-2642: Description 3, 5-Difluoro-L-phenylalaninate (D299) 3-Fluoro-L-phenylalaninate (D300) 3, 4-Difluoro-L-phenylalaninate (D301) 2-Chloro-L-phenylalaninate (D302) Methyl-3-chloro-L-phenylalaninate (D303) Methyl 4-chloro-L-phenylalaninate (D304) Methyl 3- (2-thienyl)-L-alaninate (D305) Methyl 3- (3-thienyl)-L-alaninate (D306) Methyl 3- (2-furanyl)-L-alaninate (D307) Methyl 3- (2-pyridinyl)-L-alaninate (D308) Methyl 3- (1, 3-thiazol-2-yl)-L-alaninate (D309) Methyl 3- (1H-pyrazol-1-yl)-L-alaninate (D310) Methyl 3- (3-pyridinyl)-L-alaninate (D311)
Descriptions 312-313 (D312-313) Descriptions 312-313 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Description Acid Amine [M+H] + RT (min) 3- (1, 1-dioxido-6,7-dihydro-1, 2-thiazepin-2 (3H)-yl)-N-A117 C16 630.4 2.89 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- (trifluoromethyl) phenyl] methyl} amino) propyl]-5- propylbenzamide (D312) 3- (1, 1-dioxido-6,7-dihydro-1, 2-thiazepin-2 (3H)-yl)-N- A117 C14 592.4 2.75 [ (l S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl) amino) - 1-(phenylmethyl)propyl]-5-propylbenzamide (D313 Description 314 1- [3- (Methyloxy) phenyl] cyclohexanol (D314) To a solution of 3-methoxyphenyl magnesium bromide (1 M in THF, 61 ml, 61 mmol, 1 equiv) at 0°C was slowly added cyclohexanone (6g, 61 mmol, 1 equiv) in Et2O (30 ml). The resulting mixture was stirred at room temperature for 4 h then poured in H2O at 0°C. The two layers were separated and the aqueous phase was extracted three times with Et2O. The combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo to give 1- [3- (methyloxy) phenyl] cyclohexanol (D314) (12.4 g, 100%) as a pale yellow oil which was used in the next step without further purification.
Description 315 1- (1-Azidocyclohexyl)-3- (methyloxy) benzene (D315) To a solution of 1- [3- (methyloxy) phenyl] cyclohexanol (2.93 g, 14.22 mmol, 1 equiv) in CH2CI2 (25 mi) under nitrogen at 0°C was added sodium azide (1.85 g, 28.44 mmol, 2 equiv) then TFA (4.4 ml, 56.89 mmol, 4 equiv) slowly. 40 MI of CH2CI2 were then added and the resulting suspension was stirred at room temperature for 16 h then partitioned between Et2O and H2O.
The two layers were separated and the organic phase was washed with H20 and a 1N aqueous NaOH solution then dried over MgS04 and concentrated in vacuo to give 1- (1- azidocyclohexyl)-3-(methyloxy) benzene (D315) (2.78 g, 85%) as a clear oil which was used in the next step without further purification.
Description 316 (1E/Z)-Propanal oxime (D316) (1E/Z)-Propanal oxime was obtained from propanal in a similar manner to the process described for Description 296 (D296).
Description 317 1, 1-Dimethylethyl 2-propyn-1-ylcarbamate (D317)
To a solution of 2-propyn-1-amine (2 g, 36.4 mmol, 1 equiv) in CH2CI2 (20 mi) were added NEt3 (5.3 mi, 38.18 mmol, 1.05 equiv) and bis (1, 1-dimethylethyl) dicarbonate (8.32 g, 38.18 mmol, 1.05 equiv). The resulting mixture was stirred at room temperature for 3 h then poured in a 2N aqueous HCI solution. The two layers were separated and the organic phase was washed with a saturated aqueous NaHC03 solution then dried over MgS04 and concentrated in vacuo to give 1, 1-dimethylethyl 2-propyn-1-ylcarbamate (D317) (4.05 g, 72%) as a colourless crystal.
Description G33 ( (1S, 2R)-2-hydroxy-1-isobutylcarbamoyl-pentyl)-carbamic acid tert-butyl ester (G33) (2S, 3R)-2-teff-Butoxycarbonylamino-3-hydroxy-hexanoic acid methyl ester (D94) (1.57g, 6.02 mmol, 1 equiv) was refluxed in iso-butylamine (10 ml) for 2 h. The solution was concentrated in vacuo and the residue purified by flash chromatography on silica gel to give ( (1S, 2R) -2- hydroxy-1-isobutylcarbamoyl-pentyl)-carbamic acid tert-butyl ester (G33) (1.52g, 84%) as a white solid.
The following compounds were obtained in an analogous manner to Description 96a using the appropriate (commercially available) acid and amine: Name S)-1-Cyclohexylcarbamoyl-3-methylsulfanyl-propyl)-carbamic acid tert-butyl ester (G6) [(S)-1-(3, 3-Dimethyl-butylcarbamoyl)-ethyl]-carbamic acid test-butyl ester (G36) Description G38 ((S)-1-lsobutylcarbamoyl-3-methanesulfonyl-propyl)-carbamic acid tert-butyl ester (G38) To ((S)-1-isobutylcarbamoyl-3-methylsulfanyl-propyl)-carbamic acid teint-butyl ester (D96) (1.19 g, 3.9 mmol, 1 equiv) in CH2CI2 (25 ml) at 0°C was added m-chloroperbenzoic acid (50- 55%, 4.0 g, 11.6 mmol, 3 equiv) portionwise. The resulting mixture was stirred 2 h at 0°C then diluted with AcOEt and washed with saturated NaHC03 aqueous solution, dried over MgS04 and concentrated in vacuo to give ((S)-1-isobutylcarbamoyl-3-methanesulfonyl-propyl)- carbamic acid test-butyl ester (G38) (1.06 g, 81 %) as a colourless solid.
Description G157 1, 1-Dimethylethyl 1 (3-ethyl-5-isoxazolyl) methyl] carbamate (G157) To a solution of (1E/Z)-propanal oxime (D316) (4g, 54.8 mmol, 1 equiv) in CH2CIZ (200 ml) at room temperature was added N-chloro succinamide (7.44 g, 55.8 mmol, 1.02 equiv) and the resulting solution was stirred at this temperature for 2.5 h then NEt3 (20 mi, excess) was added and the resulting mixture stirred for 2 h. DIPEA (9.52 mmol, 55.8 mmol, 1.02 equiv) and 1, 1-dimethylethyl 2-propyn-1-ylcarbamate (D317) (1.34 g, 8.76 mmol, 0.16 equiv) were added and the solution stirred for 48 h then poured into a 1 M aqueous HCI solution. The two layers were separated and the organic phase was washed with a saturated aqueous NaHC03 solution then dried over MgS04 and concentrated in vacuo. Purification of the residue by flash
chromatography on silicagel (iso-hexane/AcOEt: 4/1 to 3/1) gave 1, 1-dimethylethyl [ (3-ethyl-5- isoxazolyl) methyl] carbamate (G157) (1.28 g, 63%).
Description F5 1,1, 5-Trimethyl-hexylamine (F5) Description F5 was obtained according to S. S. Berg and D. T. Cowling, J. Chem. Soc. (C) 1971,1653-1658.
Description F33 (2S, 3R) -2-Amino-3-hydroxy-hexanoic acid isobutyl-amide hydrochloride salt (F33) (2S, 3R)-2-tert-Butoxycarbonylamino-3-hydroxy-hexanoic acid methyl ester (G33) (235 mg, 0.86 mmol, 1 equiv) was dissolved in 4M HCI in dioxan (4 ml) and the solution was stirred for 1 h at room temperature then concentrated in vacuo. The residue was triturated with Et2O to give (2S, 3R) -2-amino-3-hydroxy-hexanoic acid isobutyl-amide hydrochloride salt (F33) (176 mg, 95%) as a white solid.
The following compounds (as their hydrochloride salts) have been obtained from the appropriate precursors as indicated in the below table according to an analogous manner to that described for Description F33: Name Precursor (S)-2-Amino-N-cyclohexyl-propionamide (F6) G6 (S)-2-Amino-hexanoic acid isobutyl-amide (F36) G36 Description F15 1- (3-Methoxy-phenyl)-1-methyl-ethylamine (F15) A flask was charged with [1- (3-methoxy-phenyl)-1-methyl-ethyl]-carbamic acid benzyl ester (D100) (1 g, 3.34 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 100 mg, 10% w/w), NH4COOH (2.1 g, 33 mmol, 10 equiv), EtOH (40 ml) and H20 (8 ml). The resulting mixture was stirred at 80°C for 2 h, cooled to room temperature and the catalyst was filtered off using a pad of celite. Most of the EtOH was removed in vacuo and the residue was diluted with 1 N HCI aqueous solution. The aqueous phase was extracted with AcOEt then basified to pH 13 and extracted twice with AcOEt. These combined organic layers were dried over MgS04 and concentrated in vacuo to yield 1- (3-methoxy-phenyl)-1-methyl-ethylamine (F15) (290 mg, 53%) as a yellow gum.
Description F40 2- [3- (Trifluoromethyl) phenyl]-2-propanamine (F40) 2- [3- (Trifluoromethyl) phenyl]-2-propanamine (F40) was obtained from phenylmethyl {1- methyl-1- [3- (trifluoromethyl) phenyl] ethyl} carbamate (D272) in an analogous manner to the process described for Description F15 (F15).
Description F41 {1-13-(Methyloxy) phenyl] cyclohexyl} amine (F41)
To a solution of 1- (1-azidocyclohexyl)-3- (methyloxy) benzene (D315) (2.78 g, 12.0 mmol, 1 equiv) in THF (20 ml) at room temperature was added LiAIH4 (1 M in THF, 36 ml, 36 mmol, 3 equiv) and the resulting mixture was stirred at this temperature for 4 h. The mixture was then carefully quenched with a 1 N aqueous NaOH solution (6 ml, 60 mmol, 1 equiv) then H2O. The mixture was filtered through a pad of celite then acidified with a 2N aqueous HCI solution (50 ml). The two layers were separated and the pH of the aqueous phase adjusted to 9 using a 2N aqueous NaOH solution. The aqueous phase was extracted three times with Et2O and the combined organic phase were dried over MgS04 then concentrated in vacuo to give {1- [3- (methyloxy) phenyl] cyclohexyl} amine (F41) (1.55 g, 63%) as a clear oil which was used in the next step without further purification. [M+H] + = 189.0, RT = 1.90 min.
Descriptions F48, F61, F81 and F110-114 The following amines were obtained from their corresponding amides in an analogous manner to the process described for Description F5 (F5):
Description Precursor 2-Methyl-2-heptanamine (F48) D291 2-Methyl-1-[3-(methyloxy) phenyl]-2-propanamine (F61) D293 1-Methylcyclohexanamine (F81 D286 1-Methyicyclohexanamine (F110) D287 1-Methylcyclopentanamine (F111) D288 1-Propylcyclopentanamine (F112) D289 1-Propylcyclohexanamine (F113) D290 1- (3-Chlorophenyl)-2-methyl-2-propanamine (F114) D292
Description F52 7-(Methyloxy)-1, 2,3, 4-tetrahydro-1-naphthalenamine (F52) 7- (Methyloxy)-1, 2,3, 4-tetrahydro-1-naphthalenamine (F52) was obtained from 7- (methyloxy)- 3,4-dihydro-1 (2H)-naphthalenone in an analogous manner to the process described in US Patent 4,132, 737.
Descriptions F54-56 and F155 The following amines were prepared from their precursor in an analogous manner to the process described for Amine 1 (C1) :
Description Precursor 2-Methyl-1- (2-methylpropyl) thio] -2-propanamine hydrogen chloride (F54) D276 2-Methyl-1-(phenyloxy)-2-propanamine hydrogen chloride (F55) D274 2-Methyl-1-[(phenylmethyl) oxy]-2-propanamine hydrogen chloride (F56) D275 4,4-Difluorocyclohexanamine hydrochloride (F155) D277 Descriptions F63, F73-75 and F77-80 The following amines were prepared from their corresponding nitriles according to the general method described in: P. Bertus, J. Szvmoniak Chem. Comm., 2001, 1792: Description Precursor 1- [3- (methyloxy) phenyl] cyclopropanamine (F63) N I I 1- (4-methylpentyl) cyclopropanamine (F73) N 1-ethylcyclopropanamine (F74) N< 1-(1-methylethyl) cyclopropanamine (F75) NKC 1-propylcyclopropanamine (F77) 1- (3-methylbutyl) cyclopropanamine (F78) 1- (2-methylpropyl) cyclopropanamine (F79) N 1- [ (3-chlorophenyl) methyl] cyclopropanamine (F80) N cl CI
Descriptions F69 and F148-150 The following compounds have been obtained from their precursors in an analogous manner to the process described for Description F15 (F15) : Description Precursor 1-Ethylcyclobutanamine (F69) D282 1-Propylcyclobutanamine (F148 D283 1- (1-Methylethyl) cyclobutanamine (F149) D284 1- [ (3-Chlorophenyl) methyl] cyclobutanamine (F150) D285 Description F70 2-Methyl-1-1 (2-methylpropyl) oxy]-2-propanamine (F70) 2-Methyl-1-[(2-methylpropyl) oxy] -2-propanamine (F70) was obtained from 2-Methyl-1-[(2- methyl-2-propen-1-yl) oxy]-2-propanamine (F71) in an analogous manner to the process described for Ester 166 (B116).
Description F71 2-Methyl-1-[(2-methyl-2-propen-1-yl) oxy] -2-propanamine (F71) To a solution of NaH (60% dispersion in mineral oil, 2.0 g, 50 mmol, 1 equiv) in DMF at 0°C was added 2-amino-2-methyl-1-propanol (4.8 ml, 50 mmol, 1 equiv) and after 1 h 3-bromo-2- methyl-1-propene (5.5 ml, 55 mmol, 1.1 equiv). The resulting solution was stirred at room temperature for 15 h then partitioned between AcOEt and H2O. The two layers were separated and the organic phase was washed with H20 and brine, dried over MgS04 and distillated (45°C, P = 150 mbar) to give 2-methyl-1-[(2-methyl-2-propen-1-yl) oxy] -2- propanamine (F71) as a light pink solid.
Description F83 4, 4-Dimethylcyclohexanamine (F83) 4, 4-Dimethylcyclohexanone oxime (D296) (10 g, 71 mmol, 1 equiv) in EtOH (100 ml) was stirred with Raney Ni (1 g, 10% w/w) under an atmosphere of H2 (50 psi) for 4 days. The
catalyst was filtered off through a pad of celite and HCI (1 M in Et2O, 100 ml, 100 mmol, 1.4 equiv) were added. The precipitate formed was filtered off and dissolved in water. The aqueous phase was washed with Et2O and made strongly basic with KOH pellets then extracted twice with CH2CI2. The combined organic phases were dried over MgS04 and concentrated in vacuo to give 4, 4-dimethylcyclohexanamine (F83) (8 g, 89%) as a clear oil which was used in the next step without further purification.
Descriptions F86 and F92 The following amines were obtained from their precursor in an analogous manner to the process described for 4, 4-dimethylcyclohexanamine (F83): Amine Precursor 2, 2-Dimethyl cyclohexanamine (F86) D297 3, 3-Dimethyl cyclopentanamine (F92) D298 Description F157 [ (3-Ethyl-5-isoxazolyl) methyl] amine (F157) [ (3-Ethyl-5-isoxazolyl) methyl] amine (F157) was obtained from 1, 1-dimethylethyl [ (3-ethyl-5- isoxazolyl) methyl] carbamate (G157) in an analogous manner to the process described in Description F33 (F33).
Preparation of Esters Ester 1 3-Methylsulfanyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B1) To a solution of crude 3- (4-chloro-butanoylamino)-5-methylsulfanyl-benzoic acid methyl ester (D64) (0.17 g, 0.56 mmol, 1 equiv) in THF (2 ml) at 0°C was added portionwise NaH (60% in mineral oil, 24.6 mg, 0.616 mmol, 1.1 equiv) over 2 min. The resulting mixture was stirred at room temperature for 40 min and one drop of MeOH was added to destroy the remaining NaH. The resulting mixture was then diluted with AcOEt, washed sequentially with 2N aqueous HCI solution, saturated aqueous NaHCO3 solution and brine, dried over Na2SO4 and concentrated in vacuo. Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 1/1) gave 3- (4-chloro-butanoylamino)-5-methylsulfanyl-benzoic acid methyl ester (B1) (122 mg, 82%) as a white solid. [M+H]+ = 266. 0, RT = 2.86 min Ester 2 3-Ethylsulfanyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid ethyl ester (B2) Ester 2 was prepared from 177 mg (0.54 mmol) of 3- (4-chloro-butanoylamino)-5-ethylsulfanyl- benzoic acid ethyl ester (D65) in an analogous manner to that described for Ester 1 which yielded 129 mg (82%) of 3-ethylsulfanyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid ethyl ester (B2) as a clear colorless gum after purification by flash chromatography on silica gel (iso- hexane/AcOEt : 60/40). [M+H] + = 294.1, RT = 3.23 min Ester 3 3-(1, 1-DioXo-11e'-isothiazolidin-2-yl)-5-methylsulfanyl-benzoic acid methyl ester (B3)
To a solution of 3- (3-chloro-propane-1-sulfonylamino)-5-methylsulfanyl-benzoic acid methyl ester (D66) (183 mg, 0.54 mmol, 1 equiv) in MeOH (3 ml) was added NEt3 (150 µl, 1.08 mmol, 2 equiv). The resulting mixture was stirred at 70 C for 2 h then left to cool to room temperature overnight. A further portion of NEt3 (75 Ftl, 0.54 mmol, 1 equiv) was added and the mixture was stirred at 80 C for 3 h when another portion of NEt3 (75 µl, 0.54 mmol, 1 equiv) was added. After another 2 h at 80 C, the solution was cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and 2N aqueous HCI solution. The organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by flash chromatography on silica gel (iso-hexane/AcOEt : 60/40) gave 3- (1, 1-dioXo-113-isothiazolidin-2-yl)-5-methylsulfanyl-benzoic acid methyl ester (B3) (150 mg, 92%). [M+H] + = 302.0 RT = 2.89 min Ester 4 3-(1, 1-DioXo-11e'-isothiazolidin-2-yl)-5-ethylsulfanyl-benzoic acid ethyl ester (B4) Ester 4 was prepared from 190 mg (0.52 mmol) 3- (3-chloro-propane-1-sulfonylamino)-5- ethylsulfanyl-benzoic acid ethyl ester (D67) in an analogous manner to that described for Ester 3 which yielded 154 mg (90%) of 3- (1, 1-dioxo-I P-isothiazolidin-2-yl)-5-ethylsulfanyl- benzoic acid ethyl ester (B4) after purification by flash chromatography on silica gel (iso- hexane/AcOEt : 60/40). [M+H] + = 330.0, RT = 3.24 min Ester 11 3-Ethoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B11) To 3-hydroxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D37) (0.80 g, 3.4 mmol, 1 equiv) dissolved in DMF (10 ml) was added K2CO3 (0.94 g, 6.8 mmol, 2 equiv) and ethyl iodide (1.1 g, 6.8 mmol, 2 equiv). The resulting mixture was heated at 50 °C for 4 h, cooled to room temperature, diluted with 2N aqueous HCI solution (50 ml) and extracted with Et20 (50 ml).
The organic phase was then washed with water (50 ml), dried over MgS04 and concentrated in vacuo to give of 3-ethoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B11) (0.85 g, 95%) as a brown oil which slowly solidified to a tan solid.
Ester 11 (Alternative Procedure) 3-Ethoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B11) : 3- (4-Chloro-butanoylamino)-5-ethoxy-benzoic acid methyl ester (D51) (7 g, 20 mmol, 1 equiv) in THF (50 ml) was treated portionwise with NaH (60% in mineral oil, 0.88 g, 22 mmol, 1.1 equiv) over 15 min at room temperature. The resulting mixture was stirred for 30 min and then diluted with AcOEt (300 ml). The resulting solution was washed with 2N aqueous HCI solution (200 ml), dried over MgS04 and concentrated in vacuo. Recrystallisation of the residue from Et2O/hexane gave 3-ethoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B11) (3.5 g, 66%) as white solid.
The following esters were prepared in an analogous manner to Ester 11 from D37 using an appropriate commercially available reagent: Ester 3-Methoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B9) 3-(2-Oxo-pyrrolidin-1-yl-t-propoxy-benzoic acid methyl ester (B10) 3-Isopropoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B12) 3-(2-Oxo-pyrrolidin-1-yl)-5-pentyloxy-benzoic acid methyl ester (B13) Ester 14 The following ester was prepared in an analogous manner to Description 38 from Description 37 using the appropriate alcohol indicated in the table below :
Ester Alcohol 3- (2-Methoxy-ethoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B14) HO~Os Ester 15 3- (3-Hydroxy-propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B15) 3- (3-Benzyloxy-propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D38) in MeOH (15 ml) was hydrogenolysed initially with 10% Pd on charcoal (50% wet, 0.25 g, 0.25 equiv w/w) at atmospheric pressure for 24 hrs and then a further 0.25 g of 10% Pd on charcoal (50% wet, 0.25 g, 0.25 equiv w/w) was added and the mixture hydrogenolysed at 50psi for a further 48 hrs. The mixture was filtered through Celite and concentrated in vacuo.
Purification by flash chromatography on silica gel (AcOEt/iso-hexane : 1/1) gave 3- (3-hydroxy- propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B15) (260 mg, 69% over 2 steps). [M+H] + = 294.0 Ester 17 3- (3-Methoxy-propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B17) 3- (3-Hydroxy-propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B15) (127 mg, 0.43 mmol, 1 equiv) in CH2CI2 (2 ml) was treated with proton sponge (279 mg, 1.30 mmol, 3 equiv) and trimethyloxonium tetrafluoroborate (192 mg, 1.30 mmol, 3 equiv). After 3 hrs, further quantities of proton sponge (93 mg, 0.43 mmol, 1 equiv) and trimethyloxonium tetrafluoroborate (65 mg, 0.43 mmol, 1 equiv) were added and stirring was continued for a further 2 h. The mixture was then partitioned between AcOEt and 2N aqueous HCI solution.
The two layers were separated and the aqueous phase extracted with AcOEt. The combined organic layers were washed with saturated aqueous NaHC03 solution, 2N aqueous HCI solution and brine and then dried over Na2SO4 and concentrated in vacuo. Purification by flash chromatography on silica gel (ethyl acetate/iso-hexane: 1/4 to 1/3) gave 3- (3-methoxy- propoxy)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B17) (76 mg, 58%). [M+H] + = 308.1 Ester 18 3-(1, 1-Dioxo-116-isothiazolidin-2-yl)-5-ethoxy-benzoic acid methyl ester (B18) To 3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5-hydroxy-benzoic acid methyl ester (D41) (0.80 g, 3.0 mmol, 1 equiv) dissolved in DMF (10 ml) was added K2CO3 (0.94 g, 6.8 mmol, 2 equiv) and
ethyl iodide (1.1g, 6.8 mmol, 2 equiv) and the resulting mixture was heated at 50 °C for 4 h then cooled to room temperature and diluted with 2N aqueous HCI solution (50 ml). The aqueous phase was extracted with Et20 (50 ml). The organic phase was washed with H2O (50 ml), dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (AcOEt/iso-hexane : 1/1) gave 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-ethoxy-benzoic acid methyl ester (B18) (220 mg, 25%) as a pale yellow oil.
Ester 18 (Alternative Procedure) 3-(1, 1-Dioxo-116'-isothiazolidin-2-yl)-5-ethoxy-benzoic acid methyl ester (B18) A solution of 3-(3-chloro-propane-1-sulfonylamino)-5-ethoxy-benzoic acid methyl ester (D53) (6.7 g, 20 mmol, 1 equiv) in EtOH (100 mi) was treated with NEt3 (4.0 g, 40 mmol, 2 equiv).
The resulting mixture was refluxed for 4 h, cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt (200 mi) and the resulting solution was washed with 2N aqueous HCI solution (100 mi) followed by saturated aqueous NaHC03 solution (100 mi) then dried over MgS04 and concentrated in vacuo to give a brown oil. Crystallisation from Et20/hexane gave 3-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-5-ethoxy-benzoic acid methyl ester (B18) (4.7 g, 78%) as a light tan solid.
Ester 19 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-isopropoxy-benzoic acid methyl ester (B19) To 3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5-hydroxy-benzoic acid methyl ester (D41) (0.30 g, 1.1 mmol, 1 equiv) dissolved in DMF (5 ml) was added K2CO3 (0.306 g, 2.2 mmol, 2 equiv) and 2- iodopropane (374 mg, 2.2 mmol, 2 equiv) and the mixture heated at 50 °C for 4 h then cooled to room temperature and diluted with 2N aqueous HCI solution (50 ml). The aqueous phase was extracted with Et20 (50 ml) and the organic phase was washed with H20 (50 ml), dried over MgS04 and concentrated in vacuo to give 3-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-5- isopropoxy-benzoic acid methyl ester (B19) (290 mg, 88%) as a pale yellow oil.
The following esters were prepared from Description 41 in an analogous manner to the process described for Ester 19 using the appropriate commercially available reagents : Ester 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-methoxy-benzoic acid methyl ester (B20) 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-propoxy-benzOic acid methyl ester (B21) 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-pentyloxy-benzoic acid methyl ester (B22) The following esters were prepared in an analogous manner to the process described in Description 30 from the appropriate aryl bromide and amine starting materials listed in the below table : Ester Aryl bromide Amine [MsH] + RT (min) 3- (2-Oxo-pyrrolidin-1-yl)-5-pyrrolidin-1-D9a N 289. 1 3. 03 y-benzoic acid methyl ester (B113) H 3-Morpholin-4-yl-5-(2-oxo-pyrrolidin-1-D9a (Na 305. 0 2. 59 yl)-benzoic acid methyl ester (B29) o 3- (4-Methyl-piperazin-1-yl)-5- (2-oxo- D9a (N 318. 1 1. 91 pyrrolidin-1-yl)-benzoic acid methyl ester (B115) 3-(2-Oxo-pyrrolidin-1-yl)-5-piperidin-1-D9a N 303. 1 2. 93 yl-benzoic acid methyl ester (B28) 0 3-(2-Oxo-piperidin-1-yl)-5-pyrrolidin-1-D10 N 345. 2 3. 35 yI-benzoic acid teint-butyl ester (B54) t1 3-Morpholin-4-yl-5-(2-oxo-piperidin-1-D10 N 361. 2 2. 95 yl)-benzoic acid tert-butyl ester (B56) 0 H 3- (2-Oxo-piperidin-1-yl)-5-piperidin-1-D10 N 359. 2 3. 35 yl-benzoic acid ter butyl ester (B55) 3-(1, 1-Dioxo-1/3-isothiazolidin-2-yl)-5-D17 t 67. 1 3. 43 pyrrolidin-1-yl-benzoic acid test-butyl ester (B114) 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-D17 KN 383. 1 3. 04 morpholin-4-yl-benzoic acid tert-butyl o ester (B61)
Ester 24 3, 5-Bis- (2-oxo-pyrrolidin-1-yl) benzoic acid methyl ester (B24) To a solution of 3-bromo-5-iodobenzoic acid methyl ester (D8a) (588 mg, 1.72 mmol, 1.5 equiv) in dioxan (10 mi) was added pyrrolidin-2-one (120 Fll, 1.14 mmol, 1 equiv), CS2CO3 (720 mg, 2.21 mmol, 2 equiv), Xantphos (51 mg, 0.09 mmol, 0.08 equiv) and tris (dibenzylideneacetone) dipalladium (0) (28 mg, 0.03 mmol, 0.026 equiv). The reaction mixture was stirred at 100 °C for 16 h, then cooled to room temperature and filtered through a pad of celite and concentrated in vacuo. Purification by column chromatography on silica gel (EtOAc) yielded 3, 5-bis- (2-oxo-pyrrolidin-1-yl) benzoic acid methyl ester (B24) (411 mg, 79%) as light yellow solid.
[M+H] + = 303.2 The following esters were prepared in an analogous manner to Ester 23 from the appropriate starting materials indicated in the below table : Ester Precursor 4-Chloro-3, 5-bis- (2-oxo-pyrrolidin-1-y)-benzoic acid methyl ester (B25) D28a 4-Methoxy-3, 5-bis-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B26) D28b Ester 27 3-Nitro-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B27) To a solution of 3- (4-chloro-butanoylamino)-5-nitro-benzoic acid methyl ester (D2) (56 g, 186 mmol, 1 equiv) in THF (500 ml) under nitrogen was added portionwise NaH (60% w/w in mineral oil, 8 g, 200 mmol, 1.07 equiv) over 10 min. The resulting mixture was stirred at room temperature for 1 h then cooled to 0 C and MeOH was added dropwise until bubbling ceased.
The solution was concentrated in vacuo and the residue diluted with AcOEt. The organic phase was washed with H20, dried over MgS04 and concentrated in vacuo. The residue was triturated with iso-hexane to give 3-nitro-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B27) (38.5 g, 78%) as a light tan solid.
Ester 30 3-(2-Oxo-pyrrolidin-1-yl)-5-phenylamino-benzoic acid methyl ester (B30) A flask was charged under nitrogen with 3-bromo-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D9a) (298 mg, 1 mmol, 1 equiv), Cs2CO3 (488 mg, 1.5 mmol, 1.5 equiv), tris (dibenzylideneacetone) dipalladium (0) (18.3 mg, 0.02 mmol, 0.02 equiv), 2- (di-tert- butylphosphino) biphenyl (18 mg, 0.06 mmol, 0.06 equiv) and DME (8 ml). Aniline (136, ul, 1.5 mmol, 1.5 equiv) was then added via syringe and the resulting mixture was stirred at 100 C for 16 h then cooled to room temperature, diluted with H20 and AcOEt. The layers were separated and the aqueous phase was extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 3/1 to 1/1) gave 3-(2-oxo-pyrrolidin-1-yl)-5- phenylamino-benzoic acid methyl ester (B30) (100 mg, 32%) as a white solid. [M+H] + = 311.0, RT = 3. 14 min Ester 31 3-Ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (B31) A flask was charged with (benzyl-ethyl-amino)-2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (D30) (3 g, 7.6 mmol, 1 equiv), 10% Pd on charcoal (50% wet, 600 mg, 10% w/w), NH4COOH (4.8 g, 76 mmol, 10 equiv), MeOH (30 ml) and H20 (50 ml). The resulting mixture was stirred at 50°C for 16 h, cooled to room temperature and the catalyst was filtered off using a pad of celite. Most of the MeOH was removed in vacuo and the residue was diluted with saturated aqueous NaHC03 solution. The aqueous phase was extracted twice with AcOEt.
The combined organic phases were dried over MgS04 and concentrated in vacuo to give 3- ethylamino-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid tert-butyl ester (B31) (2.2 g, 95%) as a yellow oil. [M+H] + = 305.2, RT = 3.11 min The following esters were prepared in an analogous manner to the process described in Ester 31 (B31) from the appropriate benzyl aniline precursor listed in the below table : Ester Precursor [M+H] + RT (min) 3-Methylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic D31 291.1 2.96 acid tert-butyl ester (B32) 3-Methylamino-5- (2-oxo-piperidin-1-yl)-benzoic acid D32 249.1 2.91 tert-butyl ester (B57) (-tBu) 3-Ethylamino-5-(2-oxo-piperidin-1-yl)-benzoic acid D33 319.2 3.10 tert-butyl ester (B59) 3-(1, 1-Dioxo-1,-isothiazolidin-2-yl)-5-methylamino-D34 benzoic acid tert-butyl ester (B62) 3-(1, 1-Dioxo-115-[1, 2] thiazinan-2-yl)-5-ethylamino-D35 355. 2 3.32
benzoic acid tert-butyl ester (B73) Ester 33 Diethylamino-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B33) To a solution of 3-amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (100 mg, 0.43 mmol, 1 equiv) in (CH2CI) 2 (1.5 ml) was added acetaldehyde (0.072 ml, 1.29 mmol, 3 equiv) and sodium triacetoxyborohydride (273 mg, 1.29 mmol, 3 equiv). The resulting solution was stirred at room temperature for 1 h, diluted with AcOEt (20 ml), washed with 2N aqueous NaOH solution (20 ml), dried over MgSO4 and concentrated in vacuo to give diethylamino- (2- oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B33) (110 mg, 98%) as a pale yellow oil.
The following esters were prepared in an analogous manner to the process described in Ester 33 (B33) using the appropriate aldehyde and the appropriate aniline indicated in the below table : Ester Aniline [M+H]+ RT (min Dimethylamino- (2-oxo-pyrrolidin-1-yl)-benzoic acid D4a 263.0 2.63 methyl ester (B34) Diethylamino-(1,1-dioxo-1/6-isothiazolidin-2-yl)- D16 327. 0 2.96 benzoic acid methyl ester (B63) Diethylamino- (2-oxo-piperidin-1-yl)-benzoic acid D4b methyl ester (B60) Ester 35 3-(2-Oxo-pyrrolidin-1-yl)-5-propylamino-benzoic acid methyl ester (B35) To a solution of 3-amino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (500 mg, 2,14 mmol, 1 equiv) in (CH2CI) 2 (10 ml) was added sodium triacetoxyborohydride (640 mg, 3.02 mmol, 1.4 equiv), propionaldehyde (0.156 ml, 2.14 mmol, 1 equiv) and CH3COOH (0.125 ml, 2.18 mmol, 1.02 equiv). The resulting mixture was stirred at room temperature for 2 h, diluted with CH2CI2 (20 ml), washed with saturated aqueous NaHC03 solution (20 ml), dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 3/2) gave 3- (2-oxo-pyrrolidin-1-yl)-5-propylamino-benzoic acid methyl ester (B35) (250 mg, 42%) as a colourless oil.
The following esters were obtained in an analogous manner to the process described in Ester 35 (B35) using the appropriate aldehyde and the appropriate aniline indicated in the table below : Ester Aniline [M+H] + RT (min) 3-Benzylamino-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)- D16 benzoic acid methyl ester (B64) 3-Butylamino-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)- D16 327. 0 3.10 benzoic acid methyl ester (B65) 3-(1, 1-Dioxo-116-isothiazolidin-2-yl)-5-(3-methyl-D16 341.1 3.26 butylamino)-benzoic acid methyl ester (B66) 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-phenethylamino- D16 375. 0 3.23 benzoic acid methyl ester (B67) 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-pentylamino- D16 341. 1 3.29 benzoic acid methyl ester (B68) 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-propylamino- D16 313. 0 2.90 benzoic acid methyl ester (B69) 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-ethylamino- D16 299. 0 2.91 benzoic acid methyl ester (B70) 3-(Cyclopropylmethyl-amino)-5-(1,1-dioxo-1/6- D16 325.0 2.91 isothiazolidin-2-yl)-benzoic acid methyl ester (B71) 3-lsobutylamino-5-(2-oxo-pyrrolidin-1-yl)-benzOic acid D4a 291.1 3.03 methyl ester (B36) 3-Benzylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid D4a methyl ester (B37) 3- (3-Methyl-butylamino)-5- (2-oxo-pyrrolidin-1-yl)-D4a benzoic acid methyl ester (B38) 3- (2-Oxo-pyrrolidin-1-yl)-5-pentylamino-benzoic acid D4a methyl ester (B39 3-Butylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid D4a methyl ester (B40) 3-(2,2-Dimethyl-propylamino)-5-(2-oxo-pyrrolidin-1-yl- D4a 305.0 3.22 benzoic acid methyl ester (B41) 3-(Cyclopropylmethyl-amino)-5-(2-oxo-pyrrolidin-1-yl)-D4a benzoic acid methyl ester (B42) 3-(2-Oxo-piperidin-1-yl)-5-propylamino-benzoic acid D4b methyl ester (B58
Ester 43 3"Ethyl-propylamino)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B43) To a solution of 3-amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (200mg, 0. 87mmol, 1equiv) in (CH2CI) 2 (5ml) were added sodium triacetoxyborohydride (1.536 g, 5.22 mmol, 6 equiv), 3-pentanone (0.546 ml, 5.22 mmol, 6 equiv) and AcOH (0.050 mi, 0.87 mmol, 1 equiv). The resulting mixture was stirred at room temperature for 48 h, diluted with CH2CI2 (20moi), washed with saturated aqueous NaHC03 solution (20ml), dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso- hexane/AcOH: 3/2) gave 3- (1-ethyl-propylamino)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B43) (106 mg, 40%) as a colourless oil.
[M+H] + = 305.0 RT = 3. 19 The following esters were obtained in an analogous manner to Ester 43 (B43) using the appropriate ketone and the appropriate aniline indicated in the table below : EsterAni) ine [M+H] RT (min) 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-5-isopropylamino- D16 313. 0 2. 82 benzoic acid methyl ester (B72) 3-Isopropylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid D4a 227.0 2.75 methyl ester (B44) 3-Cyclopentylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic D4a acid methyl ester (B45) 3-Cyclohexylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic D4a acid methyl ester (B46)
Ester 47 (Acetyl-methyl-amino)- (ethyl-propionyl-amino)-benzoic acid tert-butyl ester (B47) To a solution of 3-methylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (B32) (200 mg, 0.69 mmol, 1 equiv) in CH2CI2 (5 ml) was added NEt3 (278 Ll, 2 mmol, 2.9 equiv) and acetic anhydride (195 µl, 2 mmol, 2.9 equiv). The resulting mixture was stirred at room temperature for 16h, diluted with CH2CI2, washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give (acetyl-methyl-amino)- (ethyl-propionyl- amino) -benzoic acid tert-butyl ester (B47) (203 mg, 89%) as a pale yellow oil which was used in the next step without further purification.
[M+H] + = 333.1 RT = 2.76 min The following esters were prepared in an analogous manner to the process described in Ester 47 from the appropriate amine starting materials : Ester Amine (Acetyl-propyl-amino)- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B48) B35 Acetyl-isopropyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B49) B44 Ester 50 3-Acetylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B50) To a solution of 3-amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (80 mg, 0.34 mmol, 1 equiv) in CH2CI2 (10 mi) was added NEt3 (0.142 ml, 1.02 mmol, 2 equiv) and acetic anhydride (0.078 ml, 0.82 mmol, 2.4 equiv). The resulting mixture was stirred at room temperature for 16h. The reaction was then diluted with AcOEt (20ml), washed with 2N aqueous HCI solution (20ml), dried over MgS04, and concentrated in vacuo to give 3- acetylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B50) (67 mg, 71%) as a pale yellow foam.
Ester 51 (Methanesulfonyl-methyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzo ic acid ter-butyl ester (B51) To a solution of 3-methylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (B32) (200 mg, 0.69 mmol, 1 equiv) in CH2CI2 (5 ml) was added NEt3 (278111, 2 mmol, 2.9 equiv) and methanesulphonyl chloride (162 lli, 2 mmol, 2.9 equiv). The resulting mixture was stirred
at room temperature for 16 h, diluted with CH2CI2, washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give (methanesulfonyl-methyl- amino)- (2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (B51) (203 mg, 89%) as a pale yellow oil. [M+H]'= 313.0, RT = 2.95 min Ester 52 (Methanesulfonyl-propyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzo ic acid methyl ester (B52) Ester 52 was prepared from 3- (2-oxo-pyrrolidin-1-yl)-5-propylamino-benzoic acid methyl ester (B35) in an analogous manner to that described for Ester 51 (B51).
Ester 53 3-Methanesulfonylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B53) To a solution of 3-amino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (D4a) (200 mg, 0.85 mmol, 1 equiv) in CH2CI2 (5 ml) and DMF (5 ml) was added NEt3 (0.181 ml, 1.3 mmol, 1.5 equiv) and methanesulphonyl chloride (0.071 ml, 1 mmol, 1.2 equiv). The resultant mixture was stirred at room temperature for 1 h, diluted with AcOEt (30 ml), washed with 2N aqueous HCI solution (30 ml), dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 and then filtered to give 3-methanesulfonylamino-5- (2-oxo-pyrrolidin-1-yl)- benzoic acid methyl ester (B53) as a pale yellow solid (100 mg, 38%).
Ester 74 5-(2-Oxo-pyrrolidin-1-yl)-isophthalic acid 1-tert-butyl ester 3-methyl ester (B74) A solution of 1-tert-butyl ester 3-methyl ester (D80) (4.5 g, 12.7 mmol, 1 equiv) in THF (60 mi) was treated portionwise with NaH (60% suspension in mineral oil, 560 mg, 14 mmol, 1.1 equiv) over 5 min at room temperature. The resulting mixture was stirred for 1 h, then MeOH (5 mi) was added and the mixture was concentrated in vacuo. The residue was diluted with AcOEt (200 ml) and the organic phase was washed with H20 (100 ml), dried over MgS04 and concentrated in vacuo to give 5- (2-oxo-pyrrolidin-1-yl)-isophthalic acid 1-tert-butyl ester 3- methyl ester (B74) (3.9 g, 97%) as a white solid.
Ester 76 3-Hydroxymethyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B76) A suspension of 5-(2-oxo-pyrrolidin-1-yl)-isophthalic acid monomethyl ester (A75) (200 mg, 0.76 mmol, 1 equiv) in THF (20 ml) was cooled to 0 °C and treated with BH3-Me2S (2M solution in THF, 0.64 ml, 1.28 mmol, 1.3 equiv). The resulting mixture was refluxed for 1 h and then cooled to room temperature. MeOH (5 mi) was added and the resulting mixture was concentrated in vacuo. The residue was diluted with AcOEt (50 ml) and the resulting solution was washed with saturated aqueous NaHC03 solution (30 ml) and 2N aqueous HCI solution (30 ml), dried over MgS04 and concentrated in vacuo to give 3-hydroxymethyl-5- (2-oxo- pyrrolidin-1-yl)-benzoic acid methyl ester (B76) (70 mg, 37%) as a pale yellow oil.
Ester 77 5-(2-Oxo-pyrrolidin-1-yl)-N-propyl-isophthalamic acid methyl ester (B77)
A suspension of 5- (2-oxo-pyrrolidin-1-yl)-isophthalic acid monomethyl ester (A75) (200 mg, 76 mmol, 1 equiv) in CH2C12 (20 ml) at room temperature was treated with a few drops of DMF followed by (COCI) 2 (100 mg, 0.8 mmol, 1.1 equiv). The resulting mixture was stirred for 1 h and then propylamine (140 mg, 2.4 mmol, 3.3 equiv) was added and the resulting solution was stirred for 30 min. The solution was then washed with 2N aqueous HCI solution (30moi), saturated aqueous NaHC03 solution (30 ml), dried over MgS04 and concentrated in vacuo to give 5- (2-oxo-pyrrolidin-1-yl)-N-propyl-isophthalamic acid methyl ester (B77) (127 mg, 55%) as a cream waxy solid.
The following compounds were prepared in an analogous manner to that described for Ester 77 from 5- (2-oxo-pyrrolidin-1-yl)-isophthalic acid monomethyl ester (A75) and the appropriate amine: Ester N, N-Dimethyl-5-(2-oxo-pyrrolidin-1-yl)-isophthalamic acid methyl ester (B78) N-Methyl-5-(2-oxo-pyrrolidin-1-yl)-isophthalamic acid methyl ester (B79) Ester 80 5-(2-Oxo-pyrrolidin-1-yl)-N, N-dipropyl-isophthalamic acid methyl ester (B80) A solution of 5- (4-chloro-butanoylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D89) (1.7 g, 4.4 mmol, 1 equiv) THF (20 ml) was treated portionwise with NaH (60% dispersion in mineral oil, 180 mg, 4.5 mmol, 1.1 equiv) and the resulting mixture was stirred for 1 h and then was diluted with AcOEt (100 ml). The resulting solution was washed with 2N aqueous HCI solution (50 ml), dried over MgS04 and concentrated in vacuo to give 5- (2-oxo-pyrrolidin- 1-yl)-N, N-dipropyl-isophthalamic acid methyl ester (B80) (1.38 g, 91 %) as a colourless oil.
Ester 81 5- (2-Oxo-piperidin-1-yl)-N, N-dipropyl-isophthalamic acid methyl ester (B81) Ester 81 was prepared in an analogous manner to Ester 80 from 5- (5-chloro-pentanoylamino)- N, N-dipropyl-isophthalamic acid methyl ester (D90).
Ester 82 3-Nitro-5-(2-oxo-piperidin-1-yl)-benzoic acid methyl ester (B82) NaH (60% w/w in mineral oil, 680 mg, 17 mmol, 0.9 equiv) was added portionwise to a solution of 3- (5-chloro-pentanoylamino)-5-nitro-benzoic acid methyl ester (D3) (6 g, 19 mmol, 1 equiv) in THF (40 ml) under nitrogen. The resulting mixture was stirred at room temperature for 1 h and then MeOH was added dropwise. The solution was concentrated in vacuo and the residue diluted with AcOEt. The organic phase was washed with H2O, dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (AcOEt/iso-hexane : 1/2) gave 3-nitro-5- (2-oxo-piperidin-1-yl)-benzoic acid methyl ester (B82) (2.8 g, 53%) as a pale orange oil.
Ester 83 3-(1, 1-DioXo-1/6-isothiazolidin-2-yl)-5-fluoromethyl-benzoic acid methyl ester (B83)
A solution of 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-hydroxymethyl-benzoi c acid methyl ester (D84) (400 mg, 1.4 mmol, 1 equiv) in CH2CI2 (40 ml) at 0 °C was treated with (diethylamino) sulfur trifluoride (240 mg, 1.5 mmol, 1.1 equiv). The mixture was stirred at 0 °C for 1 h and then allowed to warm to room temperature. The solution was washed with 2N aqueous HCI solution (40 ml), dried over MgS04 and concentrated in vacuo to give 3- (1, 1- dioXo-1/6-isothiazolidin-2-yl)-5-fluoromethyl-benzoic acid methyl ester (B83) (250 mg, 62%) as a white solid.
Ester 84 3-Dimethylaminomethyl-5-(dioxo-116-isothiazolidin-2-yl)-benz oic acid methyl ester (B84) A solution of 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-methanesulfonyloxyme thyl-benzoic acid methyl ester (D85) (200 mg, 0.55 mmol, 1 equiv) in EtOH (3 ml) was treated with dimethylamine (33% in EtOH, 3 mi, excess). The resulting mixture was stirred for 15 min and then concentrated in vacuo and reevaporated with toluene (5 ml). The residue was dissolved in AcOEt (50 ml) and the resulting solution was washed with saturated aqueous NaHC03 solution (50 ml), dried over MgS04 and concentrated in vacuo to give 3-dimethylaminomethyl- 5-(dioxo-1/6-isothiazolidin-2-yl)-benzoic acid methyl ester (B84) (170 mg, 99%) as a yellow waxy solid.
Ester 85 3-Azidomethyl-5-(1, 1-dioxo-1/6'-isothiazolidin-2-yl)-benzoic acid methyl ester (B85) A solution of 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-methanesulfonyloxyme thyl-benzoic acid methyl ester (D85) (200 mg, 0.55 mmol, 1 equiv) in DMF (2 ml) was treated with NaN3 (39 mg, 0.6 mmol, 1.1 equiv) and the resulting mixture was stirred for 1 h at room temperature and then diluted with AcOEt (50 ml). The resulting solution was washed sequentially with 2N aqueous HCI solution (30 ml), saturated aqueous NaHCO3 solution (30 ml) and H2O (50 ml), dried over MgS04 and concentrated in vacuo to give 3-azidomethyl-5-(1, 1-dioxo-116- isothiazolidin-2-yl)-benzoic acid methyl ester (B85) as a white solid (129 mg, 76%).
Ester 89 3-(1, 1-DioXo-116-isothiazolidin-2-yl)-5-(Z)-propenyl-benzoic acid methyl ester (B89) A suspension of (ethyl) triphenylphosphonium bromide (371 mg, 1.0 mmol, 1.4 equiv) in THF (20 mi) was treated with KOtBu (112 mg, 1.0 mmol, 1.4 equiv) and the resulting mixture was stirred for 15 min at room temperature. A solution of 3-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-5- formyl-benzoic acid methyl ester (D86) (200 mg, 0.7 mmol, 1 equiv) in THF (10 mi) was added and the resulting mixture was stirred for 1 h at room temperature and then diluted with AcOEt (100 ml). The resulting solution was washed with 2N aqueous HCI solution (100 ml), dried over MgS04 and concentrated in vacuo. Purification by flash chromatography on silica gel (EtOAc/iso-hexane : 1/1) gave 3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-(E/Z)-propenyl-benzo ic acid methyl ester (B89) (135 mg, 65%) as a colourless oil.
The following compounds were prepared in an analogous manner to the process described for Ester 89 from 3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5-formyl-benzOic acid methyl ester (D86) and the appropriate commercially available starting material : Ester 3-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-t-vinyl-benzoic acid methyl ester (B88) Z/E)-But-1-enyl-(ethanesulfonyl-ethyl-amino)-benzoic acid methyl ester (B90) 3- (1, 1-Dioxo-1-isothiazolidin-2-yl)-5- (2-methyl-propenyl)-benzoic acid methyl ester (B91)
Ester 92 5-(1, 1-Dioxo-1 f-isothiazolidin-2-yl)-isophthalamic acid methyl ester (B92) A suspension of 5-(1, 1-dioxo-1f-isothiazolidin-2-yl)-isophthalic acid monomethyl ester (D83) (750 mg, 2.5 mmol, 1 equiv) in CH2CI2 (30 ml) was treated with 2M (COCI) 2 in CH2CI2 (1.5 ml, 3.0 mmol, 1.2 equiv) followed by a few drops of DMF. The resulting mixture was stirred for 30 min and then 32% aqueous ammonia (5 ml, excess) was added. The resulting mixture was stirred for 15 min and then diluted with CH2CI2 (50 ml) and washed with 2N aqueous HCI solution (50 ml). The resulting white precipitate was filtered to give 5-(1, 1-dioxo-1f- isothiazolidin-2-yl)-isophthalamic acid methyl ester B92 (650 mg, 87%) as a white solid.
Ester 93 3-Cyano-5-(1, 1-dioxo-116-isothiazolidin-2-yl)-benzoic acid methyl ester (B93) A suspension of 5-(1, 1-dioxo-1t-isothiazolidin-2-yl)-isophthalamic acid methyl ester (B92) (500 mg, 1.68 mmol, 1 equiv) in CH2CI2 (100 ml) was treated with NEt3 (404 mg, 4.0 mmol, 2.4 equiv) and trifluoroacetic anhydride (378 mg, 1.8 mmol, 1.1 equiv). The resulting mixture was stirred for 1 h at room temperature and then treated with further portions of NEt3 (404 mg, 4.0 mmol, 2.4 equiv) and trifluoroacetic anhydride (378 mg, 1.8 mmol, 1.1 equiv) and stirred for another 45 min. The resulting solution was washed with 2N aqueous HCI solution (50 ml), saturated aqueous NaHC03 solution (50 ml), dried over MgS04. and concentrated in vacuo.
The residue was triturated with Et20 to give 3-cyano-5- (1, 1-dioxo-lP-isothiazolidin-2-yl)- benzoic acid methyl ester (B93) (350 mg, 75%) as a white solid.
Ester 94 5-(1,1-Dioxo-1/6-isothiazolidin-2-yl)-N,N-dipropyl-isophthal amic acid methyl ester (B94) A solution of 5- (3-chloro-propane-1-sulfonylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D91) (1.7 g, 4.0 mmol, 1 equiv) in EtOH (20 ml) was treated with NEt3 (799 mg, 7.9 mmol, 2 equiv) and the mixture was refluxed for 3 h and then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt (100 ml) and the organic phase was washed with 2N aqueous HCI solution (50 ml), dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 5-(1,1-dioxo-1 /6- isothiazolidin-2-yl)-N, N-dipropyl-isophthalamic acid methyl ester (B94) (1.2 g, 78%) as a white solid.
Ester 95 5-(1,1-Dioxo-1/6-[1, 2] thiazinan-2-yl)-N, N-dipropyl-isophthalamic acid methyl ester (B95)
Ester 95 was prepared in an analogous manner to Ester 94 from 5-(4-chloro-butane-1- sulfonylamino)-N, N-dipropyl-isophthalamic acid methyl ester (D92).
Ester 100 Fluoro-(2-oxo-pyrrolidin-1-yl)-trifluoromethyl-benzoic acid methyl ester (B100) 3-Bromo-2-fluoro-5-trifluoromethylbenzoic acid methyl ester (D29a) (500 mg, 1.95 mmol, 1 equiv), Cs2CO3 (950 mg, 2.92 mmol, 1.5 equiv), pyrrolidin-2-one (248 mg, 2.92 mmol, 1.5 equiv), Xantphos (68 mg, 0.117 mmol, 0.06 equiv) and tris (dibenzylideneacetone) dipalladium (0) (36 mg, 0.039 mmol, 0.02 equiv) were refluxed under argon in dioxan (7 ml) for 18h. After cooling, the mixture was filtered and evaporated in vacuo. Purification by flash chromatography on silica gel (AcOEt/iso-hexane : 1/4 to 1/2) gave fluoro-(2-oxo-pyrrolidin-1- yl)-trifluoromethyl-benzoic acid methyl ester (B100) (195 mg, 32%). [M+H] + 306.2.
The following compounds (Esters 101-102) were prepared in an analogous manner to that described for Description 68 from the appropriate aryl bromide starting material indicated in the below table using the appropriate 2,4, 6 trialkenylcyclotriboroxane-pyridine complex as described by F. Kerins and D. F. O'Shea in J. Org. Chem, 2002,67, 4968-4971: Description Aryl bromide [M+H] + RT (min) 3-(2-Methyl-propenyl)-5-(2-oxo-pyrrolidin-1-yl) D9a 274.1 3.14 benzoic acid methyl ester (B101) 3-(2-Oxo-pyrrolidin-1-yl)-5-((E)-styryl)-benzoic D9a acid methyl ester (B102) The following compounds were prepared in an analogous manner to the process described for 3-(2-oxo-piperidin-1-yl)-t-propyl-benzoic acid ter-butyl ester (B116) : Ester Alkene [M+H] + RT (min) 3-Isopropyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic D71 248.1 2.77 acid methyl ester (B104) 3- (2-Oxo-pyrrolidin-1-yl)-5-propyl-benzoic acid D72 262.1 3.04 methyl ester B106 3-Cyclopentyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic D74 288.1 3.26 acid methyl ester (B107) 3-Cyclohexyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic D74 acid methyl ester (B108) 3- (1, 1-Dioxo-11- [1, 2] thiazinan-2-yl)-5-propyl- D69 benzoic acid tert-butyl ester (B112) Ester 109 3-Ethynyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid ter-butyl ester (B109)
Ester 109 was prepared in an analogous manner to the process described for Ester 111 from 300 mg (mmol) of 3- (3-hydroxy-3-methyl-but-1-ynyl)-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid teit- butyl ester (D76) which yielded 220 mg (88%) of 3-ethynyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid tert-butyl ester (B109) as an off white solid.
Ester 111 3-(1, 1-Dioxo-116-isothiazolidin-2-yl)-5-ethynyl-benzoic acid test-butyl ester (B111) To a solution of 3-(1, 1-dioXo-115-isothiazolidin-2-yl)-5-(3-hydroxy-3-methyl-but-1 -ynyl)-benzoic acid tert-butyl ester (D75) (142 mg, 0.37 mmol, 1 equiv) in toluene (20 ml) was added NaH (60% dispersion in mineral oil, 4 mg, 0.1 mmol, 0.3 equiv). The resulting mixture was stirred at 110°C for 30 min, cooled to room temperature and diluted with AcOEt. The organic phase was washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo to give 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5-ethynyl-benzoic acid tert-butyl ester (B111) (142 mg, 118%) as a pale yellow oil.
Ester 116 3-(2-Oxo-piperidin-1-yl)-5-propyl-benzoic acid tert-butyl ester (B116) To a solution of 3-(2-oxo-piperidin-1-yl)-5-(E/Z)-propenyl-benzoic acid teint-butyl ester (D68) (485 mg, 1.5 mmol, 1 equiv) in EtOH (10 ml) and H20 (2 ml) was added 10% palladium on charcoal (50% wet, 485 mg, 5% w/w) and NH4COOH (945 mg, 15 mmol, 10 equiv). The resulting mixture was stirred at 65 C for 1h then cooled to room temperature. Most of the EtOH was removed in vacuo and the residue dissolved in AcOEt. The organic phase was washed with H2O, dried over MgS04 and concentrated in vacuo to give 3- (2-oxo-piperidin-1- yl)-5-propyl-benzoic acid tert-butyl ester (B116) (300 mg, 70%) as a colorless oil.
Ester 117 Methyl 3- (1, 1-dioxido-6, 7-dihydro-1, 2-thiazepin-2 (3e-yl)-5-propylbenzoate (B117) To a solution of methyl 3- [ (3-buten-1-ylsulfonyl) (2-propen-1-yl) amino]-5-propylbenzoate (D135) (1 g, 2.8 mmol, 1 equiv) in CH2CI2 (200 ml) was added bis (tricyclohexylphosphino) benzylidene ruthenium (IV) dichloride (117 mg, 0.14 mmol, 0.05 equiv) and the resulting solution was stirred at room temperature for 48 h then concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 9: 1) gave methyl 3- (1, 1-dioxido-6, 7-dihydro-1,2-thiazepin-2 (3H)-yl)-5-propylbenzoate (B117) (700 mg, 76%) as a pale purple oil. [M+H] + = 324.4, RT = 3.10 min.
Ester 118 Methyl 5- (ethylamino)-2-fluoro-3- (2-oxo-1-pyrrolidinyl) benzoate (B118) To a solution of methyl 5-(ethyl{[4-(methyloxy)phenyl]methyl}amino)-2-fluoro-3-(2-ox o-1- pyrrolidinyl) benzoate (D155) (7 g, 17.5 mmol, 1 equiv) in EtOH (150 ml) was added 10% palladium on charcoal (50% wet, 1.4 g, 10% w/w) and the resulting mixture was stirred under an atmosphere of hydrogen (1 atm) for 3 h. The catalyst was filtered off through a pad of celite and the solution concentrated in vacuo. The residue was triturated with AcOEt/iso-hexane to give methyl 5-(ethylamino)-2-fluoro-3-(2-oxo-1-pyrrolidinyl) benzoate (B118) (4.8 g, 98%) as a pale greenish solid which was used in the next step without further purification. [M+H] + = 281.2, RT = 2. 35 min.
The following esters have been obtained from the appropriate precursor in an analogous manner to the process described for Ester 35 (B35) using acetaldehyde instead of propionaldehyde. EsterPrecursor [M+H] RT (min) Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- D152 331.2 2.80 5-(ethylamino)-2-fluorobenzoate (B119 Methyl 3- (1, 1-dioxido-2-isothiazolidinyl)-5-DD151 317.1 2.64 (ethylamino)-2-fluorobenzoate (B122) Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- D153 343.2 2.64 5-(ethylamino)-2-(methylox benzoate (B139)
The following compounds were prepared in an analogous manner to the process described for 3- (2-oxo-piperidin-1-yl)-5-propyl-benzoic acid tert-butyl ester (B116) from their appropriate precursor: Ester Precursor [M+H]+ RT (min Methyl 2-fluoro-3-(2-oxo-1-pyrrolidinyl)-5-D159 280.2 2.73 propylbenzoate (B120) Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- D161 330.2 2.91 2-fluoro-5-propylbenzoate (B173) Methyl 3-(1,1-dioxido-2-isothiazolidinyl)-2-fluoro-5- D160 - 2. 74 propylbenzoate (B174)
Ester 121 171-Dimethylethyl 3-(2-oxo-5-phenyl-1-piperidinyl)-5-propylbenzoate (B121) 1, 1-Dimethylethyl 3-(2-oxo-5-phenyl-1-piperidinyl)-5-propylbenzoate (B121) was prepared from 1, 1-dimethylethyl 3- (2-oxo-5-phenyl-1-piperidinyl)-5- [ (1E/Z)-1-propen-1-yl] benzoate (D192) in an analogous manner to the process described for 3-(2-oxo-piperidin-1-yl)-5-propyl- benzoic acid tert-butyl ester (B116). [M+H]+ = 394.3, RT = 3.88 min.
Ester 123 Methyl 3-(1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (B123) A flask was charged under nitrogen with methyl 3-bromo-5-nitrobenzoate (D11) (136 mg, 0.52 mmol, 1,1 equiv), Cs2CO3 (216 mg, 0.66 mmol, 1.4 equiv), tris (dibenzylideneacetone) dipalladium (0) (22 mg, 0.023 mmol, 0.05 equiv), Xantphos (27 mg, 0.047 mmol, 0.1 equiv) and toluene (10 ml). 4-phenyltetrahydro-2H-1, 2-thiazine 1,1-dioxide (J.
Morris, D. G. Wishka J. Org. Chem. 1991,56, 3549-3556,100 mg, 0.47 mmol, 1 equiv) was then added and the resulting mixture was stirred at 120°C for 5 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between H2O and AcOEt and the aqueous phase was re-extracted with AcOEt. The combined organic solutions were dried over MgS04 and concentrated in vacuo. Purification of the residue by flash
chromatography on silica gel (iso-hexane/AcOEt : 7/3) gave methyl 3- (1, 1-dioxido-4- phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (B123) (110 mg, 60%) as a yellow oil.
[M+H+NH3] + = 408.3, RT = 3.24 min Ester 124 Methyl 3-amino-5- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl) benzoate (B124) Methyl 3-amino-5- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl) benzoate (B124) was obtained from methyl 3- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5-nitrobenzoate (B123) in an analogous manner to the process described for Description 16 (D16). [M+H] + = 361.3, RT = 2. 91 min Ester 125 Methyl 3- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino) benzoate (B125) Methyl 3- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino) benzoate (B125) was obtained from methyl 3-amino-5- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2- yl) benzoate (B124) in an analogous manner to the process described for Ester 35 (B35) using acetaldehyde instead of propionaldehyde. [M+H] + = 389.4, RT = 3.23 min Ester 126 Methyl 3-cyclopentyl-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (B126) Methyl 3-cyclopentyl-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (B126) was obtained from methyl 3- (1-cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- yl) benzoate, methyl 3- (2-cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- yl) benzoate and methyl 3- (3-cyclopenten-1-yl)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- yl) benzoate (D265) in an analogous manner to the process described for Ester 107 (B107).
Ester 127 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-1 (1-methylethyl) amino] benzoate (B127) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- [ (1-methylethyl) amino] benzoate (B127) was obtained from methyl 3-amino-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzoate (D194) in an analogous manner to the process described for Ester 35 (B35) using acetone instead of propionaldehyde. [M+H] + = 327.2, RT = 2.82 min.
Ester 128 1, 1-Dimethylethyl 3-[ethyl (methyl) amino]-5-(2-oxo-1-pyrrolidinyl) benzoate (B128) 1, 1-Dimethylethyl 3-[ethyl (methyl) amino]-5-(2-oxo-1-pyrrolidinyl) benzoate (B128) was obtained from 1, 1-dimethylethyl 3- (methylamino)-5- (2-oxo-1-pyrrolidinyl) benzoate (B32) in an analogous manner to the process described in Ester 35 (B35) using acetaldehyde instead of propionaldehyde. [M+H] + = 319.4, RT = 3.17 min.
The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Ester 35 (B35) using acetaldehyde instead of propionaldehyde and the appropriate precursor indicated in the below table. Ester Precursor [M+H] + RT (min) Methyl3- (ethylamino)-4-methyl-5- (2-oxo-1- D184 277.1 2.63 rrolidinyl benzoate B129 Methyl3- (1, 1-dioxido-2-isothiazolidinyl)-5- D186 313.1 2.79 (ethylamino)-4-methylbenzoate (B130) Methyl3- (1, 1-dioxidotetrahydro-2H-1, 2- D188 327.1 2.93 thiazin-2-yl)-5- (ethylamino)-4-methylbenzoate B131 Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2- D187 343.1 2.90 thiazin-2-yl)-5- (ethylamino)-4- (methyloxy) benzoate (B 132) Methyl3- (ethylamino)-4- (methyloxy)-5- (2-oxo- D183 293.1 2.64 1-pyrrolidinyl) benzoate (B133) Methyl3- (1, 1-dioxido-2-isothiazolidinyl)-5- D185 329.1 2.79 ethylamino)-4-(methylox benzoate (B134)
Ester 135 Methyl 3- (diethylamino)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-4-methylbenzoate <BR> <BR> <BR> (B135)<BR> <BR> <BR> <BR> <BR> Methyl 3- (diethylamino)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-4-methylbenzoate (B135) was obtained as a by-product during the synthesis of methyl 3-(1, 1-dioxidotetrahydro- 2H-1, 2-thiazin-2-yl)-5-(ethylamino)-4-methylbenzoate (B131) from methyl 3-amino-5- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-4-methylbenzoate (D188).
[M+H] + = 355.1, RT = 2.95 min.
Ester 136 Methyl 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-4-(methyloxy)-5-1 (1 E/Z)-1-propen-1- yl] benzoate (B136) To a solution of methyl 3-{[(4-chlorobutyl)sulfonyl]amino}-4-(methyloxy)-5-[(1E/Z)-1 -propen-1- yl] benzoate (D170) (650 mg, 1.72 mmol, 1 equiv) in EtOH (50 ml) was added NEt3 (500 tl, 3.6 mmol, 2.1 equiv) and the resulting solution was refluxed for 6 h then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution and a saturated aqueous NaHCO3 solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 3/1) gave methyl 3- (1, 1-dioxidotetrahydro- 2H-1, 2-thiazin-2-yl)-4- (methyloxy)-5- [ (1E/Z)-1-propen-1-yl] benzoate (B136) (450 mg, 77%) as a pale yellow oil. [M+H] + = 340.0, RT = 3.14 min.
Ester 138 Methyl 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (2-oxo-l-pyrrolidinyl) benzoate (B138)
Methyl 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (2-oxo-1-pyrrolidinyl) benzoate (B138) was obtained from methyl 3- [ (4-chlorobutanoyl) amino]-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D195) in an analogous manner to the process described for Ester 27 (B27). [M+H] + = 339.0, RT = 2.41 min.
Ester 140 Methyl 1-ethyl-4- H-indole-6-carboxylate (B140) To a solution of methyl 4- (2-oxo-1-pyrrolidinyl)-1H-indole-6-carboxylate (B154) (500 mg, 1.94 mmol, 1 equiv) in DMF (10 ml) at room temperature was added NaH (60% dispersion in mineral oil, 84 mg, 2.1 mmol, 1.1 equiv) and the resulting mixture was stirred 15 min. Ethyl iodide (200 RI, 2.5 mmol, 1.3 equiv) was added and the resulting solution was stirred for 30 min then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 1/4 to 1/1) gave methyl 1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-indole-6-carboxylate (B140) (400 mg, 72%) as an off-white solid. [M+H]+ = 287.0, RT = 2.73 min.
The following compounds have been obtained from their corresponding precursors in an analogous manner to the process described for Description 2 (D2) : Ester Precursor [M+H] + RT (min) Ethyl 3-ethyl-7- (2-oxo-1-pyrrolidinyl)-1H-indole- D225 5-carboxylate (B141) Methyl 1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-D227 benzimidazole-6-carboxylate (B149 Methyl 1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-D229 288.4 2.20 indazole-6-carboxylate (B52) Methyl 4-(2-oxo-1-pyrrolidinyl)-1H-indole-6-D228 259.0 2.22 carbox late B154 Ethyl 3-methyl-7-(2-oxo-1-pyrrolidinyl)-1H-D224 indole-5-carboxylate (B160) Ethyl 3- (1-methylethyl)-7- (2-oxo-1-pyrrolidinyl)- D226 1H-indole-5-carboxylate (B161 Methyl 4-ethyl-8- (2-oxo-1-pyrrolidinyl)-1, 2,3, 4- D230 304.3 2.52 tetrahydro-6-quinoxalinecarboxylate (B171) Ester 142 Ethyl 3-ethyl-1-methyl-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5-carbox ylate (B142) To a solution of ethyl 3-ethyl-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5-carboxylate (B141) (658 mg, 2.3 mmol, 1 equiv) in DMF (10 ml) at room temperature was added NaH (60% dispersion in mineral oil, 120 mg, 3.0 mmol, 1.3 equiv) and the resulting mixture was stirred 15 min at this temperature. Ethyl iodide (187 ; J, 3.0 mmol, 1.3 equiv) was added and the resulting solution was stirred for 30 min then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with H2O, dried over MgS04 and concentrated in vacuo. The
residue was triturated with iso-hexane to give ethyl 3-ethyl-1-methyl-7-(2-oxo-1-pyrrolidinyl)- 1H-indole-5-carboxylate (620 mg, 90%) as a yellow solid which was used in the next step without further purification.
Ester 143 Methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-1H-indole-6-carboxylat e (B143) To a solution of methyl 4- { [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-indole-6-carboxylate (D241) (900 mg, 2.5 mmol, 1 equiv) in EtOH (100 ml) was added NEt3 (1 ml, 7.3 mmol, 3 equiv) and the resulting solution was refluxed for 1.5 h then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo to give methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-1H-indole-6-carboxylat e (B143) (386 mg, 48%) as a brown oil which was used in the next step without further purification.
Ester 144 Ethyl 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-1H-indole-5-carboxylat e (B144) Ethyl 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-1H-indole-5-carboxylat e (B144) was obtained from ethyl 7-{[(3-chloropropyl)sulfonyl]amino}-3-ethyl-1H-indole-5-carb oxylate (D243) in an analogous manner to the process described for methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1- ethyl-1H-indole-6-carboxylate (B143). [M+H] + = 337.1, RT = 3.23 min Ester 145 Methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-2, 3-di hydro-1 H-i ndole-6- carboxylate (B145) To a solution of methyl 1-acetyl-4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2, 3-dihydro-1H- indole-6-carboxylate (D235) (300 mg, 0.85 mmol, 1 equiv) in THF (20 ml) at room temperature was added BH3 (1.5 M in THF, 2 ml, 3 mmol, 3.5 equiv) and the resulting mixture was stirred at room temperature for 15 h. EtOH (5 ml) was added and the resulting mixture was concentrated in vacuo after 5 min. The residue was partitioned between a 2N aqueous HCI solution (20 mi) and CH2CI2 (20 mi) and the biphasic mixture was vigorously stirred for 3 h.
The two layers were separated and the organic phase was dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 1/2) gave methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-2, 3- dihydro-1H-indole-6-carboxylate (B145) (200 mg, 70%) as a very pale yellow solid. [M+H] + = 339.2, RT = 2.92 min.
Ester 146 Ethyl 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-1-methyl-1H-indole-5-c arboxylate (B146) Ethyl 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-1-methyl-1H-indole-5-c arboxylate (B146) was prepared from ethyl 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-1H-indole-5-carboxylat e (B144) in an analogous manner to the process described for Ester 142 (B142).
Ester 147
Methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-1 H-indole-6-carboxylate (B147) To a solution of methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-6-carboxylate (D231) (180 mg, 0.58 mmol, 1 equiv) in DMF (3 ml) at room temperature was added NaH (60% dispersion in mineral oil, 24 mg, 0.6 mmol, 1 equiv) and the resulting mixture was stirred 15 min at this temperature. Ethyl iodide (64 gel, 0.8 mmol, 1.4 equiv) was added and the resulting solution was stirred for 1 h then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel gave methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-1H-indole-6- carboxylate (B147) (110 mg, 51 %) as a yellow solid which was used in the next step without further purification. [M+H] + = 337. 0, RT = 2.82 min.
Ester 148 Ethyl 7- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-3-ethyl-1H-indole-5-carboxylate (B148) To a solution of ethyl 7- { [ (4-chlorobutyl) sulfonyl] amino}-3-ethyl-1 H-indole-5-carboxylate (D242) (230 mg, 0.59 mmol, 1 equiv) in EtOH (10 ml) was added NEt3 (249 lui, 1.78 mmol, 3 equiv) and the resulting solution was stirred at 70°C for 3 h. NEt3 (1 ml, excess) was added and the solution was stirred at the same temperature for 15 h then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 3/7) gave ethyl 7- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-3-ethyl-1H-indole-5-carboxylate (B148) (150 mg, 72%) as a colorless oil. [M-H]-= 349.3, RT = 3.10 min.
Ester 150 Methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-1H-benzimidazole-6-car boxylate (B150) Methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-1H-benzimidazole-6-car boxylate (B150) was obtained from methyl 4- {bis [ (3-chloropropyl) sulfonyl] amino}-1-ethyl-1H-benzimidazole-6- carboxylate (D239) in an analogous manner to the process described for methyl 4- (1, 1- dioxido-2-isothiazolidinyl)-1-ethyl-1H-indazole-6-carboxylat e (B153) [M+H] + = 324. 5, RT = 2. 10 min.
Ester 151 Methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-1 H-benzimidazole-6- carboxylate (B151) To a solution of methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-benzimidazole-6- carboxylate (D253) (230 mg, 0.74 mmol, 1 equiv) in DMF (10 ml) at room temperature was added NaH (60% dispersion in mineral oil, 33 mg, 0.82 mmol, 1.1 equiv) and the resulting mixture was stirred 5 min at this temperature. Ethyl iodide (66 Ll, 0.82 mmol, 1.1 equiv) was added and the resulting solution was stirred for 30 min at 60°C then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and a
5% aqueous citric acid solution. The two layers were separated and the aqueous phase saturated with NaCI and extracted twice with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give methyl 4- (1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-yl)-1-ethyl-1H-benzimidazole-6-carboxylate (B151) (400 mg, 160%) as a pale yellow viscous oil which was used in the next step without further purification. [M+H] + = 338.1, RT = 2.43 min.
Ester 153 Methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-1H-indazole-6-carboxyl ate (B153) To a solution of methyl 4-{bis [(3-chloropropyl) sulfonyl] amino}-1-ethyl-1 H-indazole-6- carboxylate (D237) (1.5 g, 3 mmol, 1 equiv) in EtOH (20 ml) was added NEts (920 !, 6.6 mmol, 2.2 equiv) and the resulting solution was refluxed for 3 h then cooled to room temperature and concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with a 2N aqueous HCI solution, dried over MgS04 and concentrated in vacuo. The residue was triturated with AcOEt/iso-hexane to give methyl 4- (1, 1-dioxido-2- isothiazolidinyl)-1-ethyl-1H-indazole-6-carboxylate (B153) as a light brown solid which was used in the next step without further purification. [M+H] + = 324.5, RT = 2.35 min.
The following compounds have been obtained from Ester 154 (B154) in an analogous manner to the process described for Ester 140 (B140) using the appropriate alkylating reagent: Ester Alkylating reagent [M+H] + RT (min) Methyl 1-methyl-4-(2-oxo-1-pyrrolidinyl)-1 H-/1 273. 0 2. 52 indole-6-carboxylate (B156) Methyl 1-butyl-4-(2-oxo-1-pyrrolidinyl)-1 H-1A 315. 1 3. 10 indole-6-carboxylate (Bl57) Methyl 4- (2-oxo-1-pyrrolidinyl)-1-pentyl-1 H- indole-6-carboxylate (B158) Ester 159 Methyl 3-methyl-7-(2-oxo-1-pyrrolidinyl)-1-benzofuran-5-carboxylate (B159) Methyl 3-methyl-7-(2-oxo-1-pyrrolidinyl)-1-benzofuran-5-carboxylate (B159) was obtained from methyl 3-iodo-5- (2-oxo-1-pyrrolidinyl)-4- (2-propen-1-yloxy) benzoate (D259) in an analogous manner to the process described for Ester 163 (B163).
[M+H] + = 274.0, RT = 2.97 min.
Ester 162 <BR> <BR> <BR> <BR> Ethyl 1-methyl-3- (1-methylethyl)-7- (2-oxo-1-pyrrolidinyl)-1 H-indole-5-carboxylate (B162) Ethyl 1-methyl-3- (1-methylethyl)-7- (2-oxo-1-pyrrolidinyl)-1H-indole-5-carboxylate (B162) has been obtained from ethyl 3- (1-methylethyl)-7- (2-oxo-1-pyrrolidinyl)-1H-indole-5-carboxylate (B161) using an analogous procedure to the process described for ethyl 3-ethyl-1-methyl-7-(2- oxo-1-pyrrolidinyl)-1H-indole-5-carboxylate (B142).
Ester 163 Methyl 3-ethyl-7-(2-oxo-1-pyrrolidinyl)-1-benzofuran-5-carboxylate (B163) To a solution of methyl 4-[(2E/Z)-2-buten-1-yloxy]-3-iodo-5-(2-oxo-1-pyrrolidinyl) benzoate (D258) (1.4 g, 3.37 mmol, 1 equiv) in DMF (20 ml) at room temperature under nitrogen were added Pd (OAc) 2 (38 mg, 0.17 mmol, 0.05 equiv), NaCOOH (688 mg, 10.1 mmol, 3 equiv), Na2CO3 (893 mg, 8.4 mmol, 2.5 equiv) and NBu4CI (845 mg, 3.71 mmol, 1.1 equiv). The resulting suspension was stirred under nitrogen at 120°C for 1 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H20 and the two phases were separated. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/AcOEt : 1/1) gave methyl 3-ethyl-7-(2-oxo-1-pyrrolidinyl)-1-benzofuran- 5-carboxylate (B163) (250 mg, 26%) as a white solid. [M+H] + = 288.1, RT = 3.02 min.
Ester 164 Methyl 4- (ethyloxy)-3- [ethyl (propanoyl) amino]-5- (1-methylethyl) benzoate (B164) Methyl 4- (ethyloxy)-3- [ethyl (propanoyl) amino]-5- (1-methylethyl) benzoate (B164) was obtained from methyl 4-methyl-8-(2-oxo-1-pyrrolidinyl)-2H-chromene-6-carboxylate and methyl 4- (ethyloxy)-3- [ethyl (propanoyl) amino]-5- (1-methylethenyl) benzoate (D261) in an analogous manner to the process described for 3- (2-oxo-piperidin-1-yi)-5-propyl-benzoic acid test-butyl ester (B116).
Ester 165 Ethyl 3-ethyl-7-(2-oxo-1-piperidinyl)-1H-indole-5-carboxylate (B165) To a solution of ethyl 3-ethyl-7-iodo-1H-indole-5-carboxylate (D190) (1 g, 2.91 mmol, 1 equiv) in toluene (10 ml) were added 2-piperidinone (346 mg, 3.50 mmol, 1.2 equiv), K3PO4 (1.24 g, 5.83 mmol, 2 equiv), Cul (56 mg, 0.29 mmol, 0.1 equiv) and dimethyl ethylene diamine (62 p, l, 0.58 mmol, 0.2 equiv) and the resulting mixture was stirred at 100°C for 15 h then cooled to room temperature and concentrated in vacuo. The residue was partitioned between AcOEt and H20 and the layers were separated. The organic phase was dried under MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 1/0) gave ethyl 3-ethyl-7- (2-oxo-1-piperidinyl)-1H-indole-5-carboxylate (B165) (250 mg, 27%) as an off-white solid.
[M+H] += 315.4, RT = 2.98 min.
Ester 166 Ethyl 3-ethyl-7- (2-oxo-4-phenyl-1-pyrrolidinyl)-1H-indole-5-carboxylate (B166) Ethyl 3-ethyl-7- (2-oxo-4-phenyl-1-pyrrolidinyl)-1H-indole-5-carboxylate (B166) was obtained from ethyl 3-ethyl-7-iodo-1H-indole-5-carboxylate (D166) in an analogous manner to the process described for 1, 1-dimethylethyl 3-bromo-5-(2-oxo-5-phenyl-1-piperidinyl)benzoate (D190) using 4-phenyl-2-pyrrolidinone (Koelsch J Am. Chem Soc. 1943, (65), p 2093) instead of 5-phenyl-2-piperidinone. [M+H] + = 377.2, RT = 3.60 min.
Ester 167
Methyl 1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1 H-1, 2, 3-benzotriazole-6-carboxylate (B167) To a solution of ethyl methyl 4- (2-oxo-1-pyrrolidinyl)-1 H-1, 2, 3-benzotriazole-6-carboxylate (D249) (400 mg, 1.54 mmol, 1 equiv) in DMF (10 ml) at room temperature was added NaH (60% dispersion in mineral oil, 68 mg, 1.69 mmol, 1.1 equiv) and the resulting mixture was stirred 5 min at this temperature. Ethyl iodide (135 Ri, 1.69 mmol, 1.1 equiv) was added and the resulting solution was stirred for 2 h then concentrated in vacuo. The residue was dissolved in AcOEt and the organic phase was washed with H2O, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (AcOEt/iso-hexane : 100/0) gave methyl 1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1 H-1, 2, 3- benzotriazole-6-carboxylate (270 mg, 61%) as a pale yellow oil.
[M+H] + = 289.3, RT = 2.47 min.
Ester 168 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethyloxy) benzoate (B168) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethyloxy) benzoate (B168) was obtained from methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-hydroxybenzoate (D268) in an analogous manner to the process described for Ester 18 (B18) from Description 41 (D41).
Ester 169 Methyl 3-cyclopentyl-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (B169) Methyl 3-cyclopentyl-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (B169) was obtained from methyl 3- (3-cyclopenten-1-yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate, methyl 3- (2- cyclopenten-1-yi)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate and methyl 3-(1-cyclopenten-1- yl)-5- (1, 1-dioxido-2-isothiazolidinyl) benzoate (D264) in an analogous manner to the process described for Ester 107 (B107).
Ester 170 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- [ (1-methylethyl) oxy] benzoate (B170) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- [ (1-methylethyl) oxy] benzoate (B170) was obtained from methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-hydroxybenzoate (D268) in an analogous manner to the process described for Ester 18 (B18) from Description 41 (D41) using 2-iodopropane instead of iodoethane.
Ester 172 Methyl 8- (1, 1-dioxido-2-isothiazolidinyl)-4-ethyl-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxylate (B172) Methyl 8- (1, 1-dioxido-2-isothiazolidinyl)-4-ethyl-1, 2,3, 4-tetrahydro-6-quinoxalinecarboxylate (B172) was obtained from methyl 8- {bis [ (3-chloropropyl) sulfonyl] amino)-4-ethyl-1, 2,3, 4- tetrahydro-6-quinoxalinecarboxylate (D238) in an analogous manner to the process described for methyl 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-1H-indazole-6-carboxyl ate (B153). [M+H] + = 340.2, RT = 3.32 min.
Ester 175 Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-5- [ (1- methylethyl) amino] benzoate (B175) Methyl 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-5- [ (1-methylethyl) amino] benzoate (B175) was obtained from Description 152 (D152) in an analogous manner to the process described for Ester 43 (B43) using acetone instead of 3-pentanone.
Ester 176 Methyl 5-cyclopentyl-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluorobenzoate (B176) Methyl 5-cyclopentyl-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluorobenzoate (B176) was obtained from Description (D269) in an analogous manner to the process described for EsterB116 (B116).
Preparation of Epoxides Epoxide K1 1, 1-Dimethylethyl { S)-2-(3, 5-difluorophenyl)-1-[(2S)-2-oxiranylethyl} carbamate (K1) 1, 1-Dimethylethyl { (1S)-2- (3, 5-difluorophenyl)-1- [ (2S)-2-oxiranyl] ethyl} carbamate (K1) was obtained from 3, 5-difluoro-L-phenylalaninate (D299) according to the procedure described in Patent US 2003/0004360 A1 The following epoxides were obtained in an analogous manner to the process described for epoxide K1 using the appropriate alaninate : Epoxide Precursor 1, 1-dimethylethyl {(1S)-2-(3-fluorophenyl)-1-[(2S)-2-oxiranyl]ethyl} carbamate D300 (K2) 1, 1-dimethylethyl { (1S)-2- (3, 4-difluorophenyl)-1- [ (2S)-2-oxiranyl] ethyl} carbamate D301 (K3) 1, 1-dimethylethyl {(1S)-2-(2-chlorophenyl)-1-[(2S)-2-oxiranyl]ethyl}carbamate D302 (K4) 1, 1-dimethylethyl {(1S)-2-(3-chlorophenyl)-1-[(2S)-2-oxiranyl]ethyl}carbamate D303 (K5) 1, 1-dimethylethyl {(1S)-2-(4-chlorophenyl)-1-[(2S)-2-oxiranyl]ethyl}carbamate D304 (K6) 1, 1-dimethylethyl [(1S)-1-[(2S)-2-oxiranyl]-2-(2-thienyl)ethyl]carbamate (K7 D305 1, 1-dimethylethyl [(1S)-1-[(2S)-2-oxiranyl]-2-(3-thienyl)ethyl] carbamate (K8) D306 1, 1-dimethylethyl {(1S)-2-(2-furanyl)-1-[(2S)-2-oxiranyl]ethyl carbamate (K9) D307 1, 1-dimethylethyl [(1S)-1-[(2S)-2-oxiranyl]-2-(2-pyridinyl)ethyl] carbamate (K10 D308 1, 1-dimethylethyl [ (lS)-l- [ (2S)-2-oxiranyl]-2- (1, 3-thiazol-2-yl) ethyl] carbamate D309 K11 1, 1-dimethylethyl [(1S)-1-[(2S)-2-oxiranyl]-2-(1H-pyrazol-1-yl)ethyl]carbamate D310 K12
1,1-dimethylethyl [(1S)-1-[(2S)-2-oxiranyl]-2-(3-pyridinyl)ethyl]carbamate (K13) D311 Preparation of BOC-protected amines BOC-protected amine 1 (H1) ( (1S, 2R)-1-Benzyl-3-cyclohexylamino-2-hydroxy-propyl)-carbamic acid tert-butyl ester (H1) ((S)-(S)-1-Oxiranyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester (D101) (10 g, 38 mmol, 1 equiv) [Chirex 1819W94 Lot#9924382] was dissolved in EtOH (100 ml) and cyclohexylamine (13 ml, 114 mmol, 3 equiv) was added. The resulting mixture was heated, under an atmosphere of nitrogen, for 12 h at reflux temperature. The mixture was cooled and the solvent was removed by evaporation in vacuo. The resulting white solid was washed with H20 and then with Et2O before drying in vacuo to give ( (1S, 2R)-1-benzyl-3-cyclohexylamino-2- hydroxy-propyl)-carbamic acid tert-butyl ester (H1) (9.0 g, 66%). [M+H] + = 363.2 BOC-protected amines H2-H20, H24-H33 and H36 were prepared in an analogous manner to that described for BOC-protected amine H1, substituting cyclohexylamine with the amines indicated in the table below (unless amines are commercially available) : BOC-protected amine Precursor ((1S,2R)-1-Benzyl-3-cyclobutylamino-2-hydroxy-propyl)-carbam ic acid tert- butyl ester (H2) ((1S,2R)-1-Benzyl-2-hydroxy-3-isobutylamino-propyl)-carbamic acid tert- - butyl ester (H3) ( (1 S, 2R)-1-Benzyl-2-hydroxy-3-propylamino-propyl)-carbamic acid tert-butyl ester (H4) [ (1 S, 2R)-1-Benzyl-2-hydroxy-3-(1, 1, 5-trimethyl-hexylamino)-propyl]- F5 carbamic acid tert-butyl ester (H5) [(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydr oxy-F6 propyl]-carbamic acid tert-butyl ester (H6) { (1 S, 2R)-1-Benzyl-2-hydroxy-3-[(R)-1-(3-methoxy-phenyl)-ethylamin o]- - ropyl}-carbamic acid tert-butyl ester (H7) [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (1-methyl-1-phenyl-ethylamino)-propyl]-- carbamic acid tert-butyl ester (H8) [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-methyl-butylamino)-propyl]-carbamic acid- tert-butyl ester (H9) ((1S,2R)-1-Benzyl-3-tert-butylamino-2-hydroxy-propyl)-carbam ic acid tert-- butyl ester H10 [(1S,2R)-1-Benzyl-2-hydroxy-3-(3-trifluoromethoxy-benzylamin o)-propyl]- - carbamic acid tert-butyl ester (H11) [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (2, 2,3, 3, 3-pentafluoro-propylamino)-propyl]-- carbamic acid test-butyl ester (H12) [ (1 S, 2R)-1-Benzyl-3- (2, 2,3, 3,4, 4, 4-heptafluoro-butylamino)-2-hydroxy- - propyl]-carbamic acid tert-butyl ester H13 [ (1S,2R)-1-Benzyl-2-hydroxy-3-(3-methoxy-benzylamino)-propyl] -carbamic - acid test-butyl ester H14 { (1S,2R)-1-Benzyl-2-hydroxy-3-[1-(3-methoxy-phenyl)-1-methyl- ethylamino]- F15 ropyl}-carbamic acid tert-butyl ester H15 [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-trifluoromethyl-benzylamino)-propyl]-- carbamic acid tert-butyl ester (H16) {(1S,2R)-1-Benzyl-2-hydroxy-3-[(S)-1-(3-methoxy-phenyl)-ethy lamino]- - propyl}-carbamic acid tert-butyl ester H17 { (1 S, 2R)-1-Benzyl-2-hydroxy-3-[(S)-1-(3-methoxy-phenyl)-ethylamin o]- ropyl}-carbamic acid tert-butyl ester H18 [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (5-methyl-hexylamino)-propyl]-carbamic acid- test-butyl ester (H 19) [ (1S, 2R)-1-Benzyl-3- (1, 5-dimethyl-hexylamino)-2-hydroxy-propyl]-carbamic- acid tert-butyl ester (H20) ( (1S, 2R)-1-Benzyl-3-ethylamino-2-hydroxy-propyl)-carbamic acid tert-butyl - ester (H24) [ (1S, 2R)-1-Benzyl-3- (bis-trifluoromethyl-benzylamino)-2-hydroxy-propyl]-- carbamic acid test-butyl ester (H25) ( (1S, 2R)-1-Benzyl-3-cyclopropylamino-2-hydroxy-propyl)-carbamic acid test- butyl ester (H26) [ (1 S, 2R)-1-Benzyl-2-hydroxy-3-(4-methoxy-benzylamino)-propyl]-car bamic - acid tert-butyl ester (H27) ((1S,2R)-1-Benzyl-2-hydroxy-3-isopropylamino-propyl)-carbami c acid tert-- butyl ester (H28) [ (1S,2R)-1-Benzyl-2-hydroxy-3-(2-methoxy-benzylamino)-propyl] -carbamic - acid tert-butyl ester (H29) [(1 S, 2R)-1-Benzyl-2-hydroxy-3-((S)-1-phenyl-ethylamino)-propyl]-c arbamic acid tert-butyl ester (H30) [ (1S,2R)-1-Benzyl-2-hydroxy-3-((R)-1-phenyl-ethylamino)-propy l]-carbamic - acid tert butyl ester (H31) [(1S,2R)-1-Benzyl-2-hydroxy-3-(4-methyl-pentylamino)-propyl] -carbamic - acid toff-butyl ester (H32) [ (1 S, 2R)-1-Benzyl-2-hydroxy-3-((R)-2-hydroxy-1-isobutylcarbamoyl- F33 entylamino)-propyl]-carbamic acid test-butyl ester (H33) [(1 S, 2R)-1-Benzyl-2-hydroxy-3-((S)-1-isobutylcarbamoyl-pentylamin o)-F36 propyl]-carbamic acid tert-butyl ester (H36) BOC-protected amines H40-H114 were prepared in an analogous manner to that described for BOC-protected amine H1, substituting cyclohexylamine with the amines indicated in the table below (unless amines are commercially available): BOC-protected amine Precursor 1,1-dimethylethyl [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- F40 trifluoromethyl)phenyl]methyl}amino)propyl carbamate (H40) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-({1-[3-(methyloxy)phenyl]cyclohexyl} F41 amino)-1-(phenylmethyl)propyl carbamate (H41) 1, 1-dimethylethyl [(1 S, 2R)-2-hydroxy-3-{[(1-methyl-1 H-pyrazol-4- yl) methyl] amino}-1-(phenylmethyl) propyl] carbamate (H42) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- (tetrahydro-2H- ran-4-ylamino)propyl]carbamate (H43 1, 1-dimethylethyl [ (1S, 2R)-3- [ (3, 3-dimethylbutyl) amino]-2-hydroxy-1- (phenylmethyl) propyl] carbamate (H44) 1, 1-dimethylethyl { (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ (1, 1,3, 3- tetramethylbutyl)amino]propyl}carbamate (H45) 1,1-dimethylethyl [(1S,2R)-3-[(1,3-dimethylbutyl)amino]-2-hydroxy-1- (phenylmethyl)propyl]carbamate (H46) 1, 1-dimethylethyl [(1S,2R)-3-({[4-fluoro-3-(trifluoromethyl)phenyl] methyl}amino)-2-hydroxy-1-(phenylmethyl)propyl]carbamate (H47 1, 1-dimethylethyl [(1S,2R)-3-[(1,1-dimethylhexyl)amino]-2-hydroxy-1- F48 henylmethyl)propyl carbamate (H48) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-({[2-methyl-5-(trifluoromethyl)phenyl] methyl}amino)-1-(phenylmethyl)propyl carbamate (H49) 1, 1-dimethylethyl [(1S,2R)-3-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-2- hydroxy-1-(phenylmethyl)propyl carbamate (H50) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[(1S, 2R) -2-hydroxy-2, 3-dihydro-1H- inden-1-yl] amino}-1-(phenylmethyl) propyl] carbamate (H51) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[6-(methyloxy)-2,3-dihydro-1H- F52 inden-1-yl]amino}-1-(phenylmethyl)propyl]carbamate (H52 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[(1R, 2S) -2-hydroxy-2, 3-dihydro-1H- inden-1-yl] amino}-1-(phenylmethyl)propyl carbamate (H53) 1, 1-dimethylethyl [(1 S, 2R)-3-({1, 1-dimethyl-2-[(2-methylpropyl) thio] F54 ethyl}amino)-2-hydroxy-1-(phenylmethyl)propyl carbamate (H54) 1, 1-dimethylethyl [(1S,2R)-3-{[1,1-dimethyl-2-(phenyloxy)ethyl] amino}-2- F55 hydroxy-1-(phenylmethyl)propyl carbamate (H55) 1, 1-dimethylethyl [ (1S, 2R)-3-({1,1-dimethyl-2-[(phenylmethyl) oxy] F56 ethyl}amino)-2-hydroxy-1-(phenylmethyl)propyl carbamate (H56) 1, 1-dimethylethyl [ (l S, 2R)-2-hydroxy-3- { [3- (methyloxy) phenyl] amino)-l- (phenylmethyl) propyl] carbamate (H57) 1, 1-dimethylethyl [ (l S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( {2- [3- trifluoromethyl)phenyl]ethyl}amino)propyl carbamate (H58) 1, 1-dimethylethyl [(1S,2R)-3-[(1,1-dimethyl-2-phenylethyl) amino] -2-hydroxy- 1-(phenylmethyl)propyl carbamate (H59) 1, 1-dimethylethyl [(1 S, 2R)-2-hydroxy-3-{[2-(1-naphthalenyl) ethyl] amino}-1- henylmelthyl)propyl]carbamate (H60 1, 1-dimethylethyl [(1S,2R)-3-({1,1-dimethyl-2-[3-(methyloxy)phenyl] F61 ethyl}amino)-2-hydroxy-1-(phenylmethyl)propyl]carbamate (H61 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- (phenylamino)-1- (phenylmethyl) propyl] carbamate (H62) 1, 1-dimethylethyl [ (lS, 2R)-2-hydroxy-3- ( {l- [3- (methyloxy) F63 henyl]cyclopropyl}amino)-1-(phenylmethyl)propyl]carbamate (H63 1, 1-dimethylethyl [(1S,2R)-3-[(cyclohexylmethyl) amino] -2-hydroxy-1- henylmethyl)propyl carbamate (H64) 1, 1-dimethylethyl {(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H- pyran-4-ylmethyl) amino] propyl} carbamate (H65) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- (tetrahydro-2H- thiopyran-4-ylamino) propyl] carbamate (H66) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- [ (1-methylpropyl) amino]-1- henylmethyl)propyl carbamate (H67) 1, 1-dimethylethyl [ (l S, 2R)-3- { [4- (1, 1-dimethylethyl) cyclohexyl] amino} -2- hydroxy-1-(phenylmethyl)propyl carbamate (H68) 1, 1-dimethylethyl [ (1S, 2R)-3- [ (1-ethylcyclobutyl) amino]-2-hydroxy-1- F69 henylmethyl)propyl]carbamate (H69 1, 1-dimethylethyl [ S, 2R)-3-({1, 1-dimethyl-2-[(2-methylpropyl) oxy] F70 ethyl}amino)-2-hydroxy-1-(phenylmethyl)propyl]carbamate (H70 1, 1-dimethylethyl [ ( S, 2R)-3- ( {1, 1-dimethyl-2- [ (2-methyl-2-propen-1- F71 yl) oxy]ethyl}amino)-2-hydroxy-1-(phenylmethyl)propyl]carbamate (H71 1, 1-dimethylethyl [ (1S, 2R)-3- [ (1R)-2, 3-dihydro-1 H-inden-1-ylamino]-2- hydroxy-1-(phenylmethyl)propyl carbamate (H72) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[1-(4- F73 methylpentyl) lpentyl)cyclopropyl]amino}-1-(phenylmethyl)propyl]carbamate (H73 1, 1-dimethylethyl [ (1S, 2R)-3- [ (1-ethylcyclopropyl) amino]-2-hydroxy-1- F74 (phenylmethyl) propyl] carbamate (H74) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[1-(1-methylethyl)cyclopropyl] F75 amino}-1-(phenylmethyl)propyl]carbamate (H75 1, 1-dimethylethyl [(1S,2R)-3-(butylamino)-2-hydroxy-1- (phenylmethyl) propyl] carbamate (H76) 1, 1-dimethylethyl {(1S,2R)-2-hydroxy-1-(phenylmelthyl)-3-[(1- F77 ropylcyclopropyl)amino]propyl carbamate (H77) 1, 1-dimethylethyl [ (1S,2R)-2-hydroxy-3-{[1-(3-methylbutyl) F78 cyclopropyl]amino}-1-(phenylmethyl)propyl]carbamate (H78 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[1-(2-methylpropyl) F79 cyclopropyl]amino}-1-(phenylmethyl)propyl]carbamate (H79 1, 1-dimethylethyl [ (l S, 2R)-3- ( {l- [ (3-chlorophenyl) methyl] F80 cyclopropyl} amino)-2-hydroxy-1-(phenylmethyl) propyl] carbamate (H80) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- [ (1-methylcyclohexyl) amino]-1-F81 henylmethyl)propyl carbamate (H81) 1, 1-dimethylethyl [(1 S, 2R)-3-[(2S)-bicyclo [2.2. 1] hept-2-ylamino]-2-hydroxy- 1-(phenylmethyl)propyl carbamate (H82) 1, 1-dimethylethyl [(1S, 2R)-3-[(4, 4-dimethylcyclohexyl) amino]-2-hydroxy-1-F83 henylmethyl)propyl carbamate (H83) 1, 1-dimethylethyl ( (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- { [ (1R)-1, 2,2- trimethylpropyl]amino}propyl carbamate (H84) 1, 1-dimethylethyl ( (1S,2R)-2-hydroxy-1-(phenylmethyl)-3-{[(1S)-1, 2,2- trimethylpropyl] amino} propyl) carbamate (H85) 1, 1-dimethylethyl [ (l S, 2R)-3- [ (2, 2-dimethylcyclohexyl) amino]-2-hydroxy-1-F86 (phenylmethyl) propyl] carbamate (H86) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3-(pentylamino)-1- henylmethyl)propyl]carbamate (H87 1, 1-dimethylethyl [(1S,2R)-3-(hexylamino)-2-hydroxy-1- henylmethyl)propyl]carbamate (H88 1, 1-dimethylethyl [ (1S,2R)-3-[(3,3-dimethylbutyl) amino] -2-hydroxy-1- henylmethyl)propyl]carbamate (H89 1, 1-dimethylethyl [ (lS, 2R)-3- [ (1, 1-dimethylpropyl) amino]-2-hydroxy-l- henylmethyl)propyl]carbamate (H90 1, 1-dimethylethyl [(1S,2R)-3-[(cyclopropylmethyl) amino] -2-hydroxy-1- henylmethyl)propyl]carbamate (H91 1, 1-dimethylethyl [ (1S, 2R)-3- [ (3, 3-dimethylcyclopentyl) amino]-2-hydroxy-1- F92 henylmethyl)propyl]carbamate (H92 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- (methylamino)-1- henylmethyl)propyl]carbamate (H93 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- (tricyclo [3. 3.1. 13 7] dec-1-ylamino) propyllcarbamate (H94) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- (1, 2,3, 4- tetrahydro-1-naphthalenylamino) propyll carbamate (H95) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-({2-[3- methyloxy)phenyl]ethyl}amino)-1-(phenylmelthyl)propyl]carbam ate (H96 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- ( {2- [4- methyloxy)phenyl]ethyl}amino)-1-(phenylmelthyl)propyl carbamate (H97) 1, 1-dimethylethyl [(1S, 2R)-2-hydroxy-3-({2-[2- methyloxy)phenyl]ethyl}amino)-1-(phenylmelthyl)propyl carbamate (H98) 1, 1-dimethylethyl [ (1S, 2R)-3- { [2- (2-chlorophenyl) ethyl] amino}-2-hydroxy-1- henylmelthyl)propyl]carbamate (H99 1, 1-dimethylethyl [(1S,2R)-3-{[2-(3-chlorophenyl)ethyl] amino} -2-hydroxy-1- henylmethyl)propyl]carbamate (H100 1, 1-dimethylethyl [(1S,2R)-3-{[2-(4-chlorophenyl)ethyl]amino}-2-hydroxy-1- henylmethyl)propyl]carbamate (H101 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[2-(4-methylphenyl)ethyl]amino}-1- henylmethyl)propyl]carbamate (H102 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[2-(2-methylphenyl)ethyl]amino}-1- (phenylmethyl) propyl] carbamate (H103) 1, 1-dimethylethyl [(1 S, 2R)-3-{[2-(3, 4-dichlorophenyl) ethyl] amino}-2-hydroxy- 1-(phenylmelthyl)propyl carbamate (H104) 1, 1-dimethylethyl [ (lS, 2R)-3- { [2- (2, 4-dichlorophenyl) ethyl] amino} -2-hydroxy- 1-(phenylmethyl)propyl]carbamate (H105 1, 1-dimethylethyl [(1S,2R)-3-({2-[3, 5-bis (methyloxy) phenyl] ethyl} amino) -2- hydroxy-1-(phenylmethyl)propyl]carbamate (H106 1, 1-dimethylethyl [(1S,2R)-3-({2-[2, 3-bis (methyloxy) phenyl] ethyl} amino) -2- hydroxy-1-(phenylmethyl)propyl]carbamate (H107 1, 1-dimethylethyl {(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3- henylmelthyl)amino]propyl carbamate (H108) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- [ (2-phenylethyl) amino]-1- henylmethyl)propyl]carbamate (H109 1, 1-dimethylethyl [(1S,2R)-3-[(1-ethylcyclohexyl)amino]-2-hydroxy-1- F110 henylmethyl)propyl]carbamate (H110 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- [ (1-methylcyclopentyl) amino]-1-F111 henylmethyl)propyl]carbamate (H111 1, 1-dimelthylethyl {(1S,2R)-2-hydroxy-1-(phenylmelthyl)-3-[(1- F112 propylcyclopentyl) amino] propyl} carbamate (ho 12) 1, 1-dimethylethyl { (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ (1- F113 ropylcyclohexyl)amino]propyl carbamate (H113) 1, 1-dimethylethyl [(1S,2R)-3-{[2-(3-chlorophenyl)-1,1-dimethylethyl]amino}- F114 2-hydroxy-1-(phenylmethyl)propyl]carbamate (H114 The following BOC-protected amines H115-H147 were prepared in an analogous manner to that described for BOC-protected amine H1, using the appropriate epoxide and the appropriate amine indicated in the table below (only non commercial amines are given): Boc-protected amine Epoxide Amine 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] K13 methyl}amino)-1-(3-pyridinylmethyl)propyl] carbamate (H115 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] K11 methyl}amino)-1-(1,3-thiazol-2-ylmethyl)propyl carbamate H116 1, 1-dimethylethyl [(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(1,3- K11 thiazol-2-ylmethyl)propyl]carbamate (H117 1, 1-dimethylethyl [(1S,2R)-3-[(1,5-dimethylhexyl)amino]-2-hydroxy- K11 1-(1,3-thiazol-2-ylmethyl)propyl]carbamate (H118 1, 1-dimethylethyl [ (1S, 2R)-1- (2-furanylmethyl)-2-hydroxy-3- ( { [3- K9 methyloxy)phenyl]methyl}amino)propyl carbamate H119 1, 1-dimethylethyl [(1S,2R)-3-(cyclohexylamino)-1-(2- K9 furanylmelthyl)-2-hydroxypropyl]carbamate (H120 1, 1-dimethylethyl [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-1- (2- K9 furanylmethyl)-2-hydroxypropyl] carbamate (H121) 1, 1-dimethylethyl { (1S, 2R)-1- (2-furanylmethyl)-2-hydroxy-3- [ (1, 1, 5- K9 F5 trimethylhexyl)amino]propyl carbamate (H122) 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] K10 methyl}amino)-1-(2-pyridinylmethyl)propyl carbamate H123 1, 1-dimethylethyl [ (1S,2R)-1-[(4-chlorophenyl)methyl]-3- K6 cyclohexylamino)-2-hydroxypropyl]carbamate (H124 1, 1-dimethylethyl [(1S,2R)-1-[(4-chlorophenyl)methyl]-2-hydroxy-3- K6 3-(methyloxy)phenyl]methyl} amino)propyl carbamate (H125) 1, 1-dimethylethyl [(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2- K1 hydroxy-3-({[3-(trifluoromethyl)phenyl] methyl}amino)propyl]carbamate (H126 1, 1-dimethylethyl [ (1S, 2R)-1- [ (3, 5-difluorophenyl) methyl]-2- K1 hydroxy-3-({[3-(methyloxy)phenyl] methyl}amino)propyl]carbamate (H 127) 1, 1-dimethylethyl {(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(1,5- K1 dimethylhexyl)amino]-2-hydroxypropyl}carbamate (H128 1, 1-dimethylethyl {(1S,2R)-3-(cyclohexylamino)-1-[(3,5- K1 difluorophenyl) methyl]-2-hydroxypropyl} carbamate (H129) 1, 1-dimethylethyl {(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2- K1 F5 hydroxy-3-[(1,1,5-trimethylhexyl)amino]propyl carbamate H130 1, 1-dimethylethyl [ (1S, 2R)-1- [ (3, 4-difluorophenyl) methyl]-2- K3 hydroxy-3- ( { [3- (methyloxy) phenyl] methyllamino) propyl] carbamate H131 1, 1-dimethylethyl {(1S,2R)-3-(cyclohexylamino)-1-[(3,4- K3 difluorophenyl)methyl]-2-hydroxypropyl carbamate (ho32) 1, 1-dimethylethyl { (lS, 2R)-l- [ (3, 4-difluorophenyl) methyl]-2- K3 F5 hydroxy-3-[(1,1,5-trimethylhexyl)amino] propyl carbamate (H133) 1, 1-dimethylethyl [(1S,2R)-1-[(3-chlorophenyl)methyl]-2-hydroxy-3- K5 ({[3-(methyloxy) phenyl] methyl} amino) propyl] carbamate (H 134) 1, 1-dimethylethyl [(1S,2R)-1-[(3-chlorophenyl)methyl]-3- K5 cyclohexylamino)-2-hydroxypropyl]carbamate (H135 1, 1-dimethylethyl [(1S,2R)-1-[(2-chlorophenyl)methyl]-2-hydroxy-3- K4 3-(methyloxy)phenyl]methyl} amino)propyl carbamate H136 1, 1-dimethylethyl [ S, 2R)-1-[(2-chlorophenyl) methyl]-3-K4 (cyclohexylamino)-2-hydroxypropyl] carbamate (H137) 1, 1-dimethylethyl {(1S,2R)-1-[(2-chlorophenyl)methyl]-3-[(1,5- K4 dimethylhexyl)amino]-2-hydroxypropyl}carbamate (H138 1, 1-dimethylethyl {(1S,2R)-1-[(3-chlorophenyl)methyl]-3-[(1,5- K5 dimethylhexyl)amino]-2-hydroxypropyl carbamate H139 1, 1-dimethylethyl [ (1S, 2R)-1- [ (3-fluorophenyl) methyl]-2-hydroxy-3- K2 ({[3-(methyloxy)phenyl] methyl} amino) propyl] carbamate (H140) 1, 1-dimethylethyl { (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-1- [ (3- K2 fluorophenyl)methyl]-2-hydroxypropyl}carbamate (H141 1, 1-dimethylethyl [ (1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] K7 methyl} amino)-1-(2-thienylmethyl) propyl] carbamate (H142) 1, 1-dimethylethyl [(1S,2R)-3-[(1,5-dimethylhexyl)amino]-2-hydroxy- K7 1-(2-thienylmethyl)propyl]carbamate (H143 1, 1-dimethylethyl [ (1S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] K12 methyl}amino)-1-(1H-pyrazol-1-ylmethyl)propyl] carbamate (H144) 1, 1-dimethylethyl [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-2-hydroxy- K12 1-(1H-pyrazol-1-ylmethyl)propyl]carbamate (H145 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] K8 methyl}amino)-1-(3-thienylmethyl)propyl]carbamate (H146 1, 1-dimethylethyl [(1S,2R)-3-[(1,5-dimethylhexyl)amino]-2-hydroxy- K8 1-(3-thienylmethyl)propyl]carbamate (H147
BOC-protected amines H148-H156 were prepared in an analogous manner to that described for BOC-protected amine H1, substituting cyclohexylamine with the amines indicated in the table below (if amines are not commercially available) : BOC-protected amine Precursor 1,1-dimethylethyl {(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1- F148 ropylcyclobutyl)amino]propyl carbamate (H148) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-3-{[1-(1- F149 methylethyl)cyclobutyl]amino}-1-(phenylmethyl)propyl]carbama te (H149 1, 1-dimethylethyl [(1S, 2R)-3-({1-[(3-chlorophenyl) methyl] cyclobutyl} F150 amino)-2-hydroxy-1-(phenylmethyl)propyl carbamate (H150) 1, 1-dimethylethyl [(1S,2R)-2-hydroxy-1-(phenylmethyl)-3- (tricyclo [3. 3.1. 13, dec-2-ylamino)propyl carbamate (H151) 1, 1-dimethylethyl [(1S,2R)-3-[(1r,4R)-bicyclo [2.2. 1] hept-1-ylamino]-2- hydroxy-1-(phenylmethyl)propyl]carbamate (H152 1, 1-dimethylethyl [(1S,2R)-3-(bicyclo [2.2. 2] oct-1-ylamino)-2-hydroxy-1- henylmethyl)propyl]carbamate (H153 1, 1-dimethylethyl [(1 S, 2R)-3-{[(1-ethyl-1 H-pyrazol-4-yl) methyl] amino}-2- hydroxy-1-(phenylmethyl)propyl]carbamate (H154 1, 1-dimethylethyl [ (1S,2R)-3-[(4,4-difluorocyclohexyl)amino]-2-hydroxy-1- F155 henylmethyl)propyl carbamate H155 1, 1-dimethylethy) [ (1S, 2R)-3- ( { (3, 4-bis (methyloxy) phenyl] methyl} amino) -2- hydroxy-1-(phenylmethyl) propyl] carbamate (H 156) BOC-protected amine H157 1, 1-Dimethylethyl [ (1S,2R)-3-{[(3-ethyl-5-isoxazolyl)methyl]amino}-2-hydroxy-1- (phenylmethyl) propyl] carbamate (H157) 1, 1-dimethylethyl [(1S,2R)-3-[[(3-ethyl-5-isoxazolyl)methyl] amino} -2-hydroxy-1- (phenylmethyl) propyl] carbamate (H157) was prepared from Description F157 in an analogous manner to the process described for BOC-protected amine H1.
Preparation of Acids Acid 1
3-Methylsulfanyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A1) To a solution of 3-methylsulfanyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B1) (115 mg, 0.433 mmol, 1 equiv) in MeOH (8 ml) was added 2N aqueous NaOH solution (0.65 ml, 1.3 mmol, 3 equiv). The resulting mixture was stirred for 4 h, 2N aqueous NaOH solution (1 mi, mmol, equiv) was added and the resulting solution was stirred for 16 h then concentrated in vacuo. The residue was diluted with H2O and extracted with Et20. The aqueous layer was acidified using 2N aqueous HCI solution and the white precipitate formed was extracted twice with AcOEt. The combined organic solutions were dried over Na2SO4 and concentrated in vacuo to give 3-methylsulfanyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A1) (109 mg, 100%) as a white solid. [M+H] + = 252.0, RT = 2.61 min Acid 2 3-Ethylsulfanyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A2) Acid 2 was prepared from 125 mg (0.426 mmol) of 3-methylsulfanyl-5- (2-oxo-pyrrolidin-1-yl)- benzoic acid methyl ester (B2) in an analogous manner to that described for Acid 1 which yielded 11 mg (98%) of 3-methylsulfanyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A2) as a white solid. [M+H] + = 266.1, RT = 2.82 min Acid 3 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5-methylsulfanyl-benzoic acid (A3) To a solution of 3-(1, 1-dioXo-116-isothiazolidin-2-yl)-5-methylsulfanyl-benzOic acid methyl ester (B3) (144 mg, 0.48 mmol, 1 equiv) in MeOH (10 ml) was added 2N aqueous NaOH solution (2.4 mi, 4.8 mmol, 10 equiv). The resulting mixture was stirred at room temperature for 3.5 h and at 40 C for 1 h, then cooled to room temperature and concentrated in vacuo. The residue was diluted with H20 and extracted with Et2O. The aqueous layer was acidified with 2N aqueous HCI solution and the white precipitate formed was extracted twice with AcOEt. The combined organic solutions were dried over Na2S04 and concentrated in vacuo to give 3- (1, 1- dioXo-1/e-isothiazolidin-2-yl)-5-methylsulfanyl-benzOic acid (A3) (136 mg, 100%) as a white solid. [M+H] + = 288.0, RT = 2.63 min Acid 4 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-ethylsulfanyl-benzoi c acid (A4) To a solution of 3-(1,1-dioxo-1I6-isothiazolidin-2-yl)-5-ethylsulfanyl-benzoi c acid ethyl ester (B4) (145 mg, 0.44 mmol, 1 equiv) in MeOH (5 ml) was added 2N aqueous NaOH solution (2.2 mi, 4.4 mmol, 10 equiv). The resulting mixture was stirred at room temperature for 3 h then concentrated in vacuo. The residue was diluted with H20 and extracted with Et20. The aqueous layer was acidified with 2N aqueous HCI solution and the white precipitate formed extracted twice with AcOEt. The combined organic solutions were dried over Na2SO4 and concentrated in vacuo to give 3-(1,1-dioxo-1I6-isothiazolidin-2-yl)-5-ethylsulfanyl-benzoi c acid (A4) (133 mg, 100%) as a white solid. [M+H] + = 302.0, RT = 2.83 min Acid 5 3-Methanesulfonyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A5)
To a solution of 3-methylsulfanyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A1) (59 mg, 0.235 mmol, 1 equiv) in MeOH/H2O (3: 1,24 ml) was added oxone (578 mg, 0.94 mol, 4 equiv). The resulting mixture was stirred at room temperature for 50 min and then concentrated in vacuo.
The residue was partitioned between AcOEt and H20 and the layers separated. The organic layer was washed with H2O and brine, dried over Na2SO4 and concentrated in vacuo to give a solid which was triturated with Et20 to give 3-methanesulfonyl-5- (2-oxo-pyrrolidin-1-yl)- benzoic acid (A5) (57 mg, 86%) as a white solid. [M+H]+ = 284.0, RT = 2.05 min Acid 6 3-Ethanesulfonyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A6) Acid 6 was prepared from 59 mg (0.22 mmol) of 3-ethylsulfanyl-5- (2-oxo-pyrrolidin-1-yl)- benzoic acid (A2) in an analogous manner to that described for Acid 5 which yielded 59 mg (89%) of 3-ethanesulfonyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A6) as a white solid.
[M+H] + = 298.0, Rt = 2.08 min Acid 7 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-methanesulfonyl-benz oic acid (A7) Acid 7 was prepared from 78 mg (0.27 mmol) of 3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5- methylsulfanyl-benzoic acid (A3) in an analogous manner to that described for Acid 6 which yielded 78 mg (90%) of 3-(1,1-dioxo-1I6-isothiazolidin-2-yl)-5-methanesulfonyl-benz oic acid (A7) as a white solid. [M-H]- = 318.0, RT = 2.07 min Acid 8 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-methanesulfonyl-benz oic acid (A8) Acid 8 was prepared from 72 mg (0.24 mmol) of 3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5- ethylsulfanyl-benzoic acid (A4) 73 mg (91 %) in an analogous manner to that described in Acid 7 which yielded 3-(1,1-dioxo-1I6-isothiazolidin-2-yl)-5-ethanesulfonyl-benzo ic acid A8 as a white solid. [M-H]-= 332.0, RT = 2.14 min Acids A9-A15 were prepared from the corresponding ester indicated in the below table using a procedure analogous to that described in either A113 or A114 (indicated in the below table). Acid Procedure Ester 3-Methoxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A9) A113 B9 3-Propoxy-5- (2-oxo-pyrrolidin-1-I-benzoic acid A10 A113 B10 3-Ethoxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (All) A113 B11 3-lsopropoxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid A12 A113 B12 3-Pentoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid A13 A113 B13 3- (2-Methoxy-ethoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A14) 13 B14 3- (3-Hydroxy-propoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid A15 A113 B15 Acid 16 3-(2-Hydroxy-ethoxy)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A16) Acid 16 was prepared in accordance with an analogous procedure to that described for Ester 15 from 3- (2-benzyloxy-ethoxy)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (D40).
Acids A17-A22 and A24-A27 were prepared from the corresponding ester indicated in the below table using a procedure analogous to that described in either A113 or A114 (indicated in the below table). Acid Procedure Ester 3-(3-Methoxy-propoxy)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid A17 A113 B17 3- (1, 1-Dioxo-1/6-isothiazolidin-2-yI-5-ethoxy-benzoic acid A18 A113 B18 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-isopropoxy-benzoic acid A19 A113 B19 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5-methoxy-benzoic acid (A20) Al 13 B20 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-propoxy-benzoic acid (A21) A113 B21 3-(1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-pentoxy-benzoic acid (A22) Al 13 B22 3, 5-Bis- (2-oxo-pyrrolidin-1-yi)-benzoic acid (A24) A113 B24 4-Chloro-3,5-bis-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A25) A113 B25 4-Methoxy-3,5-Bis-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A26) A113 B26 3-Nitro-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A27) A113 B27 Acid 27 (Alternative Procedure) 3-Nitro-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A27) A flask was charged under nitrogen with 3-bromo-5-nitro-benzoic acid (D5) (12.3 g, 50 mmol, 1 equiv), Cs2CO3 (24.4 g, 75 mmol, 1.5 equiv), tris (dibenzylideneacetone) dipalladium (0) (229 mg, 0.25 mmol, 0.005 equiv), Xantphos (433 mg, 0.75 mmol, 0.015 equiv) and dioxan (120 ml). 2-Pyrrolidin-2-one (5.7 mi, 75 mmol, 1.5 equiv) was then added via syringe and the resulting mixture was stirred at reflux for 60 h then cooled to room temperature and concentrated in vacuo. The residue was diluted with H20 and 1 N aqueous NaOH solution and extracted twice with Et20. The aqueous phase was then acidified to pH 1 and extracted three times with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give 3-nitro-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A27) (9.3 g, 75%) as a pale brown solid.
Acids A28-A74 were prepared from the corresponding ester indicated in the below table using a procedure analogous to that described in either A113 or A114 (indicated in the below table). Acid Procedure Ester 3-(2-Oxo-pyrrolidin-1-yl)-5-piperidin-1-yl-benzoic acid (A28) A113 B28 3-Morpholin-4-yl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A29) A113 B29 3-(2-Oxo-pyrrolidin-1-yl)-5-phenylamino-benzoicacid (A30) A113 B30 3-Ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoicacid (A31) A114 B31 3-Methylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A32) A114 B32 3-Diethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A33) A113 B33 3-Dimethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A34) A113 B34 3-(2-Oxo-pyrrolidin-1-yl)-5-propylamino-benzoic acid (ASS) A113 B35 3-Isobutylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid sua36) A113 B36 3-Benzylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A37) A113 B37 3-(3-Methyl-butylamino)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A38) A113 B38 3-Pentylamino-5- (2-oxo-pyrrolidin-1-yi)-benzoic acid (A39) A113 B39 3-Butylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A40) A113 B40 3- (2, 2-Dimethyl-propylamino)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid A113 B41 (A41) 3- (Cyclopropylmethyl-amino)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid A113 B42 (A42) 3-(1-Ethyl-propylamino)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A43) A113 B43 3-Isopropylamino-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid A44 Al 13 B44 3-Cyclopentylamino-5-(2-oxo-pyrrolidin-1-yi)-benzoic acid (A45) A113 B45 3-Cyclohexylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A46) A113 B46 3-(Acetyl-methyl-amino)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A47) A113 B47 3-(Acetyl-propyl-amino)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A48) A114 B48 3-(Acetyl-isopropyl-amino)-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid A114 B49 (A49) 3-Acetylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A50) A113 B50 3- (Methanesulfonyl-methyl-amino)-5- (2-oxo-pyrrolidin-1-yl)-benzoic A113 B51 acid (A51) 3- (Methanesulfonyl-propyl-amino)-5- (2-oxo-pyrrolidin-1-yl)-benzoic A114 B52 acid (A52) 3-Methanesulfonylamino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A53) A113 B53 3-(2-Oxo-piperidin-1-yl)-5-pyrrolidin-1-yl-benzoic acid (A54) A114 B54 3-(2-Oxo-piperidin-1-yl)-5-piperidin-1-yl-benzoic acid (A55) Al 14 B55 3-Morpholin-4-yl-5-(2-oxo-piperidin-1-yl)-benzoic acid (A56) A114 B56 3-Methylamino-5-(2-oxo-piperidin-1-yl)-benzoic acid (A57) A114 B57 3-Propylamino-5-(2-oxo-piperidin-1-yl)-benzoic acid (A58) A113 B58 3-Ethylamino-5-(2-oxo-piperidin-1-yl)-benzoic acid (A59) A114 B59 3-Diethylamino-5-(2-oxo-piperidin-1-yl)-benzoic acid (A60) A113 B60 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-morpholin-4-yl-benzo ic acid A114 B61 (A61) 3-(1, 1-Dioxo-1/5-isothiazolidin-2-yl)-5-methylamino-benzoic acid (A62) A1 14 B62 3-Diethylamino-5-(1, 1-dioxo-1 15-isothiazolidin-2-yl)-benzoic acid (A63) A1 13 B63 3-Benzylamino-5-(1, 1-dioxo-1 16-isothiazolidin-2-yl)-benzoic acid (A64) A113 B64 3-Butylamino-5-(1, 1-dioxo-1/6-isothiazolidin-2-yl)-benzoic acid (A65) A113 B65 3- (1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5- (3-methyl-butylamino)-benzoic A113 B66 acid (A66) 3- (1, 1-Dioxo-1 6-isothiazolidin-2-yl)-5-phenethylamino-benzoic acid A113 B67 (A67) 3-Pentylamino-5-(1,1-dioxo-1I6-isothiazolidin-2-yl)-benzoic acid (A68) A113 B68 3-Propylamino-5-(1,1-dioxo-1I6-isothiazolidin-2-yl)-benzoic acid (A69) A113 B69 3-Ethylamino-5-(1, 1-dioxo-1/6-isothiazolidin-2-vl)-benzoic acid (A70) A113 B70 3-(Cylclopropylmethyl-amino)-5-(1,1-dioxo-1I6-isothiazolidin -2-yl)- A113 B71 benzoic acid A71 3- (1, 1-Dioxo-1/6-isothiazolidin-2-yl)-5-isopropylamino-benzoic acid A113 B72 (A72) 3-(1,1-Dioxo-1I6-[1, 2] thiazinan-2-yl)-5-ethylamino-benzoic acid (A73) A114 B73 3-tert-Butoxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A74) A113 B74 Acids A75-A85 were prepared from the corresponding ester indicated in the below table using a procedure analogous to that described in either A113 or A114 (indicated in the below table). Acid Procedure Ester 3-Methoxy-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A75) A114 B74 3-Hydroxymethyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A76) A113 B76 5-(2-Oxo-pyrrolidin-1-yl)-N-propyl-isophthalamic acid (A77) A113 B77 N,N-Dimethyl-5-(2-oxo-pyrrolidin-1-yl)-isophthalamic acid (A78) A113 B78 N-Methyl-5-(2-oxo-pyrrolidin-1-yl)-isophthalamic acid (A79) A113 B79 5-(2-Oxo-pyrrolidin-1-yl)-N,N-dipropyl-isophthalamic acid (A80) A113 B80 5-(2-Oxo-piperidin-1-yl)-N,N-dipropyl-isophthalamic acid (A81) A113 B81 3-Nitro-5-(2-oxo-piperidin-1-yl)-benzoic acid (A82) A113 B82 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-fluoromethyl-benzoic acid (A83) A113 B83 3-Dimethylaminomethyl-5- (dioxo-116-isothiazolidin-2-yl)-benzoic acid A113 B84 (A84) 3-Azidomethyl-5-(1,1-dioxo-1I6-isothiazolidin-2-yl)-benzoic acid (A85) A113 B85
Acid 86 3-(171-Dioxo-1/6-isothiazolidin-2-yl)-5-methoxymethyl-benzoi c acid (A86) A suspension of 3- (1, 1-dioxo-11-isothiazolidin-2-yl)-5-methanesulfonyloxymethyl-b enzoic acid methyl ester (D85) (200 mg, 0.55 mmol, 1 equiv) in MeOH (100 ml) was treated with 2N aqueous NaOH solution (10 ml). The resulting mixture was stirred for 4 h at room temperature and then concentrated in vacuo. The residue was dissolved in AcOEt (100 ml) and the resulting solution was washed with 2N aqueous HCI solution (50 ml), dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3-(1, 1-dioxo-1/6- isothiazolidin-2-yl)-5-methoxymethyl-benzoic acid (A86) (140 mg, 89%) as a white solid.
Acid 87 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5-ethoxymethyl-benzoic acid (A87) A suspension of 3-(1, 1-dioXo-116-isothiazolidin-2-yl)-5-methanesulfonylOxymethyl- benzOic acid methyl ester (D85) (200 mg, 0.55 mmol, 1 equiv) in EtOH (100 ml) was treated with 2N aqueous NaOH solution (10 ml). The resulting mixture was stirred for 4 h at room temperature and then concentrated in vacuo. The residue was dissolved in AcOEt (100 mi) and the resulting solution was washed with 2N aqueous HCI solution (50 ml), dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3-(1, 1-dioxo-116- isothiazolidin-2-yl)-5-ethoxymethyl-benzoic acid (A87) (100 mg, 61%) as a white solid.
Acids A88-95 and A100-A102 were prepared from the corresponding ester indicated in the below table using a procedure analogous to that described in either A113 or A114 (indicated in the below table). Acid Procedure Ester 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-vinyl-enzoic acid (A88) A113 B88 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5- (Z/E)-propenyl-benzoic acid A113 B89 (A89) 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5- (Z/E)-butenyl-benzoic acid A113 B90 (A90) 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-(2-methyl-propenyl)- benzoic A113 B91 acid (A91) 5-(1, 1-Dioxo-116-isothiazolidin-2-yl)-isophthalamic acid (A92) A113 B92 3-Cyano-5-(1, 1-dioxo-115-isothiazolidin-2-yl)-benzoic acid (A93) A113 B93 5- (1, 1-Dioxo-116-isothiazolidin-2-yl)-N, N-dipropyl-isophthalamic A113 B94 acid (A94) 5- (1, 1-Dioxo-116- [1, 2] thiazinan-2-yl)-N, N-dipropyl-isophthalamic A113 B95 acid (A95) 2-Fluoro-3- (2-oxo-pyrrolidin-1-yl)-5-trifluoromethyl-benzoic acid A113 B100 A100 3-(2-Oxo-pyrrolidin-1-yl)- (2-methyl-propenyl)-5-benzoic acid A113 B101 (A101) 3-(2-Oxo-pyrrolidin-1-yl)-5-((E)-styryl)-benzoic acid (A102) A113 B102
The following compounds were prepared from the corresponding alkene in an analogous manner to the process described for 3-(2-oxo-piperidin-1-yl)-5-propyl-benzoic acid tert-butyl ester (B116) : Acid Alkene [M+H] + RT (min) 3-(1,1-Dioxo-1I6-[1, 2] thiazinan-2-yl)-5-phenethyl-A102 310.0 3.12 benzoic acid methyl ester (A103) 3-Isobutyl-5-(2-Oxo-pyrrolidin-1-yl)-benzoic acid (A105 A101 262.1 2.98 Acids A104, A106-A109 and A111-A112 were prepared from the corresponding ester indicated in the below table using a procedure analogous to that described in either A113 or A114 (indicated in the below table). Acid Procedure Ester 3-Isopropyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A104) A113 B104 3-(2-Oxo-pyrrolidin-1-yl)-5-propyl-benzoic acid (A106) A113 B106 3-Cyclopentyl-5- (2-oxo-pyrrolidin-1-y)-benzoic acid (A107) A113 B107 3-Cyclohexyl-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A108) A113 B108 3-Ethynyl-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (AI09) A114 B109 3-(1,1-Dioxo-1I6-isothiazolidin-2-yl)-5-ethynyl-benzoid acid (A111) A114 B111 3-(1,1-Dioxo-1I6-[1,2]thiazinan-2-yl)-5-propyl-benzoic acid (A112) A114 B112
Acid 113 3-(2-Oxo-pyrrolidin-1-yl)-5-pyrrolidin-1-yl-benzoic acid (A113) To a solution 3-(2-oxo-pyrrolidin-1-yl)-5-pyrrolidin-1-yl-benzoic acid methyl ester (B113) (85 mg, 0.29 mmol, 1 equiv) in THF (5 ml) was added 1 N aqueous NaOH solution (0.60 ml, 0.6 mmol, 2 equiv). The resulting mixture was stirred for 14 h then concentrated in vacuo. The residue was diluted with H20 and extracted with Et2O. The aqueous layer was acidified using 2N aqueous HCI solution and the white precipitate formed was extracted twice with AcOEt.
The combined organic solutions were dried over MgS04 and concentrated in vacuo to give 3- (2-oxo-pyrrolidin-1-yl)-5-pyrrolidin-1-yl-benzoic acid (A113) (77 mg, 95%) as a white solid.
[M+H] + = 275.0, RT = 2.72 min Acid 114 3- (1, 1-Dioxo-116-isothiazolidin-2-yl)-5-pyrrolidin-1-yl-benzoic acid (A114) A solution of 3-(1, 1-dioXo-1/6-isothiazolidin-2-yl)-5-pyrrolidin-1-yl-benzoic acid teff-butyl ester (B114) (106 mg, 0.29 mmol, 1 equiv) in DCM/TFA (1/1,4 ml) was stirred at room temperature for 2 h then concentrated in vacuo. Traces of solvent were removed by azeotroping with toluene. The residue was triturated with Et2O to give 3- (1, 1-dioxo-116-isothiazolidin-2-yl)-5- pyrrolidin-1-yl-benzoic acid (A114) (86 mg, 96%) as a pale brown solid. [M+H] + = 311.1, RT = 2.75 min Acid 115 3- (4-Methyl-piperazin-1-yl)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A115) To a solution 3- (4-methyl-piperazin-1-yl)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester (B115) (296 mg, 0.93 mmol, 1 equiv) in THF (10 ml) was added 1N aqueous NaOH solution (1.8 ml, 1.8 mmol, 2 equiv). The resulting mixture was stirred for 14 h then concentrated in vacuo. The residual solid was extracted thoroughly with MeOH and the extracts were concentrated in vacuo to give 3- (4-methyl-piperazin-1-yl)-5- (2-oxo-pyrrolidin-1-yl)-benzoic acid (A115) (390 mg, 138%) as an off white solid. [M+H] + = 304.0, RT = 1.64 min Acid 116 3- (2-Oxo-piperidin-1-yl)-5-propyl-benzoic acid (A116) : Acid 116 was prepared from Ester 116 in an analogous manner to the process described for Acid 114.
A117-A136, A138-A154 and A156-A176 were prepared from esters B117-B136, B138-B154 and B156-B176, respectively using a procedure analogous to that described in either A113 or A114 (indicated in the below table). | Acid | Procedure T [M+H] + | RT (min) 3- (1, 1-Dioxido-6,7-dihydro-1, 2-thiazepin-2 (3H)-yf)-5- A113 308.0 2.66 propylbenzoic acid A117) ([M-H]- 5-(Ethylamino)-2-fluoro-3-(2-oxo-1-pyrrolidinyl) A113 267.2 1.62 benzoic acid (A118) 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A113 317.2 2.23 (ethylamino)-2-fluorobenzoic acid (Al 19) 2-Fluoro-3-(2-oxo-1-pyrrolidinyl)-5-propylbenzoic A113 266.2 2.71 acid A120 3-(2-Oxo-5-phenyl-1-piperidinyl)-5-propylbenzoic A114 338.2 3.37 acid A121 3- (1, 1-Dioxido-2-isothiazolidinyl)-5- (ethylamino)-2- A113 303.1 1.98 fluorobenzoic acid A122 3-(1,1-Dioxido-4-phenyltetrahydro-2H-1,2-thiazin-2- A113 394.1 3.47 yl)-5-nitrobenzoic acid (A123) 3-Amino-5-(1,1-dioxido-4-phenyltetrahydro-2H-1,2- A113 347.2 2.83 thiazin-2-yl) benzoic acid (A124) 3- (1, 1-Dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2- A113 375.2 3.17 I)-5-(ethylamino benzoic acid (A125) 3-Cyclopentyl-5- (1, 1-dioxidotetrahydro-2H-1, 2- A113 324.0 0.88 thiazin-2-yl) benzoic acid (A126) 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- [ (1- A113 313.2 2.38 methylethyl) amino] benzoic acid (A127) 3-[Ethyl(methyl)amino]-5-(2-oxo-1- A114 263.3 2.15 pyrrolidinyl) benzoic acid (A128) 3-(Ethylamino)-4-methyl-5-(2-oxo-1-A113 263.1 2.30 pyrrolidinyl) benzoic acid (A129) 3- (1, 1-Dioxido-2-isothiazolidinyl)-5- (ethylamino)-4- A113 299.0 2.44 methylbenzoic acid (A130) 3-(1,1-Dioxidotetrahydro-2H-1,2-thiazin-2-yl)-5- A113 313.1 2.59 (ethylamino)-4-methylbenzoic acid (Al 31) 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A113 329.1 2.57 ethylamino)-4-(methylox benzoic acid (Al32) 3-(Ethylamino)-4-(methyloxy)-5-(2-oxo-1- A113 279.1 2.34 pyrrolidinyl) benzoic acid (A133) 3- (1, 1-Dioxido-2-isothiazolidinyl)-5- (ethylamino)-4- A113 315.1 2.45 methylox benzoic acid (Al 34) 3- (Diethylamino)-5- (1, 1-dioxidotetrahydro-2H-1, 2- A113 341.1 2.05 thiazin-2-yl)-4-methylbenzoic acid (A135 3-(1,1-Dioxidotetrahydro-2H-1,2-thiazin-2-yl)-4- A113 326.0 2.87 (methyloxy)-5- [ (1E/Z)-1-propen-1-yl] benzoic acid (Al 36) 3- (1, 1-Dioxido-2-isothiazolidinyl)-5- (2-oxo-1-A113 325. 3 2.10 rrolidinyl)benzoic acid (A138 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A113 329.2 2.02 ethylamino)-2-(methylox benzoic acid (Al 39) 1-Ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-indole-6- A113 273.0 2.53 carboxylic acid (A140) 3-Ethyl-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5- A113 273.1 2.68 carboxylic acid (Al 41) 3-Ethyl-1-methyl-7-(2-oxo-1-pyrrolidinyl)-1H-indole- A113 287.4 2.43 5-carboxylic acid (A142 4-(1,1-Dioxido-2-isothiazolidinyl)-1-ethyl-1H-indole- A113 309. 3 2.40 6-carboxylic acid (A143) 7-(1,1-Dioxido-2-isothiazolidinyl)-3-ethyl-1H-indole- A113 309. 0 2.79 5-carboxylic acid (Al44) 4- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1- A113 325.3 2.69 ethyl-2, 3-dihydro-1 H-indole-6-carboxylic acid (Al 45) 7- (1, 1-Dioxido-2-isothiazolidinyl)-3-ethyl-1-methyl- A113 1 H-indole-5-carboxylic acid (Al 46) 4- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1- A113 ethyl-1 H-indole-6-carboxylic acid (Al 47) 7- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-3- A113 340.4 2.68 ethyl-1 H-indole-5-carboxylic acid (Al 48) 1-Ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-benzimidazole-6- A113 274.4 1.55 carboxylic acid (A149) 4- (1, 1-Dioxido-2-isothiazolidinyl)-1-ethyl-1H- A113 310.2 1.98 benzimidazole-6-carboxylic acid (Al 50) 4- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1- A113 340.4 2.68 ethyl-1 H-benzimidazole-6-carboxylic acid (A151) 1-Ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-indazole-6- A113 274.2 2.10 carboxylic acid (Al 52) 4- (1, 1-Dioxido-2-isothiazolidinyl)-1-ethyl-1H- A113 310.3 2.15 indazole-6-carboxylic acid (A153 4-(2-Oxo-1-pyrrolidinyl)-1H-indole-6-carboxylic acid A113 A154 1-Methyl-4-(2-oxo-1-pyrrolidinyl)-1H-indole-6- A113 259.4 2.20 carboxylic acid A156) 1-Butyl-4-(2-oxo-1-pyrrolidinyl)-1H-indole-6- A113 301.0 2.88 carboxylic acid A157 4-(2-Oxo-1-pyrrolidinyl)-1-pentyl-1H-indole-6- A113 315.1 3.06 carboxylic acid A158 3-Methyl-7-(2-oxoi-1-pyrrolidinyl)-1-benzofuran-5- A113 260.0 2.59 carboxylic acid (A159 3-Methyl-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5- A113 259.1 2.48 carboxylic acid (A160) 3- (1-Methylethyl)-7- (2-oxo-1-pyrrolidinyl)-1H-indole- A113 287.1 2.82 5-carboxylic acid (A161) 1-Methyl-3- (1-methylethyl)-7- (2-oxo-1-pyrrolidinyl)- A113 301.2 2.84 1 H-indole-5-carboxylic acid (A162) 3-Ethyl-7-(2-oxo-1-pyrrolidinyl)-1-benzofuran-5- A113 274.1 2.81 carboxylic acid (A163) 4-Methyl-8-(2-oxo-1-pyrrolidinyl)-3,l4-dinydro-2H- A113 chromene-6-carboxylic acid (A164) 3-Ethyl-7-(2-oxo-1-piperdinyl)-1H-indole-5- A113 287. 4 2.56 carboxylic acid (A165) 3-Ethyl-7-(2-oxo-4-phenyl-1-pyrrolidinyl)-1H-indole- A113 349.2 3.21 5-carboxylic acid (A166) 1-Ethyl-4-(2-oxo-1-pyrrolidinyl)-1H-1,2,3- A113 275.2 2.38 benzotriazole-6-carboxylic acid (A167) 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- [ (1- A113 314.15 0.77 methylethyl) oxy] benzoic acid (A168) 3-Cyclopentyl-5- (1, 1-dioxido-2- A113 310.0 0.83 isothiazolidinyl) benzoic acid A169 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A113 300.12 0.73 ethylox benzoic acid A170 4-Ethyl-8-(2-oxo-1-pyrrolidinyl)-1, 2,3, 4-tetrahydro-6- A113 290.5 2.00 quinoxaminecarboxylic acid (A171 8-(1,1-Dioxido-2-isothiazolidinyl)-4-ethyl-1, 2,3, 4- A113 326.2 2.00 tetrahydro-6-quinoxalinecarboxylic acid A172 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2- A113 316.1 2.49 fluoro-5-propylbenzoic acid A173 3- (1, 1-Dioxido-2-isothiazolidinyl)-2-fluoro-5- A113 302.1 2.48 propylbenzoic acid A174 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2- A113 316.2 2.30 fluoro-5-[(1-methylethyl)amino benzoic acid A175 5-Cyclopentyl-3- (1, 1-dioxidotetrahydro-2H-1, 2- A113 342.2 2.89 thiazin-2-yl)-2-fluorobenzoic acid A176
Acid 137 3- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-4- (methyloxy)-5-propylbenzoic acid (A137) 3- (l, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yi)-4- (methyloxy)-5-propylbenzoic acid (A137) was prepared from 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-4-(methyloxy)-5-[(1E)-1-propen-1- yl] benzoic acid (A136) in an analogous manner to the process described for 3- (2-oxo- piperidin-1-yl)-5-propyl-benzoic acid test-butyl ester (B116).
Acid 155 4- (1, 1-Dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1H-indole-6-carboxylic acid (A155)
To a solution of methyl 4-amino-1H-indole-6-carboxylate (D201) (1.0 g, 5.3 mmol, 1 equiv) in CH2CI2 (50 ml) were added pyridine (0.55 g, 6.5 mmol, 1.2 equiv), 4-chloro-1-butanesulfonyl chloride (1.14 g, 6 mmol, 1.1 equiv) and DMAP (300 mg, 2.45 mmol, 0.5 equiv) and the resulting mixture was stirred at room temperature for 5h. NEt3 (1 ml, 7.2 mmol, 1.3 equiv) was added and the resulting solution stirred for 2 h then diluted with AcOEt, washed with a 2N aqueous solution, a saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. The residue was dissolved in MeOH (20 mi) and treated with a 2N aqueous NaOH solution (10 ml, 20 mmol, excess). The resulting solution was stirred at room temperature for 15 h then most of the MeOH was removed in vacuo. The residue was partitioned between AcOEt and a 2N aqueous HCI solution. The two layers were separated and the organic phase was dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (CH2CI2/MeOH : 9/1) gave 4- (1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-1 H-indole-6-carboxylic acid (A155) (320 mg, 20%) as a pale pink solid. [M+H] + = 295.0, RT = 1. 90 min.
Preparation of Amines Amine 1 (C1) (2R, 3S)-3-Amino-1-cyclohexylamino-4-phenyl-butan-2-ol di-hydrogen chloride (C1) ( (1S, 2R)-1-Benzyl-3-cyclohexylamino-2-hydroxy-propyl)-carbamic acid tert-butyl ester (BOC- protected amine 1 (H1)) (9 g, 25 mmol, 1 equiv) was dissolved in MeOH (70 ml) and then a 4M solution of HCI in dioxane (60 ml, excess) was added. The resulting mixture was stirred for 3 h at room temperature and then the solvents were removed by evaporation in vacuo. The resulting residue was washed with AcOEt and then with Et20 before drying in vacuo to give the title compound (C1) as a white solid (7.4g, 88%).
[M+H] + 335. 31.
Amines C2-C20, C24-C33 and C36 were prepared from their corresponding BOC-protected amines (H2-H20, H24-H33 and H36, respectively) in an analogous manner to that described in C1.
For amines C8-C19, C25-C26 and C29-C32, the 4M HCI in dioxane was replaced with 3 equivalents of p-toluene sulphonic acid to yield the tosic acid salts. Amine [M+H1+ RT (min) (2R, 3S)-3-Amino-1-cyclobutylamino-4-phenyl-butan-2-ol di-235. 1 0.32 hydrochloride (C2) (2R, 3S)-3-Amino-1-isobutylamino-4-phenyl-butan-2-ol di-237. 1 0.86 hydrochloride (C3) (2R, 3S)-3-Amino-4-phenyl-1-propylamino-butan-2-ol di-hydrochloride 223.1 0.43 (C4) (2R, 3S)-3-Amino-4-phenyf-1- (1, 1, 5-trimethyl-hexylamino)-butan-2-ol 307.2 2.22 di-hydrochloride (C5) (S)-2-((2R, 3S)-3-Amino-2-hydroxy-4-phenyl-butylamino)-N-F899 cyclohexyl-propionamide di-hydrochloride (C6) (2R, 3S)-3-Amino-1-[(R)-1-(3-methoxy-phenyl)-ethylamino]-4-phenyl - - - butanol di-hydrochloride (C7 (2R, 3S)-3-Amino-1- (1-methyl-1-phenyl-ethylamino)-4-phenyl-butan-2- ol di-tosylate (C8) (2R, 3S)-3-Amino-1- (3-methyl-butylamino)-4-phenyl-butan-2-ol di- tosylate (C9) (2R, 3S)-3-Amino-1-tert-butylamino-4-phenyl-butan-2-ol di-tosylate - - C10 (2R, 3S)-3-Amino-4-phenyl-1- (3-trifluoromethoxy-benzylamino)-butan- 2-ol di-tos late C11 (2R, 3S)-3-Amino-1- (2, 2,3, 3, 3-pentafluoro-propylamino)-4-phenyl- butanol di-tosvlate (C12) (2R, 3S)-3-Amino-1- (2, 2,3, 3,4, 4, 4-heptafluoro-butylamino)-4-phenyl- 362 2.9 butan-2-ol di-tosylate (C13 (2R, 3S)-3-Amino-1- (3-methoxy-benzylamino)-4-phenyl-butan-2-ol di--- tosylate (C14 (2R, 3S)-3-Amino-1- [1- (3-methoxy-phenyl)-1-methyl-ethylamino]-4- 329. 1 2.05 henyl-butan-2-ol di-tosylate (C15 (2R, 3S)-3-Amino-4-phenyl-1- [3- (2, 2, 2-trifluoro-ethyl)-benzylamino]- butan-2-ol di-tosvlate (C16) (2R, 3S)-3-Amino-1-[(S)-1-(3-methoxy-phenyl)-ethylamino]-4-phenyl - - - butanol di-tos late C17 (2R, 3S)-3-Amino-1-[(S)-1-(3-methoxy-phenyl)-ethylamino]-4-phenyl - - - butan-2-ol di-tosylate (C18 (2R, 3S)-3-Amino-1- (5-methyl-hexylamino)-4-phenyl-butan-2-ol di--- tos late C19 (2R, 3S)-3-Amino-1-(1,5-dimethyl-hexylamino)-4-phenyl-butan-2-ol di- 293. 1 2.04 hydrochloride (C20) (2R, 3S)-3-Amino-1-ethylamino-4-phenyl-butan-2-ol di-hydrochloride - - (C24) (2R, 3S)-3-Amino-1- (bis-trifluoromethyl-benzylamino)-4-phenyl-butan--- 2-ol di-tosylate (C25) (2R, 3S)-3-Amino-1-cyclopropylamino-4-phenyl-butan-2-ol di-tosylate - - (C26) (2R, 3S)-3-Amino-1- (4-methoxy-benzylamino)-4-phenyl-butan-2-ol di--- hydrochloride (C27) (2R, 3S)-3-Amino-1-isopropylamino-4-phenyl-butan-2-ol di- - - hydrochloride (C28) (2R, 3S)-3-Amino-1-(2-methoxy-benzylamino)-4-phenyl-butan-2-ol di- 301. 1 1.7 tosylate (C29) (2R, 3S)-3-Amino-4-phenyl-1-((S)-1-phenyl-ethylamino)-butan-2-ol di- - - tosylate (C30) (2R, 3S)-3-Amino-4-phenyl-1-(RR)-1-phenyl-ethylamino)-butan-2-ol di- - - tosylate (C31 (2R, 3S)-3-Amino-1- (4-methyl-pentylamino)-4-phenyl-butan-2-ol di- tosylate (C32) (R)-2-((2R, 3S)-3-Amino-2-hydroxy-4-phenyl-butylamino)-3-hydroxy- hexanoic acid isobutyl-amide di-hydrochloride (C33 (S)-2-((2R, 3S)-3-Amino-2-hydroxy-4-phenyl-butylamino)-hexanoic acid isobutyl-amide di-hydrochloride (C36) Amines C40-C114 were prepared from their corresponding BOC-protected amines H40-H114, respectively) in an analogous manner to that described in C1. Amine [M+H1+ RT (min) (2R, 3S)-3-amino-1-({1-methyl-1-[3-(trifluoromethyl)phenyl]ethyl} 367.2 2.44 amino)-4-phenyl-2-butanol di-tosylate (C40 (2R, 3S)-3-amino-1-({1-[3-(methyloxy)phenyl]cyclohexyl} amino) -4- henyl-2-butanol di-hydroxhloride (C41 (2R, 3S)-3-amino-1-{[(1-methyl-1H-pyrazol-4-yl)methyl] amino} -4- phenyl-2-butanol di-tosylate (C42) (2R, 3S)-3-amino-4-phenyl-1- (tetrahydro-2H-pyran-4-ylamino)-2- butanol di-tosylate (C43 (2R, 3S)-3-amino-1- [ (3, 3-dimethylbutyl) amino]-4-phenyl-2-butanol di-265. 3 1.52 tosylate (C44 (2R, 3S)-3-amino-4-phenyl-1-[(1, 1,3, 3-tetramethylbutyl)amino]-2- 293. 3 1.76 butanol di-tos late C45 (2R, 3S)-3-amino-1-[(1,3-dimethylbutyl)amino]-4-phenyl-2-butanol di- 265. 3 1.53 tosylate (C46) (2R, 3S)-3-amino-1-({[4-fluoro-3-(trifluoromethyl)phenyl]methyl} 357.3 1.79 amino)-4-phenyl-2-butanol di-tosylate (C47 (2R, 3S)-3-amino-1- [ (1, 1-dimethylhexyl) amino]-4-phenyl-2-butanol di-293. 2 2.06 tosylate (C48 (2R, 3S)-3-amino-1-({[2-methyl-5-(trifluoromethyl) phenyl] methyl} 353.1 2.09 amino)-4-phenyl-2-butanol di-tosylate (C49 (2R, 3S)-3-amino-1- [ (1 S)-2, 3-dihydro-1 H-inden-1-ylamino]-4-phenyl-2- butanol di-tosylate (C50) (1 S, 2R)-1-{[(2R, 3S)-3-amino-2-hydroxy-4-phenylbutyl] amino} -2, 3- 313. 1 1.83 dihydro-1H-inden-2-ol di-tosylate (C51 (2R, 3S)-3-amino-1-{[6-(methyloxy)-2, 3-dihydro-1 H-inden-1-yl] amino}-327. 5 1.82 4-phenyl-2-butanol di-tosylate (C52 (1 R, 2S)-1-{[(2R, 3S)-3-amino-2-hydroxy-4-phenylbutyl] amino} -2, 3- 313. 4 1.56 dihydro-1H-inden-2-ol di-tosylate (C53 (2R, 3S)-3-amino-1-({1, 1-dimethyl-2-[(2- methylpropyl)thio]ethyl}amino)-4-phenyl-2-butanol di-tosylate (C54 (2R, 3S)-3-amino-1- { [1, 1-dimethyl-2- (phenyloxy) ethyl] amino} -4- henyl-2-butanol di-tosylate (C55 (2R, 3S)-3-amino-1-({1,1-dimethyl-2-[(phenylmethyl)oxy]ethyl}amin o)- 343. 5 1. 92 4-phenyl-2-butanol di-tosylate (C56) (2R, 3S)-3-amino-1- { [3- (methyloxy) phenyl] amino}-4-phenyl-2-butanol 287.4 2.11 di-tosylate (C57 (2R, 3S)-3-amino-4-phenyl-1-({2-[3- 353. 4 2.00 trifluoromethyl)phenyl]ethyl}amino)-2-butanol di-tosylate (C58 (2R, 3S)-3-amino-1- [ (1, 1-dimethyl-2-phenylethyl) amino]-4-phenyl-2- 313. 5 1.98 butanol di-tosylate (C59 (2R, 3S)-3-amino-1-{[2-(1-naphthalenyl)ethyl]amino}-4-phenyl-2- 335. 4 2.04 butanol di-tosylate (C60) (2R, 3S)-3-amino-1-({1,1-dimethyl-2-[3- 343. 3 1.93 methyloxy)phenyl]ethyl}amino)-4-phenyl-2-butanol di-tosylate (C61 (2R, 3S)-3-amino-4-phenyl-1-(phenylamino)-2-butanol di-tosylate 257.4 2.06 (C62) (2R, 3S)-3-amino-1- ( {1- [3- (methyloxy) phenyl] cyclopropyl} amino)-4- 327. 5 1.90 phenyl-2-butanol di-tosylate (C63) (2R, 3S)-3-amino-1-[(cyclohexylmethyl) amino]-4-phenyl-2-butanol di- tosylate (C64) (2R, 3S)-3-amino-4-phenyl-1-[(tetrahydro-2H-pyran-4-ylmethyl) amino] - 2-butanol di-tosylate (C65 (2R, 3S)-3-amino-4-phenyl-1- (tetrahydro-2H-thiopyran-4-ylamino)-2- butanol (C66) (2R, 3S)-3-amino-1- [ (1-methylpropyl) amino]-4-phenyl-2-butanol di-- tosylate (C67 (2R, 3S)-3-amino-1-{[4-(1,1-dimethylethyl)cyclohexyl]amino)-4-phe nyl- - 2-butanol di-tosylate (C68) (2R, 3S)-3-amino-1- [ (1-ethylcyclobutyl) amino]-4-phenyl-2-butanol di-- hydrochloride (C69) (2R, 3S)-3-amino-1-({1, 1-dimethyl-2-[(2- methylpropyl)oxy]ethyl}amino)-4-phenyl-2-butanol di-tosylate (C70 (2R, 3S)-3-amino-1- ({1,1-dimethyl-2-[(2-methyl-2-propen-1- yl) oxy] ethyl}amino)-4-phenyl-2-butanol di-tosylate (C71 (2R, 3S)-3-amino-1- [ (1R)-2, 3-dihydro-1 H-inden-1-ylamino]-4-phenyl-2- 577. 2 2.67 butanol di-tosylate (C72) (2R, 3S)-3-amino-1-{[1-(4-methylpentyl)cyclopropyl]amino}-4-pheny l- 2-butanol di-hydrochloride (C73 (2R, 3S)-3-amino-1- [ (1-ethylcyclopropyl) amino]-4-phenyl-2-butanol di- hydrochloride (C74) (2R, 3S)-3-amino-1- [ (1-ethylcyclopropyl) amino]-4-phenyl-2-butanol di- hydrochloride (C75) (2R, 3S)-3-amino-1-(butylamino)-4-phenyl-2-butanol di-hydrochloride (C76) (2R, 3S)-3-amino-4-phenyl-1-[(1-propylcyclopropyl) amino]-2-butanol di-hydrochloride (C77) (2R, 3S)-3-amino-1-{[1-(3-methylbutyl)cyclopropyl]amino}-4-phenyl -2- butanol di-hydrochloride (C78 (2R,3S)-3-amino-1-{[1-(2-methylpropyl)cyclopropyl]amino}-4-p henyl- 2-butanol di-hvdrochloride (C79 (2R, 3S)-3-amino-1-({1-[3-chlorophenyl)methyl]cyclopropyl} amino) -4- phenyl-2-butanol di-hydrochloride (C80) (2R, (3S)-3-amino-1-[(1-methylcyclohexyl)amino]-4-phenyl-2-butano l di-hydrochloride (C81 (2R, 3S)-3-amino-1-[(2S)-bicyclo [2.2. 1] hept-2-ylamino]-4-phenyl-2- butanol di-hydrochloride (C82) (2R, 3S)-3-amino-1- [ (4, 4-dimethyfcyclohexyl) amino]-4-phenyl-2- butanol di-hydrochloride (C83 (2R, 3S)-3-amino-4-phenyl-1-{[(1 R) -1,2, 2-trimethylpropyl] amino} -2- butanol di-h drochloride C84 (2R, 3S)-3-amino-4-phenyl-1-{[(1S)-1, 2, 2-trimethylpropyl]amino}-2- butanol di-h drochloride C85 (2R, 3S)-3-amino-1-[(2,2-dimethylcyclohexyl)amino]-4-phenyl-2- butanol di-hydrochloride (C86) (2R, 3S)-3-amino-1-(pentylamino)-4-phenyl-2-butanol (C87 (2R, 3S)-3-amino-1-(hexylamino)-4-phenyl-2-butanol di-hydrochloride (C88) (2R, 3S)-3-amino-1-[(3,3-dimethylbutyl)amino]-4-phenyl-2-butanol di- hydrochloride (C89) (2R, 3S)-3-amino-1-[(1,1-dimethylpropyl)amino]-4-phenyl-2-butanol di- hydrochloride (C90) (2R, 3S)-3-amino-1-[(cyclopropylmethyl)amino]-4-phenyl-2-butanol di- hydrochloride (C91) (2R, 3S)-3-amino-1- [ (3, 3-dimethylcyclopentyl) amino]-4-phenyl-2- butanol di-hydrochloride (C92) (2R, 3S)-3-amino-1-(methylamino)-4-phenyl-2-butanol di- hydrochloride (C93) (2R, 3S)-3-amino-4-phenyl-1- (tricyclo [3.3. 1. 1 7] dec-1-ylamino)-2- butanol di-h drochloride C94 (2R, 3S)-3-amino-4-phenyl-1- (1, 2,3, 4-tetrahydro-1- naphthalenylamino)-2-butanol di-hydrochloride (C95 (2R, 3S)-3-amino-1- ( {2- [3- (methyloxy) phenyl] ethyllamino)-4-phenyl-2- butanol di-hydrochloride (C96) (2R, 3S)-3-amino-1- ( {2- [4- (methyloxy) phenylethyl} amino)-4-phenyl-2- butanol di-hydrochloride (C97 (2R, 3S)-amino-1-({2-[2-(methyloxy)phenyl]ethyl}amino)-4-phenyl-2 - butanol di-hydrochloride (C98 (2R, 3S)-amino-1-{[2-(2-chlorophenyl)ethyl]amino}-4-phenyl-2- butanol di-hydrochloride (C99 (2R, 3S)-3-amino-1-{[2-(3-chlorophenyl) ethyl] amino}-4-phenyl-2- butanol di-hydrochloride (C100) (2R, 3S)-3-amino-1-{[2-(4-chlorophenyl)ethyl]amino}-4-phenyl-2- butanol di-hydrochloride (C101) (2R, 3S)-3-amino-1-{[2-(4-methylphenyl)ethyl]amino}-4-phenyl-2- butanol di-hydrochloride (C102) (2R, 3S)-3-amino-1-{[2-(2-methylphenyl)ethyl]amino}-4-phenyl-2- butanol di-hydrochloride (C103) (2R, 3S)-3-amino-1-{[2-(3,4-dichlorophenyl)ethyl]amino}-4-phenyl- 2- butanol di-h drochloride C104 (2R, 3S)-3-amino-1-{[2-(2,4-dichlorophenyl)ethyl]amino}-4-phenyl- 2- butanol di-hydrochloride (C105) (2R, 3S)-3-amino-1- ( {2- [3, 5-bis (methyloxy) phenyl] ethyl} amino) -4- phenyl-2-butanol di-hydrochloride (C106) (2R, 3S)-3-amino-1- ( {2- [2, 3-bis (methyloxy) phenyl] ethyl} amino) -4- phenyl-2-butanol di-hydrochloride (C107) (2R, 3S)-3-amino-4-phenyl-1-[(phenylmethyl)amino]-2-butanol di- hydrochloride (C108) (2R, 3S)-3-amino-4-phenyl-1-[(2-phenylethyl)amino]-2-butanol di- hydrochloride (C109) (2R, 3S)-3-amino-1- [ (1-ethylcyclohexyl) amino]-4-phenyl-2-butanol di- hydrochloride (C110) (2R, 3S)-3-amino-1- [ (1-methylcyclopentyl) amino]-4-phenyl-2-butanol di-h drochloride C111 (2R, 3S)-3-amino-4-phenyl-1- [ (1-propylcyclopentyl) amino]-2-butanol di-hydrochloride (C112) (2R, 3S)-3-amino-4-phenyl-1-{(1-propylcyclohexyl)amino]-2-butanol di- hydrochloride (Cl 13) (2R, 3S)-3-amino-1-{[2-(3-chlorophenyl)-1,1-dimethylethyl] amino} -4- henyl-2-butanol di-hydrochloride (C114 Amines C115-C147 were prepared from their corresponding BOC-protected amines H115- H147, respectively in an analogous manner to that described in C1. Amine [M+H] + RT (min) (2R, 3S)-3-amino-1-({[3-(methyloxy)phenyl]methyl}amino)-4-(3- pyridinyl)-2-butanol tri-hydrochloride (C115) (2R, 3S)-3-amino-1-({[3-(methyloxy) phenyl] methyl} amino)-4-(1, 3- thiazol-2-yl)-2-butanol di-hydrochloride (C116) (2R, 3S)-3-amino-1-(cyclohexylamino)-4-(1, 3-thiazol-2-yl)-2-butanol di-h drochloride C117 (2R, 3S)-3-amino-1-[(1,5-dimethylhexyl)amino]-4-(1,3-thiazol-2-yl )- 2-butanol di-hydrochloride (C118 (2R, 3S)-3-amino-4-(2-furanyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride (C119) (2R, 3S)-3-amino-1-(cyclohexylamino)-4-(2-furanyl)-2-butanol di- hydrochloride (C120) (2R, 3S)-3-amino-1- [ (1, 5-dimethylhexyl) amino]-4- (2-furanyl)-2- butanol di-hydrochloride (C121) (2R, 3S)-3-amino-4-(2-furanyl)-1-[(1, 1, 5-trimethylhexyl) amino] -2- butanol di-hydrochloride (C122) (2R, 3S)-3-amino-1-({[3-(methyloxy)phenyl]methyl}amino)-4-(2- ridinyl)-2-butanol tri-hydrochloride (C123 (2R, 3S)-3-amino-4-(4-chlorophenyl)-1-(cyclohexylamino)-2-butanol di-hydrochloride (C124) (2R, 3S)-3-amino-4-(4-chlorophenyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride C125 (2R, 3S)-3-amino-4-(3,5-difluorophenyl)-1-({[3-(trifluoromethyl) phenyl] methyl} amino)-2-butanol di-hydrochloride (C126) (2R, 3S)-3-amino-4-(3,5-difluorophenyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride C127 (2R, 3S)-3-amino-4-(3,5-difluorophenyl)-1-[(1, 5- dimethylhexyl) aminol-2-butanol di-hydrochloride (C128) (2R, 3S)-3-amino-1- (cyclohexylamino)-4- (3, 5-difluorophenyl)-2- butanol di-h drochloride C129 (2R, 3S)-3-amino-4- (3, 5-difluorophenyl)-1- [ (1, 1,5- trimethylhexyl)amino]-2-butanol di-hydrochloride (C130) (2R, 3S)-3-amino-4-(3,4-difluorophenyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride C131 (2R, 3S)-3-amino-1- (cyclohexylamino)-4- (3, 4-difluorophenyl)-2- butanol di-hydrochloride (C132) (2R, 3S)-3-amino-4- (3, 4-difluorophenyl)-1- [ (1, 1,5- trimethylhexyl)amino]-2-butanol di-hydrochloride (C133 (2R, 3S)-3-amino-4-(3-chlorophenyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride (C134 (2R, 3S)-3-amino-4- (3-chlorophenyl)-1- (cyclohexylamino)-2-butanol di-h drochloride C135 (2R, 3S)-3-amino-4-(2-chlorophenyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride (C136) (2R, 3S)-3-amino-4-(2-chlorophenyl)-1-(cyclohexylamino)-2-butanol di-h drochloride C137 (2R, 3S)-3-amino-4- (2-chlorophenyl)-1- [ (1, 5-dimethylhexyl) amino] - 2-butanol di-h drochloride C138 (2R, 3S)-3-amino-4- (3-chlorophenyl)-1- [ (1, 5-dimethylhexyl) amino] - 2-butanol di-h drochloride C139 (2R, 3S)-3-amino-4-(3-fluorophenyl)-1-({[3- (methyloxy) phenyl] methyl} amino)-2-butanol di-hydrochloride (Cl40) (2R, 3S)-3-amino-1- [ (1, 5-dimethylhexyl) amino]-4- (3-fluorophenyl)- 2-butanol di-hydrochloride (C141 (2R, 3S)-3-amino-1-({[3-(methyloxy)phenyl]methyl}amino)-4-(2- thienyl)-2-butanol di-hydrochloride (C142) (2R, 3S)-3-amino-1- [ (1, 5-dimethylhexyl) amino]-4- (2-thienyl)-2- butanol di-h drochloride C143 (2R, 3S)-3-amino-1-({[3-(methyloxy)phenyl]methyl}amino)-4-(1 H- pyrazol-1-yl)-2-butanol di-hydrochloride (C144) (2R, 3S)-3-amino-1-[(1,5-dimethylhexyl)amino]-4-(1H-pyrazol-1-yl) - 2-butanol di-hydrochloride (C145 (2R, 3S)-3-amino-1- ( { (3- (methyloxy) phenyl] methyl} amino)-4- (3- thienyl)-2-butanol di-hydrochloride (C146) (2R, 3S)-3-amino-1- [ (1, 5-dimethylhexyl) amino]-4- (3-thienyl)-2- butanol di-h drochloride C147 Amines C148-C156 were prepared from their corresponding BOC-protected amines H148- H156, respectively) in an analogous manner to that described in C1 Amine [M+H] + RT (min) (2R, 3S)-3-amino-4-phenyl-1-[(1-propylcyclobutyl)amino]-2-butanol di-hydrochloride (C148) (2R, 3S)-3-amino-1-{[1-(1-methylethyl)cyclobutyl]amino}-4-phenyl- 2- butanol di-h drochloride C149 (2R, 3S)-3-amino-1-({1-[(3-chlorophenyl)methyl]cyclobutyl}amino)- 4- phenyl-2-butanol di-hydrochloride (C150) (2R, 3S)-3-amino-4-phenyl-1- (tricyclo [3.3. 1. 13,7]dec-2-ylamino)-2- butanol di-h drochloride C151 (2R, 3S)-3-amino-1-[(1r,4R)-bicyclo [2.2. 1] hept-1-ylamino]-4-phenyl- 2-butanol di-hydrochloride (C152) (2R, 3S)-3-amino-1- (bicyclo [2.2. 2] oct-1-ylamino)-4-phenyl-2-butanol di-hydrochloride (C153 (2R,3S)-3-amino-1-{[(1-ethyl-1H-pyrazol-4-yl)methyl]amino}-4 - 289.5 1.13 phenyl-2-butanol di-hydrochloride (C154) (2R, 3S)-3-amino-1- [ (4, 4-difluorocyclohexyl) amino]-4-phenyl-2- 299. 3 1.65 butanol di-hydrochloride (C155)
(2R, 3S)-3-amino-1- ( { [3, 4-bis (methyloxy) phenyl] methyl} amino)-4- phenyI-2-butanol di-tosylate (C156) Amine 157 (2R, 3S)-3-Amino-1-{[(3-ethyl-5-isoxazolyl) methyl] amino}-4-phenyl-2-butanol di- hydrochloride (C157) (2R, 3S)-3-Amino-1-{[(3-ethyl-5-isoxazolyl)methyl]amino}-4-phenyl -2-butanol di-hydrochloride (C157) was obtained from BOC-protected amine H157 in an analogous manner to the process described for amine C1.
Examples Example 1 N- [ (1S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-5-(2-oxopyrrolidin-1-yl)-N',N'-dipropylisopht halamide (E1) To a solution of 5- (2-oxo-pyrrolidin-1-yl)-NN-dipropyl-isophthalamic acid (A80) (66 mg, 0.2 mmol, 1 equiv) in DMF (5 ml) at room temperature was added EDAC. HCI (46 mg, 0.24 mmol, 1.2 equiv), HOBT (37 mg, 0.24 mmol, 1.2 equiv), 4-ethylmorpholine (153 pL, 1.2 mmol, 6 equiv) and (S)-2- ( (2R, 3S)-3-amino-2-hydroxy-4-phenyl-butylamino)-N-cyclohexyl- propionamide di-hydrochloride (C6) (82 mg, 0.2 mmol, 1 equiv). The resulting mixture was stirred for 3 h then concentrated in vacuo. The residue was diluted in CH2CI2 and the organic phases washed with a saturated NaHC03 aqueous solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by preparative LC/MS gave N- [ (1S, 2R)-1- benzyl-3- ( (S)-1-cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-5- (2-oxopyrrolidin-1-yl)- N', N'-dipropylisophthalamide (E1) (78 mg, 60%) as a white foam.
[M+H] + = 648.3 RT = 2.70.
Examples 2-62 Examples 2-62 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H] + RT (min) N- [ (IS, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A80 C6 648.3 2.7 ethylamino)-2-hydroxypropyl]-5-(2-oxopyrrolidin-1-yl)-N], N'- dipropylisophthalamide (E2) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A75 C6 579.2 2.47 ethylamino)-2-hydroxypropyl]-5- (2-oxopyrrolidin-1-yl)- isophthalamic acid methyl ester (E3) N- [ (1S, 2R)-1-Benzyl-3- ( (S)-1-cyclohexylcarbamoyl A74 C6 621.2 2.74 ethylamino)-2-hydroxypropyl]-5-(2-oxopyrrolidin-1-yl)- isophthalamic acid tert-butyl ester (E4) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A77 C6 606.2 2.45 ethylamino)-2-hydroxypropyl]-5-(2-oxopyrrolidin-1-yl)-N'- propylisophthalamide (E5) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A78 C6 592.2 2.31 ethylamino)-2-hydroxypropyl]-N', N'-dimethyl-5- (2- oxopyrrolidin-1-yl)-isophthalamide (E6) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A79 C6 578.2 2.29 ethylamino)-2-hydroxypropyl]-N'-methyl-5-(2-oxopyrrolidin- 1-yl)-isophthalamide (E7) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A76 C6 551.2 2.28 ethylamino)-2-hydroxypropyl]-3-hydroxymethyl-5- (2- oxopyrrolidin-1-yl) benzamide (E8) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino)- A102 C14 590.2 2.83 propyl]-3- (2-oxopyrrolidin-1-yl)-5- ( (E)-styryl) benzamide (E9) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino)- A103 C14 592.2 2.80 propyl]-3- (2-oxopyrrolidin-1-yl)-5-phenethylbenzamide (E10) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino)- A107 C14 556.3 2.75 propyl]-3-cyclopentyl-5- (2-oxopyrrolidin-1-yl) benzamide (E11) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A107 C6 589.3 2.78 ethylamino)-2-hydroxypropyl]-3-cyclopentyl-5- (2- oxopyrrolidin-1-yl) benzamide (E12) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A108 C6 603.3 2.86 ethylamino)-2-hydroxypropyl]-3-cyclohexyl-5- (2- oxopyrrolidin-1-yl) benzamide (E13) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino)- A108 C14 570.3 2.84 propyl]-3-cyclohexyl-5-(2-oxopyrrolidin-1-yl) benzamide (E14) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) A108 C14 530.2 2.64 propyl]-3-(2-oxopyrrolidin-1-yl)-5-propyl-benzamide (E15) N- (1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3- (2- A106 C1 492.2 2.61 oxopyrrolidin-1-yl)-5-propylbenzamide (E16) N- [1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]-3- A101 C14 542.3 2.69 (2-methyl-propenyl)-5- (2-oxopyrrolidin-1-yl) benzamide (E17) N- [1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]-3- A105 C14 544.3 2.73 isobutyl-5- (2-oxopyrrolidin-1-yl) benzamide (E18) N- (1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3- A104 C1 492.3 2.60 isopropyl-5- (2-oxopyrrolidin-1-yl) benzamide (E19) N- (1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3-isobutyl- A105 C1 506.3 2.71 5- (2-oxopyrrolidin-1-yl) benzamide (E20) N- (1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3- A107 C16 518.4 2.77 cyclopentyl-5- (2-oxopyrrolidin-1-yl) benzamide (E21) N-[1-Benzyl-2-hydroxy-3-(3-trifluoromethylbenzylamino) A107 C16 594.4 2.97 propyl]-3-cyclopentyl-5-(2-oxopyrrolidin-1-yl) benzamide (E22) N-[1-Benzyl-2-hydroxy-3-(3-trifluoromethylbenzylamino) A106 C16 568.3 2.69 propyl]-3- (2-oxopyrrolidin-1-yl)-5-propylbenzamide (E23) N- [1-Benzyl-3- (1, 5-dimethylhexylamino)-2-hydroxypropyl]-3- A106 C20 522.4 2.67 (2-oxopyrrolidin-1-yl)-5-propylbenzamide formate salt (E24) N- [1-Benzyl-2-hydroxy-3- (3- A109 C16 550.3 2.47 trifluoromethylbenzylamino) propyl]-3-ethynyl- 5- (2-oxopyrrolidin-1-yl) benzamide (E25) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A106 C6 563.4 2.70 hydroxypropyl]-3- (2-oxopyrrolidin-1-yl)-5-propylbenzamide (E26) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethylbenzylamino) A100 C16 612.0 2.76 propyl]-2-fluoro-3-(2-oxopyrrolidin-1-yl)-5-trifluoromethyl- benzamide formate salt (E27) formic acid-5-cyclopentyl-3- (1, 1-dioxidotetrahydro-2H- A176 C16 662.5 3.00 1, 2-thiazin-2-yl)-2-fluoro-N-[(1S,2R)-2-hydroxy-1- (phenylmethyl)-3-({[3-trifluoromethyl)phenyl]methyl} amino) ropyl[benzamide (1 : 1) (E28) formic acid-5-cyclopentyl-3- (1, 1-dioxidotetrahydro-2H- A176 C15 652.5 2.92 1, 2-thiazin-2-yl)-2-fluoro-N-[(1 S, 2R)-2-hyd roxy-3- ( { 1- methyl-1-[3-(methoxy)phenyl]ethyl}amino)-1- (phenylmethyl) propyl] benzamide (1 : 1) (E29) formic acid-5-cyclopentyl-3- (1, 1-dioxidotetrahydro-2H- A176 C154 612.5 2.62 1, 2-thiazin-2-yl)-N- [ (1 S, 2R)-3-{[(1-ethyl-1H-pyrazol-4- yl) methyl] amino}-2-hydroxy-1-(phenylmethyl) propyl]-2- fluorobenzamide (1 : 1) (E30) formic acid - 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- A175 C16 651.5 2.78 2-fluoro-N- [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-5- [ (1- methylethyl) amino] benzamide (1 : 1) (E31) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- A175 C15 641.5 2.65 2-fluoro-N- [ (1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3- (methyloxy) phenyl]ethyl}amino)-1-(phenylmethyl)propyl]-5- 1-methylethyl)amino benzamide (1 : 1) (E32) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-A175 C154 601.5 2.34 N- [ (1 S, 2R)-3-{[(1-ethyl-1H-pyrazol-4-yl)methyl] amino} -2- hydroxy-1- (phenylmethyl) propyl]-2-fluoro-5- [ (1- methylethyl) amino] benzamide (1 : 1) (E33) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)- A175 C5 619.6 2.94 2-fluoro-N-{(1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ (1, 1,5- trimethylhexyl) amino] propyl}-5- [ (1- methylethyl) amino] benzamide (1 : 1) (E34) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-A175 C43 577.5 2.27 2-fluoro-N-[(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3- (tetrahydro-2H-pyran-4-ylamino) propyl]-5-[(1- methylethyl) amino] benzamide (1 : 1) (E35) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A24 C6 604.2 2.02 ethylamino)-2-hydroxypropyl]-3,5-bis-(2-oxopyrrolidin-1- yl) benzamide (E36) 3-Acetylamino-N-[(1S,2R)-1-benzyl-3-((S)-1- A50 C6 578.1 2.38 cyclohexylcarbamoylethylamino) -2-hydroxypropyl]-5-(2-oxopyrrolidin-1-yl) benzamide (E37) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A53 C6 614.1 2.42 ethylamino)-2-hydroxypropyl]-3-methanesulfonylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E38) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A44 C6 578.2 2.59 ethylamino)-2-hydroxypropyl]-3-isopropylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E39) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A35 C6 578.3 2.62 ethylamino)-2-hydroxypropyl]-3- (2-oxopyrrolidin-1-yl)-5- propylaminobenzamide (E40) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoylethyl A45 C6 604.2 2.69 amino)-2-hydroxypropyl]-3-cyclopentylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E41) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoylethyl A33 C6 592.2 2.69 amino)-2-hydroxypropyl]-3-diethylamino-5- (2-oxopyrrolidin- 1-yl) benzamide (E42) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A29 C6 606.2 2.43 ethylamino)-2-hydroxypropyl]-3-morpholin-4-yl-5-(2- oxopyrrolidin-1-yl) benzamide (E43) N- [ (1 S, 2R)-1-Benzyl-3- ( (S)-1-cyclohexylcarbamoyl A115 C6 619.2 2.05 ethylamino)-2-hydroxypropyl]-3- (4-methylpiperazin-1-yl)-5- (2-oxopyrrolidin-1-yl) benzamide (E44) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A28 C6 604.2 2.64 ethylamino)-2-hydroxypropyl]-3- (2-oxopyrrolidin-1-yl)-5- piperidin-1-ylbenzamide (E45) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A113 C6 590.2 2.65 ethylamino)-2-hydroxypropyl]-3-(2-oxopyrrolidin-1-yl)-5- pyrrolidin-1-ylbenzamide (E46) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A30 C6 612.2 2.70 ethylamino)-2-hydroxypropyl]-3-(2-oxopyrrolidin-1-yl)-5- phenylaminobenzamide (E47) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A26 C6 634.2 2.36 ethylamino)-2-hydroxypropyl]-4-methoxy-3, 5-bis- (2- oxopyrrolidin-1-yl) benzamide (E48) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A25 C6 638.1 2.41 ethylamino)-2-hydroxypropyl]-4-chloro-3, 5-bis- (2- oxopyrrolidin-1-yl) benzamide (E49) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A31 C6 564.2 2.48 ethylamino)-2-hydroxypropyl]-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E50) 3-Benzylamino-N- [ (1 S, 2R)-1-benzyl-3- ( (S)-1- A37 C6 626.2 2.70 cyclohexylcarbamoylethylamino) -2-hydroxypropyl]-5-(2-oxopyrrolidin-1-yl) benzamide (E51) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A38 C6 606.2 2.79 ethylamino)-2-hydroxypropyl]-3- (3-methylbutylamino)-5- (2- oxopyrrolidin-1-yl) benzamide (E52) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A46 C6 618.2 2.77 ethylamino)-2-hydroxypropyl]-3-cyclohexylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E53) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A39 C6 606.2 2.77 ethylamino)-2-hydroxypropyl]-3-(2-oxopyrrolidin-1-yl)-5- pentylaminobenzamide (E54) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A43 C6 606.2 2.77 ethylamino)-2-hydroxypropyl]-3- (1-ethylpropylamino)-5- (2- oxopyrrolidin-1-yl) benzamide (E55) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A40 C6 592.2 2.7 ethylamino)-2-hydroxypropyl]-3-butylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E56) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A41 C6 604.2 2. 78 ethylamino)-2-hydroxypropyl]-3- (2, 2-dimethylpropylamino)- 5-(2-oxopyrrolidin-1-yl) benzamide (E57) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A42 C6 590.2 2.60 ethylamino)-2-hydroxypropyl]-3- (cyclopropylmethylamino)-5- (2-oxopyrrolidin-1-yl)-benzamide (E58) 3-(Acetylpropylamino)-N-[(1S,2R)-1-benzyl-3-((S)-1- A48 C6 620.2 2.47 cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-5- (2- oxopyrrolidin-1-yl) benzamide (E59) N- [ (1S, 2R)-1-Benzyl-3- (1, 5-dimethylhexylamino)-2- A44 C20 537.3 2.69 hydroxypropyl]-3- isopropylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E60) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A27 C6 566.1 2.56 ethylamino)-2-hydroxypropyl]-3-nitro-5- (2-oxopyrrolidin-1- yl) benzamide formate salt (E61) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A27 C6 566.1 2.56 ethylamino)-2-hydroxypropyl]-3-nitro-5- (2-oxopyrrolidin-1- yl) benzamide (E62) Example 63
3-Amino-N- [ (1 S, 2R)-1-benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-5-(2-oxopyrrolidin-1-yl) benzamide (E63) A mixture of N-[(1S,2R)-1-benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino) -2-hydroxy- propyl]-3-nitro-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E62) (40 mg, 0.07 mmol, 1 equiv), 10% Pd on charcoal (50% wet, 10 mg, 12.5% w/w), NH4COOH (55 mg, 0.90 mmol, 13 equiv), EtOH (5 ml) and H20 (2.5 ml) was stirred at 50°C for 2 h, cooled to room temperature and the catalyst was filtered off through a pad of celite. Most of the EtOH was removed in vacuo and the residue was partitioned between AcOEt and saturated aqueous NaHCO3 solution. The aqueous phase was extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3-amino-N- [(1 S, 2R)-1-benzyl-3-((S)-1-cycloheXylcarbamoyl-ethylamino)-2-hydr oxypropyl]-5-(2-oXo- pyrrolidin-1-yl)-benzamide (E63) (15mg, 38%) as a pale yellow solid.
[M+H] + = 536.1 RT = 2.27 min Examples 64-65 Examples 64-65 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table: Example Acid Amine [M+H] + RT (min) 3- (Acetylisopropylamino)-N- [ (1S, 2R)-1-benzyl-3- ( (S)-1- A49 C6 620.2 2.44 cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-5- (2-oxo-pyrrolidin-1-yl) benzamide (E64) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A52 C6 656.2 2.56 ethylamino)-2-hydroxypropyl]-3- (methanesulfonyl propylamino)-5- (2-oxopyrrolidin-1-yl)-benzamide (E65) Example 66 N-((1 S, 2R)-3-Amino-1-benzyl-2-hydroxypropyl)-3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E66) Example 66 (E66) was prepared in an analogous manner to Example 182 from [(2R,3S)-3-({1-[3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-pheny l]-methanoyl}-amino)-2-hydroxy-4- phenyl-butyl]-carbamic acid benzyl ester (D106).
Examples 67-87 Examples 67-87 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table: Example Acid Amine [M+H] + RT (min) N-((1 S, 2R)-1-Benzyl-3-cyclopropylamino-2-A31 C26 451.2 2.23 hydroxypropyl)-3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E67) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(3- A31 C14 531.2 2.41 methoxybenzylamino)-propyl]-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide formate salt (E68) N-[(1S,2R)-1-Benzyl-3-cyclohexylamino-2- A31 C24 493.2 2.39 hydroxypropyl)-3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide formate salt (E69) N- ( (1S, 2R)-1-Benzyl-3-ethylamino-2-hydroxypropyl)-3- A31 C24 439.2 2.20 ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide formate salt (E70) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (4- A31 C27 531.2 2.41 methoxybenzylamino)-propyl]-3- ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E71) N-[(1S,2R)-1-Benzyl-2-hydroxy-3- A31 C28 453.2 2.20 isopropylaminopropyl)-3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E72) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(3- A31 C16 569.2 2.54 trifluoromethylbenzylamino)-propyl]- 3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E73) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(2, 2,3, 3, 3-pentafluoro- A31 C12 543.1 2.92 propylamino)-propyl]-3-ethylamino-5- (2-oxopyrrolidin-1- yl) benzamide (E74) N-[(1S,2R)-1-Benzyl-3-(2, 2,3, 3,4, 4, 4- A31 C13 593.1 3.13 heptafluorobutylamino)-2-hydroxypropyl]-3-ethylamino- 5- (2-oxopyrrolidin-1-yl) benzamide (E75) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (R)-1- A31 C31 515.2 2.38 phenylethylamino) propyl]-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E76) N-[(1 S, 2R)-1-Benzyl-2-hydroxy-3-((S)-1-A31 C30 515.2 2.38 phenylethylamino) propyl]-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E77) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(2- A31 C29 531.2 2.37 methoxybenzylamino)-propyl]-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E78) N- [ (1S, 2R)-1-Benzyl-3- (3, 5-bis-trifluoromethylbenzyl A31 C25 637.1 2.74 amino)-2-hydroxypropyl]-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E79) N- { (1 S, 2R)-1-Benzyl-2-hydroxy-3- [ (R)-1- (3- A31 C7 545.2 2.41 methoxyphenyl)-ethylamino]-propyl}-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E80) N- { (1 S, 2R)-1-Benzyl-2-hydroxy-3- [ (S)-1- (3- A31 C17 545.2 2.43 methoxyphenyl)-ethylamino]-propyl}-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E81) N- [ (1S, 2R)-1-Benzyl-3- ( (S)-1- A36 C6 592.2 2.66 cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-3- isobutylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E82) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-A34 C6 564.2 2.47 cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-3- dimethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E83) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (1-methyl-1- A31 C8 529.3 2.44 phenylethylamino)-propyl]-3- ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E84) N- ( (1S, 2R)-1-Benzyl-3-tert-butylamino-2-hydroxypropyl)- A31 C10 467.3 2.25 3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E85) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (3- A31 C11 585.3 2.61 trifluoromethoxybenzylamino)-propyl]- 3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E86) N- ( (1S, 2R)-1-Benzyl-2-hydroxy-3- (3-methylbutylamino)- A31 C9 481.3 2.38 propyl]-3-ethylamino- 5- (2-oxopyrrolidin-1-yl) benzamide (E87)
Example 88 N-((1 S, 2R)-3-Amino-1-benzyl-2-hydroxypropyl)-3-isopropylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E88) Example 88 was prepared in an analogous manner to Example 182 from [(2R,3S)-3-({1-[3-isopropylamino-5-(2-oxo-pyrrolidin-1-yl)-p henyl]-methanoyl}-amino)-2- hydroxy-4-phenyl-butyl]-carbamic acid benzyl ester (D107).
[M+H] + = 425.2, RT = 2.20 min Examples 89-102 Examples 89-102 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table: Example Acid Amine [M+H] + RT (min) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A32 C6 550.3 2.37 ethylamino)-2-hydroxypropyl]-3-methylamino-5- (2- oxopyrrolidin-1-yl) benzamide (E89) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A51 C6 628.2 2.41 ethylamino)-2-hydroxypropyl]-3- (methanesulfonyl methylamino)-5-(2-oxopyrrolidin-1-yl)-benzamide (E90) 3- (Acetylmethylamino)-N- [ (1S, 2R)-1-benzyl-3- ( (S)-1- A47 C6 592.2 2.31 cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-5- (2- oxopyrrolidin-1-yl)-benzamide (E91) N-((1S,2R)-1-Benzyl-3-cyclopentylamino-2- A31 C18 479.2 2.31 hydroxypropyl)-3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E92) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (4- A31 C32 495.3 2.51 methylpentylamino)-propyl]- 3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E93) N- [ (1S, 2R)-1-Benzyl-2-hydroxy-3- (5-methylhexylamino)- A31 C19 509.3 2.62 propyl]-3-ethylamino- 5- (2-oxopyrrolidin-1-yl) benzamide (E94) N- [ (1S, 2R)-1-Benzyl-3- (1, 5-dimethyl-hexylamino)-2- A31 C20 523.3 2.68 hydroxypropyl]-3-ethylamino-5- (2-oxopyrrolidin-1- yl) benzamide formate salt (E95) N-((1 S, 2R)-1-Benzyl-3-cyclohexylamino-2-A31 C7 493.2 2.38 hydroxypropyl)-3-ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E96) N- (1-Benzyl-3-cyclobutylamino-2-hydroxypropyl)-3- A31 C2 465.4 2.29 ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E97) N- (1-Benzyl-3-cycloheptylamino-2-hydroxypropyl)-3- A31 C33 507.3 2.52 ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E98) N- (1-Benzyl-2-hydroxy-3-isobutylaminopropyl)-3- A31 C3 424.2 2.35 ethylamino-5-(2-oxopyrrolidin-1-yl) benzamide (E99) N-[1-Benzyl-2-hydroxy-3-(1, 1, 5- A31 C5 537.3 2.80 trimethylhexylamino) propyl]-3-ethylamino- 5-(2-oxopyrrolidin-1-yl) benzamide (E100) N- (1-Benzyl-2-hydroxy-3-propylaminopropyl)-3- A31 C4 453.2 2.29 ethylamino-5- (2-oxopyrrolidin-1-yl) benzamide (E101) N- {1-Benzyl-2-hydroxy-3- [1- (3-methoxyphenyl)-1- A31 C15 559.2 2.59 methylethylamino] propyl}-3-ethylamino-5- (2- oxopyrrolidin-1-yl) benzamide formate salt (E102) Examples 103-170
Examples 103-170 were prepared by reductive amination using N-((1S, 2R)-3-amino-1-benzyl- 2-hydroxypropyl)-3-ethylamino-5-(2-oxopyrrolidin-1-yl)benzam ide (E66) in an analogous procedure to that described for E183. Example [M+H] + RT (min) N- [ (1 S, 2R)-1-Benzyl-3- (3, 4-dichloro-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E103) N-((1 S, 2R)-1-Benzyl-3-benzylamino-2-hydroxy-propyl)-3-ethylamino-5- (2- oxo-pyrrolidin-1-yl)-benzamide (E104) N- [ (1 S, 2R)-1-Benzyl-3- (4-fluoro-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E105) N-[(1 S, 2R)-1-Benzyl-2-hydroxy-3-(4-trifluoromethyl-benzylamino)-pro pyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E106) N-{(1 S, 2R)-1-Benzyl-3-[(furan-2-ylmethyl)-amino]-2-hydroxy-propyl}- 3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E107) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(quinolin-4-ylmethyl)-amino ]-propyl}-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E108) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-hydroxy-benzylamino)-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E109) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(thiophen-2-ylmethyl)-amino ]-propyl}-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E110) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(thiophen-3-ylmethyl)-amino ]-propyl}-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E111) N-[(1 S, 2R)-1-Benzyl-3-(3-chloro-4-methoxy-benzylamino)-2-hydroxy- propyl]-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E112) N- [ (l S, 2R)-l-Benzyl-3- (2, 3-dichloro-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E113) N- [ (1 S, 2R)-3- (4-Acetylamino-benzylamino)-1-benzyl-2-hydroxy-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yi)-benzamide (E 114) N- [ (1 S, 2R)-1-Benzyl-3- (4-cyano-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E115) N-((1 S, 2R)-1-Benzyl-2-hydroxy-3-phenethylamino-propyl)-3-ethylamino -5- (2-oxo-pyrrolidin-1-yl)-benzamide (E116) N- { (1 S, 2R)-1-Benzyl-2-hydroxy-3-[(1H-indol-3-ylmethyl)-amino]-propy l}-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E117) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-phenyl-butylamino)-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E118) N-{(1 S, 2R)-3- [ (1 H-Benzoimidazol-5-ylmethyl)-amino]-1-benzyl-2-hydroxy- propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E119) N-{(1S,2R)-1-Benzyl-3-[(E)-3-(4-fluoro-phenyl)-allylamino]-2 -hydroxy- propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E120) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (4-isopropoxy-benzylamino)-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E121) N- [ (l S, 2R)-l-Benzyl-2-hydroxy-3- ( (E)-3-p-tolyl-allylamino)-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E122) N-{(1S,2R)-1-Benzyl-3-[(2-ethyl-5-methyl-3H-imidazol-4-ylmet hyl)-amino]-2- hydroxy-propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E123) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (2-methyl-3-phenyl-propylamino)-propyl]- 3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E124) N- [ (l S, 2R)-l-Benzyl-2-hydroxy-3- (3-methoxy-4-nitro-benzylamino)-propyl]- 3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E125) N- [ (1 S, 2R)-1-Benzyl-3- (5-cyano-2-methoxy-benzylamino)-2-hydroxy- propyl]-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E126) N-{(1S,2R)-1-Benzyl-3-[(cyclohex-3-enylmethyl)-amino]-2-hydr oxy-propyl}- 3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E127) N- [ (l S, 2R)-l-Benzyl-2-hydroxy-3- (2-phenyl-propylamino)-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E128) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-methylsulfanyl-propylamino)-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E129) N- [ (1 S, 2R)-1-Benzyl-3- (3-cyano-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E130) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(5-methyl-thiophen-2-ylmeth yl)-amino]- propyl}-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E131) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-(2-methoxy-5-methyl-benzylam ino)- propyl]-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E132) N-{(1S,2R)-3-[(Benzofuran-2-ylmethyl)-amino]-1-benzyl-2-hydr oxy-propyl}- 3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E133) N- [ (1 S, 2R)-1-Benzyl-3- (3-fluoro-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E134) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(2-p-tolyl-ethylamino)-propy l]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E135) N- [ (1 S, 2R)-1-Benzyl-3- (dimethylamino-dimethyl-propylamino)-2-hydroxy- propyl]-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E136) N !-{(1S,2R)-1-Benzyl-2-hydroxy-3-[(1#H!-indol-5-ylmethyl)-ami no]-propyl}-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E137) N-{(1 S, 2R)-1-Benzyl-2-hydroxy-3-[(2-methyl-thiazol-4-ylmethyl)-amin o]- propyl}-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E138) N- [ (1 S, 2R)-1-Benzyl-3- (2-benzyloxy-ethylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E139) N- [ ( S, 2R)-1-Benzyl-3- (3, 4-dimethoxy-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E140) N- [ ( S, 2R)-1-Benzyl-2-hydroxy-3- (3-nitro-benzylamino)-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E141) N-[(1 S, 2R)-1-Benzyl-3-(3-chloro-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E142) N- [ (1 S, 2R)-1-Benzyl-3- (3-ethoxy-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E143) N-{(1S,2R)-1-Benzyl-3-[(5-chloro-thioiphen-2-ylmethyl)-amino ]-2-hydroxy- propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E144) N-{(1S,2R)-1-Benzyl-2-hydroxy-2-[(thiazol-2-ylmethyl)-amino] -propyl}-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E145) N-{(1 S, 2R)-1-Benzyl-2-hydroxy-3-[(pyridin-3-ylmethyl)-amino]-propyi }-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E146) N-[(1 S, 2R)-1-Benzyl-2-hydroxy-3-(4-hydroxy-3-methoxy-benzylamino)- propyl]-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E147) N- [ ( S, 2R)-1-Benzyl-2-hydroxy-3- (3-hydroxymethyl-benzylamino)-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E148) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[3-(4-methoxy-phenyl)-propyl amino]- propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E149) N- [ (1 S, 2R)-1-Benzyl-3- (4-dimethylaminomethyl-benzylamino)-2-hydroxy- propyl]-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E150) N- [ (1 S, 2R)-1-Benzyl-3- (3, 4-difluoro-benzylamino)-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E151) N- { ( S, 2R)-1-Benzyl-2-hydroxy-3- [ (5-methoxymethyl-furan-2-ylmethyl)- amino]-propyl}-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzam ide (E152) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-propoxy-benzylamino)-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E153) N- [ (1 S, 2R)-1-Benzyl-3- (4-cyano-3-methoxy-benzylamino)-2-hydroxy- propyl]-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E154) N-[(1 S, 2R)-1-Benzyl-2-hydroxy-3-(3-imidazol-1-yl-benzylamino)-propy l]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E155) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-pyrimidin-5-yl-benzylamino)-propyl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E156) N-{(1 S, 2R)-1-Benzyl-2-hydroxy-3-[(6-methoxy-pyridin-3-ylmethyl)-ami no]- propyl}-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E157) N-{(1 S, 2R)-1-Benzyl-2-hydroxy-3-[(6-methoxy-pyridin-2-ylmethyl)-ami no]- propyl}-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E158) N-[(1S,2R)-1-Benzyl-3-(3-tert-butoxymethyl-benzylamino)-2-hy droxy- propyl]-3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E159) N-[(1 S, 2R)-1-Benzyl-2-hydroxy-3-(3-prop-2-ynyloxy-benzylamino)-prop yl]-3- ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E160) N- [ (1 S, 2R)-3- (3-Acetylamino-benzylamino)-1-benzyl-2-hydroxy-propyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E161) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[3-(3-methoxy-phenyl)-propyl amino]- propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E162) N-{(1S,2R)-1-Benzyl-3-[3-(4-chloro-phenyl)-propylamino]-2-hy droxy-propyl}- 3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E163) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(3-#p!-tolyl-propylamino)-pr opyl]-3- ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E164) N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[3-(2H-tetrazol-5-yl)-benzyl amino]-propyl}- 3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E165) N- { (1 S, 2R)-1-Benzyl-2-hydroxy-3- [3- (1 H-pyrazol-3-yl)-benzylamino]-propyl}- 3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E166) N-{(1 S, 2R)-1-Benzyl-2-hydroxy-3-[3-(1H-imidazol-2-yl)-benzylamino]- propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E167) N- [ (1 S, 2R)-1-Benzyl-3- (4-fluoro-3-methoxy-benzylamino)-2-hydroxy-propyl]- 3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E168) N-{(1S,2R)-1-Benzyl-3-[2,2-dimethyl-3-(2-oxo-pyrrolidin-1-yl )-propylamino]- 2-hydroxy-propyl}-3-ethylamino-5- (2-oxo-pyrrolidin-1-yl)-benzamide (E169) N-{(1S,2R)-3-[(Benzothiazol-6-ylmethyl)-amino]-1-benzyl-2-hy droxy-propyl}- 3-ethylamino-5-(2-oxo-pyrrolidin-1-yl)-benzamide (E170) Examples 171-181 Examples 171-181 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table: Example Acid Amine [M+H] + RT (min) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A10 C6 579.4 2.34 ethylamino)-2-hydroxypropyl]-3- (2-oxopyrrolidin-1-yl)-5- propoxybenzamide formate salt (E171 N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A9 C6 551. 2 2.09 ethylamino)-2-hydroxypropyl]-3-methoxy-5- (2- oxopyrrolidin-1-yl) benzamide (E172) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A12 C6 579.2 2.68 ethylamino)-2-hydroxypropyl]-3-isopropoxy-5- (2- oxopyrrolidin-1-yl) benzamide (E173) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A15 C6 595.2 2.40 ethylamino)-2-hydroxypropyl]-3- (3-hydroxypropoxy)-5- (2- oxopyrrolidin-1-yl benzamide (E174) N- [ (1S, 2R)-1-Benzy)-3- ( (S)-1-cydohexyicarbamoyt A17 C6 609.2 2.59 ethylamino)-2-hydroxypropyl]-3- (3-methoxypropoxy)-5- (2- oxopyrrolidin-1-yl) benzamide (E175) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A16 C6 581.1 2.36 ethylamino)-2-hydroxypropyl]-3- (2-hydroxyethoxy)-5- (2- oxopyrrolidin-1-yl benzamide (E176) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A14 C6 595.2 2.50 ethylamino)-2-hydroxypropyl]-3- (2-methoxyethoxy)-5- (2- oxopyrrolidin-1-yl) benzamide (E177) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A13 C6 607.2 2.87 ethylamino)-2-hydroxypropyl]-3-(2-oxopyrrolidin-1-yl)-5- ent lox benzamide E178 N-[(1S,2R)-1-Benzyl-2-hydroxy-3-((S)-1-isobutyl A12 C36 595.2 2.75 carbamoyl-pentylamino)-propyl]-3-isopropoxy-5- (2- oxopyrrolidin-1-yl)benzamide (E179 N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3- A12 C14 546.1 2.59 methoxybenzylamino) propyl]-3- isopropoxy-5-(2-oxopyrrolidin-1-yl benzamide (E180) N- [ (1S, 2R)-1-Benzyl-3- ( (S)-1-cyclohexylcarbamoyl A11 C6 565.2 2.54 ethylamino)-2-hydroxypropyl]-3-ethoxy-5- (2-oxopyrrolidin- 1-yl) benzamide E181
Example 182 N-((1 S, 2R)-3-Amino-1-benzyl-2-hydroxypropyl)-3-(2-oxopyrrolidin-1-y l)- 5-pentyloxybenzamide (E182) A mixture of [(2R,3S)-2-hydroxy-3-({1-[3-(2-oxo-pyrrolidin-1-yl)-5-pentyl oxy-phenyl]- methanoyl}-amino)-4-phenyl-butyl]-carbamic acid benzyl ester (D105) (820 mg, 1.4 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 100 mg, 6% w/w), NH4CO2H (800 mg, 12.7 mmol, 9 equiv), EtOH (25 ml) and H20 (10 ml) was stirred at 60°C for 1 h. The mixture was then cooled to room temperature and the catalyst was filtered off through a pad of celite. Most of the EtOH was removed in vacuo and the residue was partitioned between AcOEt and H2O.
The aqueous phase was extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo to give N-((1 S, 2R)-3-amino-1-benzyl-2-hydroxy-propyl)-3- (2-oxo-pyrrolidin-1-yl)-5-pentyloxy-benzamide (420 mg, 66%) as a white solid.
[M+H] + = 454.0, RT = 2.63 min Example 183 <BR> <BR> <BR> N- [ ( S, 2R)-1-Benzyl-2-hydroxy-3- (1-propylbutylamino)-propyl]-3-<BR> <BR> <BR> <BR> <BR> (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E183) To a solution of N- ( (1S, 2R)-3-amino-1-benzyl-2-hydroxy-propyl)-3- (2-oxo-pyrrolidin-1-yl)-5- pentyloxy-benzamide (E182) (30 mg, 0.066 mmol, 1equiv) in (CHsCz (5 ml) were added sodium triacetoxyborohydride (20 mg, 0.094 mmol, 1.4 equiv), 4-heptanone (10 pI, 0.070 mmol, 1.1 equiv) and CH3COOH (4 pLI, 0.070 mmol, 1,1 equiv). The resulting mixture was stirred at room temperature for 92 hours, diluted with CH2CI2, washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. Purification of the residue by flash chromatography on silica gel (iso-hexane/ethyl acetate: 3/2) gave N- [ (1S, 2R)-1-benzyl- 2-hydroxy-3- (1-propyl-butylamino)-propyl]-3- (2-oxo-pyrrolidin-1-yl)-5-pentyloxy-benzamide (4.2 mg, 11%) as a colourless oil. [M+H] + = 552.2, RT = 2.98 min Examples 184-192 The following compounds were prepared in an analogous manner to Example 183 from 3- pentoxy-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid (A13) and the appropriate aldehyde or ketone : Example [M+H + RT (min) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino)-propyl]-3- 574. 2 2.87 (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E184) N-((1 S, 2R)-1-Benzyl-3-benzylamino-2-hydroxypropyl)-3- (2- 544. 1 2.83 oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E185) N- ( (1S, 2R)-1-Benzyl-3-ethylamino-2-hydroxypropyl)-3- (2- 482. 2 2.70 oxopyrrolidin-1-yl)-5-pentyloxy-benzamide (E186) N-((1S,2R)-1-Benzyl-2-hydroxy-3-phenethylaminopropyl)-3- 558. 2 2.91 (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E187) N-[(1S,2R)-1-Benzyl-2-hydroxy-3-(2-phenylpropylamino)-propyl ]-3- 572. 2 2.95 (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E188) N-((1S,2R)-1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3- 536. 2 2.84 (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E189) N-((1S,2R)-1-Benzyl-2-hydroxy-3-(1-methylpiperidin-4-ylamino )- 551. 2 2.43 propyl]-3- (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E190) N-((1S,2R)-1-Benzyl-2-hydroxy-3-(3-methylbutylamino)-propyl] -3- 524. 2 2.87 (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E191) N- [ (1S, 2R)-1-Benzyl-3- (1-ethylpropylamino)-2-hydroxypropyl]-3- 594. 3 3.09 (2-oxopyrrolidin-1-yl)-5-pentyloxybenzamide (E192) Examples 193-204 Examples 193-204 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H] + RT (min) N- [ (1S, 2R)-1-Benzyl-3- (1, 5-dimethylhexylamino)- A11 C20 538.3 2.81 2-hydroxy-propyl]-3-isopropoxy-5- (2- oxopyrrolidin-1-yl) benzamide E193 N- [1-Benzyl-2-hydroxy-3- (3- A11 C16 570.3 2.64 trifluoromethylbenzylamino) propyl]-3-ethoxy- 5-2-oxop rrolidin-1-I) benzamide (E194) N- [1-Benzyl-3- (1, 5-dimethylhexylamino)-2- A11 C20 524.3 2.74 hydroxypropyl]-3-ethoxy-5- (2-oxopyrrolidin-1- yl) benzamide formate salt (E195) N- (1-Benzyl-3-cyclohexylamino-2- A11 C1 494.3 2.45 hydroxypropyl)-3-ethoxy-5- 2-oxopyrrolidin-1-yl benzamide (E196) N- [1-Benzyl-2-hydroxy-3- (3- A11 C14 532.3 2.50 methoxybenzylamino) propyl]-3-ethoxy-5- (2-oxopyrrolidin-1-yl) benzamide E197 N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexyl A5 C6 599.1 2.41 carbamoylethylamino)-2-hydroxypropyl]-3- methanesulfonyl-5- (2-oxopyrrolidin-1- yl) benzamide E198 N- [1-Benzyl-2-hydroxy-3- (3- A1 C16 572.2 2.72 trifluoromethylbenzylamino) propyl]- 3-methylsulfanyl-5-(2-oxopyrrolidin-1-yl)- benzamide E199 N- [1-Benzyl-2-hydroxy-3- (3- A2 C16 586.2 2.80 trifluoromethylbenzylamino) propyl]-3- ethylsulfanyl-5- (2-oxopyrrolidin-1-yl) benzamide (E200) N- [1-Benzyl-2-hydroxy-3- (3- A6 C16 618.2 2.70 trifluoromethylbenzylamino) propyl]-3- ethanesulfonyl-5-(2-oxopyrrolidin-1-yl)- benzamide (E201) N- [1-Benzyl-2-hydroxy-3- (3- A5 C16 604.1 2.57 trifluoromethylbenzylamino) propyl]-3- methanesulfonyl-5- (2-oxopyrrolidin-1-yl)- benzamide (E202) N-[(1S,2R)-1-Benzyl-3-((S)-1- A94 C6 684.2 2.67 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)- N', N'-dipropylisophthalamide (E203) 3-Azidomethyl-N-[(1 S, 2R)-1-benzyl-3-((S)-1-A85 C6 612.2 2.52 cyclohexylcarbamoylethylamino)- 2-hydroxypropyl]-5-(1,1-dioixo-1/6-isothiazolidin-2- yl) benzamide (E204)
Example 205 3-Aminomethyl-N- [ S, 2R)-1-benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)- 2-hydroxypropyl]-5-(1, 1-dioxo-1/6-isothiazolidin-2-yl) benzamide (E205) A mixture of 3-azidomethyl-N-[(1S, 2R)-1-benzyl-3-((S)-1-cycloheXylcarbamoyl-ethylamino)-2- hydroxy-propyl]-5- (1, 1-dioxo-1/6-isothiazolidin-2-yl)-benzamide (E204) (70 mg, 0.12 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 20 mg, 15% w/w), NH4COOH (65 mg, 1 mmol, 9 equiv), EtOH (5 ml) and Ha0 (2.5 ml) was stirred at 50°C for 2 h, cooled to room temperature and the catalyst was filtered off through a pad of celite. Most of the EtOH was removed in vacuo and the residue was partitioned between AcOEt and saturated aqueous NaHC03 solution. The aqueous phase was extracted with AcOEt. The combined organic phases were dried over MgS04 and concentrated in vacuo. The residue was triturated with Et20 to give 3- aminomethyl-N-[(1S,2R)-1-benzyl-3-((S)-1-cyclohexylcarbamoyl -ethylamino)-2-hydroxy- propyl]-5-(1, 1-dioxo-116-isothiazolidin-2-yl)-benzamide (20 mg, 30%) as a white solid.
[M+H] + = 586.2 RT = 1. 98 min
Examples 206-207 Examples 206-207 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H] + RT (min) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A84 C6 614.2 1.99 ethylamino)-2-hydroxypropyl]-3-dimethylaminomethyl- 5-(1,1-dioxo-1/6-isothiazolidin-2-yl)-benzamide (E206) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A88 C6 583. 1 2.53 ethylamino)-2-hydroxypropyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-vinyl-benzamide (E207) Example 208 N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)- 2- hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-ethyl -benzamide (E208) Example 208 was prepared from Example 214 in an analogous manner to that described for Example 213. [M+H]+ = 585.2, RT = 2.56min Examples 209-212 Examples 209-212 were prepared in an analogous manner to Example 1 from the appropriatE acid and amines indicated in the below table : Example Acid Amine [M+H] + RT (min) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A86 C6 601.2 2.41 ethylamino)-2-hydroxypropyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-methoxymethylbenzamide (E209) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A87 C6 615.2 2.50 ethylamino)-2-hydroxypropyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-ethoxymethylbenzamide (E210) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A89 C6 597.2 2.61 ethylamino)-2-hydroxypropyl]-3- (1, 1-dioxo-1 f- isothiazolidin-2-yl)-5- (Z/E)-propenylbenzamide (E211) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A90 C6 611.2 2.70 ethylamino)-2-hydroxypropyl]-3- (Z/E)-but-1-enyl-5- (1, 1-dioxo-1/6-isothiazolidin-2-yl)benzamide (E212) Example 213 <BR> N- [(1S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)-2-
hydroxypropyl]-3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5-propylbenzamide (E213) A mixture of N- [ (1S, 2R)-1-benzyl-3- ( (S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy- propyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5-propenyl-ben zamide (E211) (50 mg, 0.083 mmol, 1 equiv), 10% palladium on charcoal (50% wet, 15 mg, 15% w/w), NH4COOH (50 mg, 0.79 mmol, 9 equiv) and EtOH (5 ml) was stirred at 60°C for 1 h, cooled to room temperature and the catalyst was filtered off through a pad of celite. Most of the EtOH was removed in vacuo and the residue was partitioned between AcOEt and saturated aqueous NaHC03 solution. The aqueous phase was extracted with AcOEt. The combined organic phases were dried over MgSO4 and concentrated in vacuo. The residue was triturated with Et20 to give of N-[(1S,2R)-1-benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino) -2-hydroxy-propyl]-3-(1, 1- dioXo-1/5-isothiazolidin-2-yl)-5-propyl-benzamide (45 mg, 90%) as a white solid.
[M+H] + = 599.2, RT = 2.63min Example 214 N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-butyl-5-(1, 1-dioxo-116-isothiazolidin-2-yl) benzamide (E214) Example 214 was prepared from N-[(1S,2R)-1-benzyl-3-((S)-1- cyclohexylcarbamoylethylamino)-2-hydroxypropyl]-3-(Z/E)-but- 1-enyl-5-(1,1-dioxo-1/6- isothiazolidin-2-yl) benzamide (E212) in an analogous manner to that described in Example 213. [M+H] + = 613.2, RT = 2.75min Examples 215-216 Examples 215-216 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table: Example Acid Amine [M+H] + RT (min) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A91 C6 611.2 2.70 ethylamino)-2-hydroxypropyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5- (2-methylpropenyl)- benzamide (E215) N- [ (1 S, 2R)-1-Benzyl-3- ( (S)-1- A83 C6 589.2 2.44 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3- (1, 1-dioxo-11-isothiazolidin-2-yl)-5- fluoromethylbenzamide (E216) Example 217 N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2-hydroxy-propyl]-3- (1, 1-dioxo-1 t-isothiazolidin-2-yl)-5-isobutylbenzamide (E217) Example 217 was prepared from Example 215 in an analogous manner to that described in Example 213. [M+H] + = 613.3, RT = 2.72min Examples 218-220 and 222 Examples 218-220 and 222 were prepared in an analogous manner to Example 213 from the appropriate amine indicated in the table below : Example Amine [M+H] + RT (min) N-[1-Benzyl-2-hydroxy-3-(3-trifluoromethylbenzylamino)propyl ]-3- C16 604.3 2.76 (1, 1-dioxo-1/6-isothiazolidin-2-yl)-5-propylbenzamide (E218) N- [1-Benzyl-3- (1, 5-dimethylhexylamino)-2-hydroxypropyl]-3- (1, 1- C26 558.3 2.87 dioxo-1/e-isothiazolidin-2-yl)-5-propylbenzamide formate salt (E219) N- (1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3- (1, 1-dioxo- C6 528.3 2.61 1 /6-isothiazolidin-2-yl)-5-propylbenzamide (E220) N- [1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]-3- C14 566.2 2.64 (1, 1-dioxo-1/6-isothiazolidin-2-yl)-5-propyl-benzamide (E222)
Examples 221 and 223-226 Examples 221 and 223-226 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in thr below table: Example Acid Amine [M+H] + RT (min) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A92 C6 600.2 2.23 hydroxypropyl]-5- (1, 1-dioxo-1/6-isothiazolidin-2-yl0isophthalamide (E221) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A93 C6 582.2 2.47 hydroxypropyl]-3-cyano- 5-(1, 1-dioxo-116-isothiazolidin-2-yl) benzamide (E223) N- [1-Benzyl-2-hydroxy-3- (3- A93 C16 587.2 2.43 trifluoromethylbenzylamino) propyl]-3-cyano- 5-(1, 1-dioxo-1/6-isothiazolidin-2-yl) benzamide (E224) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethylbenzyl A111 C16 586.2 2.71 amino) propyl]-3-(1, 1-dioxo-116-isothiazolidin-2-yl)-5- ethynyl-benzamide formate salt (E225) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A82 C6 580.2 2.55 ethylamino)-2-hydroxypropyl]-3-nitro-5- (2-oxopiperidin- 1-yl) benzamide (E226)
Example 227 3-Amino-N-[(1 S, 2R)-1-benzyl-3-((S)-1-cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-5- (2-oxopiperidin-1-yl) benzamide (E227) Example 227 was prepared from Example 226 in an analogous manner to the process described for Example 63. [M+H] + = 550.1, RT = 2. 31 min Examples 228-251 Examples 228-251 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H]+ RT (min) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A58 C6 592.2 2.59 ethylamino)-2-hydroxypropyl]-3- (2-oxopiperidin-1-yl)- 5-propylaminobenzamide (E228) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A60 C6 606.3 2.62 ethylamino)-2-hydroxypropyl]-3-diethylamino-5- (2- oxopiperidin-1-yl) benzamide (E229) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A59 C6 578.2 2.46 ethylamino)-2-hydroxypropyl]-3-ethylamino-5- (2- oxopiperidin-1-yl) benzamide (E230) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbmoyl A57 C6 564.3 2.40 ethylamino)-2-hydroxypropyl]-3-methylamino-5- (2- oxopiperidin-1-yl) benzamide (E231) N- [ (1S, 2R)-1-Benzyl-3- ( (S)-1-cyclohexylcarbamoyl A55 C6 618.3 2.65 ethylamino)-2-hydroxyporpyl]-3-(2-oxopiperidin-1-yl)- 5-piperidin-1-ylbenzamide (E232) N- [ (1 S, 2R)-1-Benzyl-3- ( (S)-1-cyclohexylcarbamoyl A56 C6 620.3 2.43 ethylamino)-2-hydroxypropyl]-3-morpholin-4-yl-5-(2- oxopiperidin-1-yl) benzamide (E233) N-[(1S,2R)-1-Benzyl-3-((S)-1-cycloahexylcarbamoyl A54 C6 604.3 2.64 ethylamino)-2-hydroxypropyl]-3-(2-oxopiperidin-1-yl)- 5-pyrrolidin-1-yl-benzamide (E234) N- [ (l S, 2R)-l-Benzyl-3- ( (S)-l-cyclohexylcarbamoyl A72 C6 614.2 2.58 ethylamino)-2-hydroxypropyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-isopropylaminobenzamide (E235) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- ( (1 S, 2R)-2-hydroxy- A72 C33 646.2 2.63 1-isobutylcarbamoyl-pentylamino)-propyl]-3- (1, 1- dioxo-1/6-isothiazolidin-2-yl)-5-isopropylamino- benzamide (E236) 3-Benzylamino-N-[(1S,2R)-1-benzyl-3-((S)-1- A64 C6 662.2 2.71 cyclohexylcarbamoylethylamino)- 2-hydroxy-propyl]-5-(1,1-dioxo-1/6-isothiazolidin-2- yl) benzamide (E237) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-A65 C6 628.2 2.71 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-butylamino-5-(1,1-dioxo-1/6- isothiazolidin-2-yl) benzamide (E238) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-A66 C6 642.2 2.79 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- (3-methylbutylamino)-benzamide (E239) N-[(1S,2R)-1-Benzyl-3-((S)-1- A67 C6 676.2 2.80 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- phenethylamino-benzamide (E240) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-A68 C6 642.2 2.79 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- pentylaminobenzamide (E241) N-[(1S,2R)-1-Benzyl-3-((S)-1- A69 C6 614.2 2.57 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- propylaminobenzamide (E242) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-A70 C6 600.2 2.47 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- ethylaminobenzamide (E243) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-A63 C6 628.2 2.63 cyclohexylcarbamoylethylamino)-2- hydroxypropyl]-3-diethylamino-5-(1,1-dioxo-1/6- isothiazolidin-2-yl) benzamide (E244) N- [ (1S, 2R)-1-Benzyl-3- (1, 5-dimethylhexylamino)-2- A70 C20 559.2 2.68 hydroxypropyl]-3- (1, 1-dioxo-1/6-isothiazolidin-2-yl)-5- ethylaminobenzamide (E245) N- [ (1S, 2R)-1-Benzyl-3- (1, 5-dimethylhexylamino)-2- A72 C20 573.2 2.77 hydroxypropyl]-3- (1, 1-dioxo-116-isothiazolidin-2-yl)-5- isopropylaminobenzamide (E246) N-[(1 S, 2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A71 C6 626.2 2.59 ethylamino)-2-hydroxypropyl]-3- (cyclopropylmethylamino)-5-(1,1-dioxo-1/6- isothiazolidin-2-yl) benzamide (E247) N- [ (lS, 2R)-l-Benzyl-2-hydroxy-3- (3- A70 C14 567.2 2.44 methoxybenzylamino) propyl]-3- (1, 1-dioxo-1/6-isothiazolidini-2-yl)-5-ethylamino- benzamide formate salt (E248) N- [ (1 S, 2R)-1-Benzyl-2-hydroxy-3- (3- A70 C16 605.1 2.60 trifluoromethylbenzylamino) propyl]-3-(1, 1-dioxo-116- isothiazolidin-2-yl)-5-ethylaminobenzamide formate salt (E249) N-((1S,2R)-1-Benzyl-3-cyclohexyalamino-2- A70 C1 529.3 2.40 hydroxypropyl)-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-ethylaminobenzamide (E250) N- [1-Benzyl-2-hydroxy-3- (3- A61 C16 647.3 2.39 trifluoromethylbenzylamino) propyl]-3- (1, 1-dioxo-1/6-isothiazolidini-2-yl)-5-morpholin-4-yl- benzamide formate salt (E251)
Example 252 N- [ (lS, 2R)-l-Benzyl-2-hydroxy-3- (3-trifluoromethyl-benzylamino)-propyl]-3- (1, 1-dioxo- 116-isothiazolidin-2-yl)-5-pyrrolidin-1-yl-benzamide formate salt (E252) To a solution of 3-(1,1-dioxo-1/6-isothiazolidiin-2-yl)-5-pyrrolidin-1-yl-ben zoic acid (A114) (62 mg, 0.2 mmol, 1 equiv) in DMF (5 ml) at room temperature was added (2R, 3S)-3-amino-4- phenyl-l- (3-trifluoromethyl-benzylamino)-butan-2-ol (Cl6) (82 mg, 0.2 mmol, 1 equiv), 1- (3- dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (46 mg, 0.24 mmol, 1.2 equiv), 1- hydroxybenzotriazole hydrate (37 mg, 0.24 mmol, 1.2 equiv) and 4-ethylmorpholine (152 µl, 1.2 mmol, 6 equiv). The resulting mixture was stirred for 4 h then concentrated in vacuo. The residue was diluted with AcOEt and the organic phase washed with saturated aqueous NaHC03 solution, dried over MgS04 and concentrated in vacuo. The residue was purified by trituration with Et20 to yield N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- (3-trifluoromethyl-benzylamino)- propyl]-3- (1, 1-dioxo-116-isothiazolidin-2-yl)-5-pyrrolidin-1-yl-benzamide as a white solid (46 mg, 36%). [M+H] + = 631. 2, RT = 2. 65 min Examples 253-289 Examples 253-289 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H]+ RT (min) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethylbenzylamino) A62 C16 591.2 2.58 propyl]-3- (1, 1-dioxo-1-16-isothiazolidin-2-yl)-5- methylaminobenzamide formate salt (E253) N- [ (1S, 2R)-1-Benzyl-3- ( (S)-1-cyclohexylcarbamoyl A18 C6 601.2 2.54 ethylamino)-2-hydroxpropyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-ethoxybenzamide (E254) N- [1-Benzyl-2-hydroxy-3- (3- A18 C16 606.2 2.66 trifluoromethylbenzylamino) propyl]-3- (1, 1-dioxo-1 isothiazolidin-2-yl)-5-ethoxy-benzamide (E255) N- [1-Benzyl-3- (1, 5-dimethylhexylamino)-2- A18 C20 560.3 2.74 hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- ethoxybenzamide formate salt (E256) N- [1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]- A18 C14 568.3 2.50 3-(1, 1-dioxo-1/6-isothiazol idin-2-yl)-5-ethoxybenzamide (E257) N- (1-Benzyl-3-cyclohexylamino-2-hydroxypropyl)-3- (1, 1- A18 C1 530.2 2.47 dioxo-1/3-isothiazolidin-2-yl)-5-ethoxybenzamide (E258) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A19 C6 615.4 2.68 hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- isopropoxybenzamide (E259) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A21 C6 615.4 2.89 hydroxypropyl]-3- (1, 1-dioxo-1 -isothiazolid in-2-yl)-5- propoxybenzamide (E260) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A22 C6 643.5 2.89 hydroxypropyl]-3- (1, 1-dioxo-1 -isothiazolidin-2-yl)-5- pentyloxybenzamide (E261) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A20 C6 587.4 2.49 hydroxypropyl]-3-(1,1-dioxo-1/6-isothiazolidin-2-yl)-5- methoxybenzamide (E262) N- (1-Benzyl-3-cyclopropylamino-2-hydroxypropyl)-3- (1, 1- A18 C26 488.2 2.37 dioxo-113-isothiazolidin-2-yl)-5-ethoxybenzamide (E263) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethoxybenzylamino) A18 C11 622.2 2.91 propyl]-3-(1,1-dioxo-1/6-isothiazolidiin-2-yl)-5- ethoxybenzamide (E264) N- [1-Benzyl-2-hydroxy-3- (3- A3 C16 608.2 2.73 trifluoromethylbenzylamino) propyl]-3-(1, 1-dioxo-1/6 isothiazolidin-2-yl)-5-methylsulfanylbenzamide (E265) N- [1-Benzyl-2-hydroxy-3- (3- A4 C16 622.2 2.82 trifluoromethylbenzylamino)propyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-ethylsulfanylbenzamide (E266) N- [1-Benzyl-2-hydroxy-3- (3- A8 C16 654.1 2.65 trifluoromethylbenzylamino) propyl]-3-(1, 1-dioxo-1/6 isothiazolidin-2-yl)-5-ethanesulfonylbenzamide (E267) N- [1-Benzyl-2-hydroxy-3- (3- A7 C16 640.2 2.62 trifluoromethylbenzylamino)propyl]-3-(1,1-dioxo-1/6- isothiazolidin-2-yl)-5-Methanesulfonylbenzamide (E268) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A81 C6 662.3 2.63 ethylamino)-2-hydroxypropyl]-5- (2-oxopiperidin-1-yl)- N', N'-dipropylisophthalamide (E269) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- A175 C11 667.4 2.82 yl)-2-fluoro-N-{(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3- [ ( {3- [ (trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-5- 1-methylethyl)amino]benzamide (1 : 1) (E270) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A119 C157 588.4 2.30 (ethylamino)-N-[(1S,2R)-3-{[(3-ethyl-5- isoxazolyl) methyl] amino}-2-hydroxy-1- (phenylmethyl) propyl]-2-fluorobenzamide (E271) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A151 C43 570.4 1.91 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-(tetrahydro-2H- pyran-4-ylamino) propyl]-1 H-benzimidazole-6- carboxamide (E272) 8- (1, 1-dioxido-2-isothiazolidinyl)-4-ethyl-N- [ (1S, 2R)-2- A172 C43 572.4 2.08 hydroxy-1-(phenylmethyl)-3-(tetrahydro-2H-pyran-4- ylamino)propyl]-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxamide (E273) 8- (1, 1-dioxido-2-isothiazolidinyl)-4-ethyl-N- [ (1S, 2R)-3- A172 C154 596.4 2.15 {[(1-ethyl-1H-pyrazol-4-yl)methyl] amino} -2-hydroxy-1- (phenylmethyl) propyl]-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxamide (E274) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A151 C28 528.4 1.92 [ (1 S, 2R)-2-hydroxy-3- [ (1-methylethyl) amino]-1- (phenylmethyl) propyl]-1 H-benzimidazole-6- carboxamide (E275) 8- (1, 1-dioxido-2-isothiazolidinyl)-4-ethyl-N- [ (1S, 2R)-2- A172 C28 530.4 2.11 hydrox-3- [ (1-methylethyl) amino]-1- (phenylmethyl) propyl]-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxamide (E276) N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl A95 C6 698.2 2.68 thylamino)-2-hydroxypropyl]-5-(1,1-dioxo-1/6- [1,2] thiazinan-2-yl)-N', N'-dipropylisophthalamide (E277) N- [1-Benzyl-2-hydroxy-3- (3- A95 C16 703.3 2.87 trifluoromethylbenzylamino)propyl]-5-(1,1-dioxo-1/6- [1,2] thiazinan-2-yl)-N', N'-dipropylisophthalamide (E278) N- (1-Benzyl-3-cyclopropylamino-2-hydroxypropyl)-5- (1, 1- A95 C26 585.3 2.55 dioxo-1/6-[1, 2] thiazinan-2-yl)-N', N'-dipropylisophthalamide (E279) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethylbenzylamino) A112 C16 618.2 3.07 propyl]-3- (1, 1-dioxo-1 P- [1, 2] th iazinan-2-yl)-5- propylbenzamide (E280) N- [1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]- A112 C14 580.3 2.77 3- (1, 1-dioxo-1 P- [1, 2] thiazinan-2-yl)-5-propylbenzamide formate salt (E281) N- [1-Benzyl-3- (1, 5-dimethylhexylamino)-2- A112 C20 572.3 3.01 hydroxypropyl]-3- (1, 1-dioxo-1 P- [1, 2] thiazinan-2-yl)-5- propylbenzamide formate salt (E282) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A112 C6 613.4 2.80 hydroxypropyl]-3-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-5- propylbenzamide (E283) N- [1-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]- A95 C14 665.3 2.85 5-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-N',N'-dipropyl- isophthalamide (E284) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethoxybenzylamino) A95 C11 719.2 3.02 propyl]-5-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-N', N'-dipropyl- isophthalamide formate salt (E285) N- [1-Benzyl-2-hydroxy-3- (3-trifluoromethylbenzylamino) A73 C16 619.2 2.73 propyl]-3-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-5- ethylaminobenzamide formate salt (E286) N- [l-Benzyl-2-hydroxy-3- (3-methoxybenzylamino) propyl]- A73 C14 581.2 2.72 3-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-5- ethylaminobenzamide formate salt (E287) N- [l-Benzyl-3- (1, 5-dimethylhexylamino)-2- A73 C20 573.3 2.99 hydroxypropyl]-3-(1,1-dioxo-1/6-[1, 2] thiazinan-2-yl)-5- ethylaminobenzamide formate salt (E288) N- [1-Benzyl-3- (1-cyclohexylcarbamoylethylamino)-2- A73 C6 614.3 2.75 hydroxypropyl]-3- (1, 1-dioxo-1 P- [1, 2] thiazinan-2-yl)-5- ethylaminobenzamide (E289) Examples 290-427 (E290-E427) The following compounds were prepared in an analogous manner to Example 183 from the appropriate amine and the appropriate aldehyde or ketone : Example Precursor [M+H] + RT (min) formic acid - N-{(1S,2R)-1-Benzyl-3-[(3,5-dichlorobnezyl)amino]-2- D120 619.3 2.69 hydroxypropyl}-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E290) formic acid - N-{(1S,2R)-1-Bnezyl-3-[(2-fluoro-5- D120 599.4 2.48 methoxybenzyl) amino]-2-hydroxypropyl}-3-(1,1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) lE291) formic acid-N- {(1S, 2R)-1-Benzyl-3- [ (4-fluoro-3- D120 599.4 2.52 methoxybenzyl) amino]-2-hydroxypropyl}-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino benzamide (1 : 1) (E292) formic acid - N-{(1S,2R)-1-Benzyl-3-[(3,5-dimethylbenzyl)amino]- D120 579.3 2.68 2-hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E293) N- { (1S, 2R)-1-Benzyl-3- [ (3, 5-difluorobenzyl) amino]-2- D120 587.3 2.61 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (E294) N- ( (1S, 2R)-1-Benzyl-2-hydroxy-3- { [3-nitro-5- D120 664.2 2.78 (trifluoromethyl) benzyl] amino} propyl)-3- (1, 1-dioxido-1,2-thiazinan- 2-yl)-5-(ethylamino) benzamide (E295) N-((1S,2R)-1-Benzyl-3-{[(5-cyanopyridin-3-yl)methyl]amino}-2 - D120 577.3 2.42 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (E296) formic acid-N- (1S, 2R)-1-Benzyl-3- [ (3-chloro-5- D120 615.3 2.70 methoxybenzyl) amino]-2-hydroxypropyl}-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) (E297) N- { (1S, 2R)-1-Benzyl-3- [ (3-bromo-5-fluorobenzyl) amino]-2- D120 649.2 2.70 hydroxypropyl}-3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide (E298) 5- { [ ( (2R, 3S)-3- { [3- (1, 1-Dioxido-1, 2-thiazinan-2-yi)-5- D120 609.3 2.34 (ethylamino) benzoyl] amino} -2-hydroxy-4- henylbutyl)amino]methyl}-N-methylnicotinamide (E299 formic acid-N-{(1 S, 2R)-1-Benzyl-3-[(3-bromo-5-D120 661.2 2.71 methoxybenzyl)amino]-2-hydroxypropyl}-3-(1, 1-dioxido-1,2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) (E300) Methyl 5-{[((2R,3S)-3-{[3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5- D120 610.3 2.44 (ethylamino) benzoyl] amino} -2-hydroxy-4- henylbutyl)amino]methyl nicotinate (E301) N- { (1S, 2R)-1-Benzyl-3- [ (3, 5-di-tert-butylbenzyl) amino]-2- D120 663.4 3.14 hydroxporpyl}-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5- ethylamino benzamide (E302) N-((1S,2R)-1-Benzyl-2-hydroxy-3-{[3-methyl-5- D120 643.3 2.53 (methylsulfonyl) benzyl] amino} propyl)-3-(1, 1-dioxido-1,2-thiazinan- 2-yl)-5-(ethylamino benzamide (E303) N- { (1S, 2R)-1-Benzyl-2-hydroxy-3- [ (3-methoxy-5- D120 595.3 2.65 methylbenzyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide (E304) Dimethyl 5-{[((2R,3S)-3-{[3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5- D120 667.3 2.63 (ethylamino) benzoyl] amino} -2-hydroxy-4- phenylbutyl) amino] methyl} isophthalate (E305) N- { (1S, 2R)-1-Benzyl-3- [ (3, 5-diisopropoxybenzyl) amino]-2- D120 667.4 2.91 hydroxypropyl}-3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (E306) N-((1S,2R)-1-Benzyl-3-{[(4-bromo-2-thienyl)methyl]amino}-2- D120 637.3 2.56 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (E307) N- { (1S, 2R)-1-Benzyl-3- [ (2, 3-dihydro-1-benzofuran-6- D120 593.3 2.42 ylmethyl)amino}-2-hydroxypropyl}-3-(1, 1-dioxido-1,2-thiazinan-2- l)-5-(ethylamino benzamide (E308) formic acid-N-((1 S, 2R)-1-Benzyl-3-{[(4-chloro-1-methyl-1 H-D 120 589.3 2.26 pyrazol-3-yl) methyl] amino}-2-hydroxypropyl)-3-(1, 1-dioxido-1,2- thiazinan-2-yl)-5-(ethylamino benzamide (1 : 1) (E309) N-((1S,2R)-1-Benzyl-3-{[(2-bromo-1,3-thiazol-5-yl)methyl]ami no}- D120 638.2 2.36 2-hydroxypropyl)-3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide (E310) N-((1 S, 2R)-1-Benzyl-3-{[(4-bromo-1 H-pyrrol-2-yl) methyl] amino}-2-D120 618.2 2.54 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide E311 formic acid - N-((1S,2R)-1-Benzyl-3-{[(2-butyl-1H-imidazol-4- D120 597. 4 2.11 yl) methyl] amino}-2-hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2- l)-5-(ethylamino benzamide (1 : 1) (E312) N-{(1S,2R)-1-Benzyl-3-[(3-bromobenzyl)amino]-2-hydroxypropyl }- D120 631.2 2.59 3-(1, 1-dioxido-1, 2-thiazinan-2-yI-5- (ethylamino) benzamide (E313) N- { (1S, 2R)-1-Benzyl-2-hydroxy-3- [ (3-nitrobenzyl) amino] propyl}-3- D120 596.3 2.45 (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide (E314) N- { (1S, 2R)-1-Benzyl-2-hydroxy-3- [ (3-thienylmethyl) amino] propyl}- D120 557.3 2.36 3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino benzamide (E315) N-((1S,2R)-1-Benzyl-3-{[(4-bromo-1-methyl-1H-pyrazol-3- D120 635. 3 2. 33 yl) methyl] amino}-2-hydroxpyrpopyl)-3-(1, 1-dioxido-1,2-thiazinan-2- l)-5-(ethylamino benzamide (E316) N- ( (1S, 2R)-1-Benzyl-3- { [3-fluoro-5- (trifluoromethyl) benzyl] amino}- D120 637.3 2.68 2-hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (E317) formic acid-N- { (1S, 2R)-1-Benzyl-2-hydroxy-3- [ (3- D120 577.3 2.43 vinylbenzyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E318) formic acid - N-((1S,2R)-1-Benzyl-2-hydroxy-3-{[(4-methoxy-3- D120 587.3 2.31 thienyl) methyl] amino} propyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E319) 3- { [ ( (2R, 3S)-3- { [3- (1, 1-Dioxido-1, 2-thiazinan-2-yl)-5- D120 595.3 2.27 (ethylamino) benzoyl] amino}-2-hydroxy-4- phenylbutyl) amino] methyl} benzoic acid-formic acid (1 : 1) (E320) formic acid-N- { (1S, 2R)-1-Benzyl-3- [ (3, 4- D120 611.3 2.28 dimethoxybenzyl)amino]-2-hydroxypropyl}-3-(1,1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino)benzamide (1 : 1) (E321) formic acid - N-((1S,2R)-1-Benzyl-3-{[(5-ethyl-2- D120 D120 567.4 2.34 furyl) methyl] amino}-2-hydroxypropyl)-3- (1, 1-dioxido-1,2-thiazinan- ethylamino benzamide (1 : 1) (E322) formic acid - N-{(1S,2R)-1-Bnezyl-3-[(2, 3-dihydro-1, 4-benzodioxin- D120 609.4 2.32 6-ylmethyl) amino]-2-hydroxypropyl}-3- (1, 1-dioxido-1,2-thiazinan- 2-yl)-5-(ethylamino) benzamide (1 : 1) (E323) formic acid-N- { (1S, 2R)-1-Benzyl-3- [ (3-ethoxy-4- D120 625.4 2.36 methoxybenzyl) amino]-2-hydroxypropyl}-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino benzamide (1 : 1) (E324) formic acid - N-((1S,2R)-1-Bnezyl-3-{[(5-ethyl-2- D120 585.3 2.46 thienyl) methyl] amino}-2-hydroxypropyl)-3-(1,1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino benzamide (1 : 1) (E325) formic acid-N- { (1S, 2R)-1-Benzyl-3- [ (3-chloro-4- D120 603.3 2.49 fluorobenzyl) amino]-2-hydroxypropyl}-3-(1, 1-dioxido-1,2-thiazinan- 2-yl)-5-(ethylamino benzamide (1 : 1) (E326) formic acid-N-((1 S, 2R)-1-Benzyl-3-{[(1-ethyl-1 H-pyrazol-4-D120 569. 4 2.13 yl) methyl] amino}-2-hydroxypropyl)-3- (1, 1-dioxido-1,2-thiazinan-2- l)-5-(ethylamino) benzamide (1: 1) E327 formic acid - N-((1S,2R)-1-Benzyl-3-{[(1-ethyl-3-methyl-1H- D120 583.4 2.17 pyrazol-4-yl) methyl] amino}-2-hydroxypropyl)-3-(1, 1-dioxido-1,2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) (E328) formic acid-N-((1S, 2R)-1-Benzyl-3-{[(2, 2-dimethyl-3, 4-dihydro-D120 635.4 2.60 2H-chromen-6-yl)methyl]amino}-2-hydroxypropyl)-3-(1, 1-dioxido- 1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide (1 : 1) (E329) formic acid-N- ( (1S, 2R)-1-Benzyl-3- { [4-chloro-3- D120 653.3 2.69 (trifluoromethyl) benzyl] amino}-2-hydroxypropyl)-3-(1, 1-dioxido- 1, 2-thiazinan-2-yl)-5-(ethylamino benzamide (1 : 1) (E330) formic acid - N-((1S,2R)-1-Benzyl-2-hydroxy-3-{[(6-methylpyridin- D120 566.3 2.22 2-yl) methyl] amino} propyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide (1: 1) (E331) formic acid-N- { (1S, 2R)-1-benzyl-3- [ (3-ethylbenzyl) amino]-2- D120 579.5 2.40 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E332) N-((1S,2R)-1-benzyl-2-{[(1-ethyl-1H-pyrazol-4-yl)methyl]amin o}-2- D121 587.4 2.08 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino)-2- fluorobenzamide (E333) formic acid-N- ( (1 S, 2R)-1-benzyl-3-{[(1-ethyl-1H-pyrazol-4- E66 519.5 2.00 yl) methyl] amino}-2-hydroxypropyl)-3- (ethylamino)-5- (2- oxopyrrolidin-1-yl)benzamide (1 : 1) (E334) formic acid-N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (3-methoxy-4- D120 595.2 2.65 methylbenzyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E335) formic acid-N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (3-methoxy-2- D120 595.4 2.60 methylbenzyl) amino] propyl}-3-(1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethyalmino benzamide (1 : 1) (E336) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-N- D120 531.5 0.75 [ (1 S, 2R)-2-hydroxy-3- [ (1-methylbutyl) amino]-1- (phenylmethyl) propyl] benzamide (E337) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 559.5 0.88 {(1 S, 2R)-2-hdyroxy-1-(phenylmethyl)-3-[(1- ropylbutyl)amino]propyl benzamide hydrochloride (E338 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 545.5 0.84 [ (1 S, 2R)-2-hdyroxy-3-[(1-methylpentyl)amino]-1- (phenylmethyl) propyl] benzamide hydrochloride (E339) N- [ (1S, 2R)-3- [ (1, 4-dimethylpentyl) amino]-2-hydroxy-1- D120 559.5 0.88 (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- l)-5-(ethylamino benzamide hydrochloride (E340) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 531.5 0.81 [ (1 S, 2R)-2-hydroxy-3- [ (3-methylbutyl) amino]-1- (phenylmethyl) propyl] benzamide hydrochloride (E341 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-N- D120 503.5 0.72 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-(propylamino)propyl] benzamide hydrochloride E342) N- [ (1S,2R)-3-{[1-(3-chlorophenyl)propyl]amino}-2-hydroxy-1- E66 563. 5 0.84 (phenylmethyl) propyl]-3- (ethylamino)-5- (2-oxo-1- pyrrolidinyl) benzamide hydrochloride (E343) N- [ (1S,2R)-3-{[1-(3-chlorophenyl)propyl]amino}-2-hydroxy-1- D122 588.4 1.01 (phenylmethyl) propyl]-3-cyclopentyl-5- (2-oxo-1- rrolidinyl benzamide hydrochloride (E344) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 545.5 0.85 [ (1 S, 2R)-2-hydroxy-3- [ (4-methylpentyl) amino]-1- henylmethyl)propyl benzamide h drochloride E345 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 559.6 0.89 [ (1 S, 2R)-2-hydroxy-3-[(5-methylhexyl)amino]-1- henylmethyl)propyl benzamide hydrochloride (E346) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-N D120 517.5 0.74 [(1S,2R)-2-hydroxy-3-[(1-methylpropyl)amino]-1- henvlmethyl)propyl benzamide hydrochloride (E347) 3- (I, l-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 559.6 0.89 [ (1 S, 2R)-2-hydroxy-3-[(1-methylhexyl)amino]-1- (phenylmethyl) propyl] benzamide hydrochloride (E348) N- [ (1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- D123 672.3 0.89 (phenylmethyl) propyl]-3- [ (1-methylethyl) oxy]-5- (2-oxo-1- pyrrolidinyl) benzamide (E349) N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3- D123 516.5 0.78 [(phenylmethyl) amino] propyl}-3- [ (l-methylethyl) oxy]-5- (2-oxo-1- pyrrolidinyl) benzamide (E350) N- [ (1S,2R)-3-{[(3-bromophenyl)methyl]amino}-2-hydroxy-1- D123 596.2 0.83 (phenylmethyl)propyl]-3-[(1-methylethyl)oxy]-5-(2-oxo-1- pyrrolidinyl) benzamide (E351) N-(1S,2R)-3-({[3-(ethyloxy)phenyl]methyl} amino)-2-hydroxy-1- D123 560.4 0.82 (phenylmethyl)propyl]-3-[(1-methylethyl)oxy]-5-(2-oxo-1- pyrrolidinyl) benzamide (E352) N- [ (1S,2R)-3-{[(3-chlorophenyl)methyl]amino}-2-hydroxy-1- D123 550.3 0.82 (phenylmethyl) propyl]-3- [ (1-methylethyl) oxy]-5- (2-oxo-1- pyrrolidinyl) benzamide (E353) N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[({3- D123 600.3 0.87 [(trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-3-[(1- methylethyl) oxy]-5-(2-oxo-1-pyrrolidinyl) benzamide (E354) N- [ (1S,2R)-3-({[3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D123 576.4 0.81 hydroxy-1- (phenylmethyl) propyl]-3- [ (l-methylethyl) oxy]-5- (2-oxo- 1-pyrrolidinyl) benzamide (E355) N- [ (1S,2R)-3-{[(3,5-dichlorophenyl)methyl]amino}-2-hydroxy-1- D123 584.2 0.87 (phenylmethyl) propyl]-3- [ (1-methylethyl) oxy]-5- (2-oxo-1- pyrrolidinyl) benzamide (E356) N-[(1 S, 2R)-3-{[(3, 5-difluorophenyl) methyl] amino}-2-hydroxy-1-D 123 552.3 0.80 (phenylmethyl) propyl]-3- [ (1-methylethyl) oxy]-5- (2-oxo-1- pyrrolidinyl) benzamide (E357) N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- D123 584.3 0.85 (trifluoromethyl) phenyl] methyl} amino) propyl]-3- [ (1- methylethyl)oxy]-5-(2-oxo-1-pyrrolidinyl)benzamide (E358 N-[(1S,2R)-3-({[3,5-bis(trifluoromethyl)phenyl] methyl}amino)-2- D123 652.3 0.93 hydroxy-1-(phenylmethyl) propyl]-3-[(1-methylethyl) oxy]-5-(2-oxo- 1-pyrrolidinyl)benzamide (E359 N-[(1S,2R)-2-hydroxy-3-{[(3-methylphenyl)methyl]amino}-1- D123 530.4 0.82 (phenylmethyl) propyl]-3- [ (1-methylethyl) oxy]-5- (2-oxo-1- rrolidinyl)benzamide (E360 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- [ (1S, 2R)-2- D124 634.3 0.88 hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-5- [ (1-methylethyl) oxy] benzamide hydrochloride (E361) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N-[(1S,2R)-2- D124 596.3 0.82 hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino)-1- (phenylmethyl) propyl]-5- [ (1-methylethyl) oxy] benzamide hydrochloride (E362 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N-{(1S,2R)-2- D124 650.3 0.89 hydroxy-1-(phenylmethyl)-3-[({3- [(trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-5- [ (1- methylethyl)oxy]benzamide hydrochloride (E363 N- [ (lS, 2R)-3- ( { [3, 5-bis (trifluoromethyl)phenyl] methyl}amino)-2- D124 702.3 0.96 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-yl)-5- [ (1-methylethyl) oxy] benzamide hydrochloride (E364) N- [ (1S,2R)-3-({[3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D124 626.3 0.82 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-[(1-methylethyl) oxy] benzamide hydrochloride (E365) N- [ (1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- D124 722.1 0.90 (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- I)-5-[(1-methylethyl)oxy] benzamide hydrochloride (E366) 3-cyclopentyl-5-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N-D125 644.4 0.94 [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl] benzamide hydrochloride (E367) 3-cyclopentyl-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- D125 606.4 0.88 [ (1 S, 2R)-2hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino)-1- (phenylmethyl) propyl] benzamide hydrochloride (E368) 3-cyclopentyl-5-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- D125 660.4 0.95 {(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-[({3- [(trifluoromethyl) oxy] phenyl} methyl) amino] propyl} benzamide hydrochloride (E369) N- [ (1S,2R)-3-({[3, 5-bis (trifluoromethyl)phenyl] methyl}amino)-2- D125 712.4 1.02 hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzamide hydrochloride (E370) N- [ (1S,2R)-3-({[3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D125 636.4 0.90 hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl) benzamide hydrochloride (E371) 3-cyclopentyl-N-[(1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino }-2- D125 732.2 0.99 hydroxy-1- (phenylmethyl) propyl]-5- (1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-yl) benzamide hydrochloride (E372) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-N- D120 635.3 0.83 {(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-[({3- [(trifluoromethyl) oxy] phenyl} methyl) amino] propyl} benzamide hydrochloride (E373 N-[(1S,2R)-3-({[3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2-D120 687.3 0.89 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino benzamide hydrochloride (E374 N- [ (1S,2R)-3-({[3, 5-bis (methyloxy) phenyl]methyl}amino)-2- D120 611.4 0.77 hydroxy-1-(phenylmethyl)propyl]-3-(1,1-dioxidotetrahydro-2H- 1, 2- thiazin-2-yl)-5-(ethylamino benzamide h drochloride E375 N-[(1S,2R)-3-{[ (3, 5-dibromophenyl) methyl] amino}-2-hydroxy-1- D120 707.2 0.85 (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- 1)-5-ethylamino) benzamide hydrochloride (E376) 3-(ethyloxy)-N-{(1S,2R)-2-hydroxy-1-(phenylmethyl-3-[({3- D126 586.2 0.82 [ (trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-5- (2-oxo-1- pyrrolidinyl) benzamide hydrochloride (E377 N- [ (1S,2R)-3-({[3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2- D126 638.2 0.88 hydroxy-1- (phenylmethyl) propyl]-3- (ethyloxy)-5- (2-oxo-1- rrolidinyl benzamide h drochloride E378 N-[(1S,2R)-3-({[3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D126 562. 3 0.75 hydroxy-1- (phenylmethyl) propyl]-3- (ethyloxy)-5- (2-oxo-1- rrolidinyl)benzamide hydrochloride (E379 N- [ (1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- D126 658.0 0.83 (phenylmethyl) propyl]-3- (ethyloxy)-5- (2-oxo-1- pyrrolidinyl) benzamide hydrochloride (E380) 3-cyclopentyl-N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[({3- D122 610.3 0.92 [(trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-5- (2-oxo-1- rrolidinyl)benzamide hydrochloride (E381 N-[(1S,2R)-3-({[3, 5-bis (trifluoromethyl)phenyl]methyl}amino)-2- D122 662.3 0.99 hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (2-oxo-1- pyrrolidinyl) benzamide hydrochloride (E382) N- [ (1S,2R)-3-({[3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D122 586.3 0.86 hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (2-oxo-1- rrolidinyl)benzamide hydrochloride (E383 3-cyclopentyl-N-[(1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino }-2- D122 682.1 0.94 hydroxy-1- (phenylmethyl) propyl]-5- (2-oxo-1- pyrrolidinyl) benzamide h drochloride E384 N-[(1S,2R)-3-({[3, 5-bis (methyloxy)phenyl]methyl}amino)-2- E66 561.3 0.73 hydroxy-1- (phenylmethyl) propyl]-3- (ethylamino)-5- (2-oxo-1- pyrrolidinyl) benzamide hydrochloride (E385) N-[(1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- E66 657.1 0.80 (phenylmethyl)propyl]-3-(ethylamino)-5-(2-oxo-1- pyrrolidinyl) benzamide hydrochloride (E386) N- [ (1S,2R)-3-({[3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2- D127 674.2 0.88 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)- 5-(ethylox benzamide hydrochloride (E387 N- [ (l S, 2R)-3- ( { [3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D127 598.3 0.76 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)- 5-(ethylox benzamide hydrochloride (E388 N- [ (1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- D127 694.1 0.84 (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)-5- ethylox benzamide hydrochloride (E389 3- (1, 1-dioxido-2-isothiazolidinyl)-N- [ (1S, 2R)-2-hydroxy-1- D128 620.2 0.84 (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-5- [ (l-methylethyl) oxy] benzamide hydrochloride (E390) 3-(1,1-dioxido-2-isothiazolidinyl)-N-[(1S,2R)-2-hydroxy-3-({ [3- D128 582.3 0.77 (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl]-5-[( 1- methylethyl) oxy] benzamide hydrochloride (E391 3- (1, 1-dioxido-2-isothiazolidinyl)-N- { (1S, 2R)-2-hydroxy-1- D128 636.2 0.85 (phenylmethyl)-3- [ ( {3- [ (trifluoromethyl) oxy] phenyl} methyl) amino] propyl}-5- [ (1- methylethyl)oxy]benzamide hydrochloride (E392 N- [ (1S,2R)-3-({[3, 5-bis (trifluoromethyl)phenyl] methyl}amino)-2- D128 688.2 0.91 hydroxy-1-(phenylmethyl)propyl]-3-(1,1-dioxido-2-isothiazoli dinyl)- 5-[(1-methylethyl)oxy] benzamide hydrochloride (E393) N-[(1S,2R)-3-({[3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2- D128 612.2 0.80 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)- 5-[(1-methylethyl)ox benzamide hydrochloride (E394 N-[(1 S, 2R)-3-{[(3, 5-dibromophenyl) methyl] amino}-2-hydroxy-1-D128 708.1 0.87 (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)-5- [ (1- methylethyl) oxy] benzamide hydrochloride (E395 3-cyclopentyl-5- (1, 1-dioxido-2-isothiazolidinyl)-N- [ (1S, 2R)-2- D129 630.2 0.90 hydroxy-1-(phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl}amino)propyl benzamide hydrochloride (E396) 3-cyclopentyl-5- (1, 1-dioxido-2-isothiazolidinyl)-N- [ (1S, 2R)-2- D129 592.3 0.84 hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino)-1- henylmethyl)propyl benzamide hydrochloride (E397) 3-cyclopentyl-5- (1, 1-dioxido-2-isothiazolidinyl)-N- { (1S, 2R)-2- D129 646.3 0.91 hydroxy-1-(phenylmethyl)-3-[({3- [(trifluoromethyl) oxy] phenyl} methyl) amino] propyl} benzamide hydrochloride (E398 N- [ (1S,2R)-3-({[3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2- D129 698.3 0.98 hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (1, 1-dioxido-2- isothiazolidinyl) benzamide hydrochloride (E399 N- [ (1S,2R)-3-({[3, 5-bis (methyloxy)phenyl]methyl}amino)-2- D129 622.3 0.86 hydroxy-1- (phenylmethyl) propyl]-3-cyclopentyl-5- (1, 1-dioxido-2- isothiazolidinyl) benzamide hydrochloride (E400) 3-cyclopentyl-N-[(1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino }-2- D129 718.1 0.94 hydroxy-1- (phenylmethyl) propyl]-5- (1, 1-dioxido-2- isothiazolidinyl) benzamide hydrochloride (E401) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-N- { (1S, 2R)-2- D130 621.3 0.80 hydroxy-1-(phenylmethyl)-3-[({3-[(trifluoromethyl) oxy] henyl}methyl)amino]propyl}benzamide hydrochloride (E402 N- [ (1S, 2R)-3- ( { [3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2- D130 673.3 0.86 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)- 5-(ethylamino benzamide hydrochloride (E403) N- [ (1S,2R)-3-({[3, 5-bis (methyloxy) phenyl] methyl} amino)-2- D130 597.4 0.73 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)- 5-(ethylamino benzamide hydrochloride (E404) N- [ (1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- D130 693.2 0.82 (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino) benzamide hydrochloride (E405 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethyloxy)-N- D131 620.3 0.83 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- (trifluoromethyl) phenyl] methyl} amino) propyl] benzamide hydrochloride (E406 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethyloxy)-N-D 131 582.4 0.78 [ (1S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-1- (phenylmethyl) propyl] benzamide hydrochloride (E407) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethyloxy)-N- D131 636.3 0.86 {(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[({3- [ (trifluoromethyl) oxy] phenyl} methyl) amino] propyl} benzamide hydrochloride (E408) N- [ (1S,2R)-3-({[3, 5-bis (trifluoromethyl) phenyl] methyl} amino)-2- D131 688.3 0.93 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-y)-5- (ethyloxy) benzamide hydrochloride (E409 N- [ (1S,2R)-3-({[3,5-bis(methyloxy)phenyl]methyl}amino)-2- D131 612.3 0.79 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-yl)-5-(ethyloxy) benzamide hydrochloride (E410) N- [ (1S,2R)-3-{[(3,5-dibromophenyl)methyl]amino}-2-hydroxy-1- D131 708.1 0.88 (phenylmethyl)propyl]-3-(1,1-dioxidotetrahydro-2H-1, 2-thiazin-2- l)-5-(ethylox benzamide h drochloride E411 N- [ (1S, 2R)-3- { [1- (3-chlorophenyl) propyl] amino}-2-hydroxy-1- D120 613.3 0.92 (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- l)-5-(ethylamino) benzamide hydrochloride (E412) 3-cyclopentyl-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- D125 556.6 0.92 [ (1 S, 2R)-2-hydroxy-3- [ (1-methylbutyl) amino]-1- henylmethyl)propyl benzamide hydrochloride (E413 N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1, 2,3, 4-tetrahydronaphthalen-2- D122 566.5 0.9 ylamino) propyl]-3-cyclopentyl-5- (2-oxopyrrolidin-1-yl) benzamide h drochloride E414 N-[(1S,2R)-1-benzyl-3-(2,3-dihydro-1H-inden-2-ylamino)-2- D122 552. 6 0.9 hydroxypropyl]-3-cyclopentyl-5- (2-oxopyrrolidin-1-yl) benzamide hydrochloride (E415 N-[(1S,2R)-1-benzyl-3-(2,3-dihydro-1H-inden-2-ylamino)-2- D120 577. 5 0.8 hydroxypropyl]-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E416) N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1, 2,3, 4-tetrahydronaphthalen-2- D120 591.5 0.8 ylamino) propyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E417 N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(7-methoxy-1, 2,3, 4- D122 596.6 0.9 tetrahydronaphthalen-2-yl) amino] propyl}-3-cyclopentyl-5- (2- oxopyrrolidin-1-yl)benzamide hydrochloride (E418) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D122 594.5 2.5 hydroxypropyl}-3-cyclopentyl-5- (2-oxopyrrolidin-1-yl) benzamide (E419) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D127 606.4 2.3 hydroxypropyl}-3- (1, 1-dioxidoisothiazolidin-2-yl)-5- ethoxybenzamide (E420) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D128 620.4 2.3 hydroxypropyl}-3-(1,1-dioxidoisothiazolidin-2-yl)-5- isopropoxybenzamide (E421) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D129 630.4 2.5 hydroxypropyl}-3-cyclopentyl-5-(1, 1-dioxidoisothiazolidin-2- yl) benzamide E422 N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D131 620.3 2.3 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethoxybenzamide (E423) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D124 634.3 2.4 hydroxypropyl}-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5- isopropoxybenzamide (E424) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- D125 644.4 2.6 hydroxypropyl}-3-cyclopentyl-5- (1, 1-dioxido-1, 2-thiazinan-2- yl) benzamide (E425) N- { (1S, 2R)-1-benzyl-3- [ (3, 5-dichlorobenzyl) amino]-2- E66 568.8 2.2 hydroxypropyl}-3-(ethylamino)-5-(2-oxopyrrolidin-1-yl) benzamide hydrochloride (E426) N-{(1S,2R)-1-benzyl-3-[(3,5-dichlorobenzyl)amino]-2- D130 604.9 2.2 hydroxypropyl)-3- (1, 1-dioxidoisothiazolidin-2-yl)-5- (ethylamino) benzamide hydrochloride (E427) Examples 428-570 (E428-E570) Examples E428-E570 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H] + RT (min) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-A73 C73 585.6 0.90 N- [ (1 S, 2R)-2-hydroxy-3-{[1-(4-methylpentyl)cyclopropyl] amino}-1- (phenylmethyl) propyl] benzamide hydrochloride (E428) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-A73 C74 529.5 0. 73 N- [ (1 S, 2R)-3- [ (1-ethylcyclopropyl) amino]-2-hydroxy-1- henylmethyl)propyl benzamide hydrochloride (E429) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A73 C75 543.4 0.77 N- [ (1 S, 2R)-2-hydroxy-3-{[1-(1-methylethyl)cyclopropyl] amino}-1-(phenylmethyl) propyl] benzamide hydrochloride (E430) N- [ (1 S, 2R)-3- (butylamino)-2-hydroxy-1- A73 C76 517.4 0.75 (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino) benzamide hydrochloride (E431 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A73 C77 543.5 0.79 N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1-propyl cyclopropyl)aminopropyl benzamide hydrochloride (E432) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-A73 C78 571.6 0.88 N- [ (1 S, 2R)-2-hydroxy-3-{[1-(3-methylbutyl)cyclopropyl] amino}-1-(phenylmethyl)propyl] benzamide hydrochloride (E433) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A73 C79 557.5 0.84 N- [ (1 S, 2R)-2-hydroxy-3- { [1- (2- methylpropyl)cyclopropyl]amino}-1-(phenylmethyl)propyl] benzamide hydrochloride (E434 N- [ 2R)-3-({1-[(3-chlorophenyl) methyl] A73 C80 625.4 0.90 cyclopropyl) amino)-2-hydroxy-1- (phenylmethyl) propyl]-3- (1,1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino) benzamide hydrochloride (E435) N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (1- A73 C81 557.5 0.78 methylcyclohexyl) amino] propyl}-3-(1,1-dioxido-1,2-thiazinan- 2-yl)-5-(ethylamino)benzamide hydrochloride (E436 N-{(1S,2R)-1-benzyl-3-[(1S, 2S, 4R)-bicyclo [2.2. 1] hept-2- A73 C82 555.4 0.78 ylamino]-2-hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)- 5-(ethylamino) benzamide hydrochloride (E437) N-{(1S,2R)-1-benzyl-3-[(4,4-dimethylcyclohexyl) amino]-2- A73 C83 571.3 0.82 hydroxypropyll-3- (1, 1-dioxido-1, 2-thiazinan-2-yi)-5- (ethylamino) benzamide hydrochloride (E438 N-((1S,2R)-1-benzyl-2-hydroxy-3-{[(1R)-1, 2, 2- A73 C84 545.6 0.8 trimethylpropyl]amino} propyl)-3-(1,1-dioxido-1, 2-thiazinan-2- l)-5-(ethylamino benzamide h drochloride E439 N-((1S,2R)-1-benzyl-2-hydroxy-3-{[(1S)-1, 2, 2- A73 C85 545.6 0.81 trimethylpropyl]amino} propyl)-3-(1,1-dioxido-1, 2-thiazinan-2- l)-5-(ethylamino benzamide hydrochloride (E440) N-[(1S,2R)-1-benzyl-3-[(2,2-dimethylcyclohexyl) amino]-2 A73 C86 571.6 0.83 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E441 N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- (pentylamino) propyl]-3- A73 C87 531.5 0.84 (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E442 N- [ (1S, 2R)-1-benzyl-3- (hexylamino)-2-hydroxypropyl]-3- (1, 1- A73 C88 545.5 0.9 dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino) benzamide hydrochloride (E443) N-{(1S,2R)-1-benzyl-3-[(3,3-dimethylbutyl)amino]-2- A73 C89 545.5 0.86 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E444 N- { (1S, 2R)-1-benzyl-3- [ (1, 1-dimethylpropyl) amino]-2- A73 C90 531.5 0.8 hydroxypropyl}-3- (l, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E445 N-{(1S,2R)-1-benzyl-3-[(cyclopropylmethyl) amino]-2- A73 C91 515.5 0.76 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E446) N-{(1S,2R)-1-benzyl-3-[(3,3-dimethylcyclopentyl) amino]-2- A73 C92 557.6 0.81 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E447 N- [ (1S, 2R)-1-benzyl-3- (ethylamino)-2-hydroxypropyl]-3- (1, 1- A73 C24 489.5 0.7 dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E448) N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- (methylamino) propyl]-3- A73 C93 475.5 0.68 (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino) benzamide hydrochloride (E449) N- [ (1S, 2R)-1-benzyl-3- (cyclopropylamino)-2-hydroxypropyl]- A73 C26 501.5 0.71 3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino) benzamide hydrochloride (E450) N- [ (1S, 2R)-3- (1-adamantylamino)-1-benzyl-2- A73 C94 595.6 0.85 hydroxypropyl]-3- (l, 1-dioxido-1, 2-thiazinan-2-yi)-5- ethylamino benzamide hydrochloride (E451 N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- (1, 2,3, 4- A107 C95 566.5 0.91 tetrahydronaphthalen-1-ylamino) propyl]-3-cyclopentyl-5- (2- oxopyrrolidin-1-yl) benzamide hydrochloride (E452) N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- (1, 2,3, 4- A73 C95 591.5 0.81 tetrahydronaphthalen-1-ylamino) propyl]-3- (1, 1-dioxido-1,2- thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E453) N-((1 S, 2R)-1-benzyl-2-hydroxy-3-{[2-(3-A73 C96 595.6 0.79 methoxyphenyl) ethyl] amino} propyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E454) N-((1S,2R)-1-benzyl-2-hydroxy-3-{[2-(4- A73 C97 595.6 0.78 methoxyphenyl) ethyl] amino} propyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E455) N-((1 S, 2R)-1-benzyl-2-hydroxy-3-{[2-(2-A73 C98 595.4 0.79 methoxyphenyl) ethyl] amino} propyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E456) N-((1S,2R)-1-benzyl-3-{[2-(2-chlorophenyl)ethyl]amino}-2- A73 C99 599.5 0.81 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E457) N-((1S,2R)-1-benzyl-3-{[2-(3-chlorophenyl)ethyl]amino}-2- A73 C100 599.5 0.82 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yi)-5- (ethylamino) benzamide hydrochloride (E458) N-((1S,2R)-1-benzyl-3-{[2-(4-chlorophenyl)ethyl]amino}-2- A73 C101 599.5 0.82 hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E459 N-((1S,2R)-1-benzyl-2-hydroxy-3-{[2-(4-methylphenyl) A73 C102 579.5 2.02 ethyl]amino}propyl)-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E460) N-((1S,2R)-1-benzyl-2-hydroxy-3-{[2-(2-methylphenyl) A73 C103 580.5 2.02 ethyl] amino} propyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E461) N-((1S,2R)-1-benzyl-3-{[2-(3,4-dichlorophenyl)ethyl] amino}- A73 C104 633.4 2.15 2-hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E462) N-((1S,2R)-1-benzyl-3-{[2-(2,4-dichlorophenyl)ethyl] amino}- A73 C105 633.4 0.86 2-hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E463) N-((1S,2R)-1-benzyl-3-{[2-(3,5-dimethoxyphenyl)ethyl] A73 C106 625.5 0.8 amino}-2-hydroxypropyl)-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5 - ethylamino benzamide hydrochloride (E464) N-((1S,2R)-1-benzyl-3-{[2-(2,3-dimethoxyphenyl)ethyl] A73 C107 625.4 0.79 amino}-2-hydroxypropyl)-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E465) N- [ (1 S, 2R)-1-benzyl-3- (benzylamino)-2-hydroxypropyl]-3- A73 C108 551.5 0.75 (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino) benzamide hydrochloride (E466) N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(2- A73 C109 565.4 0.79 phenylethyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)- 5-(ethylamino) benzamide hydrochloride (E467) N- { (1S, 2R)-1-benzyl-3- [ (1-ethylcyclohexyl) amino]-2- A73 C110 571.6 0.82 hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E468) N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(1- A73 C111 544.5 1.81 methylcyclopentyl) amino] propyl{-3-(1,1-dioxido-1, 2- thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E469) N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (1- A73 C112 571.7 0.83 propylcyclopentyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan- 2-yl)-5-(ethylamino benzamide hydrochloride (E470) N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (1- A73 C113 585.6 0.88 propylcyclohexyl) amino] propyl}-3- (1, 1-dioxido-1,2-thiazinan- 2-yl)-5-(ethylamino) benzamide hydrochloride (E471) N-((1S,2R)-1-benzyl-3-{[2-(3-chlorophenyl)-1,1- A73 C114 627.5 0.92 dimethylethyl] amino}-2-hydroxypropyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E472) 3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino)-N-[(1S,2R)- A73 C115 582.0 1.75 2-hydroxy-3- [ (3-methoxybenzyl) amino]-1- (pyridin-3- ylmethyl) propyl] benzamide hydrochloride (E473 3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino)-N-[(1S,2R)- A73 C116 588.0 1.91 2-hydroxy-3- [ (3-methoxybenzyl) amino]-1- (1, 3-thiazol-2- Imethyl)propyl benzamide h drochloride E474 N- [ (1S, 2R)-3- (cyclohexylamino)-2-hydroxy-1- (1, 3-thiazol-2- A73 C117 550.0 1.88 methyl) propyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino) benzamide hydrochloride (E475) N- [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-2-hydroxy-1- (1, 3- A73 C118 580.1 2.21 thiazol-2-ylmethyl)propyl]-3-(1,1-dioxido-1,2-thiazinan-2-yl )- 5-(ethylamino benzamide hydrochloride (E476) 3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino)-N- { (1S, 2R)- A73 C119 571.0 2.02 1-(2-furylmethyl)-2-hydroxy-3-[(3-methoxybenzyl) amino] ropyl}benzamide hydrochloride (E477 N- [ (1S, 2R)-3- (cyclohexylamino)-1- (2-furylmethyl)-2- A73 C120 533.0 2.01 hydroxypropyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino)benzamide hydrochloride (E478 N- [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-1- (2-furylmethyl)-2- A73 C121 563.1 2.32 hydroxypropyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide hydrochloride (E479 3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino)-N-{(1S,2R)- A73 C122 577.2 2.39 1-(2-furylmethyl)-2-hydroxy-3-[(1, 1, 5-trimethylhexyl) amino] propyl} benzamide hydrochloride (E480) 3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino)-N- [ (1S)-2- A73 C123 581.9 1.84 hydroxy-3-[(3-methoxybenzyl) amino]-1-(pyridin-2- ylmethyl) propyl] benzamide (E481) N- [ (1 S, 2R)-1- [ (4-chlorophenyl) methyl]-3- (cyclohexylamino)- A73 C124 577.4 0.82 2-hydroxypropyl]-3- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- l)-5-(ethylamino benzamide hydrochloride (E482) N-[(1S,2R)-1-[(4-chlorophenyl)methyl]-2-hydroxy-3-({[3- A73 C125 615.4 0.82 (methyloxy) phenyl] methyl} amino) propyl]-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E483 3-cyclopentyl-N- [ (1 S, 2R)-1- [ (3, 5-difluorophenyl) methyl]-2- A107 C126 630.4 0.94 hydroxy-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]- 5-(2-oxo-1-pyrrolidinyl)benzamide hydrochloride (E484 N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-({[3- A73 C126 655.4 0.85 (trifluoromethyl) phenyl] methyl} amino) propyl]-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E485 N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-({[3- A73 C127 617.3 0.8 (methyloxy) phenyl] methyl} amino) propyl]-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E486) N- { (1S, 2R)-1- [ (3, 5-difluorophenyl) methyl]-3- [ (1, 5- A73 C128 609.5 0.9 dimethylhexyl)amino]-2-hydroxypropyl}-3-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- eth lamino benzamide h drochloride E487 N- { (1S, 2R)-3- (cyclohexylamino)-1- [ (3, 5- A73 C129 579.4 0.8 difluorophenyl)methyl]-2-hydroxypropyl}-3-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E488 N- { (1S, 2R)-1- [ (3, 5-difluorophenyl) methyl]-2-hydroxy-3- A73 C130 623.6 0.93 [ (1, 1, 5-trimethylhexyl) amino] propyl}-3-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (eth lamino benzamide h drochloride (E489 N-[(1S,2R)-1-[(3,4-difluorophenyl)methyl]-2-hydroxy-3-({[3- A73 C131 617.5 0.81 (methyloxy) phenyl] methyl} amino) propyl]-3-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E490) N- { (1S, 2R)-3- (cyclohexylamino)-1- [ (3, 4- A73 C132 579.5 0.79 difluorophenyl)methyl]-2-hydroxypropyl}-3-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E491 N- { (1S, 2R)-1- [ (3, 4-difluorophenyl) methyl]-2-hydroxy-3- A73 C133 623.5 0.92 [ (1, 1, 5-trimethylhexyl) amino] propyl}-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E492) N-[(1S,2R)-1-[(3-chlorophenyl)methyl]-2-hydroxy-3-({[3- A73 C134 616.3 0.83 (methyloxy) phenyl] methyl} amino) propyl]-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E493 N- [ (1S, 2R)-1- [ (3-chlorophenyl) methyl]-3- (cyclohexylamino)- A73 C135 578.3 0.83 2-hydroxypropyl]-3- (1, 1-dioxidotetrahydro-2H-1,2-thiazin-2- l)-5-(ethylamino benzamide hydrochloride (E494 N- [ (1S,2R)-1-[(2-chlorophenyl)methyl]-2-hydroxy-3-({[3- A73 C136 616.4 0.86 (methyloxy) phenyl] methyl} amino) propyl]-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino) benzamide hydrochloride (E495) N-[(1 S, 2R)-1-[(2-chlorophenyl) methyl]-3-(cyclohexylamino)-A73 C137 578.4 0.85 2-hydroxypropyl]-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- l)-5-(ethylamino benzamide hydrochloride (E496) N- { 2R)-1-[(2-chlorophenyl) methyl]-3-[(1, 5-A73 C138 608.5 0.98 dimethylhexyl) amino]-2-hydroxypropyl}-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E497 N- { (1S, 2R)-1- [ (3-chlorophenyl) methyl]-3- [ (1, 5- A73 C139 608. 5 1 dimethylhexyl)amino]-2-hydroxypropyl}-3-(1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E498 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A73 C140 599.4 0.82 N- [ (1 S, 2R)-1- [ (3-fluorophenyl) methyl]-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino) propyl] benzamide hydrochloride (E499) N- { (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-1- [ (3-fluorophenyl) A73 C141 591.6 0.95 methyl]-2-hydroxypropyl}-3-(1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino) benzamide hydrochloride (E500) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)- A73 C142 587.4 0.79 N-[(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl]methyl amino)-1-(2-thienylmethyl) propyl] benzamide hydrochloride (E501) N- [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-2-hydroxy-1- (2- A73 C143 579.5 0.92 thienylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino benzamide hydrochloride (E502) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A73 C144 571.4 0.65 N-[(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino)-1- (1 H-pyrazol-1-ylmethyl) propyl] benzamide hydrochloride (E503) N-[(1S,2R)-3-[(1,5-dimethylhexyl)amino]-2-hydroxy-1-(1H- A73 C145 563.5 0.8 pyrazol-1-ylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1, 2- thiazin-2-yl)-5-(ethylamino) benzamide hydrochloride (E504) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)- A73 C146 587.5 0.76 N-[(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino)-1- (3-thienylmethyl) propyl] benzamide hydrochloride (E505) N- [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-2-hydroxy-1- (3- A73 C147 579.5 0.85 thienylmethyl)propyl]-3-(1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino benzamide hydrochloride (E506) formic acid-N- { (1 S, 2R)-1-benzyl-3- [ (1, 1- A31 C48 523.3 2.76 dimethylhexyl)amino]-2-hydroxypriopyl}-3-(ethylamino)-5-(2- oxopyrrolidin-1-yl) benzamide (1 : 1) (E507) formic acid - N-[(1S,2R)-1-benzyl-2-hydroxy-3-({1-methyl-1- A31 C40 597.3 3.03 [3-(trifluoromethyl)phenyl] ethyl} amino) propyl]-3- (ethylamino)-5-(2-oxopyrrolidin-1-yl benzamide (1: 1) (E508) formic acid-N-((1 S, 2R)-1-benzyl-2-hydroxy-3-{[2-methyl-5-A73 C49 633.2 2.84 (trifluoromethyl) benzyl] amino} propyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) (E509) formic acid - N-{(1S,2R)-1-benzyl-3-[91S)-2,3-dihydro-1H- A73 C50 577.2 2.68 inden-1-ylamino]-2-hydroxypropyl}-3-(1, 1-dioxido-1,2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) E510 formic acid-N-((1 S, 2R)-1-benzyl-2-hydroxy-3-{[(1 S, 2R)-2-A31 C51 543.1 2.55 hydroxy-2,3-dihydro-1 H-inden-1-yl] amino} propyl)-3- ethylamino)-5-(2-oxo-yrrolidin-1-yl)benzamide (1 : 1) E511 N-{(1 S, 2R)-1-benzyl-2-hydroxy-3-[(6-methoxy-2, 3-dihydro-A73 C52 607.5 2.55 1 H-inden-1-yl) amino] propyl}-3-(1,1-dioxido-1, 2-thiazinan-2- l)-5-(ethylamino benzamide (E512) formic acid-N-((1 S, 2R)-1-benzyl-2-hydroxy-3-{[(1 R, 2S)-2-A73 C53 593.4 2.40 hydroxy-2,3-dihydro-1 H-inden-1-yl] amino} propyl)-3-(1, 1- dioxido-1, 2-thiazinan-2-yl)-5-(ethylamino) benzamide (1: 1) (E513) N-((1 S, 2R)-1-benzyl-2-hydroxy-3-{[2-(isobutylthio)-1, 1-A31 C54 555.4 2.62 dimethylethyl] amino} propyl)-3- (ethylamino)-5- (2- oxopyrrolidin-1-yl)benzamide (E514 N- { (1S, 2R)-1-benzyl-3- [ (1, 1-dimethyl-2- A31 C55 559.4 2.56 phenoxyethyl) amino]-2-hydroxypropyl}-3- (ethylamino)-5- (2- oxopyrrolidin-1-yl)benzamide (E515) N-((1S,2R)-1-benzyl-3-{[2-(benzyloxy)-1,1- A31 C56 573.5 2.58 dimethylethyl] amino}-2-hydroxypropyl)-3- (ethylamino)-5- (2- oxopyrrolidin-1-yl) benzamide (E516) N- { (1 S, 2R)-1-benzyl-2-hydroxy-3- [ (3-methoxyphenyl) amino] A31 C57 517.4 2.92 propyl}-3- (ethylamino)-5- (2-oxopyrrolidin-1-yl) benzamide (E517) formic acid-N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- ( {2- [3- A31 C58 583.4 2.62 (trifluoromethyl) phenyl] ethyl} amino) propyl]-3- (ethylamino)-5- 2-oxopyrrolidin-1-yl benzamide (1 : 1) (E518) formic acid - N-{(1S,2R)-1-benzyl-3-[91,1-dimethyl-2- A31 C59 543.5 2.55 phenylethyl) amino]-2-hydroxypropyl}-3-(ethylamino)-5-(2- oxopyrrolidin-1-yl) benzamide (1 : 1) (E519) formic acid-N- ( (1S, 2R)-1-benzyl-2-hydroxy-3- { [2- (1- A31 C60 565.5 2.63 naphthyl)ethyl]amino} propyl)-3-(ethylamino)-5-(2- oxopyrrolidin-1-yl) benzamide (1 : 1) (E520) formic acid - N-((1S,2R)-1-benzyl-2-hydroxy-3-{[2-(3- A31 C61 573.5 2.57 methoxyphenyl)-1, 1-dimethylethyl] amino} propyl)-3- (ethylamino)-5-(2-oxopyrrolidin-1-yl) benzamide (1 : 1) (E521) N- [ (1S, 2R)-3-anilino-1-benzyl-2-hydroxypropyl]-3- A31 C62 487.4 2.90 ethylamino)-5-(2-oxopyrrolidin-1-yl benzamide (E522) N-((1S,2R)-1-benzyl-2-hydroxy-3-{[1-(3-methoxyphenyl) A31 C63 557.4 2.47 cyclopropyl] amino} propyl)-3- (ethylamino)-5- (2-oxopyrrolidin- 1-yl) benzamide (E523) formic acid-N- { (1S, 2R)-1-benzyl-3- A31 C64 507.5 2.48 [(cyclohexylmethyl)amino]-2-hydroxypropyl}-3-(ethylamino)- 5-(2-oxopyrrolidin-1-yl benzamide (1 : 1) (E524) formic acid - N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(tetrahydro- A31 C65 509.4 2.15 2H-pyran-4-ylmethyl) amino] propyl}-3-(ethylamino)-5-(2- oxopyrrolidin-1-yl) benzamide (1 : 1) (E525) N- [ (1 S, 2R)-1-benzyl-2-hydroxy-3- (tetrahydro-2H-thiopyran- A31 C66 511.4 2.30 4-ylamino)propyl]-3-(ethylamino)-5-(2-oxopyrrolidin-1- yl) benzamide (E526) formic acid-N-[(1S, 2R)-1-benzyl-2-hydroxy-3-A141 C28 478.5 2.04 (isopropylamino) propyl]-3-ethyl-7-(2-oxopyrrolidin-1-yl)-1 H- indole-5-carboxamide (1 : 1) (E527) formic acid-N- [ (1S, 2R)-1-benzyl-3- (cyclohexylamino)-2- A141 C1 517.5 2.17 hydroxypropyl]-3-ethyl-7-(2-oxopyrrolidin-1-yl)-1 H-indole-5- carboxamide (1 : 1) (E528) formic acid-N-{(1 S, 2R)-1-benzyl-2-hydroxy-3-[(1, 1, 5-A141 C5 561.5 2.56 trimethylhexyl) amino] propyl}-3-ethyl-7-(2-oxopyrrolidin-1-yl)- 1H-indole-5-carboxamide (1 : 1) (E529) formic acid-N- { (1 S, 2R)-1-benzyl-2-hydroxy-3- [ (3- A144 C14 591.4 2.36 methoxybenzyl) amino] propyl}-7- (1, 1-dioxidoisothiazolidin-2- yl)-3-ethyl-1H-indole-5-carboxamide (1: 1) (E530) N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(1, 1, 5- A144 C5 597.5 2.72 trimethylhexyl) amino] propyl}-7-(1, 1-dioxidoisothiazolidin-2- l)-3-ethyl-1H-indole-5-carboxamide (E531 formic acid - N-[(1S,2R)-1-benzyl-3-(cyclohexylamino)-2- A144 C1 554.5 2.33 hydroxypropyl]-7-(1,1-dioxidoisothiazolidin-2-yl)-3-ethyl-1 H- indole-5-carboxamide (1: 1) (E532) formic acid-N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- A144 C28 514.4 2.14 (isopropylamino) propyl]-7- (1, 1-dioxidoisothiazolidin-2-yl)-3- ethyl-1H-indole-5-carboxamide (1 : 1) (E533) formic acid-N- ( (1S, 2R)-1-benzyl-2-hydroxy-3- { [1- (3- A144 C15 619.4 2.45 methoxyphenyl)-l-methylethyl] amino} propyl)-7- (1, 1- dioxidoisothiazolidin-2-yl)-3-ethyl-1 H-indole-5-carboxamide (1 : 1) (E534) formic acid - N-[(1S,2R)-1-benzyl-2-hydroxy-3-({1-methyl-1- A144 C40 657.4 2.62 [3- (trifluoromethyl) phenyl] ethyl} amino) propyl]-7- (1, 1- dioxidoisothiazolidin-2-yl)-3-ethyl-1 H-indole-5-carboxamide (1 : 1) (E535) N- [ (1S,2R)-1-benzyl-3-(sec-butylamino)-2-hydroxypropyl]-3- A31 C67 467.3 2.4 ethylamino)-5-(2-oxopyrrolidin-1-yl benzamide (E536) N-{(1S,2R)-1-benzyl-3-[(4-tert-butylcyclohexyl)amino]-2- A31 C68 549.3 2.81 hydroxypropyl}-3- (ethylamino)-5- (2-oxopyrrolidin-1- yl) benzamide (E537) N- { (1 S, 2R)-1-benzyl-3- [ (1 S)-2, 3-dihydro-1 H-inden-1-A31 C50 527.2 2.56 ylamino]-2-hydroxypropyl}-3-(ethylamino)-5-(2-oXopyrrolidin- 1-yl) benzamide (E538) N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(2-isobutoxy-1,1- A31 C70 539.2 2.64 dimethylethyl) amino] propyl}-3- (ethylamino)-5- (2- oxopyrrolidin-1-yl) benzamide (E539) N-[(1S,2R)-1-benzyl-3-({1,1-dimethyl-2-[(2-methylprop-2-en- A31 C71 537.2 2.61 1-yl) oxy] ethyl} amino)-2-hydroxypropyl]-3-(ethylamino)-5-(2- oxopyrrolidin-1-yl)benzamide (E540 N-{(1 S, 2R)-1-benzyl-3-[(1 R)-2, 3-dihydro-1 H-inden-1-A31 C72 527.2 2.54 ylamino]-2-hydroxypropyll-3- (ethylamino)-5- (2-oxopyrrolidin- 1-yl) benzamide E541 N-{(1 S, 2R)-1-benzyl-3-[(1 R)-2, 3-dihydro-1 H-inden-1-A73 C72 577.2 2.64 ylamino]-2-hydroxypropyl}-3-(1,1-dioxido-1,2-thiazinan-2-yl) - 5-(ethylamino)benzamide (E542) N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (3-methoxybenzyl) amino] A128 C14 546.5 2.49 propyl}-3- [ethyl (methyl) amino]-5- (2-oxopyrrolidin-1- yl) benzamide (E543) N-((1S,2R)-1-benzyl-2-hydroxy-3-{[1-(3-methoxyphenyl)-1- A128 C15 574.5 2.58 methylethyl] amino} propyl)-3-[ethyl (methyl) amino]-5-(2- oxopyrrolidin-1-yl benzamide (E544) formic acid - N-((1S,2R)-1-benzyl-2-hydroxy-3-{[1-(3- A31 C41 599.5 2.60 methoxyphenyl) cyclohexyl] amino} propyl)-3- (ethylamino)-5- (2-oxopyrrolidin-1-yl) benzamide (1 : 1) (E545) formic acid - N-((1S,2R)-1-benzyl-2-hydroxy-3-{[1-(3- A73 C41 649.5 2.70 methoxyphenyl) cyclohexyl] amino} propyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino) benzamide (1: 1) (E546) formic acid - N-((1S,2R)-1-benzyl-2-hydroxy-3-{[1-methyl- A73 C42 555.3 2.35 1 H-pyrazol-4-yl) methyl] amino} propyl)-3- (1, 1-dioxido-1, 2- thiazinan-2-yl)-5-(ethylamino) benzamide (1 : 1) (E547) formic acid - N-((1S,2R)-1-benzyl-2-hydroxy-3-{[1-methyl- A31 C42 505.3 2.27 1 H-pyrazol-4-yl) methyl] amino} propyl)-3- (ethylamino)-5- (2- oxopyrrolidin-1-yl) benzamide (1 : 1) (E548) formic acid-N- [ (1 S, 2R)-1-benzyl-3- (cyclohexylamino)-2- A73 C1 543.4 2.45 hydroxypropyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- ethylamino benzamide (1 : 1) (E549) formic acid-N- [ (1 S, 2R)-1-benzyl-2-hydroxy-3- (tetrahydro- A73 C43 545.4 2.28 2H-pyran-4-ylamino) propyl]-3- (1, 1-dioxido-1, 2-thiazinan-2- l)-5-(ethylamino benzamide (1 : 1) (E550) formic acid-N- [ (1S, 2R)-1-benzyl-3- (cyclohexylamino)-2- A126 C1 568.3 2.80 hydroxypropyl]-3-cyclopentyl-5-(1, 1-dioxido-1,2-thiazinan-2- yl) benzamide (1 : 1) (E551) formic acid-N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- (tetrahydro- A126 C43 570.3 2.61 2H-pyran-4-ylamino) propyl]-3-cyclopentyl-5- (1, 1-dioxido-1, 2- thiazinan-2-yl) benzamide (1 : 1) (E552) formic acid-N- { (1S, 2R)-1-benzyl-3- [ (3, 3-dimethylbutyl) A119 C44 563.4 2.53 amino]-2-hydroxypropyl}-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino)-2-fluorobenzamide (1 : 1) (E553) N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(1, 1,3, 3- AH 9 C45 591.4 2.63 tetramethylbutyl) amino] propyl}-3-(1,1-dioxido-1, 2-thiazinan- 2-I-5-eth lamino-2-fluorobenzamide E554 formic acid-N- { (1S, 2R)-1-benzyl-3- [ (1, 3-dimethylbutyl) A119 C46 563.4 2.50 amino]-2-hydroxypropyl}-3- (l, 1-dioxido-1, 2-thiazinan-2-yi)-5- ethylamino)-2-fluorobenzamide (1 : 1) E555 formic acid-N- [ (1S, 2R)-1-benzy)-3- (cydohexyiamino)-2- A127 C1 557.4 2.35 hydroxypropyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (isopropylamino) benzamide (1 : 1) (E556) formic acid - N-((1S,2R)-1-benzyl-2-hydroxy-3- A127 C28 517. 4 2.20 (isopropylamino) propyl]-3- (1, 1-dioxido-1, 2-thiazinan-2-yl)-5- (isopropylamino) benzamide (1 : 1) (E557) formic acid-N- [ (1S, 2R)-1-benzyl-2-hydroxy-3- ( {1-methyl-1- A127 C40 661.4 2.70 [3- (trifluoromethyl) phenyl] ethyl} amino) propyl]-3- (1, 1-dioxido- 1, 2-thiazinan-2-yl)-5-(isopropylamino) benzamide (1: 1) (E558) formic acid-N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (3- A127 C14 595.4 2.41 methoxybenzyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan- 2-yl)-5-(isopropylamino benzamide (1 : 1) (E559) N-((1S,2R)-1-benzyl-2-hydroxy-3-{[3-(trifluoromethyl)benzyl] A127 C16 633.4 2.66 amino} propy)-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5- (isopropylamino) benzamide (E560) formic acid-N- { (1S, 2R)-1-benzyl-2-hydroxy-3- [ (1, 1, 5- A127 C5 601.5 2.80 trimethylhexyl) amino] propyl}-3- (1, 1-dioxido-1, 2-thiazinan-2- l)-5-(isopropylamino benzamide (1 : 1) (E561) formic acid-N- ( (1S, 2R)-1-benzyl-3- { [4-fluoro-3- A119 C47 655.4 2.50 (trifluoromethyl)benzyl] amino}-2-hydroxypropyl)-3-(1, 1- dioxido-1, 2-thiazinan-2-yl)-5- (ethylamino)-2-fluorobenzamide (1 : 1) (E562) formic acid - 3-(ethylamino)-N-[(1S,2R)-2-hydroxy-3-({[3- A59 C14 545.2 2.79 (methyloxy) phenyl] methyl}amino)-1-(phenylmethyl)propyl]-5- (2-oxo-1-piperidinyl) benzamide (1 : 1) (E563) formic acid-N- [ (1S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-2- A59 C20 537.3 2.81 hydroxy-1- (phenylmethyl) propyl]-3- (ethylamino)-5- (2-oxo-1- piperidinyl) benzamide (1: 1) (E564) 3- (ethylamino)-N- [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- A59 C16 583.2 2.69 ({[3-(trifluoromethyl)phenyl] methyl} amino) propyl]-5-(2-oxo-1- piperidinyl) benzamide (E565) formic acid-N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- A116 C14 544.3 2.74 (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl) propyl]-3- (2-oxo-1-piperidinyl)-5-propylbenzamide (1 : 1) (E566) formic acid-N- [ (1 S, 2R)-3- [ (1, 5-dimethylhexyl) amino]-2- A116 C20 536.3 3.01 hydroxy-1-(phenylmethyl)propyl]-3-(2-oxo-1-piperidinyl)-5- propylbenzamide (1 : 1) (E567) N- [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- A116 C16 582.2 2.88 (trifluoromethyl) phenyl] methyl} amino) propyl]-3-(2-oxo-1- piperidinyl)-5-propylbenzamide (E568) N-[(1 S, 2R)-3-{[(1 S)-2-(cyclohexylamino)-1-methyl-2-A116 C6 577.3 2.76 oxoethyl] amino}-2-hydroxy-1-(phenylmethyl)propyl]-3-(2- oxo-1-piperidinyl)-5-propyIbenzamide (E569) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-N- { (1S, 2R)- A70 C5 573.5 2.67 2-hydroxy-1- (phenylmethyl)-3- [ (1, 1, 5-trimethylhexyl) amino] ropyl}benzamide (E570 Examples 571-572 (E571-E572) The following compounds were prepared in an analogous manner to Example 183 from the appropriate amine and the appropriate aldehyde : Example Precursor [M+H] RT + (min) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 583.5 2.24 (ethylamino)-N-[(1S,2R)-2-hydroxy-3-[([1-(1-methylethyl)-1H- pyrazol-4-yl] methyl} amino)-1-(phenylmethyl) propyl] benzamide (1 : 1) (E571) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 623.4 2.28 (ethylamino)-N- [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[1- (2,2, 2-trifluoroethyl)-1 H-pyrazol-4-yl] methyl} amino) propyl] benzamide (1: 1) (E572)
Examples 573-695 (E573-E695) Examples E573-695 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H] + RT (min) formic acid-5- (ethylamino)-2-fluoro-N- [ (lS, 2R)-2-hydroxy-3- A118 C14 549.3 2.42 ({[3-(methyloxy)phenyl]methyl}amino)-1- (phenylmethyl) propyl]-3- (2-oxo-1-pyrrolidinyl) benzamide (1 : 1) (E573) 3-(ethyloxy)-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1-[3- A11 C40 598.4 2.76 (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-5-(2-oxo-1-pyrrolidinyl) benzamide E574 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethyloxy)-N- [ (1S, 2R)-2- A18 C40 634.3 2.78 hydroxy-3-({1-methyl-1-[3-(trifluoromethyl)phenyl] ethyl}amino)-1-(phenylmethyl)propyl benzamide (E575) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)- A73 C40 647. 4 2.78 N- [ ( 1 S, 2R)-2-hydroxy-3- ( {1-methy !-1- [3- (trifluoromethyl)phenyl] ethyl}amino)-1-(phenylmethyl)propyl] benzamide (E576) 1-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A140 C40 621.4 2.75 (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl)propyl]-4-(2-oxo-1-pyrrolidinyl)-1H-indole-6- carboxamide (E577) 3- (ethyloxy)-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A11 C15 560.4 2.62 (methyloxy) phenyl] ethyl} amino)-1-(phenylmethyl) propyl]-5- (2-oxo-1-pyrrolidinyl) benzamide (E578) 1-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A140 C15 583.4 2.61 (methyloxy) phenyl] ethyl} amino)-1-(phenylmethyl) propyl]-4- 2-oxo-1-rrolidin I-1 H-indole-6-carboxamide E579 3-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A141 C40 621.4 2.81 (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5- carboxamide (E580) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethyloxy)-N- [ (1S, 2R)-2- A18 C15 596.5 2.58 hydroxy-3- ( {1-methyl-1- [3- (methyloxy) phenyl] ethyl} amino)-1- (phenylmethyl) propyl] benzamide (E581) 3-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A141 C15 583.5 2.62 (methyloxy) phenyl] ethyl} amino)-1-(phenylmethyl)propyl]-7- (2-oxo-1-pyrrolidinyl)-1 H-indole-5-carboxamide (E582) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A119 C14 599.4 2.27 2-fluoro-N-[(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] methvl}amino)-1-(phenylmethyl)propyl benzamide (E583) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A119 C16 637.4 2.48 2-fluoro-N- [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl] benzamide (E584) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-N- [ (1S, 2R)- A70 C40 633.3 2.73 2-hydroxy-3- ( {1-methyl-1- [3- (trifluoromethyl) phenyl] ethyl}amino)-1-(phenylmethyl)propyl benzamide (E585) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-N- [ (1S, 2R)- A70 C15 595.3 2.57 2-hydroxy-3-({1-methyl-1-[3-(methyloxy)phenyl]ethyl} amino) - 1-(phenylmethyl)propyl benzamide (E586) 5- (ethylamino)-2-fluoro-N- [ (1 S, 2R)-2-hydroxy-1- A118 C16 587.3 2.60 (phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl} amino) ropyl]-3-(2-oxo-1-pyrrolidinyl)benzamide (E587 2-fluoro-N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- A120 C14 548.3 2.64 (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl]-3- (2-oxo-1-pyrrolidinyl)-5-propylbenzamide (E588) 2-fluoro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A120 C16 586.3 2.79 (trfluoromethyl)phenyl] methyl}amino)propyl]-3-(2-oxo-1- pyrrolidinyl)-5-propylbenzamide (E589) N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- A121 C14 620.5 3.02 (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl]-3- (2-oxo-5-phenyl-1-piperidinyl)-5-propylbenzamide (E590) N- [ (1S, 2R)-2-hydroxy-3- [ (1-methylethyl) amino]-1- A121 C28 542.4 2.88 (phenylmethyl) propyl]-3- (2-oxo-5-phenyl-1-piperidinyl)-5- ropylbenzamide (E591 N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A121 C1 582.6 2.99 (phenylmethyl)propyl]-3-(2-oxo-5-phenyl-1-piperidinyl)-5- propylbenzamide (E592) 5-(ethylamino)-2-fluoro-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1- A118 C40 615.3 2.61 [3-(trifluoromethyl)phenyl] ethyl}amino)-1-(phenylmethyl) ropyl]-3-(2-oxo-1-pyrrolidinyl benzamide (E593) 5- (ethylamino)-2-fluoro-N- { (1S, 2R)-2-hydroxy-1- A118 C5 555.4 2.71 (phenylmethyl)-3- [ (1, 1, 5-trimethylhexyl) amino] propyl}-3- (2- oxo-1-nvrrolidinvl) benzamide (E594) N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A118 C1 511.3 2.25 (phenylmethyl) propyl]-5- (ethylamino)-2-fluoro-3- (2-oxo-1- rrolidin I benzamide E595 5- (ethylamino)-2-fluoro-N- [ (1S, 2R)-2-hydroxy-3- [ (1- A118 C28 471.3 2.05 methylethyl)amino]-1-(phenylmethyl)propyl]-3-(2-oxo-1- pyrrolidinyl) benzamide (E596) 5-(ethylamino)-2-fluoro-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1- A118 C15 577.4 2.42 [3- (methyloxy) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]- 3-(2-oxo-1-pvrrolidinyl) benzamide (E597) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-A119 C5 605.4 2.87 2-fluoro-N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1, 1,5- trimethylhexyl)amino] propyl}benzamide (E598 N- [ (1 S, 2R)-3- (cyclohexylamino)-2-hydroxy-1- A119 C1 561.4 2.42 (phenylmethyl)propyl]-3-(1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino)-2-fluorobenzamide (E599 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-A119 C28 521.3 2.20 2-fluoro-N- [ (1 S, 2R)-2-hydroxy-3- [ (1-methylethyl) amino]-1- (phenylmethyl) propyl] benzamide (E600) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A153 C14 592.3 2.39 hydroxy-3-({[3-(methyloxy)phenyl]methyl}amino)-1- (phenylmethyl)propyl]-1H-indazole-6-carboxamide (E601 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A153 C16 630.3 2.58 hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-1 H-indazole-6-carboxamide (E602) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A153 C15 620.3 2.46 hydroxy-3-({1-methyl-1-[3-(methyloxy)phenyl]ethyl}amino)-1- (phenylmethyl) propyl]-1 H-indazole-6-carboxamide (E603) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A153 C40 658.3 2.65 hydroxy-3-({1-methyl-1-[3-(trifluoromethyl)phenyl] ethyl} amino)-1-(phenylmethyl) propyl]-1 H-indazole-6- carboxamide (E604) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- { (1S, 2R)-2- A153 C5 598.5 2.47 hydroxy-1- (phenylmethyl)-3- [ (1, 1, 5-trimethylhexyl) amino] ropyl}-1H-indazole-6-carboxamide (E605 N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A153 C1 554.4 2.08 (phenylmethyl) propyl]-4- (1, 1-dioxido-2-isothiazolidinyl)-1- ethyl-1 H-indazole-6-carboxamide (E606) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A153 C28 514.4 1.91 hydroxy-3- [ (1-methylethyl) amino]-1- (phenylmethyl) propyl]- 1 H-indazole-6-carboxamide (E607) 3-ethyl-N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] A142 C14 569.5 2.38 methyl} amino)-1-(phenylmethyl) propyl]-1-methyl-7-(2-oxo-1- pyrrolidinyl)-1 H-indole-5-carboxamide (E608) 3-ethyl-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1-[3-(methyloxy) A142 C15 597.5 2.45 phenyl] ethyl} amino)-1-(phenylmethyl) propyl]-1-methyl-7-(2- oxo-1-pyrrolidinyl)-1 H-indole-5-carboxamide (E609) 3-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A142 C40 635.4 2.71 (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-1-methyl-7- (2-oxo-1-pyrrolidinyl)-1 H- indole-5-carboxamide (E610) N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A142 C1 531.5 2.33 (phenylmethyl) propyl]-3-ethyl-1-methyl-7-(2-oxo-1- rrolidinyl)-1H-indole-5-carboxamide (E611 3-ethyl-N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1, 1, 5- A142 C5 575.4 2.80 trimethylhexyl) amino] propyl}-1-methyl-7-(2-oxo-1- rrolidinyl)-1H-indole-5-carboxamide (E612 3-ethyl-N-{(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1, 1, 5- A122 C5 591.5 2.60 trimethylhexyl) amino] propyl}-1-methyl-7-(2-oxo-1- pyrrolidinyl)-1H-indole-5-carboxamide formate salt (1: 1) (E613) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-A73 C5 587.6 2.61 (ethylamino)-N-{(1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- 1, 1, 5-trimethylhexyl) amino] propyl} benzamide (1 : 1) (E614) N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A122 C1 547.5 2.08 (phenylmethyl) propyl]-3- (1, 1-dioxido-2-isothiazolidinyl)-5- ethylamino)-2-fluorobenzamide (E615 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-N- [ (1S, 2R)-2- A146 C14 605.5 2.49 hydroxy-3- ( { [3- (methyloxy) phenyl] methyl) amino)-l- (phenylmethyl) propyl]-1-methyl-1 H-indole-5-carboxamide (E616) 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-N- [ (1S, 2R)-2- A146 C16 643.4 2.68 hydroxy-1-(phenylmethyl)-3-({[3-(trfluoromethyl)phenyl] methyl} amino) propyl]-1-methyl-1 H-indole-5-carboxamide (E617) 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-N- [ (1S, 2R)-2- A146 C15 633.4 2.57 hydroxy-3- ( {1-methyl-1- [3- (methyloxy) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-1-methyl-1 H-indole-5-carboxamide (E618) 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-N- [ (1S, 2R)-2- A146 C40 671.4 2.74 hydroxy-3- ( {l-methyl-1- [3- (trifluoromethyl) phenyl] ethyl} amino)-1-(phenylmethyl) propyl]-1-methyl-1 H-indole-5- carboxamide (E619) 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-N- { (1S, 2R)-2- A146 C5 611.5 2.84 hydroxy-1- (phenylmethyl)-3- [ (1, 1, 5-trimethylhexyl) amino] ropyl}-1-methyl-1H-indole-5-carboxamide (E620 N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A146 C1 567.5 2.46 (phenylmethyl) propyl]-7- (1, 1-dioxido-2-isothiazolidinyl)-3- ethyl-1-methyl-1H-indole-5-carboxamide (E621 3- (ethylamino)-N- [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- A129 C16 583.2 2.70 ({[3-(trifluoromethyl) phenyl] methyl} amino) propyl]-4-methyl- 5-(2-oxo-1-pyrrolidinyl)benzamide (E622 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-N- [ (1S, 2R)- A130 C16 619.2 2.77 2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-4-methylbenzamide (E623) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A131 C16 633.2 2.84 N- [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-4- methylbenzamide (E624) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)- A132 C16 649.2 2.82 N- [ ( 1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- (trifluoromethyl) phenyl] methyl} amino) propyl]-4- (methyloxy)benzamide (E625) 3-(ethylamino)-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3- A133 C16 599.2 2.71 ({[3-(trifluoromethyl)phenyl] methyl} amino) propyl]-4- (methyloxy)-5-(2-oxo-1-pyrrolidinyl) benzamide (E626) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-N- [ (1S, 2R)- A134 C16 635.2 2.76 2-hydroxy-I- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl}amino)propyl]-4-(methylox benzamide (E627) 3- (diethylamino)-5- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- A135 C16 661.2 2.94 yl)-N-[(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- (trifluoromethyl) phenyl] methyl} amino) propyl]-4- methylbenzamide (E628) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- [ (1S, 2R)-2- A136 C16 646.1 2.95 hydroxy-1-(phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl} amino) propyl]-4- (methyloxy)-5- [ (1 E)-1-propen-1- I]benzamide (E629 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- [ (1S, 2R)-2- A137 C16 648.2 2.99 hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-4- (methyloxy)-5-propylbenzamide (E630) N- [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- A154 C16 565.2 2.59 (trifluoromethyl) phenyl] methyl} amino) propyl]-4-(2-oxo-1- rrolidinyl)-1H-indole-6-carboxamide (E631 1-ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A140 C16 593.2 2.83 (trifluoromethyl) phenyl] methyl} amino) propyl]-4-(2-oxo-1- Pvrrolidinvl)-1 H-indole-6-carboxamide (E632) 1-ethyl-N-[(1S,2R)-2-hydroxy-3-({[3- A140 C14 555.2 2.36 (methyloxy) phenyl] methyl}amino)-1-(phenylmethyl)propyl]-4- (2-oxo-1-pyrrolidinyl)-1 H-indole-6-carboxamide (E633) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N-[(1S,2R)-2- A155 C14 577.1 2.31 hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-l- henylmethyl)propyl]-1H-indole-6-carboxamide (E634 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A147 C14 605.4 2.60 [(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino) - 1-(phenylmethyl)propyl]-1H-indole-6-carboxamide (E635) N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- A104 C14 530.5 2.60 (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl) propyl]-3- 1-methylethyl)-5-(2-oxo-1-pyrrolidinyl)benzamide (E636 N-[(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] A156 C14 541.2 2.50 methyl} amino)-1-(phenylmethyl) propyl]-1-methyl-4-(2-oxo-1- rrolidinyl)-1H-indole-6-carboxamide (E637 3- (1, 1-dioxido-2-isothiazolidinyl)-N- [ (1S, 2R)-2-hydroxy-3- A138 C14 607.2 2.43 ({[3-(methyloxy)phenyl]methyl}amino)-1-(phenylmethyl) propyl]-5-(2-oxo-1-pyrrolidinyl)benzamide (E638) 1-butyl-N-[(1S,2R)-2-hydroxy-3-({[3- A157 C14 583.2 2.78 (methoxy) phenyl] methyl} amino)-1-(phenylmethyl) propyl]-4- 2-oxo-1-pyrrolidinyl)-1H-indole-6-carboxamide (E639 N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] A158 C14 597.2 2.90 methyl} amino)-1-(phenylmethyl) propyl]-4-(2-oxo-1- Dvrrolidinvl)-1-Dentvl-1 H-indole-6-carboxamide (E640) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-2-fluoro-N- A122 C14 585.3 2.47 [(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino) - 1- (phenylmethyl) propyl] benzamide (E641) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-2-fluoro-N- A122 C16 623.3 2.62 [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) henyl] methyl}amino)propyl benzamide (E642) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-2-fluoro-N- A122 C15 613.3 2.56 [(1S,2R)-2-hydroxy-3-({1-methyl-1-[3-(methyloxy)phenyl] ethvl}amino)-1-(phenylmethyl)propyl benzamide (E643) 3- (1, 1-dioxido-2-isothiazolidinyl)-5- (ethylamino)-2-fluoro-N- A122 C40 651.3 2.70 [ (1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3-(trifluoromethyl)phenyl] ethyl}amino)-1-(phenylmethyl)propyl benzamide (E644) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A119 C15 627.3 2.63 2-fluoro-N- [ (1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3- (methyloxy) phenyl] ethyl}amino)-1-(phenylmethyl)propyl] benzamide (E645) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)-A119 C40 665.3 2.77 2-fluoro-N-[(1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3- (trifluoromethyl) phenyl] ethyl} amino)-1-(phenylmethyl) propyl] benzamide (E646) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A143 C14 591.3 2.60 hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-1- (phenylmethyl)propyl]-1H-indole-6-carboxamide (E647 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A143 C16 629.3 2.75 hydroxy-1-(phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl}amino)propyl]-1H-indole-6-carboxamide (E648) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A143 C15 619.4 2.67 hydroxy-3-({1-methyl-1-[3-(methyloxy)phenyl]ethyl}amino)-1- (phenylmethyl)propyl]-1H-indole-6-carboxamide (E649) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A143 C40 657.4 2.80 hydroxy-3- ( {1-methyl-1- [3- (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-1 H-indole-6- carboxamide (E650) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A139 C14 611.4 2.59 N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl) propyl]-2- methylox benzamide (E651) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-(ethylamino)- A139 C16 649.3 2.76 N- [ (1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-2- (methyloxy)benzamide (E652) 5-(1,1-dioxidotetrahydro-2H-1,2-thiazin-2-yl)-N'-[(1S,2R)-2- A95 C15 693.5 2.82 hydroxy-3- ( {l-methyl-1- [3- (methyloxy) phenyl] ethyllamino)-l- (phenylmethyl) propyl]-N, N-dipropyl-1, 3- benzenedicarboxamide (E653) 5-(1,1-dioxidotetrahydro-2H-1,2-thiazin-2-yl)-N'-[(1S,2R)-2- A95 C40 731.4 2.94 hydroxy-3-({1-methyl-1-[3-(trifluoromethyl)phenyl] ethyl}amino)-1-(phenylmethyl)propyl]-N,N-dipropyl-1, 3- benzenedicarboxamide (E654) 1-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( { [3- A152 C14 556.3 2.33 (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl) propyl]-4- (2-oxo-1-pyrrolidinyl)-1 H-indazole-6-carboxamide (E655) 1-ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A152 C16 594.3 2.42 (trifluoromethyl) phenyl] methyl} amino) propyl]-4-(2-oxo-1- pyrrolidinyl)-1 H-indazole-6-carboxamide (E656) 1-ethyl-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1-[3- A152 C15 584.4 2.42 (methyloxy)phenyl]ethyl}amino)-1-(phenylmethyl)propyl]-4- (2-oxo-1-rrolidinyl)-1 H-indazole-6-carboxamide (E657) 1-et-N- [ (1S, 2R)-2-hydroxy-3- ( {1-methyl-1- [3- A152 C40 622.4 2.61 (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-4-(2-oxo-1-pyrrolidinyl)-1 H-indazole-6- carboxamide (E658) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A145 C14 607.4 2.61 [ (1 S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino) - 1- (phenylmethyl) propyl]-2, 3-dihydro-1 H-indole-6- carboxamide (E659) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A147 C5 611.5 2.92 {(1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ (1, 1,5- trimethylhexyl) amino] propyl}-1 H-indole-6-carboxamide (E660) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- { (1S, 2R)-2- A143 C5 597.5 2.85 hydroxy-1- (phenylmethyl)-3- [ (1, 1, 5-trimethylhexyl) amino] ropyl}-1H-indole-6-carboxamide (E661 1-ethyl-N- { (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ (1, 1, 5- A140 C5 561.5 2.83 trimethylhexyl) amino] propyl}-4-(2-oxo-1-pyrrolidinyl)-1H- indole-6-carboxamide (E662) N-[(1 S, 2R)-3-(cyclohexylami no)-2-hyd roxy-1-A147 C1 567.5 2.62 (phenylmethyl)propyl]-4-(1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-1-ethyl-1H-indole-6-carboxamide (E663) N- [ 2R)-3-(cyclohexylamino)-2-hydroxy-1-A143 C1 553.5 2.54 (phenylmethyl) propyl]-4- (1, 1-dioxido-2-isothiazolidinyl)-1- ethyl-1 H-indole-6-carboxamide (E664) N- [ (1 S, 2R)-3- (cyclohexylamino)-2-hydroxy-1- A140 C1 517.4 2.51 (phenylmethyl)propyl]-1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1 H- indole-6-carboxamide (E665) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N-A147 C16 643.5 2.86 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- (trifluoromethyl) phenyl] methyl} amino) propyl]-1 H-indole-6- carboxamide (E666) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A147 C15 633.5 2.75 [ (1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3- (methyloxy) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-1 H- indole-6-carboxamide (E667) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A147 C40 671.5 2.92 [ (1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3-(trifluoromethyl)phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-1 H-indole-6- carboxamide (E668) 7- [acetyl (ethyl) amino]-N- [ (1S, 2R)-2-hydroxy-1- A159 C16 580.2 2.81 (phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl} amino) propyi]-3-methyl-1-benzofuran-5-carboxamide (E669) formic acid - N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A160 C16 579.2 2.68 (trifluoromethyl) phenyl] methyl} amino) propyl]-3-methyl-7-(2- oxo-1-pyrrolidinyl)-1H-indole-5-carboxamide (1 : 1) (E670) N-[(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3-A161 C 16 607.2 2.85 (trifluoromethyl) phenyl] methyl} amino) propyl]-3- (1- methylethyl)-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5- carboxamide (E671) formic acid - N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A162 C16 621.2 2.89 (trifluoromethyl) phenyl] methyl} amino) propyl]-l-methyl-3- (l- methylethyl)-7- (2-oxo-1-pyrrolidinyl)-1 H-indole-5- carboxamide (1 : 1) (E672) 3-ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A163 C16 594.2 2.90 (trifluoromethyl)phenyl] methyl}amino)propyl]-7-(2-oxo-1- pyrrolidinyl)-1-benzofuran-5-carboxamide (E673) formic acid - N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A164 C16 596.2 2.81 (trifluoromethyl) phenyl] methyl} amino) propyl]-4-methyl-8- (2- oxo-1-pyrrolidinyl)-3, 4-dihydro-2H-chromene-6-carboxamide (1 : 1) (E674) 3-ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A141 C16 593.2 2.81 (trifluoromethyl) phenyl] methyl} amino) propyl]-7-(2-oxo-1- rrolidinyl)-1H-indole-5-carboxamide (E675 3-ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A142 C16 607.2 2.83 (trifluoromethyl) phenyl] methyl} amino) propyl]-1-methyl-7-(2- oxo-1-pyrrolidinyl)-1 H-indole-5-carboxamide (E676) 7- (1, 1-dioxido-2-isothiazolidinyl)-3-ethyl-N- [ (1S, 2R)-2- A144 C16 629.1 2.87 hydroxy-1-(phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl} amino) propyl]-1H-indole-5-carboxamide (E677) N-[(1 S, 2R)-2-hydroxy-3-({[3-A161 C14 569.5 2.65 (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl) propyl]-3- (1-methylethyl)-7-(2-oxo-1-pyrrolidinyl)-1H-indole-5- carboxamide (E678) formic acid-3-ethyl-N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- A141 C14 555.1 2.44 (methyloxy) phenyl] methyl}amino)-1-(phenylmethyl)propyl]-7- 2-oxo-1-pyrrlidinyl)-1H-indole-5-carboxamide (1 : 1) (E679) formic acid-1-ethyl-N- [ (1S, 2R)-2-hydroxy-3- ( { [3- A149 C14 556.5 2.24 (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl]-4- (2-oxo-1-pyrrolidinyl)-1 H-benzimidazole-6-carboxamide (1: 1) (E680) formic acid-7- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-3-A148 C14 605.5 2.63 ethyl-N-[(1S,2R)-2-hydroxy-3-({[3- (methyloxy) phenyl]methyl}amino)-1-(phenylmethyl)propyl]- 1H-indole-5-carboxamide (1 : 1) (E681) formic acid-3-ethyl-N- [ (1 S, 2R)-2-hydroxy-3- ( { [3- A165 C14 569.2 2.68 (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl]-7- (2-oxo-1-piperidinyl)-1 H-indole-5-carboxamide (1 : 1) (E682) 3- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-N- A123 C14 659.3 2.95 [(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl]methyl} amino) - 1-(phenylmethyl)propyl]-5-nitrobenzamide (E683 3- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5- A125 C14 657.4 2.85 (ethylamino)-N-[(1S,2R)-2-hydroxy-3-({[3- (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl] benzamide (E684) 3-amino-5- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2- A124 C14 629.4 2.67 yl)-N- [ (l S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl)propyl] benzamide (E685) 3-ethyl-N-[(1S,2R)-2-hydroxy-3-({[3-(methyloxy)phenyl] A166 C14 631.4 2.92 methyl} amino)-1-(phenylmethyl)propyl]-7-(2-oxo-4-phenyl-1- pyrrolidinyl)-1 H-indole-5-carboxamide (E686) N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A125 C1 619.4 2.89 (phenylmethyl) propyl]-3- (1, 1-dioxido-4-phenyltetrahydro-2H- 1, 2-thiazin-2-yl)-5-(ethylamino benzamide (E687) 3- (1, 1-dioxido-4-phenyltetrahydro-2H-1, 2-thiazin-2-yl)-5- A125 C28 579.4 2.76 (ethylamino)-N- [ (1 S, 2R)-2-hydroxy-3-[(1-methylethyl) amino] - 1-(phenylmethyl) propyl] benzamide (E688) formic acid-1-ethyl-N- [ (1S, 2R)-2-hydroxy-1- (phenylmethyl)- A167 C16 595.3 2.67 3- ( { [3- (trifluoromethyl) phenyl] methyl) amino) propyl]-4- (2-oxo- 1-pyrrolidinyl)-1 H-1,2, 3-benzotriazole-6-carboxamide (1: 1) (E689) formic acid-4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1- A151 C14 606.3 2.21 ethyl-N- [ (l S, 2R)-2-hydroxy-3- ( { [3- (methyloxy)phenyl]methyl}amino)-1-(phenylmethyl)propyl]- 1H-benzimidazole-6-carboxamide (1: 1) (E690) 1-ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- A149 C16 594.5 2.21 (trifluoromethyl) phenyl] methyl} amino) propyl]-4-(2-oxo-1- rrolidinyl)-1H-benzimidazole-6-carboxamide (E691 1-ethyl-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1-[3- A149 C40 622.5 2.24 (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-4-(2-oxo-1-pyrrolidinyl)-1H- benzimidazole-6-carboxamide (E692) N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A149 C1 518.4 1.90 (phenylmethyl) propyl]-1-ethyl-4-(2-oxo-1-pyrrolidinyl)-1 H- benzimidazole-6-carboxamide (E693) 1-ethyl-N- { (1S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ (1, 1, 5- A149 C5 562.5 2.33 trimethylhexyl) amino] propyl}-4-(2-oxo-1-pyrrolidinyl)-1H- benzimidazole-6-carboxamide (E694) formic acid-1-ethyl-N- [ (l S, 2R)-2-hydroxy-3- ( {l-methyl-1- [3- A149 C15 584.5 2.09 (methyloxy)phenyl]ethyl}amino)-1-(phenylmethyl)propyl]-4-
(2-oxo-l-pyrrolidinyl)-1 H-benzimidazole-6-carboxamide (1: 1) E695 Example 696 3- (1, 1-dioxidotetrahydro-1, 2-thiazepin-2 (3H)-y))-N- [ (1S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-1-(phenylmethyl)propyl]-5-propylbenzamide (E696) Example 696 was prepared from Description 313 in an analogous manner to that described for Example 213. [M+H] + = 594.4, RT = 2.77 min Example 697 3- (1, 1-dioxidotetrahydro-1, 2-thiazepin-2 (3H)-yl)-N-1 (1 S, 2R)-2-hydroxy-1-(phenylmethyl)- 3- ( { [3- (trifluoromethyl) phenyl] methyl) amino) propyl]-5-propylbenzamide (E697) Example 697 was prepared from Description 312 in an analogous manner to that described for Example 213. [M+H] + = 632.1, RT = 3.00 min Examples 698-703 (E698-703) The following compounds were prepared in an analogous manner to Example 183 from the appropriate amine and the appropriate aldehyde or ketone: Example Precursor [M+H] + RT (min) N- [ (1S,2R)-3-{[2-(3-chlorophenyl)-1-methylethyl]amino}-2- D120 611.3 1.01 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H- 1, 2-thiazin-2-yl)-5-(ethylamino) benzamide hydrochloride (E698) N- [ (1S,2R)-3-{[2-(3-chlorophenyl)-1-methylethyl]amino}-2- D125 638.4 1.00 hydroxy-1-(phenylmethyl)propyl]-1-cyclopentyl-5-(1, 1-dioxido tetrahydro-2H-1, 2-thiazin-2-yl) benzamide hydrochloride (E699) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 585.5 2.57 (ethylamino)-N-[(1S,2R)-3-{[(5-ethyl-3-thienyl)methyl]amino} -2- hvdroxv-1-(phenvlmethvl)propyl benzamide (1 : 1) (E700) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 585.5 2.45 (ethylamino)-N-[(1S,2R)-3-{[(4-ethyl-2-thienyl)methyl] amino} -2- hydroxy-1-(phenylmethyl)propyl benzamide (1 : 1) (E701) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 569.5 2.31 (ethylamino)-N- [ (1 S, 2R)-3-{[(1-ethyl-1H-pyrazol-3- yl) methyl] amino}-2-hydroxy-1-(phenylmethyl) propyl] benzamide (1 : 1) (E702) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 583.5 2.29 (ethylamino)-N-((1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-{[(1- propyl-1H-pyrazol-4-yl)methyl] amino} propyl) benzamide (1: 1) (E703) Example 704 Example E704 was prepared in an analogous manner to Example 1 from the appropriate acid and amine indicated in the below table : Example Acid Amine [M+H] RT (min) N- [ (1S, 2R)-3- (bicyclo [2.2. 2] oct-1-ylamino)-2-hydroxy-1-A73 C153 569.5 2.02 (phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1,2- thiazin-2-yl)-5-(ethylamino) benzamide hydrochloride (E704)
Examples 705-709 (E705-709) The following compounds were prepared in an analogous manner to Example 183 from the appropriate amine and the appropriate aldehyde or ketone: Example Precursor [M+H]+ RT (min) formic acid -3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- D120 583.5 2.55 [ (1 S, 2R)-3-{[(5-ethenyl-3-thienyl)methyl] amino} -2-hydroxy-1- henylmethyl)propyl]-5-(ethylamino)benzamide (1 : 1) (E705) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- D120 567.5 2.44 [ (1 S, 2R)-3-{[(4-ethenyl-2-furanyl)methyl] amino} -2-hydroxy-1- henylmethyl)propyl]-5-(ethylamino benzamide (1 : 1) (E706) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 581.5 2.29 (ethylamino)-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-({[1-(2 - propen-1-yl)-1H-pyrazol-4-yl] methyl} amino) propyl] benzamide (1 : 1) (E707) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N-D120 583.5 2.52 [ (1 S, 2R)-3-{[(4-ethenyl-2-thienyl)methyl] amino} -2-hydroxy-1- (phenylmethyl) propyl]-5- (ethylamino) benzamide (1: 1) (E708) formic acid - 3-(1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- D120 587.5 2.22 (ethylamino)-N- [ (1 S, 2R)-3-({[1-(2-fluoroethyl)-1H-pyrazol-4- yl] methyl} amino)-2-hydroxy-1-(phenylmethyl) propyl] benzamide (1: 1) (E709)
Examples 710-744 (E710-744) Examples E710-E744 were prepared in an analogous manner to Example 1 from the appropriate acid and amines indicated in the below table : Example Acid Amine [M+H] RT (min) 3-cyclopentyl-N-[(1 S, 2R)-3-{[(1-ethyl-1 H-pyrazol-4-A107 C154 544.7 2.51 yl) methyl] amino}-2-hydroxy-1- (phenylmethyl) propyl]-5- (2-oxo-1-pyrrolidinyl) benzamide (E710) 3-(ethyloxy)-N-[(1 S, 2R)-3-{[(1-ethyl-1 H-pyrazol-4-A11 C154 520.7 2.20 yl) methyl]amino}-2-hydroxy-1-(phenylmethyl)propyl]-5- (2-oxo-1-pyrrolidinyl) benzamide E711 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A73 C154 569.6 2.19 (ethylamino)-N- [ (1 S, 2R)-3-{[(1-ethyl-1 H-pyrazol-4- yl)methyl]amino}-2-hydroxy-1-(phenylmethyl)propyl] benzamide (E712) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-N- [ (1S, 2R)- A112 C154 568.6 2.46 3-{[(1-ethyl-1H-pyrazol-4-yl)methyl]amino}-2-hydroxy-1- (phenylmethyl)propyl]-5-propylbenzamide (E713) formic acid-N- [ (1 S, 2R)-3- [ (4, 4- A119 C155 597.4 2.30 difluorocyclohexyl) amino]-2-hydroxy-1-(phenylmethyl) propyl]-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino)-2-fluorobenzamide (1 : 1) (E714) 4-ethyl-N-[(1S,2R)-2-hydroxy-3-({[3- A171 C14 572.5 2.61 (methyloxy) phenyl] methyl} amino)-1- (phenylmethyl) propyl]-8- (2-oxo-1-pyrrolidinyl)-1, 2,3, 4- tetrahydro-6-quinoxalinecarboxamide (E715 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A150 C14 592.4 2.21 hydroxy-3-({[3-(methyloxy)phenyl]methyl}amino)-1- (phenylmethyl) propyl]-1 H-benzimidazole-6-carboxamide (E716) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A150 C16 630.4 2.51 hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-1 H-benzimidazole-6-carboxamide (E717) 4- (1, 1-dioxido-2-isothiazolidinyl)-1-ethyl-N- [ (1S, 2R)-2- A150 C40 658.4 2.51 hydroxy-3- ( {1-methyl-1- [3- (trifluoromethyl) phenyl] ethyl} amino)-1-(phenylmethyl) propyl]-1 H-benzimidazole- 6-carboxamide (E718) 4- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-1-ethyl-N- A145 C40 673.5 2.90 [ (1 S, 2R)-2-hydroxy-3-({1-methyl-1-[3-(trifluoromethyl) phenyl] ethyl} amino)-1-(phenylmethyl)propyl]-2, 3- dihydro-1 H-indole-6-carboxamide (E719) 8- (1, 1-dioxido-2-isothiazolidinyl)-4-ethyl-N- [ (1S, 2R)-2- A172 C16 646.5 2.65 hydroxy-1- (phenylmethyl)-3- ( { [3- (trifluoromethyl) phenyl] methyl} amino) propyl]-1, 2,3, 4-tetrahydro-6- quinoxalinecarboxamide (E720) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- A119 C11 653.5 2.54 yl)-5-(ethylamino)-2-fluoro-N-{(1 S, 2R)-2-hydroxy-1- (phenylmethyl)-3- [ ( {3- [ (trifluoromethyl) oxy] henyl}methyl)amino] propyl}benzamide (1 : 1) (E721) formic acid-3- (1, 1-dioxido-2-isothiazolidinyl)-N- A174 C154 572.4 2.37 [ (1 S, 2R)-3-{[(1-ethyl-1 H-pyrazol-4-yl) methyl] amino} -2- hydroxy-1-(phenylmethyl) propyl]-2-fluoro-5- propylbenzamide (1 : 1) (E722) 3- (1, 1-dioxido-2-isothiazolidinyl)-2-fluoro-N- { (1S, 2R)-2- A174 C5 590.5 2.92 hydroxy-1-(phenylmethyl)-3-[(1, 1, 5-trimethylhexyl) amino] propyl}-5-propylbenzamide (E723) 3- (1, 1-dioxido-2-isothiazolidinyl)-2-fluoro-N- [ (1S, 2R)-2- A174 C15 612.5 2.66 hydroxy-3-({1-methyl-1-[3-(methyloxy)phenyl]ethyl} amino)-1-(phenylmethyl) propyl]-5-propylbenzamide (E724) 3- (1, 1-dioxido-2-isothiazolidinyl)-2-fluoro-N- [ (1S, 2R)-2- A174 C16 622.4 2.68 hydroxy-1-(phenylmethyl)-3-({[3-(trifluoromethyl)phenyl] methyl}amino)propyl]-5-propylbenzamide (E725) N- [ (1S, 2R)-3- [ (1r, 4R)-bicyclo [2.2. 1] hept-1-ylamino]-2- A73 C152 555.1 2.23 hydroxy-1- (phenylmethyl) propyl]-3- (1, 1- dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- ethylamino benzamide hydrochloride (E726) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- A173 C154 586.4 2.50 yl)-N-[(1S,2R)-3-{[(1-ethyl-1H-pyazol-4- yl) methyl]amino}-2-hydroxy-1-(phenylmethyl)propyl]-2- fluoro-5-propIbenzamide (1 : 1) (E727) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-N-A173 C43 562.4 2.45 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-(tetrahydro-2H- pyran-4-lamino) pro I-5-pro Ibenzamide (E728) formic acid-3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2- A173 C40 664.5 2.97 yl)-2-fluoro-N-[(1S,2R)-2-hydroxy-3-({1-methyl-1-[3- (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl) propyl]-5-propylbenzamide (1 : 1) (E729) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-N- A173 C16 636.4 2.84 [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3-({[3- (trifluoromethyl) phenyl] methyl} amino) propyls-5- propylbenzamide (E730) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-2-fluoro-N- A173 C14 598.4 2.70 [ (1 S, 2R)-2-hydroxy-3- ( { [3- (methyloxy) phenyl] methyl} amino)-1- henylmethyl)propyl]-5-propylbenzamide (E731 2-fluoro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3- A120 C43 512.5 2.32 (tetrahydro-2H-pyran-4-ylamino) propyl]-3- (2-oxo-1- pyrrolidinyl)-5-propylbenzamide (E732) N-[(1 S, 2R)-3-{[(1-ethyl-1 H-pyrazol-4-yl) methyl] amino}-2-A120 C154 536.5 2.36 hydroxy-1- (phenylmethyl) propyl]-2-fluoro-3- (2-oxo-1- rrolidinyl)-5-propylbenzamide (E733 N- [ (l S, 2R)-3- ( { [3, 4-bis (methyloxy) phenyl] A120 C156 578.5 2.40 methyl} amino)-2-hydroxy-1-(phenylmethyl) propyl]-2- fluoro-3-(2-oxo-1-pyrrolidinyl)-5-propylbenzamide (E734 2-fluoro-N- [ (1S, 2R)-2-hydroxy-3- [ (1-methylethyl) amino]- A120 C28 470.5 2.26 1- (phenylmethyl) propyl]-3- (2-oxo-1-pyrrolidinyl)-5- ropylbenzamide (E735 N- [ (1S,2R)-3-(cyclohexylamino)-2-hydroxy-1- A120 C1 510.5 2.44 (phenylmethyl)propyl]-2-fluoro-3-(2-oxo-1-pyrrolidinyl)-5- propylbenzamide (E736) formic acid-2-fluoro-N- {(1 S, 2R)-2-hydroxy-1- A120 C5 554.7 3.04 (phenylmethyl)-3- [ (1, 1, 5-trimethylhexyl) amino] propyl}-3- 2-oxo-1-pyrrolidinyl)-5-propylbenzamide (1:1) (E737 formic acid - 2-fluoro-N-[(1S,2R)-2-hydroxy-3-({1-methyl- A120 C40 614.6 2.77 1- [3- (trifluoromethyl) phenyl] ethyl} amino)-1- (phenylmethyl)propyl]-3-(2-oxo-1-pyrrolidinyl)-5- ropvlbenzamide (1 : 1) (E738) formic acid-2-fluoro-N-[(1 S, 2R)-2-hydroxy-3-({1-methyl-A120 C15 576.6 2.66 1- [3- (methyloxy) phenyl] ethyl} amino)-l- (phenylmethyl) propyl]-3-(2-oxo-1-pyrrolidinyl)-5- propylbenzamide (1 : 1) (E739) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A73 C69 542.9 1.05 (ethylamino)-N- [ (1 S, 2R)-3-[(1-ethylcyclobutyl) amino] -2- hydroxy-1-(phenylmethyl) propyl] benzamide hydrochloride (E740) 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-A73 C148 556.9 1.08 (ethylamino)-N-{(1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3- [(1-propylcyclbutyl) amino] propyl} benzamide hydrochloride (E741 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5-A73 C149 556.9 1.07 (ethylamino)-N-[(1S,2R)-2-hydroxy-3-{[1-(1- methylethyl) cyclobutyl] amino}-1-(phenylmethyl)propyl] benzamide hydrochloride (E742) N- [ (1S, 2R)-3-({1-[(3-chlorophenyl)methyl] A73 C150 639.3 1.41 cyclobutyl}amino)-2-hydroxy-1-(phenylmethyl)propyl]-3- (1,1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- (ethylamino) benzamide h drochloride E743 3- (1, 1-dioxidotetrahydro-2H-1, 2-thiazin-2-yl)-5- A73 C151 595.7 2.12 (ethylamino)-N- [ (1 S, 2R)-2-hydroxy-1-(phenylmethyl)-3- (tricyclo [3.3. 1. 1#,37#]dec-2-ylamino)propyl] benzamide hydrochloride (E744)
Compounds of the invention may be tested for in vitro biological activity in accordance with the following assays: (I) Asp-2 inhibitory assay For each compound being assayed, in a 384 well plate, is added:-
a) 1 pl of a DMSO solution of the test compound (IC50 curve uses ten 1 in 2 serial dilutions from 50011M). b) 10 gel of substrate (FAM-SEVNLDAEFK-TAMRA) solution in buffer. This is prepared by diluting 2ml of a 2mM DMSO solution of the substrate into 400ml of buffer (100mM Sodium acetate pH = 4.5, 1 I Milli-Q water, 0. 06% Triton X-100 (0.5 mull), pH adjusted to 4.5 using glacial acetic acid). Aminomethyl fluorescein (FAM) and tetramethyl rhodamine (TAMRA) are fluorescent molecules which co-operate to emit fluorescence at 535nm upon cleavage of the SEVNLDAEFK peptide. c) 10 gui enzyme solution. This is prepared by diluting 16m1 of a 500nM enzyme solution into 384 ml of buffer (prepared as above).
Blank wells (enzyme solution replaced by buffer) are included as controls on each plate. Wells are incubated for 1 h at room temperature and fluorescence read using a Tecan Ultra Fluorimeter/Spectrophotometer (485nm excitation, 535nm emission).
(II) Cathepsin D inhibitory assay For each compound being assayed, in a 384 well plate, is added:- a) 1 pl of a DMSO solution of the test compound (IC50 curve uses ten 1 in 2 serial dilutions from 500 1M). b) 10 pl of substrate (FAM-SEVNLDAEFK-TAMRA) solution in buffer. This is prepared by diluting 2ml of a 2mM DMSO solution of the substrate into 400ml of buffer (100mM Sodium acetate pH = 4.5, 1 I Milli-Q water, 0.06% Triton X-100 (0.5 ml/l), pH adjusted to 4.5 using glacial acetic acid). c) 10 pl enzyme solution. This is prepared by diluting 1. 6ml of a 200 unit/ml (in 10 mM HCI) enzyme solution into 398.4 ml of buffer (prepared as above).
Blank wells (enzyme solution replaced by buffer) are included as controls on each plate, Wells are incubated for 1 h at room temperature and fluorescence read using a Tecan Ultra Fluorimeter/Spectrophotometer (485nm excitation, 535nm emission).
Pharmacological Data The compounds of E1-E744 were tested in Assays (I) and (II) and exhibited inhibition within the following range: 1-10000 nM (Asp-2) and 10-10000 nM (CatD). More particularly, the compounds of E12, 22,30, 31,33, 50,54-56, 60,65, 86,102, 179,218, 222-223,241, 245- 246,249, 255,266, 270,271, 277-278,280-289, 296,299, 303,313-315, 317-318,320-322, 325, 327, 329,332-333, 361-363,373, 375,406-408, 559-560,562, 583-584,587, 632,641- 642,647-648, 656,680, 690-691,694-695, 700,703, 708,713, 716-718,720-721, 725,727, 730-731 and 733 exhibited inhibition within the following range: 1-50 nM (Asp-2) and 100- 10000 nM (CatD). Yet more particularly, the compounds of E30-31,33, 270,562, 584,700 and 721 exhibited inhibition within the following range: 1-10 nM (Asp-2) and 500-10000 nM (CatD).
Abbreviations
DMF dimethylformamide DMSO dimethylsulfoxide DMAP dimethylaminophenol DABCO 1, 4-diazabicyclo [2.2. 2] octane DME dimethyl ether EDAC N-ethyl-N- (3-dimethylamino propyl) carbodiimide THF tetrahydrofuran DEAD diethylacetylene dicarboxylate DCM dichloromethane TFA trifluoroacetic acid HOBT N-hydroxybenzotriazole FAM carboxyfluorescein TAMRA carboxytetramethylrhodamine [] single amino acid letter code relating to peptide sequence